[
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "<protein> Androgen </protein> antagonistic effect of estramustine phosphate (EMP) metabolites on wild-type and mutated <chemical> androgen receptor </chemical>.",
    "original_text": " Androgen  antagonistic effect of estramustine phosphate (EMP) metabolites on wild-type and mutated  androgen receptor .",
    "entity1": "Androgen",
    "entity2": "androgen receptor"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Androgen antagonistic effect of <protein> estramustine phosphate </protein> (EMP) metabolites on wild-type and mutated <chemical> androgen receptor </chemical>.",
    "original_text": "Androgen antagonistic effect of  estramustine phosphate  (EMP) metabolites on wild-type and mutated  androgen receptor .",
    "entity1": "estramustine phosphate",
    "entity2": "androgen receptor"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Androgen antagonistic effect of estramustine phosphate (<protein> EMP </protein>) metabolites on wild-type and mutated <chemical> androgen receptor </chemical>.",
    "original_text": "Androgen antagonistic effect of estramustine phosphate ( EMP ) metabolites on wild-type and mutated  androgen receptor .",
    "entity1": "EMP",
    "entity2": "androgen receptor"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "Binding of hydroxyflutamide to m-AR in LNCaP cells resulted in a concentration-dependent stimulation of PSA expression, suggesting that <protein> hydroxyflutamide </protein> acted as an agonist of the m-<chemical> AR </chemical>.",
    "original_text": "Binding of hydroxyflutamide to m-AR in LNCaP cells resulted in a concentration-dependent stimulation of PSA expression, suggesting that  hydroxyflutamide  acted as an agonist of the m- AR .",
    "entity1": "hydroxyflutamide",
    "entity2": "AR"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Our data indicate that <protein> estramustine phosphate </protein> metabolites perform as androgen antagonists of <chemical> AR </chemical>, an additional mechanism involved in the therapeutic effect of estramustine phosphate in patients with prostate cancer.",
    "original_text": "Our data indicate that  estramustine phosphate  metabolites perform as androgen antagonists of  AR , an additional mechanism involved in the therapeutic effect of estramustine phosphate in patients with prostate cancer.",
    "entity1": "estramustine phosphate",
    "entity2": "AR"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Our data indicate that estramustine phosphate metabolites perform as <protein> androgen </protein> antagonists of <chemical> AR </chemical>, an additional mechanism involved in the therapeutic effect of estramustine phosphate in patients with prostate cancer.",
    "original_text": "Our data indicate that estramustine phosphate metabolites perform as  androgen  antagonists of  AR , an additional mechanism involved in the therapeutic effect of estramustine phosphate in patients with prostate cancer.",
    "entity1": "androgen",
    "entity2": "AR"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "We conclude that decreased NET synthesis may contribute to the chronic, but not acute, effect of <protein> desipramine </protein> to downregulate the <chemical> NET </chemical>.",
    "original_text": "We conclude that decreased NET synthesis may contribute to the chronic, but not acute, effect of  desipramine  to downregulate the  NET .",
    "entity1": "desipramine",
    "entity2": "NET"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "While it is an antagonist at these latter receptors, <protein> ziprasidone </protein> behaves as a <chemical> 5-HT1A </chemical> agonist in vitro in adenylate cyclase measurements.",
    "original_text": "While it is an antagonist at these latter receptors,  ziprasidone  behaves as a  5-HT1A  agonist in vitro in adenylate cyclase measurements.",
    "entity1": "ziprasidone",
    "entity2": "5-HT1A"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Pretreatment with the <protein> 5-HT1A </protein> antagonist <chemical> WAY-100,635 </chemical> (10 micrograms/kg i.v.) prevented the ziprasidone-induced inhibition; the same dose of WAY-100,635 had little effect on the inhibition produced by clozapine and olanzapine.",
    "original_text": "Pretreatment with the  5-HT1A  antagonist  WAY-100,635  (10 micrograms/kg i.v.) prevented the ziprasidone-induced inhibition; the same dose of WAY-100,635 had little effect on the inhibition produced by clozapine and olanzapine.",
    "entity1": "5-HT1A",
    "entity2": "WAY-100,635"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Pretreatment with the <protein> 5-HT1A </protein> antagonist WAY-100,635 (10 micrograms/kg i.v.) prevented the ziprasidone-induced inhibition; the same dose of <chemical> WAY-100,635 </chemical> had little effect on the inhibition produced by clozapine and olanzapine.",
    "original_text": "Pretreatment with the  5-HT1A  antagonist WAY-100,635 (10 micrograms/kg i.v.) prevented the ziprasidone-induced inhibition; the same dose of  WAY-100,635  had little effect on the inhibition produced by clozapine and olanzapine.",
    "entity1": "5-HT1A",
    "entity2": "WAY-100,635"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "These profiles suggest a mechanism of action for each agent, <protein> 5-HT1A </protein> agonism for <chemical> ziprasidone </chemical> and alpha 1 antagonism for clozapine and olanzapine.",
    "original_text": "These profiles suggest a mechanism of action for each agent,  5-HT1A  agonism for  ziprasidone  and alpha 1 antagonism for clozapine and olanzapine.",
    "entity1": "5-HT1A",
    "entity2": "ziprasidone"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "The <protein> 5-HT1A </protein> agonist activity reported here clearly distinguishes <chemical> ziprasidone </chemical> from currently available antipsychotic agents and suggests that this property may play a significant role in its pharmacologic actions.",
    "original_text": "The  5-HT1A  agonist activity reported here clearly distinguishes  ziprasidone  from currently available antipsychotic agents and suggests that this property may play a significant role in its pharmacologic actions.",
    "entity1": "5-HT1A",
    "entity2": "ziprasidone"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "Agonist and antagonist actions of <protein> yohimbine </protein> as compared to fluparoxan at alpha(2)-adrenergic receptors <chemical> (AR)s </chemical>, serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors.",
    "original_text": "Agonist and antagonist actions of  yohimbine  as compared to fluparoxan at alpha(2)-adrenergic receptors  (AR)s , serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors.",
    "entity1": "yohimbine",
    "entity2": "(AR)s"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "Agonist and antagonist actions of <protein> yohimbine </protein> as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin <chemical> (5-HT)(1A) </chemical>, 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors.",
    "original_text": "Agonist and antagonist actions of  yohimbine  as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin  (5-HT)(1A) , 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors.",
    "entity1": "yohimbine",
    "entity2": "(5-HT)(1A)"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "Agonist and antagonist actions of <protein> yohimbine </protein> as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), <chemical> 5-HT(1B) </chemical>, 5-HT(1D) and dopamine D(2) and D(3) receptors.",
    "original_text": "Agonist and antagonist actions of  yohimbine  as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A),  5-HT(1B) , 5-HT(1D) and dopamine D(2) and D(3) receptors.",
    "entity1": "yohimbine",
    "entity2": "5-HT(1B)"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "Agonist and antagonist actions of <protein> yohimbine </protein> as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), 5-HT(1B), <chemical> 5-HT(1D) </chemical> and dopamine D(2) and D(3) receptors.",
    "original_text": "Agonist and antagonist actions of  yohimbine  as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), 5-HT(1B),  5-HT(1D)  and dopamine D(2) and D(3) receptors.",
    "entity1": "yohimbine",
    "entity2": "5-HT(1D)"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "Agonist and antagonist actions of <protein> yohimbine </protein> as compared to fluparoxan at <chemical> alpha(2)-adrenergic receptors </chemical> (AR)s, serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors.",
    "original_text": "Agonist and antagonist actions of  yohimbine  as compared to fluparoxan at  alpha(2)-adrenergic receptors  (AR)s, serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors.",
    "entity1": "yohimbine",
    "entity2": "alpha(2)-adrenergic receptors"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "Agonist and antagonist actions of yohimbine as compared to <protein> fluparoxan </protein> at alpha(2)-adrenergic receptors <chemical> (AR)s </chemical>, serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors.",
    "original_text": "Agonist and antagonist actions of yohimbine as compared to  fluparoxan  at alpha(2)-adrenergic receptors  (AR)s , serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors.",
    "entity1": "fluparoxan",
    "entity2": "(AR)s"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "Agonist and antagonist actions of yohimbine as compared to <protein> fluparoxan </protein> at <chemical> alpha(2)-adrenergic receptors </chemical> (AR)s, serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors.",
    "original_text": "Agonist and antagonist actions of yohimbine as compared to  fluparoxan  at  alpha(2)-adrenergic receptors  (AR)s, serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors.",
    "entity1": "fluparoxan",
    "entity2": "alpha(2)-adrenergic receptors"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Agonist and antagonist actions of <protein> yohimbine </protein> as compared to fluparoxan at alpha(2)-adrenergic receptors <chemical> (AR)s </chemical>, serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors.",
    "original_text": "Agonist and antagonist actions of  yohimbine  as compared to fluparoxan at alpha(2)-adrenergic receptors  (AR)s , serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors.",
    "entity1": "yohimbine",
    "entity2": "(AR)s"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Agonist and antagonist actions of <protein> yohimbine </protein> as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin <chemical> (5-HT)(1A) </chemical>, 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors.",
    "original_text": "Agonist and antagonist actions of  yohimbine  as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin  (5-HT)(1A) , 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors.",
    "entity1": "yohimbine",
    "entity2": "(5-HT)(1A)"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Agonist and antagonist actions of <protein> yohimbine </protein> as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), <chemical> 5-HT(1B) </chemical>, 5-HT(1D) and dopamine D(2) and D(3) receptors.",
    "original_text": "Agonist and antagonist actions of  yohimbine  as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A),  5-HT(1B) , 5-HT(1D) and dopamine D(2) and D(3) receptors.",
    "entity1": "yohimbine",
    "entity2": "5-HT(1B)"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Agonist and antagonist actions of <protein> yohimbine </protein> as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), 5-HT(1B), <chemical> 5-HT(1D) </chemical> and dopamine D(2) and D(3) receptors.",
    "original_text": "Agonist and antagonist actions of  yohimbine  as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), 5-HT(1B),  5-HT(1D)  and dopamine D(2) and D(3) receptors.",
    "entity1": "yohimbine",
    "entity2": "5-HT(1D)"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Agonist and antagonist actions of <protein> yohimbine </protein> as compared to fluparoxan at <chemical> alpha(2)-adrenergic receptors </chemical> (AR)s, serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors.",
    "original_text": "Agonist and antagonist actions of  yohimbine  as compared to fluparoxan at  alpha(2)-adrenergic receptors  (AR)s, serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors.",
    "entity1": "yohimbine",
    "entity2": "alpha(2)-adrenergic receptors"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Agonist and antagonist actions of yohimbine as compared to <protein> fluparoxan </protein> at alpha(2)-adrenergic receptors <chemical> (AR)s </chemical>, serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors.",
    "original_text": "Agonist and antagonist actions of yohimbine as compared to  fluparoxan  at alpha(2)-adrenergic receptors  (AR)s , serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors.",
    "entity1": "fluparoxan",
    "entity2": "(AR)s"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Agonist and antagonist actions of yohimbine as compared to <protein> fluparoxan </protein> at <chemical> alpha(2)-adrenergic receptors </chemical> (AR)s, serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors.",
    "original_text": "Agonist and antagonist actions of yohimbine as compared to  fluparoxan  at  alpha(2)-adrenergic receptors  (AR)s, serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors.",
    "entity1": "fluparoxan",
    "entity2": "alpha(2)-adrenergic receptors"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Herein, we evaluate the interaction of the <protein> alpha(2)-AR antagonist </protein>, <chemical> yohimbine </chemical>, as compared to fluparoxan, at multiple monoaminergic receptors and examine their roles in the modulation of adrenergic, dopaminergic and serotonergic transmission in freely-moving rats.",
    "original_text": "Herein, we evaluate the interaction of the  alpha(2)-AR antagonist ,  yohimbine , as compared to fluparoxan, at multiple monoaminergic receptors and examine their roles in the modulation of adrenergic, dopaminergic and serotonergic transmission in freely-moving rats.",
    "entity1": "alpha(2)-AR antagonist",
    "entity2": "yohimbine"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Herein, we evaluate the interaction of the <protein> alpha(2)-AR antagonist </protein>, yohimbine, as compared to <chemical> fluparoxan </chemical>, at multiple monoaminergic receptors and examine their roles in the modulation of adrenergic, dopaminergic and serotonergic transmission in freely-moving rats.",
    "original_text": "Herein, we evaluate the interaction of the  alpha(2)-AR antagonist , yohimbine, as compared to  fluparoxan , at multiple monoaminergic receptors and examine their roles in the modulation of adrenergic, dopaminergic and serotonergic transmission in freely-moving rats.",
    "entity1": "alpha(2)-AR antagonist",
    "entity2": "fluparoxan"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "In [(35)S]GTPgammaS binding protocols, <protein> yohimbine </protein> exerts antagonist actions at halpha(2A)-AR, h5-HT(1B), h5-HT(1D), and hD(2) sites, yet partial agonist actions at <chemical> h5-HT(1A) </chemical> sites.",
    "original_text": "In [(35)S]GTPgammaS binding protocols,  yohimbine  exerts antagonist actions at halpha(2A)-AR, h5-HT(1B), h5-HT(1D), and hD(2) sites, yet partial agonist actions at  h5-HT(1A)  sites.",
    "entity1": "yohimbine",
    "entity2": "h5-HT(1A)"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "In [(35)S]GTPgammaS binding protocols, <protein> yohimbine </protein> exerts antagonist actions at <chemical> halpha(2A)-AR </chemical>, h5-HT(1B), h5-HT(1D), and hD(2) sites, yet partial agonist actions at h5-HT(1A) sites.",
    "original_text": "In [(35)S]GTPgammaS binding protocols,  yohimbine  exerts antagonist actions at  halpha(2A)-AR , h5-HT(1B), h5-HT(1D), and hD(2) sites, yet partial agonist actions at h5-HT(1A) sites.",
    "entity1": "yohimbine",
    "entity2": "halpha(2A)-AR"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "In [(35)S]GTPgammaS binding protocols, <protein> yohimbine </protein> exerts antagonist actions at halpha(2A)-AR, <chemical> h5-HT(1B) </chemical>, h5-HT(1D), and hD(2) sites, yet partial agonist actions at h5-HT(1A) sites.",
    "original_text": "In [(35)S]GTPgammaS binding protocols,  yohimbine  exerts antagonist actions at halpha(2A)-AR,  h5-HT(1B) , h5-HT(1D), and hD(2) sites, yet partial agonist actions at h5-HT(1A) sites.",
    "entity1": "yohimbine",
    "entity2": "h5-HT(1B)"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "In [(35)S]GTPgammaS binding protocols, <protein> yohimbine </protein> exerts antagonist actions at halpha(2A)-AR, h5-HT(1B), <chemical> h5-HT(1D) </chemical>, and hD(2) sites, yet partial agonist actions at h5-HT(1A) sites.",
    "original_text": "In [(35)S]GTPgammaS binding protocols,  yohimbine  exerts antagonist actions at halpha(2A)-AR, h5-HT(1B),  h5-HT(1D) , and hD(2) sites, yet partial agonist actions at h5-HT(1A) sites.",
    "entity1": "yohimbine",
    "entity2": "h5-HT(1D)"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "In [(35)S]GTPgammaS binding protocols, <protein> yohimbine </protein> exerts antagonist actions at halpha(2A)-AR, h5-HT(1B), h5-HT(1D), and <chemical> hD(2) </chemical> sites, yet partial agonist actions at h5-HT(1A) sites.",
    "original_text": "In [(35)S]GTPgammaS binding protocols,  yohimbine  exerts antagonist actions at halpha(2A)-AR, h5-HT(1B), h5-HT(1D), and  hD(2)  sites, yet partial agonist actions at h5-HT(1A) sites.",
    "entity1": "yohimbine",
    "entity2": "hD(2)"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "In vivo, agonist actions of <protein> yohimbine </protein> at <chemical> 5-HT(1A) </chemical> sites are revealed by WAY100,635-reversible induction of hypothermia in the rat.",
    "original_text": "In vivo, agonist actions of  yohimbine  at  5-HT(1A)  sites are revealed by WAY100,635-reversible induction of hypothermia in the rat.",
    "entity1": "yohimbine",
    "entity2": "5-HT(1A)"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "In vivo, agonist actions of yohimbine at <protein> 5-HT(1A) </protein> sites are revealed by <chemical> WAY100,635 </chemical>-reversible induction of hypothermia in the rat.",
    "original_text": "In vivo, agonist actions of yohimbine at  5-HT(1A)  sites are revealed by  WAY100,635 -reversible induction of hypothermia in the rat.",
    "entity1": "5-HT(1A)",
    "entity2": "WAY100,635"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "In guinea pigs, antagonist actions of yohimbine at 5-HT(1B) receptors are revealed by blockade of hypothermia evoked by the <protein> 5-HT(1B) </protein> agonist, <chemical> GR46,611 </chemical>.",
    "original_text": "In guinea pigs, antagonist actions of yohimbine at 5-HT(1B) receptors are revealed by blockade of hypothermia evoked by the  5-HT(1B)  agonist,  GR46,611 .",
    "entity1": "5-HT(1B)",
    "entity2": "GR46,611"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "In guinea pigs, antagonist actions of <protein> yohimbine </protein> at <chemical> 5-HT(1B) </chemical> receptors are revealed by blockade of hypothermia evoked by the 5-HT(1B) agonist, GR46,611.",
    "original_text": "In guinea pigs, antagonist actions of  yohimbine  at  5-HT(1B)  receptors are revealed by blockade of hypothermia evoked by the 5-HT(1B) agonist, GR46,611.",
    "entity1": "yohimbine",
    "entity2": "5-HT(1B)"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "In distinction to <protein> yohimbine </protein>, fluparoxan shows only modest partial agonist actions at <chemical> h5-HT(1A) </chemical> sites versus marked antagonist actions at halpha(2)-ARs.",
    "original_text": "In distinction to  yohimbine , fluparoxan shows only modest partial agonist actions at  h5-HT(1A)  sites versus marked antagonist actions at halpha(2)-ARs.",
    "entity1": "yohimbine",
    "entity2": "h5-HT(1A)"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "In distinction to yohimbine, <protein> fluparoxan </protein> shows only modest partial agonist actions at <chemical> h5-HT(1A) </chemical> sites versus marked antagonist actions at halpha(2)-ARs.",
    "original_text": "In distinction to yohimbine,  fluparoxan  shows only modest partial agonist actions at  h5-HT(1A)  sites versus marked antagonist actions at halpha(2)-ARs.",
    "entity1": "fluparoxan",
    "entity2": "h5-HT(1A)"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "In distinction to <protein> yohimbine </protein>, fluparoxan shows only modest partial agonist actions at h5-HT(1A) sites versus marked antagonist actions at <chemical> halpha(2)-ARs </chemical>.",
    "original_text": "In distinction to  yohimbine , fluparoxan shows only modest partial agonist actions at h5-HT(1A) sites versus marked antagonist actions at  halpha(2)-ARs .",
    "entity1": "yohimbine",
    "entity2": "halpha(2)-ARs"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "In distinction to yohimbine, <protein> fluparoxan </protein> shows only modest partial agonist actions at h5-HT(1A) sites versus marked antagonist actions at <chemical> halpha(2)-ARs </chemical>.",
    "original_text": "In distinction to yohimbine,  fluparoxan  shows only modest partial agonist actions at h5-HT(1A) sites versus marked antagonist actions at  halpha(2)-ARs .",
    "entity1": "fluparoxan",
    "entity2": "halpha(2)-ARs"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "In conclusion, the <protein> alpha(2)-AR </protein> antagonist properties of <chemical> yohimbine </chemical> increase DA and NAD levels both alone and in association with fluoxetine.",
    "original_text": "In conclusion, the  alpha(2)-AR  antagonist properties of  yohimbine  increase DA and NAD levels both alone and in association with fluoxetine.",
    "entity1": "alpha(2)-AR",
    "entity2": "yohimbine"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "However, in contrast to the selective alpha(2)-AR antagonist, fluparoxan, the <protein> 5-HT(1A) </protein> agonist actions of <chemical> yohimbine </chemical> suppress 5-HT levels alone and underlie its inability to augment the influence of fluoxetine upon 5-HT levels.",
    "original_text": "However, in contrast to the selective alpha(2)-AR antagonist, fluparoxan, the  5-HT(1A)  agonist actions of  yohimbine  suppress 5-HT levels alone and underlie its inability to augment the influence of fluoxetine upon 5-HT levels.",
    "entity1": "5-HT(1A)",
    "entity2": "yohimbine"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "However, in contrast to the selective <protein> alpha(2)-AR </protein> antagonist, <chemical> fluparoxan </chemical>, the 5-HT(1A) agonist actions of yohimbine suppress 5-HT levels alone and underlie its inability to augment the influence of fluoxetine upon 5-HT levels.",
    "original_text": "However, in contrast to the selective  alpha(2)-AR  antagonist,  fluparoxan , the 5-HT(1A) agonist actions of yohimbine suppress 5-HT levels alone and underlie its inability to augment the influence of fluoxetine upon 5-HT levels.",
    "entity1": "alpha(2)-AR",
    "entity2": "fluparoxan"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "In this study, the activity of the <protein> delta-opioid receptor </protein> subtype-selective agonist, <chemical> SB 227122 </chemical>, was investigated in a guinea pig model of citric acid-induced cough.",
    "original_text": "In this study, the activity of the  delta-opioid receptor  subtype-selective agonist,  SB 227122 , was investigated in a guinea pig model of citric acid-induced cough.",
    "entity1": "delta-opioid receptor",
    "entity2": "SB 227122"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "Parenteral administration of selective agonists of the delta-opioid receptor (SB 227122), mu-opioid receptor (codeine and hydrocodone), and <protein> kappa-opioid receptor </protein> (<chemical> BRL 52974 </chemical>) produced dose-related inhibition of citric acid-induced cough with ED(50) values of 7.3, 5.2, 5.1, and 5.3 mg/kg, respectively.",
    "original_text": "Parenteral administration of selective agonists of the delta-opioid receptor (SB 227122), mu-opioid receptor (codeine and hydrocodone), and  kappa-opioid receptor  ( BRL 52974 ) produced dose-related inhibition of citric acid-induced cough with ED(50) values of 7.3, 5.2, 5.1, and 5.3 mg/kg, respectively.",
    "entity1": "kappa-opioid receptor",
    "entity2": "BRL 52974"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "Parenteral administration of selective agonists of the <protein> delta-opioid receptor </protein> (<chemical> SB 227122 </chemical>), mu-opioid receptor (codeine and hydrocodone), and kappa-opioid receptor (BRL 52974) produced dose-related inhibition of citric acid-induced cough with ED(50) values of 7.3, 5.2, 5.1, and 5.3 mg/kg, respectively.",
    "original_text": "Parenteral administration of selective agonists of the  delta-opioid receptor  ( SB 227122 ), mu-opioid receptor (codeine and hydrocodone), and kappa-opioid receptor (BRL 52974) produced dose-related inhibition of citric acid-induced cough with ED(50) values of 7.3, 5.2, 5.1, and 5.3 mg/kg, respectively.",
    "entity1": "delta-opioid receptor",
    "entity2": "SB 227122"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "Parenteral administration of selective agonists of the delta-opioid receptor (SB 227122), <protein> mu-opioid receptor </protein> (<chemical> codeine </chemical> and hydrocodone), and kappa-opioid receptor (BRL 52974) produced dose-related inhibition of citric acid-induced cough with ED(50) values of 7.3, 5.2, 5.1, and 5.3 mg/kg, respectively.",
    "original_text": "Parenteral administration of selective agonists of the delta-opioid receptor (SB 227122),  mu-opioid receptor  ( codeine  and hydrocodone), and kappa-opioid receptor (BRL 52974) produced dose-related inhibition of citric acid-induced cough with ED(50) values of 7.3, 5.2, 5.1, and 5.3 mg/kg, respectively.",
    "entity1": "mu-opioid receptor",
    "entity2": "codeine"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "Parenteral administration of selective agonists of the delta-opioid receptor (SB 227122), <protein> mu-opioid receptor </protein> (codeine and <chemical> hydrocodone </chemical>), and kappa-opioid receptor (BRL 52974) produced dose-related inhibition of citric acid-induced cough with ED(50) values of 7.3, 5.2, 5.1, and 5.3 mg/kg, respectively.",
    "original_text": "Parenteral administration of selective agonists of the delta-opioid receptor (SB 227122),  mu-opioid receptor  (codeine and  hydrocodone ), and kappa-opioid receptor (BRL 52974) produced dose-related inhibition of citric acid-induced cough with ED(50) values of 7.3, 5.2, 5.1, and 5.3 mg/kg, respectively.",
    "entity1": "mu-opioid receptor",
    "entity2": "hydrocodone"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "The nonselective <protein> opioid receptor </protein> antagonist, naloxone (3 mg/kg, i.m.), attenuated the antitussive effects of <chemical> codeine </chemical> or SB 227122, indicating that the antitussive activity of both compounds is opioid receptor-mediated.",
    "original_text": "The nonselective  opioid receptor  antagonist, naloxone (3 mg/kg, i.m.), attenuated the antitussive effects of  codeine  or SB 227122, indicating that the antitussive activity of both compounds is opioid receptor-mediated.",
    "entity1": "opioid receptor",
    "entity2": "codeine"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "The nonselective opioid receptor antagonist, naloxone (3 mg/kg, i.m.), attenuated the antitussive effects of <protein> codeine </protein> or SB 227122, indicating that the antitussive activity of both compounds is <chemical> opioid receptor </chemical>-mediated.",
    "original_text": "The nonselective opioid receptor antagonist, naloxone (3 mg/kg, i.m.), attenuated the antitussive effects of  codeine  or SB 227122, indicating that the antitussive activity of both compounds is  opioid receptor -mediated.",
    "entity1": "codeine",
    "entity2": "opioid receptor"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "The nonselective <protein> opioid receptor </protein> antagonist, naloxone (3 mg/kg, i.m.), attenuated the antitussive effects of codeine or <chemical> SB 227122 </chemical>, indicating that the antitussive activity of both compounds is opioid receptor-mediated.",
    "original_text": "The nonselective  opioid receptor  antagonist, naloxone (3 mg/kg, i.m.), attenuated the antitussive effects of codeine or  SB 227122 , indicating that the antitussive activity of both compounds is opioid receptor-mediated.",
    "entity1": "opioid receptor",
    "entity2": "SB 227122"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "The nonselective opioid receptor antagonist, naloxone (3 mg/kg, i.m.), attenuated the antitussive effects of codeine or <protein> SB 227122 </protein>, indicating that the antitussive activity of both compounds is <chemical> opioid receptor </chemical>-mediated.",
    "original_text": "The nonselective opioid receptor antagonist, naloxone (3 mg/kg, i.m.), attenuated the antitussive effects of codeine or  SB 227122 , indicating that the antitussive activity of both compounds is  opioid receptor -mediated.",
    "entity1": "SB 227122",
    "entity2": "opioid receptor"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "The nonselective <protein> opioid receptor </protein> antagonist, <chemical> naloxone </chemical> (3 mg/kg, i.m.), attenuated the antitussive effects of codeine or SB 227122, indicating that the antitussive activity of both compounds is opioid receptor-mediated.",
    "original_text": "The nonselective  opioid receptor  antagonist,  naloxone  (3 mg/kg, i.m.), attenuated the antitussive effects of codeine or SB 227122, indicating that the antitussive activity of both compounds is opioid receptor-mediated.",
    "entity1": "opioid receptor",
    "entity2": "naloxone"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "The <protein> delta-receptor </protein> antagonist, SB 244525 (10 mg/kg, i.p.), inhibited the antitussive effect of <chemical> SB 227122 </chemical> (20 mg/kg, i.p.).",
    "original_text": "The  delta-receptor  antagonist, SB 244525 (10 mg/kg, i.p.), inhibited the antitussive effect of  SB 227122  (20 mg/kg, i.p.).",
    "entity1": "delta-receptor",
    "entity2": "SB 227122"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "The <protein> delta-receptor </protein> antagonist, <chemical> SB 244525 </chemical> (10 mg/kg, i.p.), inhibited the antitussive effect of SB 227122 (20 mg/kg, i.p.).",
    "original_text": "The  delta-receptor  antagonist,  SB 244525  (10 mg/kg, i.p.), inhibited the antitussive effect of SB 227122 (20 mg/kg, i.p.).",
    "entity1": "delta-receptor",
    "entity2": "SB 244525"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "In contrast, combined pretreatment with <protein> beta-funaltrexamine </protein> (<chemical> mu-receptor </chemical> antagonist; 20 mg/kg, s.c.) and norbinaltorphimine (kappa-receptor antagonist; 20 mg/kg, s.c.), at doses that inhibited the antitussive activity of mu- and kappa-receptor agonists, respectively, was without effect on the antitussive response of SB 227122 (20 mg/kg, i.p.).",
    "original_text": "In contrast, combined pretreatment with  beta-funaltrexamine  ( mu-receptor  antagonist; 20 mg/kg, s.c.) and norbinaltorphimine (kappa-receptor antagonist; 20 mg/kg, s.c.), at doses that inhibited the antitussive activity of mu- and kappa-receptor agonists, respectively, was without effect on the antitussive response of SB 227122 (20 mg/kg, i.p.).",
    "entity1": "beta-funaltrexamine",
    "entity2": "mu-receptor"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "In contrast, combined pretreatment with beta-funaltrexamine (mu-receptor antagonist; 20 mg/kg, s.c.) and <protein> norbinaltorphimine </protein> (<chemical> kappa-receptor </chemical> antagonist; 20 mg/kg, s.c.), at doses that inhibited the antitussive activity of mu- and kappa-receptor agonists, respectively, was without effect on the antitussive response of SB 227122 (20 mg/kg, i.p.).",
    "original_text": "In contrast, combined pretreatment with beta-funaltrexamine (mu-receptor antagonist; 20 mg/kg, s.c.) and  norbinaltorphimine  ( kappa-receptor  antagonist; 20 mg/kg, s.c.), at doses that inhibited the antitussive activity of mu- and kappa-receptor agonists, respectively, was without effect on the antitussive response of SB 227122 (20 mg/kg, i.p.).",
    "entity1": "norbinaltorphimine",
    "entity2": "kappa-receptor"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "The <protein> sigma-receptor </protein> antagonist rimcazole (3 mg/kg, i.p.) inhibited the antitussive effect of <chemical> dextromethorphan </chemical> (30 mg/kg, i.p.), a sigma-receptor agonist, but not that of SB 227122.",
    "original_text": "The  sigma-receptor  antagonist rimcazole (3 mg/kg, i.p.) inhibited the antitussive effect of  dextromethorphan  (30 mg/kg, i.p.), a sigma-receptor agonist, but not that of SB 227122.",
    "entity1": "sigma-receptor",
    "entity2": "dextromethorphan"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "The <protein> sigma-receptor </protein> antagonist <chemical> rimcazole </chemical> (3 mg/kg, i.p.) inhibited the antitussive effect of dextromethorphan (30 mg/kg, i.p.), a sigma-receptor agonist, but not that of SB 227122.",
    "original_text": "The  sigma-receptor  antagonist  rimcazole  (3 mg/kg, i.p.) inhibited the antitussive effect of dextromethorphan (30 mg/kg, i.p.), a sigma-receptor agonist, but not that of SB 227122.",
    "entity1": "sigma-receptor",
    "entity2": "rimcazole"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "These studies provide compelling evidence that the antitussive effects of <protein> SB 227122 </protein> in this guinea pig cough model are mediated by agonist activity at the <chemical> delta-opioid receptor </chemical>.",
    "original_text": "These studies provide compelling evidence that the antitussive effects of  SB 227122  in this guinea pig cough model are mediated by agonist activity at the  delta-opioid receptor .",
    "entity1": "SB 227122",
    "entity2": "delta-opioid receptor"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "With respect to the <protein> quinone </protein> co-substrate of the <chemical> dihydroorotate dehydrogenase </chemical>, atovaquone (Kic = 2.7 microM) and dichloroally-lawsone (Kic = 9.8 nM) were shown to be competitive inhibitors of human dihydroorotate dehydrogenase.",
    "original_text": "With respect to the  quinone  co-substrate of the  dihydroorotate dehydrogenase , atovaquone (Kic = 2.7 microM) and dichloroally-lawsone (Kic = 9.8 nM) were shown to be competitive inhibitors of human dihydroorotate dehydrogenase.",
    "entity1": "quinone",
    "entity2": "dihydroorotate dehydrogenase"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "Iontophoresis of <protein> +/- propranolol </protein>, whose serotonergic actions include antagonism and partial agonism at <chemical> 5-HT1 </chemical> receptors, also increased serotonin and decreased firing (n=4).",
    "original_text": "Iontophoresis of  +/- propranolol , whose serotonergic actions include antagonism and partial agonism at  5-HT1  receptors, also increased serotonin and decreased firing (n=4).",
    "entity1": "+/- propranolol",
    "entity2": "5-HT1"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Iontophoresis of <protein> +/- propranolol </protein>, whose serotonergic actions include antagonism and partial agonism at <chemical> 5-HT1 </chemical> receptors, also increased serotonin and decreased firing (n=4).",
    "original_text": "Iontophoresis of  +/- propranolol , whose serotonergic actions include antagonism and partial agonism at  5-HT1  receptors, also increased serotonin and decreased firing (n=4).",
    "entity1": "+/- propranolol",
    "entity2": "5-HT1"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "<protein> Methiothepin </protein> (intravenous, 1 mg/kg), whose serotonergic actions include <chemical> 5-HT1 </chemical> and 5-HT2 antagonism, typically raised serotonin levels (four of five cells) and always blocked inhibition by clomipramine (n = 3).",
    "original_text": " Methiothepin  (intravenous, 1 mg/kg), whose serotonergic actions include  5-HT1  and 5-HT2 antagonism, typically raised serotonin levels (four of five cells) and always blocked inhibition by clomipramine (n = 3).",
    "entity1": "Methiothepin",
    "entity2": "5-HT1"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "<protein> Methiothepin </protein> (intravenous, 1 mg/kg), whose serotonergic actions include 5-HT1 and <chemical> 5-HT2 </chemical> antagonism, typically raised serotonin levels (four of five cells) and always blocked inhibition by clomipramine (n = 3).",
    "original_text": " Methiothepin  (intravenous, 1 mg/kg), whose serotonergic actions include 5-HT1 and  5-HT2  antagonism, typically raised serotonin levels (four of five cells) and always blocked inhibition by clomipramine (n = 3).",
    "entity1": "Methiothepin",
    "entity2": "5-HT2"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "<protein> gamma-Butyrobetaine hydroxylase </protein> catalyse the last step in carnitine biosynthesis, the formation of L-carnitine from <chemical> gamma-butyrobetaine </chemical>, a reaction dependent on Fe2+, alpha-ketoglutarate, ascorbate and oxygen.",
    "original_text": " gamma-Butyrobetaine hydroxylase  catalyse the last step in carnitine biosynthesis, the formation of L-carnitine from  gamma-butyrobetaine , a reaction dependent on Fe2+, alpha-ketoglutarate, ascorbate and oxygen.",
    "entity1": "gamma-Butyrobetaine hydroxylase",
    "entity2": "gamma-butyrobetaine"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "A unique cytosolic activity related but distinct from <protein> NQO1 </protein> catalyses metabolic activation of <chemical> mitomycin C </chemical>.",
    "original_text": "A unique cytosolic activity related but distinct from  NQO1  catalyses metabolic activation of  mitomycin C .",
    "entity1": "NQO1",
    "entity2": "mitomycin C"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Among the various enzymes, dicoumarol inhibitable cytosolic <protein> NAD(P)H:quinone oxidoreductase1 </protein> (NQO1) was shown to catalyse bioreductive activation of <chemical> MMC </chemical> leading to cross-linking of the DNA and cytotoxicity.",
    "original_text": "Among the various enzymes, dicoumarol inhibitable cytosolic  NAD(P)H:quinone oxidoreductase1  (NQO1) was shown to catalyse bioreductive activation of  MMC  leading to cross-linking of the DNA and cytotoxicity.",
    "entity1": "NAD(P)H:quinone oxidoreductase1",
    "entity2": "MMC"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Among the various enzymes, dicoumarol inhibitable cytosolic NAD(P)H:quinone oxidoreductase1 (<protein> NQO1 </protein>) was shown to catalyse bioreductive activation of <chemical> MMC </chemical> leading to cross-linking of the DNA and cytotoxicity.",
    "original_text": "Among the various enzymes, dicoumarol inhibitable cytosolic NAD(P)H:quinone oxidoreductase1 ( NQO1 ) was shown to catalyse bioreductive activation of  MMC  leading to cross-linking of the DNA and cytotoxicity.",
    "entity1": "NQO1",
    "entity2": "MMC"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "However, the role of <protein> NQO1 </protein> in metabolic activation of <chemical> MMC </chemical> has been disputed.",
    "original_text": "However, the role of  NQO1  in metabolic activation of  MMC  has been disputed.",
    "entity1": "NQO1",
    "entity2": "MMC"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "In this report, we present cellular and animal models to demonstrate that <protein> NQO1 </protein> may play only a minor role in metabolic activation of <chemical> MMC </chemical>.",
    "original_text": "In this report, we present cellular and animal models to demonstrate that  NQO1  may play only a minor role in metabolic activation of  MMC .",
    "entity1": "NQO1",
    "entity2": "MMC"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "We examined the effect of JTH-601 (3- inverted question mark<protein> N-[2-(4-hydroxy-2-isopropyl-5-methylphenoxy)ethyl]-N-methylaminom </protein> ethyl inverted question mark-4-methoxy-2,5,6-trimethylphenol hemifumarate), a new <chemical> alpha(1L)-adrenoceptor </chemical> antagonist, on prostatic function in isolated canine prostate and in anesthetized dogs.",
    "original_text": "We examined the effect of JTH-601 (3- inverted question mark N-[2-(4-hydroxy-2-isopropyl-5-methylphenoxy)ethyl]-N-methylaminom  ethyl inverted question mark-4-methoxy-2,5,6-trimethylphenol hemifumarate), a new  alpha(1L)-adrenoceptor  antagonist, on prostatic function in isolated canine prostate and in anesthetized dogs.",
    "entity1": "N-[2-(4-hydroxy-2-isopropyl-5-methylphenoxy)ethyl]-N-methylaminom",
    "entity2": "alpha(1L)-adrenoceptor"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "We examined the effect of JTH-601 (3- inverted question markN-[2-(4-hydroxy-2-isopropyl-5-methylphenoxy)ethyl]-N-methylaminom <protein> ethyl </protein> inverted question mark-4-methoxy-2,5,6-trimethylphenol hemifumarate), a new <chemical> alpha(1L)-adrenoceptor </chemical> antagonist, on prostatic function in isolated canine prostate and in anesthetized dogs.",
    "original_text": "We examined the effect of JTH-601 (3- inverted question markN-[2-(4-hydroxy-2-isopropyl-5-methylphenoxy)ethyl]-N-methylaminom  ethyl  inverted question mark-4-methoxy-2,5,6-trimethylphenol hemifumarate), a new  alpha(1L)-adrenoceptor  antagonist, on prostatic function in isolated canine prostate and in anesthetized dogs.",
    "entity1": "ethyl",
    "entity2": "alpha(1L)-adrenoceptor"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "We examined the effect of JTH-601 (3- inverted question markN-[2-(4-hydroxy-2-isopropyl-5-methylphenoxy)ethyl]-N-methylaminom ethyl inverted question mark-<protein> 4-methoxy-2,5,6-trimethylphenol hemifumarate </protein>), a new <chemical> alpha(1L)-adrenoceptor </chemical> antagonist, on prostatic function in isolated canine prostate and in anesthetized dogs.",
    "original_text": "We examined the effect of JTH-601 (3- inverted question markN-[2-(4-hydroxy-2-isopropyl-5-methylphenoxy)ethyl]-N-methylaminom ethyl inverted question mark- 4-methoxy-2,5,6-trimethylphenol hemifumarate ), a new  alpha(1L)-adrenoceptor  antagonist, on prostatic function in isolated canine prostate and in anesthetized dogs.",
    "entity1": "4-methoxy-2,5,6-trimethylphenol hemifumarate",
    "entity2": "alpha(1L)-adrenoceptor"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "We examined the effect of <protein> JTH-601 </protein> (3- inverted question markN-[2-(4-hydroxy-2-isopropyl-5-methylphenoxy)ethyl]-N-methylaminom ethyl inverted question mark-4-methoxy-2,5,6-trimethylphenol hemifumarate), a new <chemical> alpha(1L)-adrenoceptor </chemical> antagonist, on prostatic function in isolated canine prostate and in anesthetized dogs.",
    "original_text": "We examined the effect of  JTH-601  (3- inverted question markN-[2-(4-hydroxy-2-isopropyl-5-methylphenoxy)ethyl]-N-methylaminom ethyl inverted question mark-4-methoxy-2,5,6-trimethylphenol hemifumarate), a new  alpha(1L)-adrenoceptor  antagonist, on prostatic function in isolated canine prostate and in anesthetized dogs.",
    "entity1": "JTH-601",
    "entity2": "alpha(1L)-adrenoceptor"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "In these tissues, <protein> JTH-601 </protein>, prazosin (a non-selective <chemical> alpha(1)-adrenoceptor </chemical> antagonist), and tamsulosin (an alpha(1A)-adrenoceptor antagonist) competitively antagonized contraction in a concentration-dependent manner.",
    "original_text": "In these tissues,  JTH-601 , prazosin (a non-selective  alpha(1)-adrenoceptor  antagonist), and tamsulosin (an alpha(1A)-adrenoceptor antagonist) competitively antagonized contraction in a concentration-dependent manner.",
    "entity1": "JTH-601",
    "entity2": "alpha(1)-adrenoceptor"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "In these tissues, JTH-601, <protein> prazosin </protein> (a non-selective <chemical> alpha(1)-adrenoceptor </chemical> antagonist), and tamsulosin (an alpha(1A)-adrenoceptor antagonist) competitively antagonized contraction in a concentration-dependent manner.",
    "original_text": "In these tissues, JTH-601,  prazosin  (a non-selective  alpha(1)-adrenoceptor  antagonist), and tamsulosin (an alpha(1A)-adrenoceptor antagonist) competitively antagonized contraction in a concentration-dependent manner.",
    "entity1": "prazosin",
    "entity2": "alpha(1)-adrenoceptor"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "In these tissues, JTH-601, prazosin (a non-selective alpha(1)-adrenoceptor antagonist), and <protein> tamsulosin </protein> (an <chemical> alpha(1A)-adrenoceptor </chemical> antagonist) competitively antagonized contraction in a concentration-dependent manner.",
    "original_text": "In these tissues, JTH-601, prazosin (a non-selective alpha(1)-adrenoceptor antagonist), and  tamsulosin  (an  alpha(1A)-adrenoceptor  antagonist) competitively antagonized contraction in a concentration-dependent manner.",
    "entity1": "tamsulosin",
    "entity2": "alpha(1A)-adrenoceptor"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "<protein> JTH-601 </protein> is expected to be an effective <chemical> alpha(1)-adrenoceptor </chemical> antagonist for the treatment of urinary outlet obstruction by benign prostatic hypertrophy with a minimum effect on the cardiovascular system.",
    "original_text": " JTH-601  is expected to be an effective  alpha(1)-adrenoceptor  antagonist for the treatment of urinary outlet obstruction by benign prostatic hypertrophy with a minimum effect on the cardiovascular system.",
    "entity1": "JTH-601",
    "entity2": "alpha(1)-adrenoceptor"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "The salivary fluid secretory mechanism is thought to require <protein> Na(+)/K(+)/2Cl(-) cotransporter </protein>-mediated <chemical> Cl(-) </chemical> uptake.",
    "original_text": "The salivary fluid secretory mechanism is thought to require  Na(+)/K(+)/2Cl(-) cotransporter -mediated  Cl(-)  uptake.",
    "entity1": "Na(+)/K(+)/2Cl(-) cotransporter",
    "entity2": "Cl(-)"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "These data directly demonstrate that <protein> NKCC1 </protein> is the major <chemical> Cl(-) </chemical> uptake mechanism across the basolateral membrane of acinar cells and is critical for driving saliva secretion in vivo.",
    "original_text": "These data directly demonstrate that  NKCC1  is the major  Cl(-)  uptake mechanism across the basolateral membrane of acinar cells and is critical for driving saliva secretion in vivo.",
    "entity1": "NKCC1",
    "entity2": "Cl(-)"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "UNLABELLED: Apparent <protein> muscarinic acetylcholine (mAch) receptor </protein> occupancy in mouse cerebral cortex, hippocampus, and striatum by <chemical> scopolamine </chemical>, an antagonist, and biperiden, a relatively selective M1 antagonist, was estimated with competitive binding studies using two different radioligands: 3H-N-methyl piperidyl benzilate (3H-NMPB) and 3H-quinuclidinyl benzilate (3H-QNB).",
    "original_text": "UNLABELLED: Apparent  muscarinic acetylcholine (mAch) receptor  occupancy in mouse cerebral cortex, hippocampus, and striatum by  scopolamine , an antagonist, and biperiden, a relatively selective M1 antagonist, was estimated with competitive binding studies using two different radioligands: 3H-N-methyl piperidyl benzilate (3H-NMPB) and 3H-quinuclidinyl benzilate (3H-QNB).",
    "entity1": "muscarinic acetylcholine (mAch) receptor",
    "entity2": "scopolamine"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "UNLABELLED: Apparent muscarinic acetylcholine (mAch) receptor occupancy in mouse cerebral cortex, hippocampus, and striatum by scopolamine, an antagonist, and <protein> biperiden </protein>, a relatively selective <chemical> M1 </chemical> antagonist, was estimated with competitive binding studies using two different radioligands: 3H-N-methyl piperidyl benzilate (3H-NMPB) and 3H-quinuclidinyl benzilate (3H-QNB).",
    "original_text": "UNLABELLED: Apparent muscarinic acetylcholine (mAch) receptor occupancy in mouse cerebral cortex, hippocampus, and striatum by scopolamine, an antagonist, and  biperiden , a relatively selective  M1  antagonist, was estimated with competitive binding studies using two different radioligands: 3H-N-methyl piperidyl benzilate (3H-NMPB) and 3H-quinuclidinyl benzilate (3H-QNB).",
    "entity1": "biperiden",
    "entity2": "M1"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "OBJECTIVES: The hypothesis of the present study was that differences among <protein> dopamine transporter </protein> (DAT) ligands in potency and effectiveness as a positive reinforcers were related to potency and effectiveness as <chemical> DA </chemical> uptake inhibitors.",
    "original_text": "OBJECTIVES: The hypothesis of the present study was that differences among  dopamine transporter  (DAT) ligands in potency and effectiveness as a positive reinforcers were related to potency and effectiveness as  DA  uptake inhibitors.",
    "entity1": "dopamine transporter",
    "entity2": "DA"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "OBJECTIVES: The hypothesis of the present study was that differences among dopamine transporter (<protein> DAT </protein>) ligands in potency and effectiveness as a positive reinforcers were related to potency and effectiveness as <chemical> DA </chemical> uptake inhibitors.",
    "original_text": "OBJECTIVES: The hypothesis of the present study was that differences among dopamine transporter ( DAT ) ligands in potency and effectiveness as a positive reinforcers were related to potency and effectiveness as  DA  uptake inhibitors.",
    "entity1": "DAT",
    "entity2": "DA"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Accordingly, self-administration of a group of local anesthetics that are <protein> DAT </protein> ligands was compared to their effects as <chemical> DA </chemical> uptake blockers in vitro in brain tissue.",
    "original_text": "Accordingly, self-administration of a group of local anesthetics that are  DAT  ligands was compared to their effects as  DA  uptake blockers in vitro in brain tissue.",
    "entity1": "DAT",
    "entity2": "DA"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Contribution of the <protein> Na+-K+-2Cl- cotransporter </protein> NKCC1 to <chemical> Cl- </chemical> secretion in rat OMCD.",
    "original_text": "Contribution of the  Na+-K+-2Cl- cotransporter  NKCC1 to  Cl-  secretion in rat OMCD.",
    "entity1": "Na+-K+-2Cl- cotransporter",
    "entity2": "Cl-"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Contribution of the Na+-K+-2Cl- cotransporter <protein> NKCC1 </protein> to <chemical> Cl- </chemical> secretion in rat OMCD.",
    "original_text": "Contribution of the Na+-K+-2Cl- cotransporter  NKCC1  to  Cl-  secretion in rat OMCD.",
    "entity1": "NKCC1",
    "entity2": "Cl-"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "The purpose of this study was to determine whether rat outer medullary collecting duct (OMCD) secretes Cl- and whether transepithelial Cl- transport occurs, in part, through <protein> Cl- </protein> uptake across the basolateral membrane mediated by <chemical> NKCC1 </chemical> in series with Cl- efflux across the apical membrane.",
    "original_text": "The purpose of this study was to determine whether rat outer medullary collecting duct (OMCD) secretes Cl- and whether transepithelial Cl- transport occurs, in part, through  Cl-  uptake across the basolateral membrane mediated by  NKCC1  in series with Cl- efflux across the apical membrane.",
    "entity1": "Cl-",
    "entity2": "NKCC1"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "The purpose of this study was to determine whether rat outer medullary collecting duct (OMCD) secretes Cl- and whether transepithelial Cl- transport occurs, in part, through Cl- uptake across the basolateral membrane mediated by <protein> NKCC1 </protein> in series with <chemical> Cl- </chemical> efflux across the apical membrane.",
    "original_text": "The purpose of this study was to determine whether rat outer medullary collecting duct (OMCD) secretes Cl- and whether transepithelial Cl- transport occurs, in part, through Cl- uptake across the basolateral membrane mediated by  NKCC1  in series with  Cl-  efflux across the apical membrane.",
    "entity1": "NKCC1",
    "entity2": "Cl-"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Bumetanide-sensitive Cl- secretion was dependent on extracellular Na+ and either K+ or NH, consistent with the ion dependency of <protein> NKCC1 </protein>-mediated <chemical> Cl- </chemical> transport.",
    "original_text": "Bumetanide-sensitive Cl- secretion was dependent on extracellular Na+ and either K+ or NH, consistent with the ion dependency of  NKCC1 -mediated  Cl-  transport.",
    "entity1": "NKCC1",
    "entity2": "Cl-"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "In conclusion, OMCD tubules from deoxycorticosterone pivalate-treated rats secrete <protein> Cl- </protein> into the luminal fluid through <chemical> NKCC1 </chemical>-mediated Cl- uptake across the basolateral membrane in series with Cl- efflux across the apical membrane.",
    "original_text": "In conclusion, OMCD tubules from deoxycorticosterone pivalate-treated rats secrete  Cl-  into the luminal fluid through  NKCC1 -mediated Cl- uptake across the basolateral membrane in series with Cl- efflux across the apical membrane.",
    "entity1": "Cl-",
    "entity2": "NKCC1"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "In conclusion, OMCD tubules from deoxycorticosterone pivalate-treated rats secrete Cl- into the luminal fluid through <protein> NKCC1 </protein>-mediated <chemical> Cl- </chemical> uptake across the basolateral membrane in series with Cl- efflux across the apical membrane.",
    "original_text": "In conclusion, OMCD tubules from deoxycorticosterone pivalate-treated rats secrete Cl- into the luminal fluid through  NKCC1 -mediated  Cl-  uptake across the basolateral membrane in series with Cl- efflux across the apical membrane.",
    "entity1": "NKCC1",
    "entity2": "Cl-"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "In conclusion, OMCD tubules from deoxycorticosterone pivalate-treated rats secrete Cl- into the luminal fluid through <protein> NKCC1 </protein>-mediated Cl- uptake across the basolateral membrane in series with <chemical> Cl- </chemical> efflux across the apical membrane.",
    "original_text": "In conclusion, OMCD tubules from deoxycorticosterone pivalate-treated rats secrete Cl- into the luminal fluid through  NKCC1 -mediated Cl- uptake across the basolateral membrane in series with  Cl-  efflux across the apical membrane.",
    "entity1": "NKCC1",
    "entity2": "Cl-"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "The physiological role of <protein> NKCC1 </protein>-mediated <chemical> Cl- </chemical> uptake remains to be determined.",
    "original_text": "The physiological role of  NKCC1 -mediated  Cl-  uptake remains to be determined.",
    "entity1": "NKCC1",
    "entity2": "Cl-"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "The broad-spectrum anti-emetic activity of <protein> AS-8112 </protein>, a novel dopamine D2, D3 and <chemical> 5-HT3 receptors </chemical> antagonist.",
    "original_text": "The broad-spectrum anti-emetic activity of  AS-8112 , a novel dopamine D2, D3 and  5-HT3 receptors  antagonist.",
    "entity1": "AS-8112",
    "entity2": "5-HT3 receptors"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "In guinea-pig isolated colon, AS-8112 produced a rightward shift of the concentration-response curves of <protein> 2-methyl-5HT </protein>, a <chemical> 5-HT3 receptor </chemical> agonist (pA2 value of 7.04).",
    "original_text": "In guinea-pig isolated colon, AS-8112 produced a rightward shift of the concentration-response curves of  2-methyl-5HT , a  5-HT3 receptor  agonist (pA2 value of 7.04).",
    "entity1": "2-methyl-5HT",
    "entity2": "5-HT3 receptor"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "In guinea-pig isolated colon, <protein> AS-8112 </protein> produced a rightward shift of the concentration-response curves of 2-methyl-5HT, a <chemical> 5-HT3 receptor </chemical> agonist (pA2 value of 7.04).",
    "original_text": "In guinea-pig isolated colon,  AS-8112  produced a rightward shift of the concentration-response curves of 2-methyl-5HT, a  5-HT3 receptor  agonist (pA2 value of 7.04).",
    "entity1": "AS-8112",
    "entity2": "5-HT3 receptor"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Other <protein> 5-HT3 receptor </protein> antagonists also produced such a shift in the following antagonistic-potency order: <chemical> granisetron </chemical>> ondansetron=AS-8112</protein>metoclopramide.",
    "original_text": "Other  5-HT3 receptor  antagonists also produced such a shift in the following antagonistic-potency order:  granisetron > ondansetron=AS-8112metoclopramide.",
    "entity1": "5-HT3 receptor",
    "entity2": "granisetron"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Other <protein> 5-HT3 receptor </protein> antagonists also produced such a shift in the following antagonistic-potency order: granisetron> <chemical> ondansetron </chemical>=AS-8112</protein>metoclopramide.",
    "original_text": "Other  5-HT3 receptor  antagonists also produced such a shift in the following antagonistic-potency order: granisetron>  ondansetron =AS-8112metoclopramide.",
    "entity1": "5-HT3 receptor",
    "entity2": "ondansetron"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Other <protein> 5-HT3 receptor </protein> antagonists also produced such a shift in the following antagonistic-potency order: granisetron> ondansetron=<chemical> AS-8112 </chemical></protein>metoclopramide.",
    "original_text": "Other  5-HT3 receptor  antagonists also produced such a shift in the following antagonistic-potency order: granisetron> ondansetron= AS-8112 metoclopramide.",
    "entity1": "5-HT3 receptor",
    "entity2": "AS-8112"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Other <protein> 5-HT3 receptor </protein> antagonists also produced such a shift in the following antagonistic-potency order: granisetron> ondansetron=AS-8112</protein><chemical> metoclopramide </chemical>.",
    "original_text": "Other  5-HT3 receptor  antagonists also produced such a shift in the following antagonistic-potency order: granisetron> ondansetron=AS-8112 metoclopramide .",
    "entity1": "5-HT3 receptor",
    "entity2": "metoclopramide"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "In mice, AS-8112 (1.0 - 3.0 mg kg(-1) s.c.) potently inhibited hypothermia induced by the <protein> dopamine D3 receptor </protein> agonist; <chemical> R(+)-7-OH-DPAT </chemical> (R(+)-7-hydroxy-2-(N,N-di-n-propylamino)tetraline) (0.3 mg kg(-1) s.c.).",
    "original_text": "In mice, AS-8112 (1.0 - 3.0 mg kg(-1) s.c.) potently inhibited hypothermia induced by the  dopamine D3 receptor  agonist;  R(+)-7-OH-DPAT  (R(+)-7-hydroxy-2-(N,N-di-n-propylamino)tetraline) (0.3 mg kg(-1) s.c.).",
    "entity1": "dopamine D3 receptor",
    "entity2": "R(+)-7-OH-DPAT"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "In mice, AS-8112 (1.0 - 3.0 mg kg(-1) s.c.) potently inhibited hypothermia induced by the <protein> dopamine D3 receptor </protein> agonist; R(+)-7-OH-DPAT (<chemical> R(+)-7-hydroxy-2-(N,N-di-n-propylamino)tetraline </chemical>) (0.3 mg kg(-1) s.c.).",
    "original_text": "In mice, AS-8112 (1.0 - 3.0 mg kg(-1) s.c.) potently inhibited hypothermia induced by the  dopamine D3 receptor  agonist; R(+)-7-OH-DPAT ( R(+)-7-hydroxy-2-(N,N-di-n-propylamino)tetraline ) (0.3 mg kg(-1) s.c.).",
    "entity1": "dopamine D3 receptor",
    "entity2": "R(+)-7-hydroxy-2-(N,N-di-n-propylamino)tetraline"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "In conclusion, <protein> AS-8112 </protein> is a potent dopamine D2, D3 and <chemical> 5-HT3 receptors </chemical> antagonist, and a novel anti-emetic agent with a broad-spectrum of anti-emetic activity.",
    "original_text": "In conclusion,  AS-8112  is a potent dopamine D2, D3 and  5-HT3 receptors  antagonist, and a novel anti-emetic agent with a broad-spectrum of anti-emetic activity.",
    "entity1": "AS-8112",
    "entity2": "5-HT3 receptors"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "It showed high rat lymphoma growth-inhibitory and lytic activity in vitro (IC50 = 0.16 mM), based specifically on inhibition of <protein> x(c) </protein>--mediated <chemical> cystine </chemical> uptake, in contrast to its colonic metabolites, sulfapyridine and 5-aminosalicylic acid.",
    "original_text": "It showed high rat lymphoma growth-inhibitory and lytic activity in vitro (IC50 = 0.16 mM), based specifically on inhibition of  x(c) --mediated  cystine  uptake, in contrast to its colonic metabolites, sulfapyridine and 5-aminosalicylic acid.",
    "entity1": "x(c)",
    "entity2": "cystine"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "The <protein> x(c)- cystine transporter </protein> represents a novel target for sulfasalazine-like drugs with high potential for application in therapy of lymphoblastic and other malignancies dependent on extracellular <chemical> cyst(e)ine </chemical>.",
    "original_text": "The  x(c)- cystine transporter  represents a novel target for sulfasalazine-like drugs with high potential for application in therapy of lymphoblastic and other malignancies dependent on extracellular  cyst(e)ine .",
    "entity1": "x(c)- cystine transporter",
    "entity2": "cyst(e)ine"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "The transport amiloride-sensitive mechanism, that decreased the acidic intracellular pH change occurring in this medium, would correspond to <protein> Na+ </protein>-H+ exchange (<chemical> NHE1 </chemical> isoform).",
    "original_text": "The transport amiloride-sensitive mechanism, that decreased the acidic intracellular pH change occurring in this medium, would correspond to  Na+ -H+ exchange ( NHE1  isoform).",
    "entity1": "Na+",
    "entity2": "NHE1"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "The transport amiloride-sensitive mechanism, that decreased the acidic intracellular pH change occurring in this medium, would correspond to Na+-<protein> H+ </protein> exchange (<chemical> NHE1 </chemical> isoform).",
    "original_text": "The transport amiloride-sensitive mechanism, that decreased the acidic intracellular pH change occurring in this medium, would correspond to Na+- H+  exchange ( NHE1  isoform).",
    "entity1": "H+",
    "entity2": "NHE1"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "The specific activity of only <protein> ornithine aminotransferase </protein> (OAT), the rate-limiting enzyme in the conversion of <chemical> ornithine </chemical> to proline, increased in 2 weeks of hypertrophy.",
    "original_text": "The specific activity of only  ornithine aminotransferase  (OAT), the rate-limiting enzyme in the conversion of  ornithine  to proline, increased in 2 weeks of hypertrophy.",
    "entity1": "ornithine aminotransferase",
    "entity2": "ornithine"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "The specific activity of only ornithine aminotransferase (<protein> OAT </protein>), the rate-limiting enzyme in the conversion of <chemical> ornithine </chemical> to proline, increased in 2 weeks of hypertrophy.",
    "original_text": "The specific activity of only ornithine aminotransferase ( OAT ), the rate-limiting enzyme in the conversion of  ornithine  to proline, increased in 2 weeks of hypertrophy.",
    "entity1": "OAT",
    "entity2": "ornithine"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Acute and chronic PLZ administration increase brain GABA levels, an effect due, at least in part, to an inhibition of the activity of the <protein> GABA </protein> metabolizing enzyme, <chemical> GABA transaminase </chemical> (GABA-T).",
    "original_text": "Acute and chronic PLZ administration increase brain GABA levels, an effect due, at least in part, to an inhibition of the activity of the  GABA  metabolizing enzyme,  GABA transaminase  (GABA-T).",
    "entity1": "GABA",
    "entity2": "GABA transaminase"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Acute and chronic PLZ administration increase brain GABA levels, an effect due, at least in part, to an inhibition of the activity of the <protein> GABA </protein> metabolizing enzyme, GABA transaminase (<chemical> GABA-T </chemical>).",
    "original_text": "Acute and chronic PLZ administration increase brain GABA levels, an effect due, at least in part, to an inhibition of the activity of the  GABA  metabolizing enzyme, GABA transaminase ( GABA-T ).",
    "entity1": "GABA",
    "entity2": "GABA-T"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "As with GABA, the metabolism of <protein> alanine </protein> involves a <chemical> pyridoxal phosphate-dependent transaminase </chemical>.",
    "original_text": "As with GABA, the metabolism of  alanine  involves a  pyridoxal phosphate-dependent transaminase .",
    "entity1": "alanine",
    "entity2": "pyridoxal phosphate-dependent transaminase"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "In the study reported here, the effects of acute PLZ treatment on the levels of various <protein> amino acids </protein>, some of which are also metabolized by <chemical> pyridoxal phosphate-dependent transaminases </chemical> were compared in rat whole brain.",
    "original_text": "In the study reported here, the effects of acute PLZ treatment on the levels of various  amino acids , some of which are also metabolized by  pyridoxal phosphate-dependent transaminases  were compared in rat whole brain.",
    "entity1": "amino acids",
    "entity2": "pyridoxal phosphate-dependent transaminases"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "The elevation in brain <protein> alanine </protein> levels could be explained, at least in part, by a time- and dose-dependent inhibitory effect of PLZ on <chemical> alanine transaminase </chemical> (ALA-T), although as with GABA the increases are higher than expected from the degree of enzyme inhibition produced.",
    "original_text": "The elevation in brain  alanine  levels could be explained, at least in part, by a time- and dose-dependent inhibitory effect of PLZ on  alanine transaminase  (ALA-T), although as with GABA the increases are higher than expected from the degree of enzyme inhibition produced.",
    "entity1": "alanine",
    "entity2": "alanine transaminase"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "The elevation in brain <protein> alanine </protein> levels could be explained, at least in part, by a time- and dose-dependent inhibitory effect of PLZ on alanine transaminase (<chemical> ALA-T </chemical>), although as with GABA the increases are higher than expected from the degree of enzyme inhibition produced.",
    "original_text": "The elevation in brain  alanine  levels could be explained, at least in part, by a time- and dose-dependent inhibitory effect of PLZ on alanine transaminase ( ALA-T ), although as with GABA the increases are higher than expected from the degree of enzyme inhibition produced.",
    "entity1": "alanine",
    "entity2": "ALA-T"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "In addition, we also showed that the elevation in <protein> alanine </protein> levels and the inhibition of <chemical> alanine transaminase </chemical> in the brain are retained after 14 days of PLZ treatment, and that PLZ produces a marked increase in extracellular levels of alanine.",
    "original_text": "In addition, we also showed that the elevation in  alanine  levels and the inhibition of  alanine transaminase  in the brain are retained after 14 days of PLZ treatment, and that PLZ produces a marked increase in extracellular levels of alanine.",
    "entity1": "alanine",
    "entity2": "alanine transaminase"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "A <protein> TXA2 receptor </protein> antagonist (<chemical> S-1452 </chemical>) attenuated the contraction in a concentration-dependent manner.",
    "original_text": "A  TXA2 receptor  antagonist ( S-1452 ) attenuated the contraction in a concentration-dependent manner.",
    "entity1": "TXA2 receptor",
    "entity2": "S-1452"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "A <protein> nicotinic receptor </protein> antagonist (<chemical> hexamethonium </chemical>) attenuated the contraction in part and an alpha-adrenoceptor antagonist (prazosin) nearly abolished the contraction.",
    "original_text": "A  nicotinic receptor  antagonist ( hexamethonium ) attenuated the contraction in part and an alpha-adrenoceptor antagonist (prazosin) nearly abolished the contraction.",
    "entity1": "nicotinic receptor",
    "entity2": "hexamethonium"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "A nicotinic receptor antagonist (hexamethonium) attenuated the contraction in part and an <protein> alpha-adrenoceptor </protein> antagonist (<chemical> prazosin </chemical>) nearly abolished the contraction.",
    "original_text": "A nicotinic receptor antagonist (hexamethonium) attenuated the contraction in part and an  alpha-adrenoceptor  antagonist ( prazosin ) nearly abolished the contraction.",
    "entity1": "alpha-adrenoceptor",
    "entity2": "prazosin"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Non-steroidal anti-inflammatory drugs (NSAIDs) are competitive inhibitors of <protein> cyclooxygenase </protein> (COX), the enzyme that mediates biosynthesis of prostaglandins and thromboxanes from <chemical> arachidonic acid </chemical>.",
    "original_text": "Non-steroidal anti-inflammatory drugs (NSAIDs) are competitive inhibitors of  cyclooxygenase  (COX), the enzyme that mediates biosynthesis of prostaglandins and thromboxanes from  arachidonic acid .",
    "entity1": "cyclooxygenase",
    "entity2": "arachidonic acid"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Non-steroidal anti-inflammatory drugs (NSAIDs) are competitive inhibitors of cyclooxygenase (<protein> COX </protein>), the enzyme that mediates biosynthesis of prostaglandins and thromboxanes from <chemical> arachidonic acid </chemical>.",
    "original_text": "Non-steroidal anti-inflammatory drugs (NSAIDs) are competitive inhibitors of cyclooxygenase ( COX ), the enzyme that mediates biosynthesis of prostaglandins and thromboxanes from  arachidonic acid .",
    "entity1": "COX",
    "entity2": "arachidonic acid"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Olopatadine hydrochloride (<protein> olopatadine </protein>, 11-[(Z)-3-(dimethylamino)propylidene]-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid monohydrochloride) is a novel antiallergic/<chemical> histamine H1-receptor </chemical> antagonistic drug that was synthesized and evaluated in our laboratories.",
    "original_text": "Olopatadine hydrochloride ( olopatadine , 11-[(Z)-3-(dimethylamino)propylidene]-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid monohydrochloride) is a novel antiallergic/ histamine H1-receptor  antagonistic drug that was synthesized and evaluated in our laboratories.",
    "entity1": "olopatadine",
    "entity2": "histamine H1-receptor"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Olopatadine hydrochloride (olopatadine, <protein> 11-[(Z)-3-(dimethylamino)propylidene]-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid monohydrochloride </protein>) is a novel antiallergic/<chemical> histamine H1-receptor </chemical> antagonistic drug that was synthesized and evaluated in our laboratories.",
    "original_text": "Olopatadine hydrochloride (olopatadine,  11-[(Z)-3-(dimethylamino)propylidene]-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid monohydrochloride ) is a novel antiallergic/ histamine H1-receptor  antagonistic drug that was synthesized and evaluated in our laboratories.",
    "entity1": "11-[(Z)-3-(dimethylamino)propylidene]-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid monohydrochloride",
    "entity2": "histamine H1-receptor"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "<protein> Olopatadine hydrochloride </protein> (olopatadine, 11-[(Z)-3-(dimethylamino)propylidene]-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid monohydrochloride) is a novel antiallergic/<chemical> histamine H1-receptor </chemical> antagonistic drug that was synthesized and evaluated in our laboratories.",
    "original_text": " Olopatadine hydrochloride  (olopatadine, 11-[(Z)-3-(dimethylamino)propylidene]-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid monohydrochloride) is a novel antiallergic/ histamine H1-receptor  antagonistic drug that was synthesized and evaluated in our laboratories.",
    "entity1": "Olopatadine hydrochloride",
    "entity2": "histamine H1-receptor"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "<protein> Olopatadine </protein> is a selective <chemical> histamine H1-receptor </chemical> antagonist possessing inhibitory effects on the release of inflammatory lipid mediators such as leukotriene and thromboxane from human polymorphonuclear leukocytes and eosinophils.",
    "original_text": " Olopatadine  is a selective  histamine H1-receptor  antagonist possessing inhibitory effects on the release of inflammatory lipid mediators such as leukotriene and thromboxane from human polymorphonuclear leukocytes and eosinophils.",
    "entity1": "Olopatadine",
    "entity2": "histamine H1-receptor"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Rifampicin (10 micromol/L) inhibited <protein> OATP8 </protein>-mediated <chemical> BSP </chemical> uptake by 50%, whereas inhibition of OATP-C-, OATP-B-, and OATP-A-mediated BSP transport was below 15%.",
    "original_text": "Rifampicin (10 micromol/L) inhibited  OATP8 -mediated  BSP  uptake by 50%, whereas inhibition of OATP-C-, OATP-B-, and OATP-A-mediated BSP transport was below 15%.",
    "entity1": "OATP8",
    "entity2": "BSP"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Rifampicin (10 micromol/L) inhibited OATP8-mediated BSP uptake by 50%, whereas inhibition of <protein> OATP-C </protein>-, OATP-B-, and OATP-A-mediated <chemical> BSP </chemical> transport was below 15%.",
    "original_text": "Rifampicin (10 micromol/L) inhibited OATP8-mediated BSP uptake by 50%, whereas inhibition of  OATP-C -, OATP-B-, and OATP-A-mediated  BSP  transport was below 15%.",
    "entity1": "OATP-C",
    "entity2": "BSP"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Rifampicin (10 micromol/L) inhibited OATP8-mediated BSP uptake by 50%, whereas inhibition of OATP-C-, <protein> OATP-B </protein>-, and OATP-A-mediated <chemical> BSP </chemical> transport was below 15%.",
    "original_text": "Rifampicin (10 micromol/L) inhibited OATP8-mediated BSP uptake by 50%, whereas inhibition of OATP-C-,  OATP-B -, and OATP-A-mediated  BSP  transport was below 15%.",
    "entity1": "OATP-B",
    "entity2": "BSP"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Rifampicin (10 micromol/L) inhibited OATP8-mediated BSP uptake by 50%, whereas inhibition of OATP-C-, OATP-B-, and <protein> OATP-A </protein>-mediated <chemical> BSP </chemical> transport was below 15%.",
    "original_text": "Rifampicin (10 micromol/L) inhibited OATP8-mediated BSP uptake by 50%, whereas inhibition of OATP-C-, OATP-B-, and  OATP-A -mediated  BSP  transport was below 15%.",
    "entity1": "OATP-A",
    "entity2": "BSP"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "100 micromol/L rifampicin inhibited <protein> OATP-C </protein>- and OATP8-, OATP-B- and OATP-A-mediated <chemical> BSP </chemical> uptake by 66%, 96%, 25%, and 49%, respectively.",
    "original_text": "100 micromol/L rifampicin inhibited  OATP-C - and OATP8-, OATP-B- and OATP-A-mediated  BSP  uptake by 66%, 96%, 25%, and 49%, respectively.",
    "entity1": "OATP-C",
    "entity2": "BSP"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "100 micromol/L rifampicin inhibited OATP-C- and <protein> OATP8 </protein>-, OATP-B- and OATP-A-mediated <chemical> BSP </chemical> uptake by 66%, 96%, 25%, and 49%, respectively.",
    "original_text": "100 micromol/L rifampicin inhibited OATP-C- and  OATP8 -, OATP-B- and OATP-A-mediated  BSP  uptake by 66%, 96%, 25%, and 49%, respectively.",
    "entity1": "OATP8",
    "entity2": "BSP"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "100 micromol/L rifampicin inhibited OATP-C- and OATP8-, <protein> OATP-B </protein>- and OATP-A-mediated <chemical> BSP </chemical> uptake by 66%, 96%, 25%, and 49%, respectively.",
    "original_text": "100 micromol/L rifampicin inhibited OATP-C- and OATP8-,  OATP-B - and OATP-A-mediated  BSP  uptake by 66%, 96%, 25%, and 49%, respectively.",
    "entity1": "OATP-B",
    "entity2": "BSP"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "100 micromol/L rifampicin inhibited OATP-C- and OATP8-, OATP-B- and <protein> OATP-A </protein>-mediated <chemical> BSP </chemical> uptake by 66%, 96%, 25%, and 49%, respectively.",
    "original_text": "100 micromol/L rifampicin inhibited OATP-C- and OATP8-, OATP-B- and  OATP-A -mediated  BSP  uptake by 66%, 96%, 25%, and 49%, respectively.",
    "entity1": "OATP-A",
    "entity2": "BSP"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Direct transport of <protein> rifampicin </protein> could be shown for <chemical> OATP-C </chemical> (apparent K(m) value 13 micromol/L) and OATP8 (2.3 micromol/L).",
    "original_text": "Direct transport of  rifampicin  could be shown for  OATP-C  (apparent K(m) value 13 micromol/L) and OATP8 (2.3 micromol/L).",
    "entity1": "rifampicin",
    "entity2": "OATP-C"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Direct transport of <protein> rifampicin </protein> could be shown for OATP-C (apparent K(m) value 13 micromol/L) and <chemical> OATP8 </chemical> (2.3 micromol/L).",
    "original_text": "Direct transport of  rifampicin  could be shown for OATP-C (apparent K(m) value 13 micromol/L) and  OATP8  (2.3 micromol/L).",
    "entity1": "rifampicin",
    "entity2": "OATP8"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "<protein> AMP-activated protein kinase </protein> (AMPK) activity increases in response to depletion of cellular energy stores, and this enzyme has been implicated in the stimulation of <chemical> glucose </chemical> uptake into skeletal muscle and the inhibition of liver gluconeogenesis.",
    "original_text": " AMP-activated protein kinase  (AMPK) activity increases in response to depletion of cellular energy stores, and this enzyme has been implicated in the stimulation of  glucose  uptake into skeletal muscle and the inhibition of liver gluconeogenesis.",
    "entity1": "AMP-activated protein kinase",
    "entity2": "glucose"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "AMP-activated protein kinase (<protein> AMPK </protein>) activity increases in response to depletion of cellular energy stores, and this enzyme has been implicated in the stimulation of <chemical> glucose </chemical> uptake into skeletal muscle and the inhibition of liver gluconeogenesis.",
    "original_text": "AMP-activated protein kinase ( AMPK ) activity increases in response to depletion of cellular energy stores, and this enzyme has been implicated in the stimulation of  glucose  uptake into skeletal muscle and the inhibition of liver gluconeogenesis.",
    "entity1": "AMPK",
    "entity2": "glucose"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "During polyamine catabolism, <protein> spermine </protein> and spermidine are first acetylated by spermidine/spermine N(1)-acetyltransferase (<chemical> SSAT </chemical>) and subsequently oxidized by polyamine oxidase (PAO) to produce spermidine and putrescine, respectively.",
    "original_text": "During polyamine catabolism,  spermine  and spermidine are first acetylated by spermidine/spermine N(1)-acetyltransferase ( SSAT ) and subsequently oxidized by polyamine oxidase (PAO) to produce spermidine and putrescine, respectively.",
    "entity1": "spermine",
    "entity2": "SSAT"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "During polyamine catabolism, <protein> spermine </protein> and spermidine are first acetylated by <chemical> spermidine/spermine N(1)-acetyltransferase </chemical> (SSAT) and subsequently oxidized by polyamine oxidase (PAO) to produce spermidine and putrescine, respectively.",
    "original_text": "During polyamine catabolism,  spermine  and spermidine are first acetylated by  spermidine/spermine N(1)-acetyltransferase  (SSAT) and subsequently oxidized by polyamine oxidase (PAO) to produce spermidine and putrescine, respectively.",
    "entity1": "spermine",
    "entity2": "spermidine/spermine N(1)-acetyltransferase"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "During polyamine catabolism, spermine and <protein> spermidine </protein> are first acetylated by spermidine/spermine N(1)-acetyltransferase (<chemical> SSAT </chemical>) and subsequently oxidized by polyamine oxidase (PAO) to produce spermidine and putrescine, respectively.",
    "original_text": "During polyamine catabolism, spermine and  spermidine  are first acetylated by spermidine/spermine N(1)-acetyltransferase ( SSAT ) and subsequently oxidized by polyamine oxidase (PAO) to produce spermidine and putrescine, respectively.",
    "entity1": "spermidine",
    "entity2": "SSAT"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "During polyamine catabolism, spermine and <protein> spermidine </protein> are first acetylated by <chemical> spermidine/spermine N(1)-acetyltransferase </chemical> (SSAT) and subsequently oxidized by polyamine oxidase (PAO) to produce spermidine and putrescine, respectively.",
    "original_text": "During polyamine catabolism, spermine and  spermidine  are first acetylated by  spermidine/spermine N(1)-acetyltransferase  (SSAT) and subsequently oxidized by polyamine oxidase (PAO) to produce spermidine and putrescine, respectively.",
    "entity1": "spermidine",
    "entity2": "spermidine/spermine N(1)-acetyltransferase"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "During <protein> polyamine </protein> catabolism, spermine and spermidine are first acetylated by spermidine/spermine N(1)-acetyltransferase (<chemical> SSAT </chemical>) and subsequently oxidized by polyamine oxidase (PAO) to produce spermidine and putrescine, respectively.",
    "original_text": "During  polyamine  catabolism, spermine and spermidine are first acetylated by spermidine/spermine N(1)-acetyltransferase ( SSAT ) and subsequently oxidized by polyamine oxidase (PAO) to produce spermidine and putrescine, respectively.",
    "entity1": "polyamine",
    "entity2": "SSAT"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "During <protein> polyamine </protein> catabolism, spermine and spermidine are first acetylated by <chemical> spermidine/spermine N(1)-acetyltransferase </chemical> (SSAT) and subsequently oxidized by polyamine oxidase (PAO) to produce spermidine and putrescine, respectively.",
    "original_text": "During  polyamine  catabolism, spermine and spermidine are first acetylated by  spermidine/spermine N(1)-acetyltransferase  (SSAT) and subsequently oxidized by polyamine oxidase (PAO) to produce spermidine and putrescine, respectively.",
    "entity1": "polyamine",
    "entity2": "spermidine/spermine N(1)-acetyltransferase"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "In attempting to clone the PAO involved in this back-conversion pathway, we encountered an oxidase that preferentially cleaves <protein> spermine </protein> in the absence of prior acetylation by <chemical> SSAT </chemical>.",
    "original_text": "In attempting to clone the PAO involved in this back-conversion pathway, we encountered an oxidase that preferentially cleaves  spermine  in the absence of prior acetylation by  SSAT .",
    "entity1": "spermine",
    "entity2": "SSAT"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Substrate specificity using lysates of oxidase-transfected HEK-293 cells revealed that the newly identified <protein> oxidase </protein> strongly favoured <chemical> spermine </chemical> over N (1)-acetylspermine and that it failed to act on N (1)-acetylspermidine, spermidine or the preferred PAO substrate, N (1), N (12)-diacetylspermine.",
    "original_text": "Substrate specificity using lysates of oxidase-transfected HEK-293 cells revealed that the newly identified  oxidase  strongly favoured  spermine  over N (1)-acetylspermine and that it failed to act on N (1)-acetylspermidine, spermidine or the preferred PAO substrate, N (1), N (12)-diacetylspermine.",
    "entity1": "oxidase",
    "entity2": "spermine"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Substrate specificity using lysates of oxidase-transfected HEK-293 cells revealed that the newly identified <protein> oxidase </protein> strongly favoured spermine over <chemical> N (1)-acetylspermine </chemical> and that it failed to act on N (1)-acetylspermidine, spermidine or the preferred PAO substrate, N (1), N (12)-diacetylspermine.",
    "original_text": "Substrate specificity using lysates of oxidase-transfected HEK-293 cells revealed that the newly identified  oxidase  strongly favoured spermine over  N (1)-acetylspermine  and that it failed to act on N (1)-acetylspermidine, spermidine or the preferred PAO substrate, N (1), N (12)-diacetylspermine.",
    "entity1": "oxidase",
    "entity2": "N (1)-acetylspermine"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Substrate specificity using lysates of oxidase-transfected HEK-293 cells revealed that the newly identified oxidase strongly favoured spermine over N (1)-acetylspermine and that it failed to act on N (1)-acetylspermidine, spermidine or the preferred <protein> PAO </protein> substrate, <chemical> N (1), N (12)-diacetylspermine </chemical>.",
    "original_text": "Substrate specificity using lysates of oxidase-transfected HEK-293 cells revealed that the newly identified oxidase strongly favoured spermine over N (1)-acetylspermine and that it failed to act on N (1)-acetylspermidine, spermidine or the preferred  PAO  substrate,  N (1), N (12)-diacetylspermine .",
    "entity1": "PAO",
    "entity2": "N (1), N (12)-diacetylspermine"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "The PAO inhibitor, MDL-72,527, only partially blocked oxidation of spermine while a previously reported <protein> PAO </protein> substrate, <chemical> N (1)-( n -octanesulphonyl)spermine </chemical>, potently inhibited the reaction.",
    "original_text": "The PAO inhibitor, MDL-72,527, only partially blocked oxidation of spermine while a previously reported  PAO  substrate,  N (1)-( n -octanesulphonyl)spermine , potently inhibited the reaction.",
    "entity1": "PAO",
    "entity2": "N (1)-( n -octanesulphonyl)spermine"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Most halogenated <protein> cysteine S-conjugates </protein> are metabolized by cysteine S-conjugate <chemical> beta-lyases </chemical> to pyruvate, ammonia, and an alpha-chloroenethiolate (with DCVC) or an alpha-difluoroalkylthiolate (with TFEC) that may eliminate halide to give a thioacyl halide, which reacts with epsilon-amino groups of lysine residues in proteins.",
    "original_text": "Most halogenated  cysteine S-conjugates  are metabolized by cysteine S-conjugate  beta-lyases  to pyruvate, ammonia, and an alpha-chloroenethiolate (with DCVC) or an alpha-difluoroalkylthiolate (with TFEC) that may eliminate halide to give a thioacyl halide, which reacts with epsilon-amino groups of lysine residues in proteins.",
    "entity1": "cysteine S-conjugates",
    "entity2": "beta-lyases"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "The juvenile visceral steatosis (jvs) mouse, having a mutation in the <protein> carnitine </protein> transporter gene <chemical> Octn2 </chemical>, is a model of primary systemic carnitine deficiency in humans (SCD, OMIM 212140).",
    "original_text": "The juvenile visceral steatosis (jvs) mouse, having a mutation in the  carnitine  transporter gene  Octn2 , is a model of primary systemic carnitine deficiency in humans (SCD, OMIM 212140).",
    "entity1": "carnitine",
    "entity2": "Octn2"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Reuptake of extracellular <protein> noradrenaline </protein> (NA) into superior cervical ganglion (SCG) neurones is mediated by means of the <chemical> noradrenaline transporter </chemical> (NAT, uptake 1).",
    "original_text": "Reuptake of extracellular  noradrenaline  (NA) into superior cervical ganglion (SCG) neurones is mediated by means of the  noradrenaline transporter  (NAT, uptake 1).",
    "entity1": "noradrenaline",
    "entity2": "noradrenaline transporter"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Reuptake of extracellular <protein> noradrenaline </protein> (NA) into superior cervical ganglion (SCG) neurones is mediated by means of the noradrenaline transporter (<chemical> NAT </chemical>, uptake 1).",
    "original_text": "Reuptake of extracellular  noradrenaline  (NA) into superior cervical ganglion (SCG) neurones is mediated by means of the noradrenaline transporter ( NAT , uptake 1).",
    "entity1": "noradrenaline",
    "entity2": "NAT"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Reuptake of extracellular noradrenaline (<protein> NA </protein>) into superior cervical ganglion (SCG) neurones is mediated by means of the <chemical> noradrenaline transporter </chemical> (NAT, uptake 1).",
    "original_text": "Reuptake of extracellular noradrenaline ( NA ) into superior cervical ganglion (SCG) neurones is mediated by means of the  noradrenaline transporter  (NAT, uptake 1).",
    "entity1": "NA",
    "entity2": "noradrenaline transporter"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Reuptake of extracellular noradrenaline (<protein> NA </protein>) into superior cervical ganglion (SCG) neurones is mediated by means of the noradrenaline transporter (<chemical> NAT </chemical>, uptake 1).",
    "original_text": "Reuptake of extracellular noradrenaline ( NA ) into superior cervical ganglion (SCG) neurones is mediated by means of the noradrenaline transporter ( NAT , uptake 1).",
    "entity1": "NA",
    "entity2": "NAT"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "The outflow of <protein> [3H]-MPP+ </protein> was significantly enhanced by MPP+, guanidine, choline and amantadine as potential substrates for <chemical> OCT </chemical>-related transmembrane transporters.",
    "original_text": "The outflow of  [3H]-MPP+  was significantly enhanced by MPP+, guanidine, choline and amantadine as potential substrates for  OCT -related transmembrane transporters.",
    "entity1": "[3H]-MPP+",
    "entity2": "OCT"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "The outflow of <protein> [3H]-MPP+ </protein> was significantly enhanced by MPP+, guanidine, choline and amantadine as potential substrates for OCT-related <chemical> transmembrane transporters </chemical>.",
    "original_text": "The outflow of  [3H]-MPP+  was significantly enhanced by MPP+, guanidine, choline and amantadine as potential substrates for OCT-related  transmembrane transporters .",
    "entity1": "[3H]-MPP+",
    "entity2": "transmembrane transporters"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "The outflow of [3H]-MPP+ was significantly enhanced by <protein> MPP+ </protein>, guanidine, choline and amantadine as potential substrates for <chemical> OCT </chemical>-related transmembrane transporters.",
    "original_text": "The outflow of [3H]-MPP+ was significantly enhanced by  MPP+ , guanidine, choline and amantadine as potential substrates for  OCT -related transmembrane transporters.",
    "entity1": "MPP+",
    "entity2": "OCT"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "The outflow of [3H]-MPP+ was significantly enhanced by <protein> MPP+ </protein>, guanidine, choline and amantadine as potential substrates for OCT-related <chemical> transmembrane transporters </chemical>.",
    "original_text": "The outflow of [3H]-MPP+ was significantly enhanced by  MPP+ , guanidine, choline and amantadine as potential substrates for OCT-related  transmembrane transporters .",
    "entity1": "MPP+",
    "entity2": "transmembrane transporters"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "The outflow of [3H]-MPP+ was significantly enhanced by MPP+, <protein> guanidine </protein>, choline and amantadine as potential substrates for <chemical> OCT </chemical>-related transmembrane transporters.",
    "original_text": "The outflow of [3H]-MPP+ was significantly enhanced by MPP+,  guanidine , choline and amantadine as potential substrates for  OCT -related transmembrane transporters.",
    "entity1": "guanidine",
    "entity2": "OCT"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "The outflow of [3H]-MPP+ was significantly enhanced by MPP+, <protein> guanidine </protein>, choline and amantadine as potential substrates for OCT-related <chemical> transmembrane transporters </chemical>.",
    "original_text": "The outflow of [3H]-MPP+ was significantly enhanced by MPP+,  guanidine , choline and amantadine as potential substrates for OCT-related  transmembrane transporters .",
    "entity1": "guanidine",
    "entity2": "transmembrane transporters"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "The outflow of [3H]-MPP+ was significantly enhanced by MPP+, guanidine, <protein> choline </protein> and amantadine as potential substrates for <chemical> OCT </chemical>-related transmembrane transporters.",
    "original_text": "The outflow of [3H]-MPP+ was significantly enhanced by MPP+, guanidine,  choline  and amantadine as potential substrates for  OCT -related transmembrane transporters.",
    "entity1": "choline",
    "entity2": "OCT"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "The outflow of [3H]-MPP+ was significantly enhanced by MPP+, guanidine, <protein> choline </protein> and amantadine as potential substrates for OCT-related <chemical> transmembrane transporters </chemical>.",
    "original_text": "The outflow of [3H]-MPP+ was significantly enhanced by MPP+, guanidine,  choline  and amantadine as potential substrates for OCT-related  transmembrane transporters .",
    "entity1": "choline",
    "entity2": "transmembrane transporters"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "The outflow of [3H]-MPP+ was significantly enhanced by MPP+, guanidine, choline and <protein> amantadine </protein> as potential substrates for <chemical> OCT </chemical>-related transmembrane transporters.",
    "original_text": "The outflow of [3H]-MPP+ was significantly enhanced by MPP+, guanidine, choline and  amantadine  as potential substrates for  OCT -related transmembrane transporters.",
    "entity1": "amantadine",
    "entity2": "OCT"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "The outflow of [3H]-MPP+ was significantly enhanced by MPP+, guanidine, choline and <protein> amantadine </protein> as potential substrates for OCT-related <chemical> transmembrane transporters </chemical>.",
    "original_text": "The outflow of [3H]-MPP+ was significantly enhanced by MPP+, guanidine, choline and  amantadine  as potential substrates for OCT-related  transmembrane transporters .",
    "entity1": "amantadine",
    "entity2": "transmembrane transporters"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "However, desipramine at a low concentration essentially blocked the radioactive outflow induced by all of these substances with the exception of <protein> MPP+ </protein>, indicating the <chemical> NAT </chemical> and not an OCT as their primary site of action.",
    "original_text": "However, desipramine at a low concentration essentially blocked the radioactive outflow induced by all of these substances with the exception of  MPP+ , indicating the  NAT  and not an OCT as their primary site of action.",
    "entity1": "MPP+",
    "entity2": "NAT"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Our observations indicate an <protein> OCT </protein>-mediated transmembrane transport of <chemical> [3H]-MPP+ </chemical>.",
    "original_text": "Our observations indicate an  OCT -mediated transmembrane transport of  [3H]-MPP+ .",
    "entity1": "OCT",
    "entity2": "[3H]-MPP+"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Amongst the three <protein> OCTs </protein> expressed in the SCG, OCT3 best fits the profile of substrates and antagonists that cause trans-stimulation and trans-inhibition, respectively, of <chemical> [3H]-MPP+ </chemical> release.",
    "original_text": "Amongst the three  OCTs  expressed in the SCG, OCT3 best fits the profile of substrates and antagonists that cause trans-stimulation and trans-inhibition, respectively, of  [3H]-MPP+  release.",
    "entity1": "OCTs",
    "entity2": "[3H]-MPP+"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Amongst the three OCTs expressed in the SCG, <protein> OCT3 </protein> best fits the profile of substrates and antagonists that cause trans-stimulation and trans-inhibition, respectively, of <chemical> [3H]-MPP+ </chemical> release.",
    "original_text": "Amongst the three OCTs expressed in the SCG,  OCT3  best fits the profile of substrates and antagonists that cause trans-stimulation and trans-inhibition, respectively, of  [3H]-MPP+  release.",
    "entity1": "OCT3",
    "entity2": "[3H]-MPP+"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Practical asymmetric synthesis of <protein> aprepitant </protein>, a potent human <chemical> NK-1 receptor </chemical> antagonist, via a stereoselective Lewis acid-catalyzed trans acetalization reaction.",
    "original_text": "Practical asymmetric synthesis of  aprepitant , a potent human  NK-1 receptor  antagonist, via a stereoselective Lewis acid-catalyzed trans acetalization reaction.",
    "entity1": "aprepitant",
    "entity2": "NK-1 receptor"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "A streamlined and high-yielding synthesis of <protein> aprepitant </protein> (1), a potent <chemical> substance P (SP) receptor </chemical> antagonist, is described.",
    "original_text": "A streamlined and high-yielding synthesis of  aprepitant  (1), a potent  substance P (SP) receptor  antagonist, is described.",
    "entity1": "aprepitant",
    "entity2": "substance P (SP) receptor"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Pentosan polysulfate <protein> sodium </protein> (PPS) has been shown to exert antitumor activity by antagonizing the binding of <chemical> bFGF </chemical> to cell surface receptors.",
    "original_text": "Pentosan polysulfate  sodium  (PPS) has been shown to exert antitumor activity by antagonizing the binding of  bFGF  to cell surface receptors.",
    "entity1": "sodium",
    "entity2": "bFGF"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "These findings suggest that <protein> RhBG </protein> and RhCG may play important and cell-specific roles in <chemical> ammonium </chemical> transport and signaling in these regions of the kidney.",
    "original_text": "These findings suggest that  RhBG  and RhCG may play important and cell-specific roles in  ammonium  transport and signaling in these regions of the kidney.",
    "entity1": "RhBG",
    "entity2": "ammonium"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "These findings suggest that RhBG and <protein> RhCG </protein> may play important and cell-specific roles in <chemical> ammonium </chemical> transport and signaling in these regions of the kidney.",
    "original_text": "These findings suggest that RhBG and  RhCG  may play important and cell-specific roles in  ammonium  transport and signaling in these regions of the kidney.",
    "entity1": "RhCG",
    "entity2": "ammonium"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "<protein> PDE5 </protein> is the predominant PDE in the corpus cavernosum, and <chemical> cGMP </chemical> is its primary substrate.",
    "original_text": " PDE5  is the predominant PDE in the corpus cavernosum, and  cGMP  is its primary substrate.",
    "entity1": "PDE5",
    "entity2": "cGMP"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "PDE5 is the predominant <protein> PDE </protein> in the corpus cavernosum, and <chemical> cGMP </chemical> is its primary substrate.",
    "original_text": "PDE5 is the predominant  PDE  in the corpus cavernosum, and  cGMP  is its primary substrate.",
    "entity1": "PDE",
    "entity2": "cGMP"
  },
  {
    "_id": 1,
    "label": "Upregulator",
    "text": "However, when coapplied with 10 micro m GABA, <protein> ivermectin </protein> potentiated the GABA-evoked current of the <chemical> GAB-1 </chemical>/HG1A receptor, but attenuated the GABA response of the GAB-1/HG1E receptor.",
    "original_text": "However, when coapplied with 10 micro m GABA,  ivermectin  potentiated the GABA-evoked current of the  GAB-1 /HG1A receptor, but attenuated the GABA response of the GAB-1/HG1E receptor.",
    "entity1": "ivermectin",
    "entity2": "GAB-1"
  },
  {
    "_id": 1,
    "label": "Upregulator",
    "text": "However, when coapplied with 10 micro m GABA, <protein> ivermectin </protein> potentiated the GABA-evoked current of the GAB-1/<chemical> HG1A </chemical> receptor, but attenuated the GABA response of the GAB-1/HG1E receptor.",
    "original_text": "However, when coapplied with 10 micro m GABA,  ivermectin  potentiated the GABA-evoked current of the GAB-1/ HG1A  receptor, but attenuated the GABA response of the GAB-1/HG1E receptor.",
    "entity1": "ivermectin",
    "entity2": "HG1A"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "However, when coapplied with 10 micro m GABA, <protein> ivermectin </protein> potentiated the GABA-evoked current of the GAB-1/HG1A receptor, but attenuated the GABA response of the <chemical> GAB-1 </chemical>/HG1E receptor.",
    "original_text": "However, when coapplied with 10 micro m GABA,  ivermectin  potentiated the GABA-evoked current of the GAB-1/HG1A receptor, but attenuated the GABA response of the  GAB-1 /HG1E receptor.",
    "entity1": "ivermectin",
    "entity2": "GAB-1"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "However, when coapplied with 10 micro m GABA, <protein> ivermectin </protein> potentiated the GABA-evoked current of the GAB-1/HG1A receptor, but attenuated the GABA response of the GAB-1/<chemical> HG1E </chemical> receptor.",
    "original_text": "However, when coapplied with 10 micro m GABA,  ivermectin  potentiated the GABA-evoked current of the GAB-1/HG1A receptor, but attenuated the GABA response of the GAB-1/ HG1E  receptor.",
    "entity1": "ivermectin",
    "entity2": "HG1E"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "<protein> Yohimbine </protein> is a potent and selective <chemical> alpha2- versus alpha1-adrenoceptor </chemical> antagonist.",
    "original_text": " Yohimbine  is a potent and selective  alpha2- versus alpha1-adrenoceptor  antagonist.",
    "entity1": "Yohimbine",
    "entity2": "alpha2- versus alpha1-adrenoceptor"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "Plasmacytoid dendritic cells produce cytokines and mature in response to the <protein> TLR7 </protein> agonists, imiquimod and <chemical> resiquimod </chemical>.",
    "original_text": "Plasmacytoid dendritic cells produce cytokines and mature in response to the  TLR7  agonists, imiquimod and  resiquimod .",
    "entity1": "TLR7",
    "entity2": "resiquimod"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "Plasmacytoid dendritic cells produce cytokines and mature in response to the <protein> TLR7 </protein> agonists, <chemical> imiquimod </chemical> and resiquimod.",
    "original_text": "Plasmacytoid dendritic cells produce cytokines and mature in response to the  TLR7  agonists,  imiquimod  and resiquimod.",
    "entity1": "TLR7",
    "entity2": "imiquimod"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "The immune response modifiers, <protein> imiquimod </protein> and resiquimod, are <chemical> TLR7 </chemical> agonists that induce type I interferon in numerous species, including humans.",
    "original_text": "The immune response modifiers,  imiquimod  and resiquimod, are  TLR7  agonists that induce type I interferon in numerous species, including humans.",
    "entity1": "imiquimod",
    "entity2": "TLR7"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "The immune response modifiers, imiquimod and <protein> resiquimod </protein>, are <chemical> TLR7 </chemical> agonists that induce type I interferon in numerous species, including humans.",
    "original_text": "The immune response modifiers, imiquimod and  resiquimod , are  TLR7  agonists that induce type I interferon in numerous species, including humans.",
    "entity1": "resiquimod",
    "entity2": "TLR7"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "Here, we characterize the activation of human pDC with the <protein> TLR7 </protein> agonists <chemical> imiquimod </chemical> and resiquimod.",
    "original_text": "Here, we characterize the activation of human pDC with the  TLR7  agonists  imiquimod  and resiquimod.",
    "entity1": "TLR7",
    "entity2": "imiquimod"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "Here, we characterize the activation of human pDC with the <protein> TLR7 </protein> agonists imiquimod and <chemical> resiquimod </chemical>.",
    "original_text": "Here, we characterize the activation of human pDC with the  TLR7  agonists imiquimod and  resiquimod .",
    "entity1": "TLR7",
    "entity2": "resiquimod"
  },
  {
    "_id": 1,
    "label": "Upregulator",
    "text": "Induction of <protein> heat shock proteins </protein> (HSPs) by <chemical> sodium arsenite </chemical> in cultured astrocytes and reduction of hydrogen peroxide-induced cell death.",
    "original_text": "Induction of  heat shock proteins  (HSPs) by  sodium arsenite  in cultured astrocytes and reduction of hydrogen peroxide-induced cell death.",
    "entity1": "heat shock proteins",
    "entity2": "sodium arsenite"
  },
  {
    "_id": 1,
    "label": "Upregulator",
    "text": "Induction of heat shock proteins (<protein> HSPs </protein>) by <chemical> sodium arsenite </chemical> in cultured astrocytes and reduction of hydrogen peroxide-induced cell death.",
    "original_text": "Induction of heat shock proteins ( HSPs ) by  sodium arsenite  in cultured astrocytes and reduction of hydrogen peroxide-induced cell death.",
    "entity1": "HSPs",
    "entity2": "sodium arsenite"
  },
  {
    "_id": 1,
    "label": "Upregulator",
    "text": "<protein> Arsenite </protein> triggered strong induction of <chemical> HSPs </chemical>, which was prevented by 1 micro g/mL cycloheximide (CXH).",
    "original_text": " Arsenite  triggered strong induction of  HSPs , which was prevented by 1 micro g/mL cycloheximide (CXH).",
    "entity1": "Arsenite",
    "entity2": "HSPs"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "Arsenite triggered strong induction of <protein> HSPs </protein>, which was prevented by 1 micro g/mL <chemical> cycloheximide </chemical> (CXH).",
    "original_text": "Arsenite triggered strong induction of  HSPs , which was prevented by 1 micro g/mL  cycloheximide  (CXH).",
    "entity1": "HSPs",
    "entity2": "cycloheximide"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "Arsenite triggered strong induction of <protein> HSPs </protein>, which was prevented by 1 micro g/mL cycloheximide (<chemical> CXH </chemical>).",
    "original_text": "Arsenite triggered strong induction of  HSPs , which was prevented by 1 micro g/mL cycloheximide ( CXH ).",
    "entity1": "HSPs",
    "entity2": "CXH"
  },
  {
    "_id": 1,
    "label": "Upregulator",
    "text": "The results show that transient <protein> arsenite </protein> pre-treatment induces <chemical> Hsp72 </chemical>, HO-1 and, to a lesser extent, Hsp27; it reduces H2O2-induced astrocyte death; and it causes selective activation of Akt following H2O2.",
    "original_text": "The results show that transient  arsenite  pre-treatment induces  Hsp72 , HO-1 and, to a lesser extent, Hsp27; it reduces H2O2-induced astrocyte death; and it causes selective activation of Akt following H2O2.",
    "entity1": "arsenite",
    "entity2": "Hsp72"
  },
  {
    "_id": 1,
    "label": "Upregulator",
    "text": "The results show that transient <protein> arsenite </protein> pre-treatment induces Hsp72, <chemical> HO-1 </chemical> and, to a lesser extent, Hsp27; it reduces H2O2-induced astrocyte death; and it causes selective activation of Akt following H2O2.",
    "original_text": "The results show that transient  arsenite  pre-treatment induces Hsp72,  HO-1  and, to a lesser extent, Hsp27; it reduces H2O2-induced astrocyte death; and it causes selective activation of Akt following H2O2.",
    "entity1": "arsenite",
    "entity2": "HO-1"
  },
  {
    "_id": 1,
    "label": "Upregulator",
    "text": "The results show that transient <protein> arsenite </protein> pre-treatment induces Hsp72, HO-1 and, to a lesser extent, <chemical> Hsp27 </chemical>; it reduces H2O2-induced astrocyte death; and it causes selective activation of Akt following H2O2.",
    "original_text": "The results show that transient  arsenite  pre-treatment induces Hsp72, HO-1 and, to a lesser extent,  Hsp27 ; it reduces H2O2-induced astrocyte death; and it causes selective activation of Akt following H2O2.",
    "entity1": "arsenite",
    "entity2": "Hsp27"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Acetylcholinesterase (<protein> AChE </protein>) predominates in the healthy brain, with butyrylcholinesterase (BuChE) considered to play a minor role in regulating brain <chemical> acetylcholine </chemical> (ACh) levels.",
    "original_text": "Acetylcholinesterase ( AChE ) predominates in the healthy brain, with butyrylcholinesterase (BuChE) considered to play a minor role in regulating brain  acetylcholine  (ACh) levels.",
    "entity1": "AChE",
    "entity2": "acetylcholine"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Acetylcholinesterase (AChE) predominates in the healthy brain, with <protein> butyrylcholinesterase </protein> (BuChE) considered to play a minor role in regulating brain <chemical> acetylcholine </chemical> (ACh) levels.",
    "original_text": "Acetylcholinesterase (AChE) predominates in the healthy brain, with  butyrylcholinesterase  (BuChE) considered to play a minor role in regulating brain  acetylcholine  (ACh) levels.",
    "entity1": "butyrylcholinesterase",
    "entity2": "acetylcholine"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Acetylcholinesterase (AChE) predominates in the healthy brain, with butyrylcholinesterase (<protein> BuChE </protein>) considered to play a minor role in regulating brain <chemical> acetylcholine </chemical> (ACh) levels.",
    "original_text": "Acetylcholinesterase (AChE) predominates in the healthy brain, with butyrylcholinesterase ( BuChE ) considered to play a minor role in regulating brain  acetylcholine  (ACh) levels.",
    "entity1": "BuChE",
    "entity2": "acetylcholine"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "<protein> Acetylcholinesterase </protein> (AChE) predominates in the healthy brain, with butyrylcholinesterase (BuChE) considered to play a minor role in regulating brain <chemical> acetylcholine </chemical> (ACh) levels.",
    "original_text": " Acetylcholinesterase  (AChE) predominates in the healthy brain, with butyrylcholinesterase (BuChE) considered to play a minor role in regulating brain  acetylcholine  (ACh) levels.",
    "entity1": "Acetylcholinesterase",
    "entity2": "acetylcholine"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Acetylcholinesterase (<protein> AChE </protein>) predominates in the healthy brain, with butyrylcholinesterase (BuChE) considered to play a minor role in regulating brain acetylcholine (<chemical> ACh </chemical>) levels.",
    "original_text": "Acetylcholinesterase ( AChE ) predominates in the healthy brain, with butyrylcholinesterase (BuChE) considered to play a minor role in regulating brain acetylcholine ( ACh ) levels.",
    "entity1": "AChE",
    "entity2": "ACh"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Acetylcholinesterase (AChE) predominates in the healthy brain, with <protein> butyrylcholinesterase </protein> (BuChE) considered to play a minor role in regulating brain acetylcholine (<chemical> ACh </chemical>) levels.",
    "original_text": "Acetylcholinesterase (AChE) predominates in the healthy brain, with  butyrylcholinesterase  (BuChE) considered to play a minor role in regulating brain acetylcholine ( ACh ) levels.",
    "entity1": "butyrylcholinesterase",
    "entity2": "ACh"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Acetylcholinesterase (AChE) predominates in the healthy brain, with butyrylcholinesterase (<protein> BuChE </protein>) considered to play a minor role in regulating brain acetylcholine (<chemical> ACh </chemical>) levels.",
    "original_text": "Acetylcholinesterase (AChE) predominates in the healthy brain, with butyrylcholinesterase ( BuChE ) considered to play a minor role in regulating brain acetylcholine ( ACh ) levels.",
    "entity1": "BuChE",
    "entity2": "ACh"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "<protein> Acetylcholinesterase </protein> (AChE) predominates in the healthy brain, with butyrylcholinesterase (BuChE) considered to play a minor role in regulating brain acetylcholine (<chemical> ACh </chemical>) levels.",
    "original_text": " Acetylcholinesterase  (AChE) predominates in the healthy brain, with butyrylcholinesterase (BuChE) considered to play a minor role in regulating brain acetylcholine ( ACh ) levels.",
    "entity1": "Acetylcholinesterase",
    "entity2": "ACh"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "<protein> Angiotensin AT1 receptor </protein> antagonist <chemical> losartan </chemical> and the defence reaction in the anaesthetised rat.",
    "original_text": " Angiotensin AT1 receptor  antagonist  losartan  and the defence reaction in the anaesthetised rat.",
    "entity1": "Angiotensin AT1 receptor",
    "entity2": "losartan"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "The potent anabolic effects of the <protein> beta 2-adrenoceptor </protein> agonist <chemical> clenbuterol </chemical> on skeletal muscle have been reported to be independent of actions on beta-adrenoceptors.",
    "original_text": "The potent anabolic effects of the  beta 2-adrenoceptor  agonist  clenbuterol  on skeletal muscle have been reported to be independent of actions on beta-adrenoceptors.",
    "entity1": "beta 2-adrenoceptor",
    "entity2": "clenbuterol"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "These effects were not mimicked by oral administration of the <protein> beta 2-adrenoceptor </protein> agonist <chemical> salbutamol </chemical> even at high dose (52 mg/kg diet), and the effects of clenbuterol were not inhibited by addition of DL-propranolol (200 mg/kg diet).",
    "original_text": "These effects were not mimicked by oral administration of the  beta 2-adrenoceptor  agonist  salbutamol  even at high dose (52 mg/kg diet), and the effects of clenbuterol were not inhibited by addition of DL-propranolol (200 mg/kg diet).",
    "entity1": "beta 2-adrenoceptor",
    "entity2": "salbutamol"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "These effects were not mimicked by oral administration of the <protein> beta 2-adrenoceptor </protein> agonist salbutamol even at high dose (52 mg/kg diet), and the effects of <chemical> clenbuterol </chemical> were not inhibited by addition of DL-propranolol (200 mg/kg diet).",
    "original_text": "These effects were not mimicked by oral administration of the  beta 2-adrenoceptor  agonist salbutamol even at high dose (52 mg/kg diet), and the effects of  clenbuterol  were not inhibited by addition of DL-propranolol (200 mg/kg diet).",
    "entity1": "beta 2-adrenoceptor",
    "entity2": "clenbuterol"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "In the hot-plate test in mice, the antinociceptive action of the <protein> alpha 2-adrenoceptor </protein> agonist, <chemical> UK 14,304 </chemical>, was abolished by the alpha 2-adrenoceptor antagonist, idazoxan, the potent alpha 2A-adrenoceptor antagonist, RX 821002 and the preferential alpha 2A-adrenoceptor antagonist, BRL 44408.",
    "original_text": "In the hot-plate test in mice, the antinociceptive action of the  alpha 2-adrenoceptor  agonist,  UK 14,304 , was abolished by the alpha 2-adrenoceptor antagonist, idazoxan, the potent alpha 2A-adrenoceptor antagonist, RX 821002 and the preferential alpha 2A-adrenoceptor antagonist, BRL 44408.",
    "entity1": "alpha 2-adrenoceptor",
    "entity2": "UK 14,304"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "In the hot-plate test in mice, the antinociceptive action of the alpha 2-adrenoceptor agonist, UK 14,304, was abolished by the <protein> alpha 2-adrenoceptor </protein> antagonist, <chemical> idazoxan </chemical>, the potent alpha 2A-adrenoceptor antagonist, RX 821002 and the preferential alpha 2A-adrenoceptor antagonist, BRL 44408.",
    "original_text": "In the hot-plate test in mice, the antinociceptive action of the alpha 2-adrenoceptor agonist, UK 14,304, was abolished by the  alpha 2-adrenoceptor  antagonist,  idazoxan , the potent alpha 2A-adrenoceptor antagonist, RX 821002 and the preferential alpha 2A-adrenoceptor antagonist, BRL 44408.",
    "entity1": "alpha 2-adrenoceptor",
    "entity2": "idazoxan"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "In the hot-plate test in mice, the antinociceptive action of the alpha 2-adrenoceptor agonist, UK 14,304, was abolished by the alpha 2-adrenoceptor antagonist, idazoxan, the potent <protein> alpha 2A-adrenoceptor </protein> antagonist, <chemical> RX 821002 </chemical> and the preferential alpha 2A-adrenoceptor antagonist, BRL 44408.",
    "original_text": "In the hot-plate test in mice, the antinociceptive action of the alpha 2-adrenoceptor agonist, UK 14,304, was abolished by the alpha 2-adrenoceptor antagonist, idazoxan, the potent  alpha 2A-adrenoceptor  antagonist,  RX 821002  and the preferential alpha 2A-adrenoceptor antagonist, BRL 44408.",
    "entity1": "alpha 2A-adrenoceptor",
    "entity2": "RX 821002"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "In the hot-plate test in mice, the antinociceptive action of the alpha 2-adrenoceptor agonist, UK 14,304, was abolished by the alpha 2-adrenoceptor antagonist, idazoxan, the potent alpha 2A-adrenoceptor antagonist, RX 821002 and the preferential <protein> alpha 2A-adrenoceptor </protein> antagonist, <chemical> BRL 44408 </chemical>.",
    "original_text": "In the hot-plate test in mice, the antinociceptive action of the alpha 2-adrenoceptor agonist, UK 14,304, was abolished by the alpha 2-adrenoceptor antagonist, idazoxan, the potent alpha 2A-adrenoceptor antagonist, RX 821002 and the preferential  alpha 2A-adrenoceptor  antagonist,  BRL 44408 .",
    "entity1": "alpha 2A-adrenoceptor",
    "entity2": "BRL 44408"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "The preferential <protein> alpha 2A-adrenoceptor </protein> partial agonist, <chemical> guanfacine </chemical>, partially inhibited UK 14,304-induced antinociception.",
    "original_text": "The preferential  alpha 2A-adrenoceptor  partial agonist,  guanfacine , partially inhibited UK 14,304-induced antinociception.",
    "entity1": "alpha 2A-adrenoceptor",
    "entity2": "guanfacine"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "The preferential <protein> alpha 2A-adrenoceptor </protein> partial agonist, guanfacine, partially inhibited <chemical> UK 14,304 </chemical>-induced antinociception.",
    "original_text": "The preferential  alpha 2A-adrenoceptor  partial agonist, guanfacine, partially inhibited  UK 14,304 -induced antinociception.",
    "entity1": "alpha 2A-adrenoceptor",
    "entity2": "UK 14,304"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "<protein> SDH </protein> (L-serine dehydratase, EC 4.3.1.17) catalyzes the pyridoxal 5'-phosphate (PLP)-dependent dehydration of <chemical> L-serine </chemical> to yield pyruvate and ammonia.",
    "original_text": " SDH  (L-serine dehydratase, EC 4.3.1.17) catalyzes the pyridoxal 5'-phosphate (PLP)-dependent dehydration of  L-serine  to yield pyruvate and ammonia.",
    "entity1": "SDH",
    "entity2": "L-serine"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "SDH (L-serine dehydratase, <protein> EC 4.3.1.17 </protein>) catalyzes the pyridoxal 5'-phosphate (PLP)-dependent dehydration of <chemical> L-serine </chemical> to yield pyruvate and ammonia.",
    "original_text": "SDH (L-serine dehydratase,  EC 4.3.1.17 ) catalyzes the pyridoxal 5'-phosphate (PLP)-dependent dehydration of  L-serine  to yield pyruvate and ammonia.",
    "entity1": "EC 4.3.1.17",
    "entity2": "L-serine"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "SDH <protein> (L-serine dehydratase </protein>, EC 4.3.1.17) catalyzes the pyridoxal 5'-phosphate (PLP)-dependent dehydration of <chemical> L-serine </chemical> to yield pyruvate and ammonia.",
    "original_text": "SDH  (L-serine dehydratase , EC 4.3.1.17) catalyzes the pyridoxal 5'-phosphate (PLP)-dependent dehydration of  L-serine  to yield pyruvate and ammonia.",
    "entity1": "(L-serine dehydratase",
    "entity2": "L-serine"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Formation of pyruvate by <protein> SDH </protein> is a two-step reaction in which the hydroxyl group of serine is cleaved to produce <chemical> aminoacrylate </chemical>, and then the aminoacrylate is deaminated by nonenzymatic hydrolysis to produce pyruvate.",
    "original_text": "Formation of pyruvate by  SDH  is a two-step reaction in which the hydroxyl group of serine is cleaved to produce  aminoacrylate , and then the aminoacrylate is deaminated by nonenzymatic hydrolysis to produce pyruvate.",
    "entity1": "SDH",
    "entity2": "aminoacrylate"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "(-)-Isoprenaline and a nonconventional <protein> beta(3)-adrenoceptor </protein> agonist, <chemical> (+/-)-[4-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]-1,3-dihydro-2H-benzimida zol-2-one] hydrochloride </chemical> ((+/-)-CGP12177A), induced concentration-dependent relaxation of (-)-phenylephrine (0.3 microM) preconstricted spiral preparations.",
    "original_text": "(-)-Isoprenaline and a nonconventional  beta(3)-adrenoceptor  agonist,  (+/-)-[4-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]-1,3-dihydro-2H-benzimida zol-2-one] hydrochloride  ((+/-)-CGP12177A), induced concentration-dependent relaxation of (-)-phenylephrine (0.3 microM) preconstricted spiral preparations.",
    "entity1": "beta(3)-adrenoceptor",
    "entity2": "(+/-)-[4-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]-1,3-dihydro-2H-benzimida zol-2-one] hydrochloride"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "(-)-Isoprenaline and a nonconventional <protein> beta(3)-adrenoceptor </protein> agonist, (+/-)-[4-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]-1,3-dihydro-2H-benzimida zol-2-one] hydrochloride (<chemical> (+/-)-CGP12177A </chemical>), induced concentration-dependent relaxation of (-)-phenylephrine (0.3 microM) preconstricted spiral preparations.",
    "original_text": "(-)-Isoprenaline and a nonconventional  beta(3)-adrenoceptor  agonist, (+/-)-[4-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]-1,3-dihydro-2H-benzimida zol-2-one] hydrochloride ( (+/-)-CGP12177A ), induced concentration-dependent relaxation of (-)-phenylephrine (0.3 microM) preconstricted spiral preparations.",
    "entity1": "beta(3)-adrenoceptor",
    "entity2": "(+/-)-CGP12177A"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Pretreatment with a combination of <protein> (+/-)-2-hydroxy-5-[2-<chemical>2-hydroxy-3-[4-[1-methyl-4-(trifluoromethyl)-1H-imidazol-2 -yl]phenoxy]propyl]amino]ethoxy]-benzamide methanesulfonate </protein> (CGP20712A, a selective <chemical> beta(1)-adrenoceptor </chemical> antagonist) and (+/-)-1-[2,3-(dihydro-7-methyl-1H-inden-4-yl)oxy]-3-[(1-methylethyl)amino]-2-buta nol hydrochloride (ICI-118,5511, a selective beta(2)-adrenoceptor antagonist) (0.1 microM for each) produced a 14-fold rightward shift of the concentration-response curve for (-)-isoprenaline; however, the relaxation in response to (+/-)-CGP12177A was unaffected by the blockade of beta(1)- and beta(2)-adrenoceptors.",
    "original_text": "Pretreatment with a combination of  (+/-)-2-hydroxy-5-[2-2-hydroxy-3-[4-[1-methyl-4-(trifluoromethyl)-1H-imidazol-2 -yl]phenoxy]propyl]amino]ethoxy]-benzamide methanesulfonate  (CGP20712A, a selective  beta(1)-adrenoceptor  antagonist) and (+/-)-1-[2,3-(dihydro-7-methyl-1H-inden-4-yl)oxy]-3-[(1-methylethyl)amino]-2-buta nol hydrochloride (ICI-118,5511, a selective beta(2)-adrenoceptor antagonist) (0.1 microM for each) produced a 14-fold rightward shift of the concentration-response curve for (-)-isoprenaline; however, the relaxation in response to (+/-)-CGP12177A was unaffected by the blockade of beta(1)- and beta(2)-adrenoceptors.",
    "entity1": "(+/-)-2-hydroxy-5-[2-[[2-hydroxy-3-[4-[1-methyl-4-(trifluoromethyl)-1H-imidazol-2 -yl]phenoxy]propyl]amino]ethoxy]-benzamide methanesulfonate",
    "entity2": "2-hydroxy-3-[4-[1-methyl-4-(trifluoromethyl)-1H-imidazol-2 -yl]phenoxy]propyl]amino]ethoxy]-benzamide methanesulfonate >> (CGP20712A, a selective [[ beta(1)-adrenoceptor"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Pretreatment with a combination of (+/-)-2-hydroxy-5-[2-<chemical>2-hydroxy-3-[4-[1-methyl-4-(trifluoromethyl)-1H-imidazol-2 -yl]phenoxy]propyl]amino]ethoxy]-benzamide methanesulfonate (<protein> CGP20712A </protein>, a selective <chemical> beta(1)-adrenoceptor </chemical> antagonist) and (+/-)-1-[2,3-(dihydro-7-methyl-1H-inden-4-yl)oxy]-3-[(1-methylethyl)amino]-2-buta nol hydrochloride (ICI-118,5511, a selective beta(2)-adrenoceptor antagonist) (0.1 microM for each) produced a 14-fold rightward shift of the concentration-response curve for (-)-isoprenaline; however, the relaxation in response to (+/-)-CGP12177A was unaffected by the blockade of beta(1)- and beta(2)-adrenoceptors.",
    "original_text": "Pretreatment with a combination of (+/-)-2-hydroxy-5-[2-2-hydroxy-3-[4-[1-methyl-4-(trifluoromethyl)-1H-imidazol-2 -yl]phenoxy]propyl]amino]ethoxy]-benzamide methanesulfonate ( CGP20712A , a selective  beta(1)-adrenoceptor  antagonist) and (+/-)-1-[2,3-(dihydro-7-methyl-1H-inden-4-yl)oxy]-3-[(1-methylethyl)amino]-2-buta nol hydrochloride (ICI-118,5511, a selective beta(2)-adrenoceptor antagonist) (0.1 microM for each) produced a 14-fold rightward shift of the concentration-response curve for (-)-isoprenaline; however, the relaxation in response to (+/-)-CGP12177A was unaffected by the blockade of beta(1)- and beta(2)-adrenoceptors.",
    "entity1": "CGP20712A",
    "entity2": "2-hydroxy-3-[4-[1-methyl-4-(trifluoromethyl)-1H-imidazol-2 -yl]phenoxy]propyl]amino]ethoxy]-benzamide methanesulfonate (<< CGP20712A >>, a selective [[ beta(1)-adrenoceptor"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Pretreatment with a combination of (+/-)-2-hydroxy-5-[2-<chemical>2-hydroxy-3-[4-[1-methyl-4-(trifluoromethyl)-1H-imidazol-2 -yl]phenoxy]propyl]amino]ethoxy]-benzamide methanesulfonate (CGP20712A, a selective beta(1)-adrenoceptor antagonist) and <protein> (+/-)-1-[2,3-(dihydro-7-methyl-1H-inden-4-yl)oxy]-3-[(1-methylethyl)amino]-2-buta nol hydrochloride </protein> (ICI-118,5511, a selective <chemical> beta(2)-adrenoceptor </chemical> antagonist) (0.1 microM for each) produced a 14-fold rightward shift of the concentration-response curve for (-)-isoprenaline; however, the relaxation in response to (+/-)-CGP12177A was unaffected by the blockade of beta(1)- and beta(2)-adrenoceptors.",
    "original_text": "Pretreatment with a combination of (+/-)-2-hydroxy-5-[2-2-hydroxy-3-[4-[1-methyl-4-(trifluoromethyl)-1H-imidazol-2 -yl]phenoxy]propyl]amino]ethoxy]-benzamide methanesulfonate (CGP20712A, a selective beta(1)-adrenoceptor antagonist) and  (+/-)-1-[2,3-(dihydro-7-methyl-1H-inden-4-yl)oxy]-3-[(1-methylethyl)amino]-2-buta nol hydrochloride  (ICI-118,5511, a selective  beta(2)-adrenoceptor  antagonist) (0.1 microM for each) produced a 14-fold rightward shift of the concentration-response curve for (-)-isoprenaline; however, the relaxation in response to (+/-)-CGP12177A was unaffected by the blockade of beta(1)- and beta(2)-adrenoceptors.",
    "entity1": "(+/-)-1-[2,3-(dihydro-7-methyl-1H-inden-4-yl)oxy]-3-[(1-methylethyl)amino]-2-buta nol hydrochloride",
    "entity2": "2-hydroxy-3-[4-[1-methyl-4-(trifluoromethyl)-1H-imidazol-2 -yl]phenoxy]propyl]amino]ethoxy]-benzamide methanesulfonate (CGP20712A, a selective beta(1)-adrenoceptor antagonist) and << (+/-)-1-[2,3-(dihydro-7-methyl-1H-inden-4-yl)oxy]-3-[(1-methylethyl)amino]-2-buta nol hydrochloride >> (ICI-118,5511, a selective [[ beta(2)-adrenoceptor"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Pretreatment with a combination of (+/-)-2-hydroxy-5-[2-<chemical>2-hydroxy-3-[4-[1-methyl-4-(trifluoromethyl)-1H-imidazol-2 -yl]phenoxy]propyl]amino]ethoxy]-benzamide methanesulfonate (CGP20712A, a selective beta(1)-adrenoceptor antagonist) and (+/-)-1-[2,3-(dihydro-7-methyl-1H-inden-4-yl)oxy]-3-[(1-methylethyl)amino]-2-buta nol hydrochloride (<protein> ICI-118,5511 </protein>, a selective <chemical> beta(2)-adrenoceptor </chemical> antagonist) (0.1 microM for each) produced a 14-fold rightward shift of the concentration-response curve for (-)-isoprenaline; however, the relaxation in response to (+/-)-CGP12177A was unaffected by the blockade of beta(1)- and beta(2)-adrenoceptors.",
    "original_text": "Pretreatment with a combination of (+/-)-2-hydroxy-5-[2-2-hydroxy-3-[4-[1-methyl-4-(trifluoromethyl)-1H-imidazol-2 -yl]phenoxy]propyl]amino]ethoxy]-benzamide methanesulfonate (CGP20712A, a selective beta(1)-adrenoceptor antagonist) and (+/-)-1-[2,3-(dihydro-7-methyl-1H-inden-4-yl)oxy]-3-[(1-methylethyl)amino]-2-buta nol hydrochloride ( ICI-118,5511 , a selective  beta(2)-adrenoceptor  antagonist) (0.1 microM for each) produced a 14-fold rightward shift of the concentration-response curve for (-)-isoprenaline; however, the relaxation in response to (+/-)-CGP12177A was unaffected by the blockade of beta(1)- and beta(2)-adrenoceptors.",
    "entity1": "ICI-118,5511",
    "entity2": "2-hydroxy-3-[4-[1-methyl-4-(trifluoromethyl)-1H-imidazol-2 -yl]phenoxy]propyl]amino]ethoxy]-benzamide methanesulfonate (CGP20712A, a selective beta(1)-adrenoceptor antagonist) and (+/-)-1-[2,3-(dihydro-7-methyl-1H-inden-4-yl)oxy]-3-[(1-methylethyl)amino]-2-buta nol hydrochloride (<< ICI-118,5511 >>, a selective [[ beta(2)-adrenoceptor"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "<protein> [(131)I]MIBG </protein> uptake in PC12 cells, which express the <chemical> NET </chemical> endogenously, was 20- to 28-fold lower than in transduced cells.",
    "original_text": " [(131)I]MIBG  uptake in PC12 cells, which express the  NET  endogenously, was 20- to 28-fold lower than in transduced cells.",
    "entity1": "[(131)I]MIBG",
    "entity2": "NET"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "In vivo, A431<protein> NET </protein> tumors demonstrated a 33-fold higher <chemical> [(123)I]MIBG </chemical> uptake than parental tumors.",
    "original_text": "In vivo, A431 NET  tumors demonstrated a 33-fold higher  [(123)I]MIBG  uptake than parental tumors.",
    "entity1": "NET",
    "entity2": "[(123)I]MIBG"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, <protein> formoterol </protein>, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of <chemical> human beta-adrenergic receptors </chemical> in an identical cellular background.",
    "original_text": "The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin,  formoterol , broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of  human beta-adrenergic receptors  in an identical cellular background.",
    "entity1": "formoterol",
    "entity2": "human beta-adrenergic receptors"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, <protein> broxaterol </protein>) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of <chemical> human beta-adrenergic receptors </chemical> in an identical cellular background.",
    "original_text": "The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol,  broxaterol ) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of  human beta-adrenergic receptors  in an identical cellular background.",
    "entity1": "broxaterol",
    "entity2": "human beta-adrenergic receptors"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "The aim of this study was, therefore, to provide comparative binding characteristics of agonists (<protein> epinephrine </protein>, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of <chemical> human beta-adrenergic receptors </chemical> in an identical cellular background.",
    "original_text": "The aim of this study was, therefore, to provide comparative binding characteristics of agonists ( epinephrine , norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of  human beta-adrenergic receptors  in an identical cellular background.",
    "entity1": "epinephrine",
    "entity2": "human beta-adrenergic receptors"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, <protein> norepinephrine </protein>, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of <chemical> human beta-adrenergic receptors </chemical> in an identical cellular background.",
    "original_text": "The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine,  norepinephrine , isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of  human beta-adrenergic receptors  in an identical cellular background.",
    "entity1": "norepinephrine",
    "entity2": "human beta-adrenergic receptors"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, <protein> isoproterenol </protein>, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of <chemical> human beta-adrenergic receptors </chemical> in an identical cellular background.",
    "original_text": "The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine,  isoproterenol , fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of  human beta-adrenergic receptors  in an identical cellular background.",
    "entity1": "isoproterenol",
    "entity2": "human beta-adrenergic receptors"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, <protein> fenoterol </protein>, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of <chemical> human beta-adrenergic receptors </chemical> in an identical cellular background.",
    "original_text": "The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol,  fenoterol , salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of  human beta-adrenergic receptors  in an identical cellular background.",
    "entity1": "fenoterol",
    "entity2": "human beta-adrenergic receptors"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, <protein> salbutamol </protein>, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of <chemical> human beta-adrenergic receptors </chemical> in an identical cellular background.",
    "original_text": "The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol,  salbutamol , salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of  human beta-adrenergic receptors  in an identical cellular background.",
    "entity1": "salbutamol",
    "entity2": "human beta-adrenergic receptors"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, <protein> salmeterol </protein>, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of <chemical> human beta-adrenergic receptors </chemical> in an identical cellular background.",
    "original_text": "The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol,  salmeterol , terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of  human beta-adrenergic receptors  in an identical cellular background.",
    "entity1": "salmeterol",
    "entity2": "human beta-adrenergic receptors"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, <protein> terbutalin </protein>, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of <chemical> human beta-adrenergic receptors </chemical> in an identical cellular background.",
    "original_text": "The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol,  terbutalin , formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of  human beta-adrenergic receptors  in an identical cellular background.",
    "entity1": "terbutalin",
    "entity2": "human beta-adrenergic receptors"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (<protein> propranolol </protein>, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of <chemical> human beta-adrenergic receptors </chemical> in an identical cellular background.",
    "original_text": "The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists ( propranolol , alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of  human beta-adrenergic receptors  in an identical cellular background.",
    "entity1": "propranolol",
    "entity2": "human beta-adrenergic receptors"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, <protein> alprenolol </protein>, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of <chemical> human beta-adrenergic receptors </chemical> in an identical cellular background.",
    "original_text": "The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol,  alprenolol , atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of  human beta-adrenergic receptors  in an identical cellular background.",
    "entity1": "alprenolol",
    "entity2": "human beta-adrenergic receptors"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, <protein> atenolol </protein>, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of <chemical> human beta-adrenergic receptors </chemical> in an identical cellular background.",
    "original_text": "The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol,  atenolol , metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of  human beta-adrenergic receptors  in an identical cellular background.",
    "entity1": "atenolol",
    "entity2": "human beta-adrenergic receptors"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, <protein> metoprolol </protein>, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of <chemical> human beta-adrenergic receptors </chemical> in an identical cellular background.",
    "original_text": "The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol,  metoprolol , bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of  human beta-adrenergic receptors  in an identical cellular background.",
    "entity1": "metoprolol",
    "entity2": "human beta-adrenergic receptors"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, <protein> bisoprolol </protein>, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of <chemical> human beta-adrenergic receptors </chemical> in an identical cellular background.",
    "original_text": "The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol,  bisoprolol , carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of  human beta-adrenergic receptors  in an identical cellular background.",
    "entity1": "bisoprolol",
    "entity2": "human beta-adrenergic receptors"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, <protein> carvedilol </protein>, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of <chemical> human beta-adrenergic receptors </chemical> in an identical cellular background.",
    "original_text": "The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol,  carvedilol , pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of  human beta-adrenergic receptors  in an identical cellular background.",
    "entity1": "carvedilol",
    "entity2": "human beta-adrenergic receptors"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, <protein> pindolol </protein>, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of <chemical> human beta-adrenergic receptors </chemical> in an identical cellular background.",
    "original_text": "The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol,  pindolol , BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of  human beta-adrenergic receptors  in an identical cellular background.",
    "entity1": "pindolol",
    "entity2": "human beta-adrenergic receptors"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, <protein> BRL 37344 </protein>, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of <chemical> human beta-adrenergic receptors </chemical> in an identical cellular background.",
    "original_text": "The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol,  BRL 37344 , CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of  human beta-adrenergic receptors  in an identical cellular background.",
    "entity1": "BRL 37344",
    "entity2": "human beta-adrenergic receptors"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, <protein> CGP 20712 </protein>, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of <chemical> human beta-adrenergic receptors </chemical> in an identical cellular background.",
    "original_text": "The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344,  CGP 20712 , SR 59230A, CGP 12177, ICI 118551) at all three subtypes of  human beta-adrenergic receptors  in an identical cellular background.",
    "entity1": "CGP 20712",
    "entity2": "human beta-adrenergic receptors"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, <protein> SR 59230A </protein>, CGP 12177, ICI 118551) at all three subtypes of <chemical> human beta-adrenergic receptors </chemical> in an identical cellular background.",
    "original_text": "The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712,  SR 59230A , CGP 12177, ICI 118551) at all three subtypes of  human beta-adrenergic receptors  in an identical cellular background.",
    "entity1": "SR 59230A",
    "entity2": "human beta-adrenergic receptors"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, <protein> CGP 12177 </protein>, ICI 118551) at all three subtypes of <chemical> human beta-adrenergic receptors </chemical> in an identical cellular background.",
    "original_text": "The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A,  CGP 12177 , ICI 118551) at all three subtypes of  human beta-adrenergic receptors  in an identical cellular background.",
    "entity1": "CGP 12177",
    "entity2": "human beta-adrenergic receptors"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, <protein> ICI 118551 </protein>) at all three subtypes of <chemical> human beta-adrenergic receptors </chemical> in an identical cellular background.",
    "original_text": "The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177,  ICI 118551 ) at all three subtypes of  human beta-adrenergic receptors  in an identical cellular background.",
    "entity1": "ICI 118551",
    "entity2": "human beta-adrenergic receptors"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "<protein> Irbesartan </protein> is a long-acting <chemical> angiotensin II </chemical> antagonist acting specifically at the level of the Type 1-receptor subtype (AT1-receptor).",
    "original_text": " Irbesartan  is a long-acting  angiotensin II  antagonist acting specifically at the level of the Type 1-receptor subtype (AT1-receptor).",
    "entity1": "Irbesartan",
    "entity2": "angiotensin II"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "<protein> Irbesartan </protein> may have antiatherosclerotic properties beyond those expected from blood pressure lowering per se: this AT1-blocker decreases the vascular oxidative stress and prevents the procoagulant as well as the pro-inflammatory effects of <chemical> angiotensin II </chemical>.",
    "original_text": " Irbesartan  may have antiatherosclerotic properties beyond those expected from blood pressure lowering per se: this AT1-blocker decreases the vascular oxidative stress and prevents the procoagulant as well as the pro-inflammatory effects of  angiotensin II .",
    "entity1": "Irbesartan",
    "entity2": "angiotensin II"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "To verify the hypothesis that the non-conventional partial agonist <protein> (-)-CGP12177 </protein> binds at two beta(1)-adrenoceptor sites, <chemical> human beta(1)-adrenoceptors </chemical>, expressed in CHO cells, were labelled with (-)-[(3)H]-CGP12177.",
    "original_text": "To verify the hypothesis that the non-conventional partial agonist  (-)-CGP12177  binds at two beta(1)-adrenoceptor sites,  human beta(1)-adrenoceptors , expressed in CHO cells, were labelled with (-)-[(3)H]-CGP12177.",
    "entity1": "(-)-CGP12177",
    "entity2": "human beta(1)-adrenoceptors"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "To verify the hypothesis that the non-conventional partial agonist <protein> (-)-CGP12177 </protein> binds at two <chemical> beta(1)-adrenoceptor </chemical> sites, human beta(1)-adrenoceptors, expressed in CHO cells, were labelled with (-)-[(3)H]-CGP12177.",
    "original_text": "To verify the hypothesis that the non-conventional partial agonist  (-)-CGP12177  binds at two  beta(1)-adrenoceptor  sites, human beta(1)-adrenoceptors, expressed in CHO cells, were labelled with (-)-[(3)H]-CGP12177.",
    "entity1": "(-)-CGP12177",
    "entity2": "beta(1)-adrenoceptor"
  },
  {
    "_id": 1,
    "label": "Upregulator",
    "text": "<protein> Imiquimod </protein>, a Toll-like receptor-7 agonist, induces <chemical> perforin </chemical> in cytotoxic T lymphocytes in vitro.",
    "original_text": " Imiquimod , a Toll-like receptor-7 agonist, induces  perforin  in cytotoxic T lymphocytes in vitro.",
    "entity1": "Imiquimod",
    "entity2": "perforin"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "<protein> Imiquimod </protein>, a <chemical> Toll-like receptor-7 </chemical> agonist, induces perforin in cytotoxic T lymphocytes in vitro.",
    "original_text": " Imiquimod , a  Toll-like receptor-7  agonist, induces perforin in cytotoxic T lymphocytes in vitro.",
    "entity1": "Imiquimod",
    "entity2": "Toll-like receptor-7"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "BACKGROUND: To assess the sensitivity of biochemical, physiological, and pharmacological markers of peripheral norepinephrine (NE) transporter (NET) function, we chronically antagonized <protein> NET </protein> by a range of doses of <chemical> duloxetine </chemical> [(+)-N-methyl-3-(1-naphthalenyloxy)-2 thiophenepropanamine], which blocks the NE reuptake process.",
    "original_text": "BACKGROUND: To assess the sensitivity of biochemical, physiological, and pharmacological markers of peripheral norepinephrine (NE) transporter (NET) function, we chronically antagonized  NET  by a range of doses of  duloxetine  [(+)-N-methyl-3-(1-naphthalenyloxy)-2 thiophenepropanamine], which blocks the NE reuptake process.",
    "entity1": "NET",
    "entity2": "duloxetine"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "BACKGROUND: To assess the sensitivity of biochemical, physiological, and pharmacological markers of peripheral norepinephrine (NE) transporter (NET) function, we chronically antagonized <protein> NET </protein> by a range of doses of duloxetine <chemical>[ (+)-N-methyl-3-(1-naphthalenyloxy)-2 thiophenepropanamine </chemical>], which blocks the NE reuptake process.",
    "original_text": "BACKGROUND: To assess the sensitivity of biochemical, physiological, and pharmacological markers of peripheral norepinephrine (NE) transporter (NET) function, we chronically antagonized  NET  by a range of doses of duloxetine [ (+)-N-methyl-3-(1-naphthalenyloxy)-2 thiophenepropanamine ], which blocks the NE reuptake process.",
    "entity1": "NET",
    "entity2": "[ (+)-N-methyl-3-(1-naphthalenyloxy)-2 thiophenepropanamine"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "BACKGROUND: To assess the sensitivity of biochemical, physiological, and pharmacological markers of peripheral norepinephrine (NE) transporter (NET) function, we chronically antagonized <protein> NET </protein> by a range of doses of duloxetine [(+)-N-methyl-3-(1-naphthalenyloxy)-2 thiophenepropanamine], which blocks the <chemical> NE </chemical> reuptake process.",
    "original_text": "BACKGROUND: To assess the sensitivity of biochemical, physiological, and pharmacological markers of peripheral norepinephrine (NE) transporter (NET) function, we chronically antagonized  NET  by a range of doses of duloxetine [(+)-N-methyl-3-(1-naphthalenyloxy)-2 thiophenepropanamine], which blocks the  NE  reuptake process.",
    "entity1": "NET",
    "entity2": "NE"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "GABA-evoked currents were completely and reversibly blocked by the competitive <protein> GABAA receptor </protein> antagonist <chemical> bicuculline </chemical> (IC50 = 1.7 microM), indicating expression of GABAA but not GABAC receptors.",
    "original_text": "GABA-evoked currents were completely and reversibly blocked by the competitive  GABAA receptor  antagonist  bicuculline  (IC50 = 1.7 microM), indicating expression of GABAA but not GABAC receptors.",
    "entity1": "GABAA receptor",
    "entity2": "bicuculline"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "<protein> Histamine H1-receptor </protein> (H1R) antagonists, or <chemical> antihistamines </chemical>, often induce sedative side effects when used for the treatment of allergic disorders.",
    "original_text": " Histamine H1-receptor  (H1R) antagonists, or  antihistamines , often induce sedative side effects when used for the treatment of allergic disorders.",
    "entity1": "Histamine H1-receptor",
    "entity2": "antihistamines"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Histamine H1-receptor (<protein> H1R </protein>) antagonists, or <chemical> antihistamines </chemical>, often induce sedative side effects when used for the treatment of allergic disorders.",
    "original_text": "Histamine H1-receptor ( H1R ) antagonists, or  antihistamines , often induce sedative side effects when used for the treatment of allergic disorders.",
    "entity1": "H1R",
    "entity2": "antihistamines"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "A novel membrane sensor for <protein> histamine H1-receptor </protein> antagonist \"<chemical> fexofenadine </chemical>\".",
    "original_text": "A novel membrane sensor for  histamine H1-receptor  antagonist \" fexofenadine \".",
    "entity1": "histamine H1-receptor",
    "entity2": "fexofenadine"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "The availability of the 5-FU prodrugs offers the possibility of greater therapeutic selectivity based on the demonstration that <protein> thymidine phosphorylase </protein>, the activating enzyme for <chemical> 5-FU </chemical>, is expressed at a higher level in tumor tissue compared with normal tissue counterparts.",
    "original_text": "The availability of the 5-FU prodrugs offers the possibility of greater therapeutic selectivity based on the demonstration that  thymidine phosphorylase , the activating enzyme for  5-FU , is expressed at a higher level in tumor tissue compared with normal tissue counterparts.",
    "entity1": "thymidine phosphorylase",
    "entity2": "5-FU"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Troglitazone, bosentan and glibenclamide inhibit the <protein> bile salt export pump </protein> (Bsep) which transports <chemical> taurocholate </chemical> into bile.",
    "original_text": "Troglitazone, bosentan and glibenclamide inhibit the  bile salt export pump  (Bsep) which transports  taurocholate  into bile.",
    "entity1": "bile salt export pump",
    "entity2": "taurocholate"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Troglitazone, bosentan and glibenclamide inhibit the bile salt export pump (<protein> Bsep </protein>) which transports <chemical> taurocholate </chemical> into bile.",
    "original_text": "Troglitazone, bosentan and glibenclamide inhibit the bile salt export pump ( Bsep ) which transports  taurocholate  into bile.",
    "entity1": "Bsep",
    "entity2": "taurocholate"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "Unique binding interactions of <protein> valdecoxib </protein> with COX-2 translate into a fast rate of inactivation of <chemical> COX-2 </chemical> (110,000 M/s compared with 7000 M/s for rofecoxib and 80 M/s for etoricoxib).",
    "original_text": "Unique binding interactions of  valdecoxib  with COX-2 translate into a fast rate of inactivation of  COX-2  (110,000 M/s compared with 7000 M/s for rofecoxib and 80 M/s for etoricoxib).",
    "entity1": "valdecoxib",
    "entity2": "COX-2"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "An <protein> angiotensin II AT1 receptor </protein> antagonist, <chemical> telmisartan </chemical> augments glucose uptake and GLUT4 protein expression in 3T3-L1 adipocytes.",
    "original_text": "An  angiotensin II AT1 receptor  antagonist,  telmisartan  augments glucose uptake and GLUT4 protein expression in 3T3-L1 adipocytes.",
    "entity1": "angiotensin II AT1 receptor",
    "entity2": "telmisartan"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "An angiotensin II AT1 receptor antagonist, telmisartan augments <protein> glucose </protein> uptake and <chemical> GLUT4 </chemical> protein expression in 3T3-L1 adipocytes.",
    "original_text": "An angiotensin II AT1 receptor antagonist, telmisartan augments  glucose  uptake and  GLUT4  protein expression in 3T3-L1 adipocytes.",
    "entity1": "glucose",
    "entity2": "GLUT4"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Of note, we demonstrated for the first time that telmisartan augmented <protein> GLUT4 </protein> protein expression and <chemical> 2-deoxy glucose </chemical> uptake both in basal and insulin-stimulated state of adipocytes, which may contribute, at least partly, to its insulin-sensitizing ability.",
    "original_text": "Of note, we demonstrated for the first time that telmisartan augmented  GLUT4  protein expression and  2-deoxy glucose  uptake both in basal and insulin-stimulated state of adipocytes, which may contribute, at least partly, to its insulin-sensitizing ability.",
    "entity1": "GLUT4",
    "entity2": "2-deoxy glucose"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "<protein> Oxytocin </protein> antagonist (OTA), <chemical> TT-235 </chemical>, was developed by our group and shown to inhibit either spontaneous or oxytocin-induced uterine contractions in primates.",
    "original_text": " Oxytocin  antagonist (OTA),  TT-235 , was developed by our group and shown to inhibit either spontaneous or oxytocin-induced uterine contractions in primates.",
    "entity1": "Oxytocin",
    "entity2": "TT-235"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "In conclusion, TT-235 may inhibit the uterine response to oxytocin by decreasing oxytocin receptor numbers and oxytocin binding affinity, which might explain the prolonged <protein> oxytocin </protein> antagonist activity of <chemical> TT-235 </chemical>.",
    "original_text": "In conclusion, TT-235 may inhibit the uterine response to oxytocin by decreasing oxytocin receptor numbers and oxytocin binding affinity, which might explain the prolonged  oxytocin  antagonist activity of  TT-235 .",
    "entity1": "oxytocin",
    "entity2": "TT-235"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "As <protein> thiamine </protein> metabolism deficiencies have been seen in placental infarcts previously, these indicate that <chemical> PP20 </chemical>/hTPK may have a role in placental diseases.",
    "original_text": "As  thiamine  metabolism deficiencies have been seen in placental infarcts previously, these indicate that  PP20 /hTPK may have a role in placental diseases.",
    "entity1": "thiamine",
    "entity2": "PP20"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "As <protein> thiamine </protein> metabolism deficiencies have been seen in placental infarcts previously, these indicate that PP20/<chemical> hTPK </chemical> may have a role in placental diseases.",
    "original_text": "As  thiamine  metabolism deficiencies have been seen in placental infarcts previously, these indicate that PP20/ hTPK  may have a role in placental diseases.",
    "entity1": "thiamine",
    "entity2": "hTPK"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "Safety and tolerability of <protein> denufosol tetrasodium </protein> inhalation solution, a novel <chemical> P2Y2 receptor </chemical> agonist: results of a phase 1/phase 2 multicenter study in mild to moderate cystic fibrosis.",
    "original_text": "Safety and tolerability of  denufosol tetrasodium  inhalation solution, a novel  P2Y2 receptor  agonist: results of a phase 1/phase 2 multicenter study in mild to moderate cystic fibrosis.",
    "entity1": "denufosol tetrasodium",
    "entity2": "P2Y2 receptor"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "<protein> Denufosol tetrasodium </protein> (INS37217) is a selective <chemical> P2Y(2) </chemical> agonist that stimulates ciliary beat frequency and Cl(-) secretion in normal and cystic fibrosis (CF) airway epithelia, and is being investigated as an inhaled treatment for CF.",
    "original_text": " Denufosol tetrasodium  (INS37217) is a selective  P2Y(2)  agonist that stimulates ciliary beat frequency and Cl(-) secretion in normal and cystic fibrosis (CF) airway epithelia, and is being investigated as an inhaled treatment for CF.",
    "entity1": "Denufosol tetrasodium",
    "entity2": "P2Y(2)"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "Denufosol tetrasodium (<protein> INS37217 </protein>) is a selective <chemical> P2Y(2) </chemical> agonist that stimulates ciliary beat frequency and Cl(-) secretion in normal and cystic fibrosis (CF) airway epithelia, and is being investigated as an inhaled treatment for CF.",
    "original_text": "Denufosol tetrasodium ( INS37217 ) is a selective  P2Y(2)  agonist that stimulates ciliary beat frequency and Cl(-) secretion in normal and cystic fibrosis (CF) airway epithelia, and is being investigated as an inhaled treatment for CF.",
    "entity1": "INS37217",
    "entity2": "P2Y(2)"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "The <protein> Cl(-) </protein> secretory response is mediated via a non-<chemical> CFTR </chemical> pathway, and the driving force for Cl(-) secretion is enhanced by the effect of P2Y(2) activation to also inhibit epithelial Na(+) transport.",
    "original_text": "The  Cl(-)  secretory response is mediated via a non- CFTR  pathway, and the driving force for Cl(-) secretion is enhanced by the effect of P2Y(2) activation to also inhibit epithelial Na(+) transport.",
    "entity1": "Cl(-)",
    "entity2": "CFTR"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "<protein> Denufosol </protein> is metabolically more stable and better tolerated, and may enhance mucociliary clearance for a longer period of time than previously investigated <chemical> P2Y(2) </chemical> agonists.",
    "original_text": " Denufosol  is metabolically more stable and better tolerated, and may enhance mucociliary clearance for a longer period of time than previously investigated  P2Y(2)  agonists.",
    "entity1": "Denufosol",
    "entity2": "P2Y(2)"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "The anticonvulsant action of dextromethorphan or dimemorfan was significantly counteracted by a selective <protein> sigma1 receptor </protein> antagonist <chemical> BD 1047 </chemical>, suggesting that the anticonvulsant action of dextromethorphan or dimemorfan is, at least in part, related to sigma1 receptor-activated modulation of AP-1 transcription factors.",
    "original_text": "The anticonvulsant action of dextromethorphan or dimemorfan was significantly counteracted by a selective  sigma1 receptor  antagonist  BD 1047 , suggesting that the anticonvulsant action of dextromethorphan or dimemorfan is, at least in part, related to sigma1 receptor-activated modulation of AP-1 transcription factors.",
    "entity1": "sigma1 receptor",
    "entity2": "BD 1047"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "Binding domains of the oxytocin receptor for the selective <protein> oxytocin receptor </protein> antagonist barusiban in comparison to the agonists <chemical> oxytocin </chemical> and carbetocin.",
    "original_text": "Binding domains of the oxytocin receptor for the selective  oxytocin receptor  antagonist barusiban in comparison to the agonists  oxytocin  and carbetocin.",
    "entity1": "oxytocin receptor",
    "entity2": "oxytocin"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "Binding domains of the oxytocin receptor for the selective <protein> oxytocin receptor </protein> antagonist barusiban in comparison to the agonists oxytocin and <chemical> carbetocin </chemical>.",
    "original_text": "Binding domains of the oxytocin receptor for the selective  oxytocin receptor  antagonist barusiban in comparison to the agonists oxytocin and  carbetocin .",
    "entity1": "oxytocin receptor",
    "entity2": "carbetocin"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Binding domains of the oxytocin receptor for the selective <protein> oxytocin receptor </protein> antagonist <chemical> barusiban </chemical> in comparison to the agonists oxytocin and carbetocin.",
    "original_text": "Binding domains of the oxytocin receptor for the selective  oxytocin receptor  antagonist  barusiban  in comparison to the agonists oxytocin and carbetocin.",
    "entity1": "oxytocin receptor",
    "entity2": "barusiban"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "We have analyzed binding domains of the oxytocin receptor for barusiban, a highly selective oxytocin receptor antagonist, in comparison to the combined <protein> vasopressin V1A/oxytocin receptor </protein> antagonist atosiban and the agonists <chemical> oxytocin </chemical> and carbetocin.",
    "original_text": "We have analyzed binding domains of the oxytocin receptor for barusiban, a highly selective oxytocin receptor antagonist, in comparison to the combined  vasopressin V1A/oxytocin receptor  antagonist atosiban and the agonists  oxytocin  and carbetocin.",
    "entity1": "vasopressin V1A/oxytocin receptor",
    "entity2": "oxytocin"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "We have analyzed binding domains of the oxytocin receptor for barusiban, a highly selective oxytocin receptor antagonist, in comparison to the combined <protein> vasopressin V1A/oxytocin receptor </protein> antagonist atosiban and the agonists oxytocin and <chemical> carbetocin </chemical>.",
    "original_text": "We have analyzed binding domains of the oxytocin receptor for barusiban, a highly selective oxytocin receptor antagonist, in comparison to the combined  vasopressin V1A/oxytocin receptor  antagonist atosiban and the agonists oxytocin and  carbetocin .",
    "entity1": "vasopressin V1A/oxytocin receptor",
    "entity2": "carbetocin"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "We have analyzed binding domains of the oxytocin receptor for barusiban, a highly selective oxytocin receptor antagonist, in comparison to the combined <protein> vasopressin V1A/oxytocin receptor </protein> antagonist <chemical> atosiban </chemical> and the agonists oxytocin and carbetocin.",
    "original_text": "We have analyzed binding domains of the oxytocin receptor for barusiban, a highly selective oxytocin receptor antagonist, in comparison to the combined  vasopressin V1A/oxytocin receptor  antagonist  atosiban  and the agonists oxytocin and carbetocin.",
    "entity1": "vasopressin V1A/oxytocin receptor",
    "entity2": "atosiban"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "We have analyzed binding domains of the oxytocin receptor for <protein> barusiban </protein>, a highly selective <chemical> oxytocin receptor </chemical> antagonist, in comparison to the combined vasopressin V1A/oxytocin receptor antagonist atosiban and the agonists oxytocin and carbetocin.",
    "original_text": "We have analyzed binding domains of the oxytocin receptor for  barusiban , a highly selective  oxytocin receptor  antagonist, in comparison to the combined vasopressin V1A/oxytocin receptor antagonist atosiban and the agonists oxytocin and carbetocin.",
    "entity1": "barusiban",
    "entity2": "oxytocin receptor"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "For the <protein> vasopressin V1A/oxytocin receptor </protein> antagonist <chemical> atosiban </chemical>, none of the receptor constructs were able to provide a binding with higher affinity than the starting vasopressin V2 receptor.",
    "original_text": "For the  vasopressin V1A/oxytocin receptor  antagonist  atosiban , none of the receptor constructs were able to provide a binding with higher affinity than the starting vasopressin V2 receptor.",
    "entity1": "vasopressin V1A/oxytocin receptor",
    "entity2": "atosiban"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "The binding domain of barusiban differs from the binding domain of the agonists and the nonselective <protein> oxytocin receptor </protein> antagonist <chemical> d(CH2)5[Tyr-(Me)2,Thr4,Orn8,Tyr9]vasotocin </chemical> that has been used in previous studies.",
    "original_text": "The binding domain of barusiban differs from the binding domain of the agonists and the nonselective  oxytocin receptor  antagonist  d(CH2)5[Tyr-(Me)2,Thr4,Orn8,Tyr9]vasotocin  that has been used in previous studies.",
    "entity1": "oxytocin receptor",
    "entity2": "d(CH2)5[Tyr-(Me)2,Thr4,Orn8,Tyr9]vasotocin"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "The identity of the lung <protein> beta-ADHs </protein> was further demonstrated by their characteristic pH-activity profiles for <chemical> ethanol </chemical> oxidation, Km values for NAD and ethanol, and inhibition by 4-methylpyrazole or 1,10-phenanthroline.",
    "original_text": "The identity of the lung  beta-ADHs  was further demonstrated by their characteristic pH-activity profiles for  ethanol  oxidation, Km values for NAD and ethanol, and inhibition by 4-methylpyrazole or 1,10-phenanthroline.",
    "entity1": "beta-ADHs",
    "entity2": "ethanol"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "The identity of the lung <protein> beta-ADHs </protein> was further demonstrated by their characteristic pH-activity profiles for ethanol oxidation, Km values for NAD and <chemical> ethanol </chemical>, and inhibition by 4-methylpyrazole or 1,10-phenanthroline.",
    "original_text": "The identity of the lung  beta-ADHs  was further demonstrated by their characteristic pH-activity profiles for ethanol oxidation, Km values for NAD and  ethanol , and inhibition by 4-methylpyrazole or 1,10-phenanthroline.",
    "entity1": "beta-ADHs",
    "entity2": "ethanol"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "These findings indicate that human pulmonary <protein> ethanol </protein>-metabolizing activities differ significantly with respect to genetic polymorphism at both the <chemical> ADH2 </chemical> and the ALDH2 loci.",
    "original_text": "These findings indicate that human pulmonary  ethanol -metabolizing activities differ significantly with respect to genetic polymorphism at both the  ADH2  and the ALDH2 loci.",
    "entity1": "ethanol",
    "entity2": "ADH2"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "These findings indicate that human pulmonary <protein> ethanol </protein>-metabolizing activities differ significantly with respect to genetic polymorphism at both the ADH2 and the <chemical> ALDH2 </chemical> loci.",
    "original_text": "These findings indicate that human pulmonary  ethanol -metabolizing activities differ significantly with respect to genetic polymorphism at both the ADH2 and the  ALDH2  loci.",
    "entity1": "ethanol",
    "entity2": "ALDH2"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "The results suggest that individuals with high Vmax <protein> beta 2-ADH </protein> and deficient in low-Km mitochondrial ALDH2, accounting for approximately 45% of the Chinese population, may end up with acetaldehyde accumulation during <chemical> alcohol </chemical> consumption, rendering them vulnerable to tissue injury caused by this highly reactive and toxic metabolite.",
    "original_text": "The results suggest that individuals with high Vmax  beta 2-ADH  and deficient in low-Km mitochondrial ALDH2, accounting for approximately 45% of the Chinese population, may end up with acetaldehyde accumulation during  alcohol  consumption, rendering them vulnerable to tissue injury caused by this highly reactive and toxic metabolite.",
    "entity1": "beta 2-ADH",
    "entity2": "alcohol"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "The results suggest that individuals with high Vmax beta 2-ADH and deficient in low-Km mitochondrial <protein> ALDH2 </protein>, accounting for approximately 45% of the Chinese population, may end up with acetaldehyde accumulation during <chemical> alcohol </chemical> consumption, rendering them vulnerable to tissue injury caused by this highly reactive and toxic metabolite.",
    "original_text": "The results suggest that individuals with high Vmax beta 2-ADH and deficient in low-Km mitochondrial  ALDH2 , accounting for approximately 45% of the Chinese population, may end up with acetaldehyde accumulation during  alcohol  consumption, rendering them vulnerable to tissue injury caused by this highly reactive and toxic metabolite.",
    "entity1": "ALDH2",
    "entity2": "alcohol"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "Evaluation of histamine H1-, H2-, and H3-receptor ligands at the human histamine H4 receptor: identification of <protein> 4-methylhistamine </protein> as the first potent and selective <chemical> H4 receptor </chemical> agonist.",
    "original_text": "Evaluation of histamine H1-, H2-, and H3-receptor ligands at the human histamine H4 receptor: identification of  4-methylhistamine  as the first potent and selective  H4 receptor  agonist.",
    "entity1": "4-methylhistamine",
    "entity2": "H4 receptor"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Moreover, 4-methylhistamine potently activated the hH(4)R (pEC(50) = 7.4 +/- 0.1; alpha = 1), and this response was competitively antagonized by the selective <protein> H(4)R </protein> antagonist <chemical> JNJ 7777120 </chemical> [1-[(5-chloro-1H-indol-2-yl)-carbonyl]-4-methylpiperazine] (pA(2) = 7.8).",
    "original_text": "Moreover, 4-methylhistamine potently activated the hH(4)R (pEC(50) = 7.4 +/- 0.1; alpha = 1), and this response was competitively antagonized by the selective  H(4)R  antagonist  JNJ 7777120  [1-[(5-chloro-1H-indol-2-yl)-carbonyl]-4-methylpiperazine] (pA(2) = 7.8).",
    "entity1": "H(4)R",
    "entity2": "JNJ 7777120"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Moreover, 4-methylhistamine potently activated the hH(4)R (pEC(50) = 7.4 +/- 0.1; alpha = 1), and this response was competitively antagonized by the selective <protein> H(4)R </protein> antagonist JNJ 7777120 <chemical>[ 1-[(5-chloro-1H-indol-2-yl)-carbonyl]-4-methylpiperazine </chemical>] (pA(2) = 7.8).",
    "original_text": "Moreover, 4-methylhistamine potently activated the hH(4)R (pEC(50) = 7.4 +/- 0.1; alpha = 1), and this response was competitively antagonized by the selective  H(4)R  antagonist JNJ 7777120 [ 1-[(5-chloro-1H-indol-2-yl)-carbonyl]-4-methylpiperazine ] (pA(2) = 7.8).",
    "entity1": "H(4)R",
    "entity2": "[ 1-[(5-chloro-1H-indol-2-yl)-carbonyl]-4-methylpiperazine"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "The identification of <protein> 4-methylhistamine </protein> as a potent <chemical> H(4)R </chemical> agonist is of major importance for future studies to unravel the physiological roles of the H(4)R.",
    "original_text": "The identification of  4-methylhistamine  as a potent  H(4)R  agonist is of major importance for future studies to unravel the physiological roles of the H(4)R.",
    "entity1": "4-methylhistamine",
    "entity2": "H(4)R"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "<protein> Pyridoxal kinase </protein> (PDXK) catalyzes the phosphorylation of <chemical> pyridoxal </chemical>, pyridoxamine, and pyridoxine in the presence of ATP and Zn2+.",
    "original_text": " Pyridoxal kinase  (PDXK) catalyzes the phosphorylation of  pyridoxal , pyridoxamine, and pyridoxine in the presence of ATP and Zn2+.",
    "entity1": "Pyridoxal kinase",
    "entity2": "pyridoxal"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Pyridoxal kinase (<protein> PDXK </protein>) catalyzes the phosphorylation of <chemical> pyridoxal </chemical>, pyridoxamine, and pyridoxine in the presence of ATP and Zn2+.",
    "original_text": "Pyridoxal kinase ( PDXK ) catalyzes the phosphorylation of  pyridoxal , pyridoxamine, and pyridoxine in the presence of ATP and Zn2+.",
    "entity1": "PDXK",
    "entity2": "pyridoxal"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "<protein> Pyridoxal kinase </protein> (PDXK) catalyzes the phosphorylation of pyridoxal, <chemical> pyridoxamine </chemical>, and pyridoxine in the presence of ATP and Zn2+.",
    "original_text": " Pyridoxal kinase  (PDXK) catalyzes the phosphorylation of pyridoxal,  pyridoxamine , and pyridoxine in the presence of ATP and Zn2+.",
    "entity1": "Pyridoxal kinase",
    "entity2": "pyridoxamine"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Pyridoxal kinase (<protein> PDXK </protein>) catalyzes the phosphorylation of pyridoxal, <chemical> pyridoxamine </chemical>, and pyridoxine in the presence of ATP and Zn2+.",
    "original_text": "Pyridoxal kinase ( PDXK ) catalyzes the phosphorylation of pyridoxal,  pyridoxamine , and pyridoxine in the presence of ATP and Zn2+.",
    "entity1": "PDXK",
    "entity2": "pyridoxamine"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "<protein> Pyridoxal kinase </protein> (PDXK) catalyzes the phosphorylation of pyridoxal, pyridoxamine, and <chemical> pyridoxine </chemical> in the presence of ATP and Zn2+.",
    "original_text": " Pyridoxal kinase  (PDXK) catalyzes the phosphorylation of pyridoxal, pyridoxamine, and  pyridoxine  in the presence of ATP and Zn2+.",
    "entity1": "Pyridoxal kinase",
    "entity2": "pyridoxine"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Pyridoxal kinase (<protein> PDXK </protein>) catalyzes the phosphorylation of pyridoxal, pyridoxamine, and <chemical> pyridoxine </chemical> in the presence of ATP and Zn2+.",
    "original_text": "Pyridoxal kinase ( PDXK ) catalyzes the phosphorylation of pyridoxal, pyridoxamine, and  pyridoxine  in the presence of ATP and Zn2+.",
    "entity1": "PDXK",
    "entity2": "pyridoxine"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Both inhibitors, moreover, blunted the mucin secretory responses to beta-adrenergic agonist-generated second messenger, <protein> cAMP </protein> as well as <chemical> adenylate cyclase </chemical> activator, forskolin.",
    "original_text": "Both inhibitors, moreover, blunted the mucin secretory responses to beta-adrenergic agonist-generated second messenger,  cAMP  as well as  adenylate cyclase  activator, forskolin.",
    "entity1": "cAMP",
    "entity2": "adenylate cyclase"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "<protein> Losartan </protein>: a selective <chemical> angiotensin II type 1 (AT1) receptor </chemical> antagonist for the treatment of heart failure.",
    "original_text": " Losartan : a selective  angiotensin II type 1 (AT1) receptor  antagonist for the treatment of heart failure.",
    "entity1": "Losartan",
    "entity2": "angiotensin II type 1 (AT1) receptor"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "<protein> Losartan </protein> (COZAAR) is the prototype of a new class of potent and selective <chemical> angiotensin II (AII) type 1 (AT(1)) receptor </chemical> antagonists with the largest published preclinical and clinical data base.",
    "original_text": " Losartan  (COZAAR) is the prototype of a new class of potent and selective  angiotensin II (AII) type 1 (AT(1)) receptor  antagonists with the largest published preclinical and clinical data base.",
    "entity1": "Losartan",
    "entity2": "angiotensin II (AII) type 1 (AT(1)) receptor"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Losartan (<protein> COZAAR </protein>) is the prototype of a new class of potent and selective <chemical> angiotensin II (AII) type 1 (AT(1)) receptor </chemical> antagonists with the largest published preclinical and clinical data base.",
    "original_text": "Losartan ( COZAAR ) is the prototype of a new class of potent and selective  angiotensin II (AII) type 1 (AT(1)) receptor  antagonists with the largest published preclinical and clinical data base.",
    "entity1": "COZAAR",
    "entity2": "angiotensin II (AII) type 1 (AT(1)) receptor"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "This process was reduced by a protonophore, carbonylcyanide p-trifluoromethoxyphenylhydrazone, and a typical monocarboxylate transporter (MCT) inhibitor, alpha-cyano-4-hydroxycinnamic acid, suggesting that <protein> nicotinate </protein> uptake by rat astrocytes is mediated by H(+)-coupled <chemical> monocarboxylate transport system </chemical>.",
    "original_text": "This process was reduced by a protonophore, carbonylcyanide p-trifluoromethoxyphenylhydrazone, and a typical monocarboxylate transporter (MCT) inhibitor, alpha-cyano-4-hydroxycinnamic acid, suggesting that  nicotinate  uptake by rat astrocytes is mediated by H(+)-coupled  monocarboxylate transport system .",
    "entity1": "nicotinate",
    "entity2": "monocarboxylate transport system"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Because l-lactate reduced to 67% of the nicotinate uptake even at 10mM, it is unlikely that <protein> nicotinate </protein> uptake in rat astrocytes is mediated by <chemical> MCT1 </chemical> and/or MCT2.",
    "original_text": "Because l-lactate reduced to 67% of the nicotinate uptake even at 10mM, it is unlikely that  nicotinate  uptake in rat astrocytes is mediated by  MCT1  and/or MCT2.",
    "entity1": "nicotinate",
    "entity2": "MCT1"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Because l-lactate reduced to 67% of the nicotinate uptake even at 10mM, it is unlikely that <protein> nicotinate </protein> uptake in rat astrocytes is mediated by MCT1 and/or <chemical> MCT2 </chemical>.",
    "original_text": "Because l-lactate reduced to 67% of the nicotinate uptake even at 10mM, it is unlikely that  nicotinate  uptake in rat astrocytes is mediated by MCT1 and/or  MCT2 .",
    "entity1": "nicotinate",
    "entity2": "MCT2"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "These results provide biochemical evidence of a H(+)-coupled and saturable transport system, presumed to be a <protein> low-affinity monocarboxylate transporter </protein> MCT4 or other unknown H(+)-coupled monocarboxylate transport system, for <chemical> nicotinate </chemical> in rat cerebrocortical astrocytes.",
    "original_text": "These results provide biochemical evidence of a H(+)-coupled and saturable transport system, presumed to be a  low-affinity monocarboxylate transporter  MCT4 or other unknown H(+)-coupled monocarboxylate transport system, for  nicotinate  in rat cerebrocortical astrocytes.",
    "entity1": "low-affinity monocarboxylate transporter",
    "entity2": "nicotinate"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "These results provide biochemical evidence of a H(+)-coupled and saturable transport system, presumed to be a low-affinity monocarboxylate transporter <protein> MCT4 </protein> or other unknown H(+)-coupled monocarboxylate transport system, for <chemical> nicotinate </chemical> in rat cerebrocortical astrocytes.",
    "original_text": "These results provide biochemical evidence of a H(+)-coupled and saturable transport system, presumed to be a low-affinity monocarboxylate transporter  MCT4  or other unknown H(+)-coupled monocarboxylate transport system, for  nicotinate  in rat cerebrocortical astrocytes.",
    "entity1": "MCT4",
    "entity2": "nicotinate"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "These results provide biochemical evidence of a H(+)-coupled and saturable transport system, presumed to be a low-affinity monocarboxylate transporter MCT4 or other unknown <protein> H(+)-coupled monocarboxylate transport system </protein>, for <chemical> nicotinate </chemical> in rat cerebrocortical astrocytes.",
    "original_text": "These results provide biochemical evidence of a H(+)-coupled and saturable transport system, presumed to be a low-affinity monocarboxylate transporter MCT4 or other unknown  H(+)-coupled monocarboxylate transport system , for  nicotinate  in rat cerebrocortical astrocytes.",
    "entity1": "H(+)-coupled monocarboxylate transport system",
    "entity2": "nicotinate"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "After that, a wide range of concentrations of drugs, concomitantly with ATR (0.1 microM), was studied in the presence of <protein> haloperidol </protein> (HAL; 0.01 microM), a <chemical> dopamine D2 </chemical> antagonist.",
    "original_text": "After that, a wide range of concentrations of drugs, concomitantly with ATR (0.1 microM), was studied in the presence of  haloperidol  (HAL; 0.01 microM), a  dopamine D2  antagonist.",
    "entity1": "haloperidol",
    "entity2": "dopamine D2"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "After that, a wide range of concentrations of drugs, concomitantly with ATR (0.1 microM), was studied in the presence of haloperidol (<protein> HAL </protein>; 0.01 microM), a <chemical> dopamine D2 </chemical> antagonist.",
    "original_text": "After that, a wide range of concentrations of drugs, concomitantly with ATR (0.1 microM), was studied in the presence of haloperidol ( HAL ; 0.01 microM), a  dopamine D2  antagonist.",
    "entity1": "HAL",
    "entity2": "dopamine D2"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "Preincubation (30 min) of bovine tracheal smooth muscle with various concentrations (0.1, 1 and 10 microM) of <protein> fenoterol </protein> decreased isoprenaline-induced maximal relaxation (E(max)) of methacholine-contracted preparations in a concentration dependent fashion, indicating desensitization of the <chemical> beta(2)-adrenoceptor </chemical>.",
    "original_text": "Preincubation (30 min) of bovine tracheal smooth muscle with various concentrations (0.1, 1 and 10 microM) of  fenoterol  decreased isoprenaline-induced maximal relaxation (E(max)) of methacholine-contracted preparations in a concentration dependent fashion, indicating desensitization of the  beta(2)-adrenoceptor .",
    "entity1": "fenoterol",
    "entity2": "beta(2)-adrenoceptor"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "Preincubation (30 min) of bovine tracheal smooth muscle with various concentrations (0.1, 1 and 10 microM) of fenoterol decreased <protein> isoprenaline </protein>-induced maximal relaxation (E(max)) of methacholine-contracted preparations in a concentration dependent fashion, indicating desensitization of the <chemical> beta(2)-adrenoceptor </chemical>.",
    "original_text": "Preincubation (30 min) of bovine tracheal smooth muscle with various concentrations (0.1, 1 and 10 microM) of fenoterol decreased  isoprenaline -induced maximal relaxation (E(max)) of methacholine-contracted preparations in a concentration dependent fashion, indicating desensitization of the  beta(2)-adrenoceptor .",
    "entity1": "isoprenaline",
    "entity2": "beta(2)-adrenoceptor"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "Preincubation with 1 microM of the protein kinase C (PKC) activator phorbol 12-myristate 13-acetate (<protein> PMA </protein>) caused a small but significant decrease in isoprenaline-induced E(max), indicating activated PKC-mediated heterologous <chemical> beta(2)-adrenoceptor </chemical> desensitization.",
    "original_text": "Preincubation with 1 microM of the protein kinase C (PKC) activator phorbol 12-myristate 13-acetate ( PMA ) caused a small but significant decrease in isoprenaline-induced E(max), indicating activated PKC-mediated heterologous  beta(2)-adrenoceptor  desensitization.",
    "entity1": "PMA",
    "entity2": "beta(2)-adrenoceptor"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "Preincubation with 1 microM of the protein kinase C (PKC) activator <protein> phorbol 12-myristate 13-acetate </protein> (PMA) caused a small but significant decrease in isoprenaline-induced E(max), indicating activated PKC-mediated heterologous <chemical> beta(2)-adrenoceptor </chemical> desensitization.",
    "original_text": "Preincubation with 1 microM of the protein kinase C (PKC) activator  phorbol 12-myristate 13-acetate  (PMA) caused a small but significant decrease in isoprenaline-induced E(max), indicating activated PKC-mediated heterologous  beta(2)-adrenoceptor  desensitization.",
    "entity1": "phorbol 12-myristate 13-acetate",
    "entity2": "beta(2)-adrenoceptor"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "Preincubation with 1 microM of the protein kinase C (PKC) activator phorbol 12-myristate 13-acetate (PMA) caused a small but significant decrease in <protein> isoprenaline </protein>-induced E(max), indicating activated PKC-mediated heterologous <chemical> beta(2)-adrenoceptor </chemical> desensitization.",
    "original_text": "Preincubation with 1 microM of the protein kinase C (PKC) activator phorbol 12-myristate 13-acetate (PMA) caused a small but significant decrease in  isoprenaline -induced E(max), indicating activated PKC-mediated heterologous  beta(2)-adrenoceptor  desensitization.",
    "entity1": "isoprenaline",
    "entity2": "beta(2)-adrenoceptor"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "When expressed heterologously in a mammalian cell line, <protein> rabbit PAT1 </protein> mediates pH-dependent, Na(+)-independent uptake of <chemical> proline </chemical>, glycine, l-alanine and alpha-(methylamino)isobutyric acid.",
    "original_text": "When expressed heterologously in a mammalian cell line,  rabbit PAT1  mediates pH-dependent, Na(+)-independent uptake of  proline , glycine, l-alanine and alpha-(methylamino)isobutyric acid.",
    "entity1": "rabbit PAT1",
    "entity2": "proline"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "When expressed heterologously in a mammalian cell line, <protein> rabbit PAT1 </protein> mediates pH-dependent, Na(+)-independent uptake of proline, <chemical> glycine </chemical>, l-alanine and alpha-(methylamino)isobutyric acid.",
    "original_text": "When expressed heterologously in a mammalian cell line,  rabbit PAT1  mediates pH-dependent, Na(+)-independent uptake of proline,  glycine , l-alanine and alpha-(methylamino)isobutyric acid.",
    "entity1": "rabbit PAT1",
    "entity2": "glycine"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "When expressed heterologously in a mammalian cell line, <protein> rabbit PAT1 </protein> mediates pH-dependent, Na(+)-independent uptake of proline, glycine, <chemical> l-alanine </chemical> and alpha-(methylamino)isobutyric acid.",
    "original_text": "When expressed heterologously in a mammalian cell line,  rabbit PAT1  mediates pH-dependent, Na(+)-independent uptake of proline, glycine,  l-alanine  and alpha-(methylamino)isobutyric acid.",
    "entity1": "rabbit PAT1",
    "entity2": "l-alanine"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "When expressed heterologously in a mammalian cell line, <protein> rabbit PAT1 </protein> mediates pH-dependent, Na(+)-independent uptake of proline, glycine, l-alanine and <chemical> alpha-(methylamino)isobutyric acid </chemical>.",
    "original_text": "When expressed heterologously in a mammalian cell line,  rabbit PAT1  mediates pH-dependent, Na(+)-independent uptake of proline, glycine, l-alanine and  alpha-(methylamino)isobutyric acid .",
    "entity1": "rabbit PAT1",
    "entity2": "alpha-(methylamino)isobutyric acid"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "In the presence of Na+ and under conditions in which <protein> PAT1 </protein> transport function was suppressed, a second <chemical> proline </chemical> uptake system was detected that exhibited functional characteristics similar to those of the IMINO system.",
    "original_text": "In the presence of Na+ and under conditions in which  PAT1  transport function was suppressed, a second  proline  uptake system was detected that exhibited functional characteristics similar to those of the IMINO system.",
    "entity1": "PAT1",
    "entity2": "proline"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "The functional characteristics of rabbit PAT1 in either mammalian cells or renal BBMV suggest that <protein> PAT1 </protein> is the low-affinity transporter of <chemical> proline </chemical>, glycine and hydroxyproline believed to be defective in patients with iminoglycinuria.",
    "original_text": "The functional characteristics of rabbit PAT1 in either mammalian cells or renal BBMV suggest that  PAT1  is the low-affinity transporter of  proline , glycine and hydroxyproline believed to be defective in patients with iminoglycinuria.",
    "entity1": "PAT1",
    "entity2": "proline"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "The functional characteristics of rabbit PAT1 in either mammalian cells or renal BBMV suggest that <protein> PAT1 </protein> is the low-affinity transporter of proline, <chemical> glycine </chemical> and hydroxyproline believed to be defective in patients with iminoglycinuria.",
    "original_text": "The functional characteristics of rabbit PAT1 in either mammalian cells or renal BBMV suggest that  PAT1  is the low-affinity transporter of proline,  glycine  and hydroxyproline believed to be defective in patients with iminoglycinuria.",
    "entity1": "PAT1",
    "entity2": "glycine"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "The functional characteristics of rabbit PAT1 in either mammalian cells or renal BBMV suggest that <protein> PAT1 </protein> is the low-affinity transporter of proline, glycine and <chemical> hydroxyproline </chemical> believed to be defective in patients with iminoglycinuria.",
    "original_text": "The functional characteristics of rabbit PAT1 in either mammalian cells or renal BBMV suggest that  PAT1  is the low-affinity transporter of proline, glycine and  hydroxyproline  believed to be defective in patients with iminoglycinuria.",
    "entity1": "PAT1",
    "entity2": "hydroxyproline"
  },
  {
    "_id": 1,
    "label": "Upregulator",
    "text": "In addition, <protein> sorafenib </protein> demonstrated significant activity against several receptor tyrosine kinases involved in neovascularization and tumor progression, including vascular-endothelial growth factor (VEGFR)-2, <chemical> VEGFR-3 </chemical>, platelet-derived growth factor (PDGFR)-beta Flt-3, and c-KIT.",
    "original_text": "In addition,  sorafenib  demonstrated significant activity against several receptor tyrosine kinases involved in neovascularization and tumor progression, including vascular-endothelial growth factor (VEGFR)-2,  VEGFR-3 , platelet-derived growth factor (PDGFR)-beta Flt-3, and c-KIT.",
    "entity1": "sorafenib",
    "entity2": "VEGFR-3"
  },
  {
    "_id": 1,
    "label": "Upregulator",
    "text": "In addition, <protein> sorafenib </protein> demonstrated significant activity against several receptor tyrosine kinases involved in neovascularization and tumor progression, including vascular-endothelial growth factor (VEGFR)-2, VEGFR-3, <chemical> platelet-derived growth factor (PDGFR)-beta </chemical> Flt-3, and c-KIT.",
    "original_text": "In addition,  sorafenib  demonstrated significant activity against several receptor tyrosine kinases involved in neovascularization and tumor progression, including vascular-endothelial growth factor (VEGFR)-2, VEGFR-3,  platelet-derived growth factor (PDGFR)-beta  Flt-3, and c-KIT.",
    "entity1": "sorafenib",
    "entity2": "platelet-derived growth factor (PDGFR)-beta"
  },
  {
    "_id": 1,
    "label": "Upregulator",
    "text": "In addition, <protein> sorafenib </protein> demonstrated significant activity against several receptor tyrosine kinases involved in neovascularization and tumor progression, including vascular-endothelial growth factor (VEGFR)-2, VEGFR-3, platelet-derived growth factor (PDGFR)-beta <chemical> Flt-3 </chemical>, and c-KIT.",
    "original_text": "In addition,  sorafenib  demonstrated significant activity against several receptor tyrosine kinases involved in neovascularization and tumor progression, including vascular-endothelial growth factor (VEGFR)-2, VEGFR-3, platelet-derived growth factor (PDGFR)-beta  Flt-3 , and c-KIT.",
    "entity1": "sorafenib",
    "entity2": "Flt-3"
  },
  {
    "_id": 1,
    "label": "Upregulator",
    "text": "In addition, <protein> sorafenib </protein> demonstrated significant activity against several receptor tyrosine kinases involved in neovascularization and tumor progression, including vascular-endothelial growth factor (VEGFR)-2, VEGFR-3, platelet-derived growth factor (PDGFR)-beta Flt-3, and <chemical> c-KIT </chemical>.",
    "original_text": "In addition,  sorafenib  demonstrated significant activity against several receptor tyrosine kinases involved in neovascularization and tumor progression, including vascular-endothelial growth factor (VEGFR)-2, VEGFR-3, platelet-derived growth factor (PDGFR)-beta Flt-3, and  c-KIT .",
    "entity1": "sorafenib",
    "entity2": "c-KIT"
  },
  {
    "_id": 1,
    "label": "Upregulator",
    "text": "In addition, <protein> sorafenib </protein> demonstrated significant activity against several <chemical> receptor tyrosine kinases </chemical> involved in neovascularization and tumor progression, including vascular-endothelial growth factor (VEGFR)-2, VEGFR-3, platelet-derived growth factor (PDGFR)-beta Flt-3, and c-KIT.",
    "original_text": "In addition,  sorafenib  demonstrated significant activity against several  receptor tyrosine kinases  involved in neovascularization and tumor progression, including vascular-endothelial growth factor (VEGFR)-2, VEGFR-3, platelet-derived growth factor (PDGFR)-beta Flt-3, and c-KIT.",
    "entity1": "sorafenib",
    "entity2": "receptor tyrosine kinases"
  },
  {
    "_id": 1,
    "label": "Upregulator",
    "text": "In addition, <protein> sorafenib </protein> demonstrated significant activity against several receptor tyrosine kinases involved in neovascularization and tumor progression, including <chemical> vascular-endothelial growth factor (VEGFR)-2 </chemical>, VEGFR-3, platelet-derived growth factor (PDGFR)-beta Flt-3, and c-KIT.",
    "original_text": "In addition,  sorafenib  demonstrated significant activity against several receptor tyrosine kinases involved in neovascularization and tumor progression, including  vascular-endothelial growth factor (VEGFR)-2 , VEGFR-3, platelet-derived growth factor (PDGFR)-beta Flt-3, and c-KIT.",
    "entity1": "sorafenib",
    "entity2": "vascular-endothelial growth factor (VEGFR)-2"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "A selective <protein> retinoid X receptor </protein> agonist <chemical> bexarotene </chemical> (LGD1069, targretin) inhibits angiogenesis and metastasis in solid tumours.",
    "original_text": "A selective  retinoid X receptor  agonist  bexarotene  (LGD1069, targretin) inhibits angiogenesis and metastasis in solid tumours.",
    "entity1": "retinoid X receptor",
    "entity2": "bexarotene"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "A selective <protein> retinoid X receptor </protein> agonist bexarotene (<chemical> LGD1069 </chemical>, targretin) inhibits angiogenesis and metastasis in solid tumours.",
    "original_text": "A selective  retinoid X receptor  agonist bexarotene ( LGD1069 , targretin) inhibits angiogenesis and metastasis in solid tumours.",
    "entity1": "retinoid X receptor",
    "entity2": "LGD1069"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "A selective <protein> retinoid X receptor </protein> agonist bexarotene (LGD1069, <chemical> targretin </chemical>) inhibits angiogenesis and metastasis in solid tumours.",
    "original_text": "A selective  retinoid X receptor  agonist bexarotene (LGD1069,  targretin ) inhibits angiogenesis and metastasis in solid tumours.",
    "entity1": "retinoid X receptor",
    "entity2": "targretin"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "The present study determined the influence of a <protein> retinoid X receptor </protein> agonist <chemical> bexarotene </chemical> on angiogenesis and metastasis in solid tumours.",
    "original_text": "The present study determined the influence of a  retinoid X receptor  agonist  bexarotene  on angiogenesis and metastasis in solid tumours.",
    "entity1": "retinoid X receptor",
    "entity2": "bexarotene"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Novel highly affine histamine H3 receptor ligands with additional inhibitory effects on the main <protein> histamine </protein> metabolizing enzyme in the brain, <chemical> N-methyltransferase </chemical>, chemically show structural elements of the acetylcholinesterase inhibitor tacrine.",
    "original_text": "Novel highly affine histamine H3 receptor ligands with additional inhibitory effects on the main  histamine  metabolizing enzyme in the brain,  N-methyltransferase , chemically show structural elements of the acetylcholinesterase inhibitor tacrine.",
    "entity1": "histamine",
    "entity2": "N-methyltransferase"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Some of the new compounds proved in a slightly modified colorimetric Ellmann's assay to be potent inhibitors of <protein> acetylcholinesterase </protein> and of butyrylcholinesterase which is another catalytic enzyme hydrolysing <chemical> acetylcholine </chemical>.",
    "original_text": "Some of the new compounds proved in a slightly modified colorimetric Ellmann's assay to be potent inhibitors of  acetylcholinesterase  and of butyrylcholinesterase which is another catalytic enzyme hydrolysing  acetylcholine .",
    "entity1": "acetylcholinesterase",
    "entity2": "acetylcholine"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Some of the new compounds proved in a slightly modified colorimetric Ellmann's assay to be potent inhibitors of acetylcholinesterase and of <protein> butyrylcholinesterase </protein> which is another catalytic enzyme hydrolysing <chemical> acetylcholine </chemical>.",
    "original_text": "Some of the new compounds proved in a slightly modified colorimetric Ellmann's assay to be potent inhibitors of acetylcholinesterase and of  butyrylcholinesterase  which is another catalytic enzyme hydrolysing  acetylcholine .",
    "entity1": "butyrylcholinesterase",
    "entity2": "acetylcholine"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "This aminophospholipid \"<protein> flippase </protein>\" selectively transports <chemical> PS </chemical> to the cytosolic leaflet of the bilayer and is sensitive to vanadate, Ca(2+), and modification by sulfhydryl reagents.",
    "original_text": "This aminophospholipid \" flippase \" selectively transports  PS  to the cytosolic leaflet of the bilayer and is sensitive to vanadate, Ca(2+), and modification by sulfhydryl reagents.",
    "entity1": "flippase",
    "entity2": "PS"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "Activation of <protein> Atp8a1 </protein> is also reduced by these modifications; <chemical> phosphatidylserine-O-methyl ester </chemical>, lysophosphatidylserine, glycerophosphoserine, and phosphoserine, which are not transported by the plasma membrane flippase, do not activate Atp8a1.",
    "original_text": "Activation of  Atp8a1  is also reduced by these modifications;  phosphatidylserine-O-methyl ester , lysophosphatidylserine, glycerophosphoserine, and phosphoserine, which are not transported by the plasma membrane flippase, do not activate Atp8a1.",
    "entity1": "Atp8a1",
    "entity2": "phosphatidylserine-O-methyl ester"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "Activation of <protein> Atp8a1 </protein> is also reduced by these modifications; phosphatidylserine-O-methyl ester, <chemical> lysophosphatidylserine </chemical>, glycerophosphoserine, and phosphoserine, which are not transported by the plasma membrane flippase, do not activate Atp8a1.",
    "original_text": "Activation of  Atp8a1  is also reduced by these modifications; phosphatidylserine-O-methyl ester,  lysophosphatidylserine , glycerophosphoserine, and phosphoserine, which are not transported by the plasma membrane flippase, do not activate Atp8a1.",
    "entity1": "Atp8a1",
    "entity2": "lysophosphatidylserine"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "Activation of <protein> Atp8a1 </protein> is also reduced by these modifications; phosphatidylserine-O-methyl ester, lysophosphatidylserine, <chemical> glycerophosphoserine </chemical>, and phosphoserine, which are not transported by the plasma membrane flippase, do not activate Atp8a1.",
    "original_text": "Activation of  Atp8a1  is also reduced by these modifications; phosphatidylserine-O-methyl ester, lysophosphatidylserine,  glycerophosphoserine , and phosphoserine, which are not transported by the plasma membrane flippase, do not activate Atp8a1.",
    "entity1": "Atp8a1",
    "entity2": "glycerophosphoserine"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "Activation of <protein> Atp8a1 </protein> is also reduced by these modifications; phosphatidylserine-O-methyl ester, lysophosphatidylserine, glycerophosphoserine, and <chemical> phosphoserine </chemical>, which are not transported by the plasma membrane flippase, do not activate Atp8a1.",
    "original_text": "Activation of  Atp8a1  is also reduced by these modifications; phosphatidylserine-O-methyl ester, lysophosphatidylserine, glycerophosphoserine, and  phosphoserine , which are not transported by the plasma membrane flippase, do not activate Atp8a1.",
    "entity1": "Atp8a1",
    "entity2": "phosphoserine"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "However, <protein> N-methyl-phosphatidylserine </protein>, which is transported by the plasma membrane <chemical> flippase </chemical> at a rate equivalent to PS, is incapable of activating Atp8a1 activity.",
    "original_text": "However,  N-methyl-phosphatidylserine , which is transported by the plasma membrane  flippase  at a rate equivalent to PS, is incapable of activating Atp8a1 activity.",
    "entity1": "N-methyl-phosphatidylserine",
    "entity2": "flippase"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Hydrogen sulfide (H(2)S), a regulatory gaseous molecule that is endogenously synthesized by cystathionine gamma-lyase (<protein> CSE </protein>) and/or cystathionine beta-synthase (CBS) from <chemical> L-cysteine </chemical> (L-Cys) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored.",
    "original_text": "Hydrogen sulfide (H(2)S), a regulatory gaseous molecule that is endogenously synthesized by cystathionine gamma-lyase ( CSE ) and/or cystathionine beta-synthase (CBS) from  L-cysteine  (L-Cys) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored.",
    "entity1": "CSE",
    "entity2": "L-cysteine"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Hydrogen sulfide (H(2)S), a regulatory gaseous molecule that is endogenously synthesized by cystathionine gamma-lyase (CSE) and/or <protein> cystathionine beta-synthase </protein> (CBS) from <chemical> L-cysteine </chemical> (L-Cys) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored.",
    "original_text": "Hydrogen sulfide (H(2)S), a regulatory gaseous molecule that is endogenously synthesized by cystathionine gamma-lyase (CSE) and/or  cystathionine beta-synthase  (CBS) from  L-cysteine  (L-Cys) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored.",
    "entity1": "cystathionine beta-synthase",
    "entity2": "L-cysteine"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Hydrogen sulfide (H(2)S), a regulatory gaseous molecule that is endogenously synthesized by cystathionine gamma-lyase (CSE) and/or cystathionine beta-synthase (<protein> CBS </protein>) from <chemical> L-cysteine </chemical> (L-Cys) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored.",
    "original_text": "Hydrogen sulfide (H(2)S), a regulatory gaseous molecule that is endogenously synthesized by cystathionine gamma-lyase (CSE) and/or cystathionine beta-synthase ( CBS ) from  L-cysteine  (L-Cys) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored.",
    "entity1": "CBS",
    "entity2": "L-cysteine"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Hydrogen sulfide (H(2)S), a regulatory gaseous molecule that is endogenously synthesized by <protein> cystathionine gamma-lyase </protein> (CSE) and/or cystathionine beta-synthase (CBS) from <chemical> L-cysteine </chemical> (L-Cys) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored.",
    "original_text": "Hydrogen sulfide (H(2)S), a regulatory gaseous molecule that is endogenously synthesized by  cystathionine gamma-lyase  (CSE) and/or cystathionine beta-synthase (CBS) from  L-cysteine  (L-Cys) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored.",
    "entity1": "cystathionine gamma-lyase",
    "entity2": "L-cysteine"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Hydrogen sulfide (H(2)S), a regulatory gaseous molecule that is endogenously synthesized by cystathionine gamma-lyase (<protein> CSE </protein>) and/or cystathionine beta-synthase (CBS) from L-cysteine (<chemical> L-Cys </chemical>) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored.",
    "original_text": "Hydrogen sulfide (H(2)S), a regulatory gaseous molecule that is endogenously synthesized by cystathionine gamma-lyase ( CSE ) and/or cystathionine beta-synthase (CBS) from L-cysteine ( L-Cys ) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored.",
    "entity1": "CSE",
    "entity2": "L-Cys"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Hydrogen sulfide (H(2)S), a regulatory gaseous molecule that is endogenously synthesized by cystathionine gamma-lyase (CSE) and/or <protein> cystathionine beta-synthase </protein> (CBS) from L-cysteine (<chemical> L-Cys </chemical>) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored.",
    "original_text": "Hydrogen sulfide (H(2)S), a regulatory gaseous molecule that is endogenously synthesized by cystathionine gamma-lyase (CSE) and/or  cystathionine beta-synthase  (CBS) from L-cysteine ( L-Cys ) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored.",
    "entity1": "cystathionine beta-synthase",
    "entity2": "L-Cys"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Hydrogen sulfide (H(2)S), a regulatory gaseous molecule that is endogenously synthesized by cystathionine gamma-lyase (CSE) and/or cystathionine beta-synthase (<protein> CBS </protein>) from L-cysteine (<chemical> L-Cys </chemical>) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored.",
    "original_text": "Hydrogen sulfide (H(2)S), a regulatory gaseous molecule that is endogenously synthesized by cystathionine gamma-lyase (CSE) and/or cystathionine beta-synthase ( CBS ) from L-cysteine ( L-Cys ) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored.",
    "entity1": "CBS",
    "entity2": "L-Cys"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Hydrogen sulfide (H(2)S), a regulatory gaseous molecule that is endogenously synthesized by <protein> cystathionine gamma-lyase </protein> (CSE) and/or cystathionine beta-synthase (CBS) from L-cysteine (<chemical> L-Cys </chemical>) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored.",
    "original_text": "Hydrogen sulfide (H(2)S), a regulatory gaseous molecule that is endogenously synthesized by  cystathionine gamma-lyase  (CSE) and/or cystathionine beta-synthase (CBS) from L-cysteine ( L-Cys ) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored.",
    "entity1": "cystathionine gamma-lyase",
    "entity2": "L-Cys"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Moreover, NO production in LPS-stimulated macrophages that are expressing <protein> CSE </protein> mRNA was significantly reduced by the addition of <chemical> L-Cys </chemical>, a substrate for H(2)S, but enhanced by the selective CSE inhibitor beta-cyano-L-alanine but not by the CBS inhibitor aminooxyacetic acid.",
    "original_text": "Moreover, NO production in LPS-stimulated macrophages that are expressing  CSE  mRNA was significantly reduced by the addition of  L-Cys , a substrate for H(2)S, but enhanced by the selective CSE inhibitor beta-cyano-L-alanine but not by the CBS inhibitor aminooxyacetic acid.",
    "entity1": "CSE",
    "entity2": "L-Cys"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "<protein> L-arg </protein> is converted to urea by <chemical> arginase I </chemical> in the liver and arginase II in the kidney.",
    "original_text": " L-arg  is converted to urea by  arginase I  in the liver and arginase II in the kidney.",
    "entity1": "L-arg",
    "entity2": "arginase I"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "<protein> L-arg </protein> is converted to urea by arginase I in the liver and <chemical> arginase II </chemical> in the kidney.",
    "original_text": " L-arg  is converted to urea by arginase I in the liver and  arginase II  in the kidney.",
    "entity1": "L-arg",
    "entity2": "arginase II"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "We hypothesized that preservation of plasma <protein> L-arg </protein> in CRF may be, partly, due to downregulation/inhibition of <chemical> arginase </chemical>.",
    "original_text": "We hypothesized that preservation of plasma  L-arg  in CRF may be, partly, due to downregulation/inhibition of  arginase .",
    "entity1": "L-arg",
    "entity2": "arginase"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "However, several promising nonpeptide, <protein> vasopressin receptor </protein> antagonists have been described; these agents are <chemical> VPA-985 </chemical> (lixivaptan), YM-087 (conivaptan), OPC-41061 (tolvaptan), and SR-121463.",
    "original_text": "However, several promising nonpeptide,  vasopressin receptor  antagonists have been described; these agents are  VPA-985  (lixivaptan), YM-087 (conivaptan), OPC-41061 (tolvaptan), and SR-121463.",
    "entity1": "vasopressin receptor",
    "entity2": "VPA-985"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "However, several promising nonpeptide, <protein> vasopressin receptor </protein> antagonists have been described; these agents are VPA-985 (<chemical> lixivaptan </chemical>), YM-087 (conivaptan), OPC-41061 (tolvaptan), and SR-121463.",
    "original_text": "However, several promising nonpeptide,  vasopressin receptor  antagonists have been described; these agents are VPA-985 ( lixivaptan ), YM-087 (conivaptan), OPC-41061 (tolvaptan), and SR-121463.",
    "entity1": "vasopressin receptor",
    "entity2": "lixivaptan"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "However, several promising nonpeptide, <protein> vasopressin receptor </protein> antagonists have been described; these agents are VPA-985 (lixivaptan), <chemical> YM-087 </chemical> (conivaptan), OPC-41061 (tolvaptan), and SR-121463.",
    "original_text": "However, several promising nonpeptide,  vasopressin receptor  antagonists have been described; these agents are VPA-985 (lixivaptan),  YM-087  (conivaptan), OPC-41061 (tolvaptan), and SR-121463.",
    "entity1": "vasopressin receptor",
    "entity2": "YM-087"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "However, several promising nonpeptide, <protein> vasopressin receptor </protein> antagonists have been described; these agents are VPA-985 (lixivaptan), YM-087 (<chemical> conivaptan </chemical>), OPC-41061 (tolvaptan), and SR-121463.",
    "original_text": "However, several promising nonpeptide,  vasopressin receptor  antagonists have been described; these agents are VPA-985 (lixivaptan), YM-087 ( conivaptan ), OPC-41061 (tolvaptan), and SR-121463.",
    "entity1": "vasopressin receptor",
    "entity2": "conivaptan"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "However, several promising nonpeptide, <protein> vasopressin receptor </protein> antagonists have been described; these agents are VPA-985 (lixivaptan), YM-087 (conivaptan), <chemical> OPC-41061 </chemical> (tolvaptan), and SR-121463.",
    "original_text": "However, several promising nonpeptide,  vasopressin receptor  antagonists have been described; these agents are VPA-985 (lixivaptan), YM-087 (conivaptan),  OPC-41061  (tolvaptan), and SR-121463.",
    "entity1": "vasopressin receptor",
    "entity2": "OPC-41061"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "However, several promising nonpeptide, <protein> vasopressin receptor </protein> antagonists have been described; these agents are VPA-985 (lixivaptan), YM-087 (conivaptan), OPC-41061 (<chemical> tolvaptan </chemical>), and SR-121463.",
    "original_text": "However, several promising nonpeptide,  vasopressin receptor  antagonists have been described; these agents are VPA-985 (lixivaptan), YM-087 (conivaptan), OPC-41061 ( tolvaptan ), and SR-121463.",
    "entity1": "vasopressin receptor",
    "entity2": "tolvaptan"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "However, several promising nonpeptide, <protein> vasopressin receptor </protein> antagonists have been described; these agents are VPA-985 (lixivaptan), YM-087 (conivaptan), OPC-41061 (tolvaptan), and <chemical> SR-121463 </chemical>.",
    "original_text": "However, several promising nonpeptide,  vasopressin receptor  antagonists have been described; these agents are VPA-985 (lixivaptan), YM-087 (conivaptan), OPC-41061 (tolvaptan), and  SR-121463 .",
    "entity1": "vasopressin receptor",
    "entity2": "SR-121463"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Sedation and <protein> histamine H1-receptor </protein> antagonism: studies in man with the enantiomers of chlorpheniramine and <chemical> dimethindene </chemical>.",
    "original_text": "Sedation and  histamine H1-receptor  antagonism: studies in man with the enantiomers of chlorpheniramine and  dimethindene .",
    "entity1": "histamine H1-receptor",
    "entity2": "dimethindene"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Sedation and <protein> histamine H1-receptor </protein> antagonism: studies in man with the enantiomers of <chemical> chlorpheniramine </chemical> and dimethindene.",
    "original_text": "Sedation and  histamine H1-receptor  antagonism: studies in man with the enantiomers of  chlorpheniramine  and dimethindene.",
    "entity1": "histamine H1-receptor",
    "entity2": "chlorpheniramine"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "<protein> Diacylglycerol </protein> (DAG) acts as an allosteric activator of protein kinase C (PKC) and is converted to phosphatidic acid by <chemical> DAG kinase </chemical> (DGK).",
    "original_text": " Diacylglycerol  (DAG) acts as an allosteric activator of protein kinase C (PKC) and is converted to phosphatidic acid by  DAG kinase  (DGK).",
    "entity1": "Diacylglycerol",
    "entity2": "DAG kinase"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "<protein> Diacylglycerol </protein> (DAG) acts as an allosteric activator of protein kinase C (PKC) and is converted to phosphatidic acid by DAG kinase (<chemical> DGK </chemical>).",
    "original_text": " Diacylglycerol  (DAG) acts as an allosteric activator of protein kinase C (PKC) and is converted to phosphatidic acid by DAG kinase ( DGK ).",
    "entity1": "Diacylglycerol",
    "entity2": "DGK"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Diacylglycerol (<protein> DAG </protein>) acts as an allosteric activator of protein kinase C (PKC) and is converted to phosphatidic acid by <chemical> DAG kinase </chemical> (DGK).",
    "original_text": "Diacylglycerol ( DAG ) acts as an allosteric activator of protein kinase C (PKC) and is converted to phosphatidic acid by  DAG kinase  (DGK).",
    "entity1": "DAG",
    "entity2": "DAG kinase"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Diacylglycerol (<protein> DAG </protein>) acts as an allosteric activator of protein kinase C (PKC) and is converted to phosphatidic acid by DAG kinase (<chemical> DGK </chemical>).",
    "original_text": "Diacylglycerol ( DAG ) acts as an allosteric activator of protein kinase C (PKC) and is converted to phosphatidic acid by DAG kinase ( DGK ).",
    "entity1": "DAG",
    "entity2": "DGK"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "Monoclonal antibody 25B1 appears to be directed against a conformational epitope located in close proximity to the catalytic center of the enzyme and was found to be most suitable for studying the stabilization of the active site of <protein> acetylcholinesterase </protein> against denaturation by heat or <chemical> guanidine </chemical> following phosphorylation by organophosphorus anticholinesterase compounds.",
    "original_text": "Monoclonal antibody 25B1 appears to be directed against a conformational epitope located in close proximity to the catalytic center of the enzyme and was found to be most suitable for studying the stabilization of the active site of  acetylcholinesterase  against denaturation by heat or  guanidine  following phosphorylation by organophosphorus anticholinesterase compounds.",
    "entity1": "acetylcholinesterase",
    "entity2": "guanidine"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "It has been known for decades that lithium chloride (LiCl) leads to <protein> D-myo-inositol 1-phosphate </protein> accumulation on GPCR activation by inhibiting <chemical> inositol monophosphatase </chemical>, the final enzyme of the IP3 metabolic cascade.",
    "original_text": "It has been known for decades that lithium chloride (LiCl) leads to  D-myo-inositol 1-phosphate  accumulation on GPCR activation by inhibiting  inositol monophosphatase , the final enzyme of the IP3 metabolic cascade.",
    "entity1": "D-myo-inositol 1-phosphate",
    "entity2": "inositol monophosphatase"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "It has been known for decades that lithium chloride (LiCl) leads to D-myo-inositol 1-phosphate accumulation on GPCR activation by inhibiting <protein> inositol monophosphatase </protein>, the final enzyme of the <chemical> IP3 </chemical> metabolic cascade.",
    "original_text": "It has been known for decades that lithium chloride (LiCl) leads to D-myo-inositol 1-phosphate accumulation on GPCR activation by inhibiting  inositol monophosphatase , the final enzyme of the  IP3  metabolic cascade.",
    "entity1": "inositol monophosphatase",
    "entity2": "IP3"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "<protein> 11Beta-HSD1 </protein> activates <chemical> cortisone </chemical> to cortisol to facilitate glucocorticoid receptor (GR)-mediated action.",
    "original_text": " 11Beta-HSD1  activates  cortisone  to cortisol to facilitate glucocorticoid receptor (GR)-mediated action.",
    "entity1": "11Beta-HSD1",
    "entity2": "cortisone"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "By contrast, <protein> 11beta-HSD2 </protein> plays a pivotal role in aldosterone target tissues where it catalyses the opposite reaction (i.e. inactivation of <chemical> cortisol </chemical> to cortisone) to prevent activation of the mineralocorticoid receptor (MR) by cortisol.",
    "original_text": "By contrast,  11beta-HSD2  plays a pivotal role in aldosterone target tissues where it catalyses the opposite reaction (i.e. inactivation of  cortisol  to cortisone) to prevent activation of the mineralocorticoid receptor (MR) by cortisol.",
    "entity1": "11beta-HSD2",
    "entity2": "cortisol"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Here we demonstrate that PPARgamma, turns on retinoic acid synthesis by inducing the expression of <protein> retinol </protein> and retinal metabolizing enzymes such as <chemical> retinol dehydrogenase 10 </chemical> and retinaldehyde dehydrogenase type 2 (RALDH2).",
    "original_text": "Here we demonstrate that PPARgamma, turns on retinoic acid synthesis by inducing the expression of  retinol  and retinal metabolizing enzymes such as  retinol dehydrogenase 10  and retinaldehyde dehydrogenase type 2 (RALDH2).",
    "entity1": "retinol",
    "entity2": "retinol dehydrogenase 10"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Here we demonstrate that PPARgamma, turns on retinoic acid synthesis by inducing the expression of <protein> retinol </protein> and retinal metabolizing enzymes such as retinol dehydrogenase 10 and <chemical> retinaldehyde dehydrogenase type 2 </chemical> (RALDH2).",
    "original_text": "Here we demonstrate that PPARgamma, turns on retinoic acid synthesis by inducing the expression of  retinol  and retinal metabolizing enzymes such as retinol dehydrogenase 10 and  retinaldehyde dehydrogenase type 2  (RALDH2).",
    "entity1": "retinol",
    "entity2": "retinaldehyde dehydrogenase type 2"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Here we demonstrate that PPARgamma, turns on retinoic acid synthesis by inducing the expression of <protein> retinol </protein> and retinal metabolizing enzymes such as retinol dehydrogenase 10 and retinaldehyde dehydrogenase type 2 (<chemical> RALDH2 </chemical>).",
    "original_text": "Here we demonstrate that PPARgamma, turns on retinoic acid synthesis by inducing the expression of  retinol  and retinal metabolizing enzymes such as retinol dehydrogenase 10 and retinaldehyde dehydrogenase type 2 ( RALDH2 ).",
    "entity1": "retinol",
    "entity2": "RALDH2"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Here we demonstrate that PPARgamma, turns on retinoic acid synthesis by inducing the expression of retinol and <protein> retinal </protein> metabolizing enzymes such as <chemical> retinol dehydrogenase 10 </chemical> and retinaldehyde dehydrogenase type 2 (RALDH2).",
    "original_text": "Here we demonstrate that PPARgamma, turns on retinoic acid synthesis by inducing the expression of retinol and  retinal  metabolizing enzymes such as  retinol dehydrogenase 10  and retinaldehyde dehydrogenase type 2 (RALDH2).",
    "entity1": "retinal",
    "entity2": "retinol dehydrogenase 10"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Here we demonstrate that PPARgamma, turns on retinoic acid synthesis by inducing the expression of retinol and <protein> retinal </protein> metabolizing enzymes such as retinol dehydrogenase 10 and <chemical> retinaldehyde dehydrogenase type 2 </chemical> (RALDH2).",
    "original_text": "Here we demonstrate that PPARgamma, turns on retinoic acid synthesis by inducing the expression of retinol and  retinal  metabolizing enzymes such as retinol dehydrogenase 10 and  retinaldehyde dehydrogenase type 2  (RALDH2).",
    "entity1": "retinal",
    "entity2": "retinaldehyde dehydrogenase type 2"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Here we demonstrate that PPARgamma, turns on retinoic acid synthesis by inducing the expression of retinol and <protein> retinal </protein> metabolizing enzymes such as retinol dehydrogenase 10 and retinaldehyde dehydrogenase type 2 (<chemical> RALDH2 </chemical>).",
    "original_text": "Here we demonstrate that PPARgamma, turns on retinoic acid synthesis by inducing the expression of retinol and  retinal  metabolizing enzymes such as retinol dehydrogenase 10 and retinaldehyde dehydrogenase type 2 ( RALDH2 ).",
    "entity1": "retinal",
    "entity2": "RALDH2"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "CONTEXT: <protein> Ramelteon </protein> is a novel <chemical> MT1 </chemical> and MT2 melatonin receptor selective agonist recently approved for insomnia treatment.",
    "original_text": "CONTEXT:  Ramelteon  is a novel  MT1  and MT2 melatonin receptor selective agonist recently approved for insomnia treatment.",
    "entity1": "Ramelteon",
    "entity2": "MT1"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "CONTEXT: <protein> Ramelteon </protein> is a novel MT1 and <chemical> MT2 melatonin receptor </chemical> selective agonist recently approved for insomnia treatment.",
    "original_text": "CONTEXT:  Ramelteon  is a novel MT1 and  MT2 melatonin receptor  selective agonist recently approved for insomnia treatment.",
    "entity1": "Ramelteon",
    "entity2": "MT2 melatonin receptor"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "<protein> Methylthioadenosine phosphorylase </protein> (MTAP) salvages purines by releasing adenine from <chemical> methylthioadenosine </chemical> and is often deleted in mesothelioma.",
    "original_text": " Methylthioadenosine phosphorylase  (MTAP) salvages purines by releasing adenine from  methylthioadenosine  and is often deleted in mesothelioma.",
    "entity1": "Methylthioadenosine phosphorylase",
    "entity2": "methylthioadenosine"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Methylthioadenosine phosphorylase (<protein> MTAP </protein>) salvages purines by releasing adenine from <chemical> methylthioadenosine </chemical> and is often deleted in mesothelioma.",
    "original_text": "Methylthioadenosine phosphorylase ( MTAP ) salvages purines by releasing adenine from  methylthioadenosine  and is often deleted in mesothelioma.",
    "entity1": "MTAP",
    "entity2": "methylthioadenosine"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "Our work shows that <protein> sulfonylureas </protein> and glinides additionally bind to PPARgamma and exhibit <chemical> PPARgamma </chemical> agonistic activity.",
    "original_text": "Our work shows that  sulfonylureas  and glinides additionally bind to PPARgamma and exhibit  PPARgamma  agonistic activity.",
    "entity1": "sulfonylureas",
    "entity2": "PPARgamma"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "Our work shows that sulfonylureas and <protein> glinides </protein> additionally bind to PPARgamma and exhibit <chemical> PPARgamma </chemical> agonistic activity.",
    "original_text": "Our work shows that sulfonylureas and  glinides  additionally bind to PPARgamma and exhibit  PPARgamma  agonistic activity.",
    "entity1": "glinides",
    "entity2": "PPARgamma"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "Among the measured compounds, <protein> gliquidone </protein> and glipizide (two sulfonylureas), as well as nateglinide (a glinide), exhibit <chemical> PPARgamma </chemical> agonistic activity at concentrations comparable with those reached under pharmacological treatment.",
    "original_text": "Among the measured compounds,  gliquidone  and glipizide (two sulfonylureas), as well as nateglinide (a glinide), exhibit  PPARgamma  agonistic activity at concentrations comparable with those reached under pharmacological treatment.",
    "entity1": "gliquidone",
    "entity2": "PPARgamma"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "Among the measured compounds, gliquidone and <protein> glipizide </protein> (two sulfonylureas), as well as nateglinide (a glinide), exhibit <chemical> PPARgamma </chemical> agonistic activity at concentrations comparable with those reached under pharmacological treatment.",
    "original_text": "Among the measured compounds, gliquidone and  glipizide  (two sulfonylureas), as well as nateglinide (a glinide), exhibit  PPARgamma  agonistic activity at concentrations comparable with those reached under pharmacological treatment.",
    "entity1": "glipizide",
    "entity2": "PPARgamma"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "Among the measured compounds, gliquidone and glipizide (two <protein> sulfonylureas </protein>), as well as nateglinide (a glinide), exhibit <chemical> PPARgamma </chemical> agonistic activity at concentrations comparable with those reached under pharmacological treatment.",
    "original_text": "Among the measured compounds, gliquidone and glipizide (two  sulfonylureas ), as well as nateglinide (a glinide), exhibit  PPARgamma  agonistic activity at concentrations comparable with those reached under pharmacological treatment.",
    "entity1": "sulfonylureas",
    "entity2": "PPARgamma"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "Among the measured compounds, gliquidone and glipizide (two sulfonylureas), as well as <protein> nateglinide </protein> (a glinide), exhibit <chemical> PPARgamma </chemical> agonistic activity at concentrations comparable with those reached under pharmacological treatment.",
    "original_text": "Among the measured compounds, gliquidone and glipizide (two sulfonylureas), as well as  nateglinide  (a glinide), exhibit  PPARgamma  agonistic activity at concentrations comparable with those reached under pharmacological treatment.",
    "entity1": "nateglinide",
    "entity2": "PPARgamma"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "Among the measured compounds, gliquidone and glipizide (two sulfonylureas), as well as nateglinide (a <protein> glinide </protein>), exhibit <chemical> PPARgamma </chemical> agonistic activity at concentrations comparable with those reached under pharmacological treatment.",
    "original_text": "Among the measured compounds, gliquidone and glipizide (two sulfonylureas), as well as nateglinide (a  glinide ), exhibit  PPARgamma  agonistic activity at concentrations comparable with those reached under pharmacological treatment.",
    "entity1": "glinide",
    "entity2": "PPARgamma"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "<protein> Glinides </protein>, sulfonylureas, and other acidified sulfonamides may be promising leads in the development of new <chemical> PPARgamma </chemical> agonists.",
    "original_text": " Glinides , sulfonylureas, and other acidified sulfonamides may be promising leads in the development of new  PPARgamma  agonists.",
    "entity1": "Glinides",
    "entity2": "PPARgamma"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "Glinides, <protein> sulfonylureas </protein>, and other acidified sulfonamides may be promising leads in the development of new <chemical> PPARgamma </chemical> agonists.",
    "original_text": "Glinides,  sulfonylureas , and other acidified sulfonamides may be promising leads in the development of new  PPARgamma  agonists.",
    "entity1": "sulfonylureas",
    "entity2": "PPARgamma"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "Glinides, sulfonylureas, and other <protein> acidified sulfonamides </protein> may be promising leads in the development of new <chemical> PPARgamma </chemical> agonists.",
    "original_text": "Glinides, sulfonylureas, and other  acidified sulfonamides  may be promising leads in the development of new  PPARgamma  agonists.",
    "entity1": "acidified sulfonamides",
    "entity2": "PPARgamma"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "By using pharmacological and genetic manipulation of phosphodiesterases (PDEs), we demonstrate that compartmentalized <protein> PDE4B </protein> and PDE4D are responsible for selectively modulating the concentration of <chemical> cAMP </chemical> in individual subcellular compartments.",
    "original_text": "By using pharmacological and genetic manipulation of phosphodiesterases (PDEs), we demonstrate that compartmentalized  PDE4B  and PDE4D are responsible for selectively modulating the concentration of  cAMP  in individual subcellular compartments.",
    "entity1": "PDE4B",
    "entity2": "cAMP"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "By using pharmacological and genetic manipulation of phosphodiesterases (PDEs), we demonstrate that compartmentalized PDE4B and <protein> PDE4D </protein> are responsible for selectively modulating the concentration of <chemical> cAMP </chemical> in individual subcellular compartments.",
    "original_text": "By using pharmacological and genetic manipulation of phosphodiesterases (PDEs), we demonstrate that compartmentalized PDE4B and  PDE4D  are responsible for selectively modulating the concentration of  cAMP  in individual subcellular compartments.",
    "entity1": "PDE4D",
    "entity2": "cAMP"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "We propose a model whereby compartmentalized <protein> PDEs </protein>, rather than representing an enzymatic barrier to cAMP diffusion, act as a sink to drain the second messenger from discrete locations, resulting in multiple and simultaneous domains with different <chemical> cAMP </chemical> concentrations irrespective of their distance from the site of cAMP synthesis.",
    "original_text": "We propose a model whereby compartmentalized  PDEs , rather than representing an enzymatic barrier to cAMP diffusion, act as a sink to drain the second messenger from discrete locations, resulting in multiple and simultaneous domains with different  cAMP  concentrations irrespective of their distance from the site of cAMP synthesis.",
    "entity1": "PDEs",
    "entity2": "cAMP"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "We propose a model whereby compartmentalized <protein> PDEs </protein>, rather than representing an enzymatic barrier to cAMP diffusion, act as a sink to drain the second messenger from discrete locations, resulting in multiple and simultaneous domains with different cAMP concentrations irrespective of their distance from the site of <chemical> cAMP </chemical> synthesis.",
    "original_text": "We propose a model whereby compartmentalized  PDEs , rather than representing an enzymatic barrier to cAMP diffusion, act as a sink to drain the second messenger from discrete locations, resulting in multiple and simultaneous domains with different cAMP concentrations irrespective of their distance from the site of  cAMP  synthesis.",
    "entity1": "PDEs",
    "entity2": "cAMP"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "The changes in CysLT1 receptor expression 24 h after NMDA injection and the effects of a <protein> CysLT1 receptor </protein> antagonist, <chemical> pranlukast </chemical> (0.01 and 0.1 mg/kg), an NMDA receptor antagonist, ketamine (30 mg/kg), and an antioxidant, edaravone (9 mg/kg) were observed.",
    "original_text": "The changes in CysLT1 receptor expression 24 h after NMDA injection and the effects of a  CysLT1 receptor  antagonist,  pranlukast  (0.01 and 0.1 mg/kg), an NMDA receptor antagonist, ketamine (30 mg/kg), and an antioxidant, edaravone (9 mg/kg) were observed.",
    "entity1": "CysLT1 receptor",
    "entity2": "pranlukast"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "The changes in CysLT1 receptor expression 24 h after NMDA injection and the effects of a CysLT1 receptor antagonist, pranlukast (0.01 and 0.1 mg/kg), an <protein> NMDA receptor </protein> antagonist, <chemical> ketamine </chemical> (30 mg/kg), and an antioxidant, edaravone (9 mg/kg) were observed.",
    "original_text": "The changes in CysLT1 receptor expression 24 h after NMDA injection and the effects of a CysLT1 receptor antagonist, pranlukast (0.01 and 0.1 mg/kg), an  NMDA receptor  antagonist,  ketamine  (30 mg/kg), and an antioxidant, edaravone (9 mg/kg) were observed.",
    "entity1": "NMDA receptor",
    "entity2": "ketamine"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "The mechanism(s) responsible for arterial vasodilation observed following acute administration of <protein> racemic carvedilol </protein>, a novel vasodilator/<chemical> beta adrenoceptor </chemical> antagonist, has been investigated in rats.",
    "original_text": "The mechanism(s) responsible for arterial vasodilation observed following acute administration of  racemic carvedilol , a novel vasodilator/ beta adrenoceptor  antagonist, has been investigated in rats.",
    "entity1": "racemic carvedilol",
    "entity2": "beta adrenoceptor"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Carvedilol produced significant inhibition of the alpha 1 adrenoceptor mediated pressor response to cirazoline in the pithed rat, but had no effect on the alpha 2 adrenoceptor mediated pressor response to B-HT 933, suggesting that <protein> carvedilol </protein> is also an <chemical> alpha 1 adrenoceptor </chemical> antagonist at antihypertensive doses.",
    "original_text": "Carvedilol produced significant inhibition of the alpha 1 adrenoceptor mediated pressor response to cirazoline in the pithed rat, but had no effect on the alpha 2 adrenoceptor mediated pressor response to B-HT 933, suggesting that  carvedilol  is also an  alpha 1 adrenoceptor  antagonist at antihypertensive doses.",
    "entity1": "carvedilol",
    "entity2": "alpha 1 adrenoceptor"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "The vasopressor response to the calcium channel activator, BAY-K-8644, which is mediated through the opening of voltage dependent calcium channels and the subsequent translocation of extracellular calcium, was significantly inhibited by carvedilol (1 mg/kg, iv), suggesting that <protein> carvedilol </protein> is also a <chemical> calcium channel </chemical> antagonist, consistent with our previous in vitro studies.",
    "original_text": "The vasopressor response to the calcium channel activator, BAY-K-8644, which is mediated through the opening of voltage dependent calcium channels and the subsequent translocation of extracellular calcium, was significantly inhibited by carvedilol (1 mg/kg, iv), suggesting that  carvedilol  is also a  calcium channel  antagonist, consistent with our previous in vitro studies.",
    "entity1": "carvedilol",
    "entity2": "calcium channel"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "The vasopressor response to the calcium channel activator, BAY-K-8644, which is mediated through the opening of <protein> voltage dependent calcium channels </protein> and the subsequent translocation of extracellular <chemical> calcium </chemical>, was significantly inhibited by carvedilol (1 mg/kg, iv), suggesting that carvedilol is also a calcium channel antagonist, consistent with our previous in vitro studies.",
    "original_text": "The vasopressor response to the calcium channel activator, BAY-K-8644, which is mediated through the opening of  voltage dependent calcium channels  and the subsequent translocation of extracellular  calcium , was significantly inhibited by carvedilol (1 mg/kg, iv), suggesting that carvedilol is also a calcium channel antagonist, consistent with our previous in vitro studies.",
    "entity1": "voltage dependent calcium channels",
    "entity2": "calcium"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "In anesthetized spontaneously hypertensive rats, the antihypertensive activity of carvedilol was nearly abolished by combined pretreatment of the rats with high doses of the <protein> alpha 1 adrenoceptor </protein> antagonist, <chemical> prazosin </chemical> (1 mg/kg, iv), and the nonselective beta adrenoceptor antagonist, propranolol (3 mg/kg, iv), suggesting that the majority of the antihypertensive response produced by carvedilol may be accounted for by blockade of beta and alpha 1 adrenoceptors.",
    "original_text": "In anesthetized spontaneously hypertensive rats, the antihypertensive activity of carvedilol was nearly abolished by combined pretreatment of the rats with high doses of the  alpha 1 adrenoceptor  antagonist,  prazosin  (1 mg/kg, iv), and the nonselective beta adrenoceptor antagonist, propranolol (3 mg/kg, iv), suggesting that the majority of the antihypertensive response produced by carvedilol may be accounted for by blockade of beta and alpha 1 adrenoceptors.",
    "entity1": "alpha 1 adrenoceptor",
    "entity2": "prazosin"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "In anesthetized spontaneously hypertensive rats, the antihypertensive activity of carvedilol was nearly abolished by combined pretreatment of the rats with high doses of the alpha 1 adrenoceptor antagonist, prazosin (1 mg/kg, iv), and the nonselective <protein> beta adrenoceptor </protein> antagonist, <chemical> propranolol </chemical> (3 mg/kg, iv), suggesting that the majority of the antihypertensive response produced by carvedilol may be accounted for by blockade of beta and alpha 1 adrenoceptors.",
    "original_text": "In anesthetized spontaneously hypertensive rats, the antihypertensive activity of carvedilol was nearly abolished by combined pretreatment of the rats with high doses of the alpha 1 adrenoceptor antagonist, prazosin (1 mg/kg, iv), and the nonselective  beta adrenoceptor  antagonist,  propranolol  (3 mg/kg, iv), suggesting that the majority of the antihypertensive response produced by carvedilol may be accounted for by blockade of beta and alpha 1 adrenoceptors.",
    "entity1": "beta adrenoceptor",
    "entity2": "propranolol"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "We therefore conclude that <protein> carvedilol </protein>, at antihypertensive doses, is an antagonist of beta 1, beta 2, and alpha 1 adrenoceptors, and also of <chemical> calcium channels </chemical> in vascular smooth muscle.(ABSTRACT TRUNCATED AT 400 WORDS)",
    "original_text": "We therefore conclude that  carvedilol , at antihypertensive doses, is an antagonist of beta 1, beta 2, and alpha 1 adrenoceptors, and also of  calcium channels  in vascular smooth muscle.(ABSTRACT TRUNCATED AT 400 WORDS)",
    "entity1": "carvedilol",
    "entity2": "calcium channels"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "<protein> 5-HT3 receptor </protein> antagonism with <chemical> alosetron </chemical> reduced responses to 5-HT in controls but not during inflammation.",
    "original_text": " 5-HT3 receptor  antagonism with  alosetron  reduced responses to 5-HT in controls but not during inflammation.",
    "entity1": "5-HT3 receptor",
    "entity2": "alosetron"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "i.p. injection of a subthreshold dose of <protein> picrotoxin </protein>, a use-dependent <chemical> gamma-aminobutyric acid receptor </chemical> antagonist, reduces cortical electroencephalogram delta power and transiently inhibits spontaneous seizure activity in ADNFLE mutant mice.",
    "original_text": "i.p. injection of a subthreshold dose of  picrotoxin , a use-dependent  gamma-aminobutyric acid receptor  antagonist, reduces cortical electroencephalogram delta power and transiently inhibits spontaneous seizure activity in ADNFLE mutant mice.",
    "entity1": "picrotoxin",
    "entity2": "gamma-aminobutyric acid receptor"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "MicroPET imaging in nonhuman primates with [<protein> 11C </protein>]1 and [11C]2 demonstrated that both tracers behave similarly in vivo with high uptake being observed in the <chemical> SERT </chemical>-rich brain regions and peak uptake being achieved in about 55 min postinjection.",
    "original_text": "MicroPET imaging in nonhuman primates with [ 11C ]1 and [11C]2 demonstrated that both tracers behave similarly in vivo with high uptake being observed in the  SERT -rich brain regions and peak uptake being achieved in about 55 min postinjection.",
    "entity1": "11C",
    "entity2": "SERT"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "MicroPET imaging in nonhuman primates with [11C]1 and [<protein> 11C </protein>]2 demonstrated that both tracers behave similarly in vivo with high uptake being observed in the <chemical> SERT </chemical>-rich brain regions and peak uptake being achieved in about 55 min postinjection.",
    "original_text": "MicroPET imaging in nonhuman primates with [11C]1 and [ 11C ]2 demonstrated that both tracers behave similarly in vivo with high uptake being observed in the  SERT -rich brain regions and peak uptake being achieved in about 55 min postinjection.",
    "entity1": "11C",
    "entity2": "SERT"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "This trial investigated the possibility of pharmacokinetic interactions between the <protein> AT1 receptor </protein> antagonist <chemical> olmesartan medoxomil </chemical> and the thiazide diuretic hydrochlorothiazide in healthy subjects.",
    "original_text": "This trial investigated the possibility of pharmacokinetic interactions between the  AT1 receptor  antagonist  olmesartan medoxomil  and the thiazide diuretic hydrochlorothiazide in healthy subjects.",
    "entity1": "AT1 receptor",
    "entity2": "olmesartan medoxomil"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "<protein> SecS </protein> required selenophosphate and <chemical> O-phosphoseryl </chemical>-tRNA([Ser]Sec) as substrates to generate selenocysteyl-tRNA([Ser]Sec).",
    "original_text": " SecS  required selenophosphate and  O-phosphoseryl -tRNA([Ser]Sec) as substrates to generate selenocysteyl-tRNA([Ser]Sec).",
    "entity1": "SecS",
    "entity2": "O-phosphoseryl"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "<protein> SecS </protein> required <chemical> selenophosphate </chemical> and O-phosphoseryl-tRNA([Ser]Sec) as substrates to generate selenocysteyl-tRNA([Ser]Sec).",
    "original_text": " SecS  required  selenophosphate  and O-phosphoseryl-tRNA([Ser]Sec) as substrates to generate selenocysteyl-tRNA([Ser]Sec).",
    "entity1": "SecS",
    "entity2": "selenophosphate"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "<protein> Glutamate </protein> stimulates <chemical> glutamate receptor interacting protein 1 </chemical> degradation by ubiquitin-proteasome system to regulate surface expression of GluR2.",
    "original_text": " Glutamate  stimulates  glutamate receptor interacting protein 1  degradation by ubiquitin-proteasome system to regulate surface expression of GluR2.",
    "entity1": "Glutamate",
    "entity2": "glutamate receptor interacting protein 1"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "Down-regulation of <protein> GRIP1 </protein> by <chemical> glutamate </chemical> was blocked by carbobenzoxyl-leucinyl-leucinyl-leucinal (MG132), a proteasome inhibitor and by expression of K48R-ubiquitin, a dominant negative form of ubiquitin.",
    "original_text": "Down-regulation of  GRIP1  by  glutamate  was blocked by carbobenzoxyl-leucinyl-leucinyl-leucinal (MG132), a proteasome inhibitor and by expression of K48R-ubiquitin, a dominant negative form of ubiquitin.",
    "entity1": "GRIP1",
    "entity2": "glutamate"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "The GRIP1 reduction was inhibited by <protein> MK-801 </protein>, an <chemical> N-methyl-d-aspartate (NMDA) receptor </chemical> antagonist, but not by 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX), an AMPA receptor antagonist.",
    "original_text": "The GRIP1 reduction was inhibited by  MK-801 , an  N-methyl-d-aspartate (NMDA) receptor  antagonist, but not by 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX), an AMPA receptor antagonist.",
    "entity1": "MK-801",
    "entity2": "N-methyl-d-aspartate (NMDA) receptor"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "The GRIP1 reduction was inhibited by MK-801, an N-methyl-d-aspartate (NMDA) receptor antagonist, but not by <protein> 6-cyano-7-nitroquinoxaline-2,3-dione </protein> (CNQX), an <chemical> AMPA receptor </chemical> antagonist.",
    "original_text": "The GRIP1 reduction was inhibited by MK-801, an N-methyl-d-aspartate (NMDA) receptor antagonist, but not by  6-cyano-7-nitroquinoxaline-2,3-dione  (CNQX), an  AMPA receptor  antagonist.",
    "entity1": "6-cyano-7-nitroquinoxaline-2,3-dione",
    "entity2": "AMPA receptor"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "The GRIP1 reduction was inhibited by MK-801, an N-methyl-d-aspartate (NMDA) receptor antagonist, but not by 6-cyano-7-nitroquinoxaline-2,3-dione (<protein> CNQX </protein>), an <chemical> AMPA receptor </chemical> antagonist.",
    "original_text": "The GRIP1 reduction was inhibited by MK-801, an N-methyl-d-aspartate (NMDA) receptor antagonist, but not by 6-cyano-7-nitroquinoxaline-2,3-dione ( CNQX ), an  AMPA receptor  antagonist.",
    "entity1": "CNQX",
    "entity2": "AMPA receptor"
  },
  {
    "_id": 1,
    "label": "Upregulator",
    "text": "<protein> EGTA </protein> and 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetra acetic acid tetrakis (BAPTA), two Ca2+ chelators, but not nifedipine, an L-type Ca2+ channel blocker, prevented <chemical> GRIP1 </chemical> degradation.",
    "original_text": " EGTA  and 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetra acetic acid tetrakis (BAPTA), two Ca2+ chelators, but not nifedipine, an L-type Ca2+ channel blocker, prevented  GRIP1  degradation.",
    "entity1": "EGTA",
    "entity2": "GRIP1"
  },
  {
    "_id": 1,
    "label": "Upregulator",
    "text": "EGTA and <protein> 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetra acetic acid tetrakis </protein> (BAPTA), two Ca2+ chelators, but not nifedipine, an L-type Ca2+ channel blocker, prevented <chemical> GRIP1 </chemical> degradation.",
    "original_text": "EGTA and  1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetra acetic acid tetrakis  (BAPTA), two Ca2+ chelators, but not nifedipine, an L-type Ca2+ channel blocker, prevented  GRIP1  degradation.",
    "entity1": "1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetra acetic acid tetrakis",
    "entity2": "GRIP1"
  },
  {
    "_id": 1,
    "label": "Upregulator",
    "text": "EGTA and 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetra acetic acid tetrakis (<protein> BAPTA </protein>), two Ca2+ chelators, but not nifedipine, an L-type Ca2+ channel blocker, prevented <chemical> GRIP1 </chemical> degradation.",
    "original_text": "EGTA and 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetra acetic acid tetrakis ( BAPTA ), two Ca2+ chelators, but not nifedipine, an L-type Ca2+ channel blocker, prevented  GRIP1  degradation.",
    "entity1": "BAPTA",
    "entity2": "GRIP1"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "Our results suggest that <protein> glutamate </protein> induces <chemical> GRIP1 </chemical> degradation by proteasome through an NMDA receptor-Ca2+ pathway and that GRIP1 degradation may play an important role in regulating GluR2 surface expression.",
    "original_text": "Our results suggest that  glutamate  induces  GRIP1  degradation by proteasome through an NMDA receptor-Ca2+ pathway and that GRIP1 degradation may play an important role in regulating GluR2 surface expression.",
    "entity1": "glutamate",
    "entity2": "GRIP1"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "Our results suggest that <protein> glutamate </protein> induces GRIP1 degradation by proteasome through an NMDA receptor-Ca2+ pathway and that <chemical> GRIP1 </chemical> degradation may play an important role in regulating GluR2 surface expression.",
    "original_text": "Our results suggest that  glutamate  induces GRIP1 degradation by proteasome through an NMDA receptor-Ca2+ pathway and that  GRIP1  degradation may play an important role in regulating GluR2 surface expression.",
    "entity1": "glutamate",
    "entity2": "GRIP1"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "METHODS: The effect of leukotriene D(4) and the <protein> leukotriene receptor </protein> antagonist, <chemical> pranlukast hydrate </chemical> (ONO-1078) on the regulation of MUC2/5AC gene expression and mucin secretion were observed in human airway NCI-H292 epithelial cells.",
    "original_text": "METHODS: The effect of leukotriene D(4) and the  leukotriene receptor  antagonist,  pranlukast hydrate  (ONO-1078) on the regulation of MUC2/5AC gene expression and mucin secretion were observed in human airway NCI-H292 epithelial cells.",
    "entity1": "leukotriene receptor",
    "entity2": "pranlukast hydrate"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "METHODS: The effect of leukotriene D(4) and the <protein> leukotriene receptor </protein> antagonist, pranlukast hydrate (<chemical> ONO-1078 </chemical>) on the regulation of MUC2/5AC gene expression and mucin secretion were observed in human airway NCI-H292 epithelial cells.",
    "original_text": "METHODS: The effect of leukotriene D(4) and the  leukotriene receptor  antagonist, pranlukast hydrate ( ONO-1078 ) on the regulation of MUC2/5AC gene expression and mucin secretion were observed in human airway NCI-H292 epithelial cells.",
    "entity1": "leukotriene receptor",
    "entity2": "ONO-1078"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "We studied in a clinical trial whether isolated isoflavone treatment in postmenopausal women could affect reverse cholesterol transport as evaluated by <protein> adenosine triphosphate-binding cassette A1 </protein>- (ABCA1), dependent <chemical> cholesterol </chemical> efflux from macrophages.",
    "original_text": "We studied in a clinical trial whether isolated isoflavone treatment in postmenopausal women could affect reverse cholesterol transport as evaluated by  adenosine triphosphate-binding cassette A1 - (ABCA1), dependent  cholesterol  efflux from macrophages.",
    "entity1": "adenosine triphosphate-binding cassette A1",
    "entity2": "cholesterol"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "We studied in a clinical trial whether isolated isoflavone treatment in postmenopausal women could affect reverse cholesterol transport as evaluated by adenosine triphosphate-binding cassette A1- (<protein> ABCA1 </protein>), dependent <chemical> cholesterol </chemical> efflux from macrophages.",
    "original_text": "We studied in a clinical trial whether isolated isoflavone treatment in postmenopausal women could affect reverse cholesterol transport as evaluated by adenosine triphosphate-binding cassette A1- ( ABCA1 ), dependent  cholesterol  efflux from macrophages.",
    "entity1": "ABCA1",
    "entity2": "cholesterol"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "[H]-Cholesterol-labeled J774 macrophage cells, with and without ABCA1 up-regulation, were incubated with the samples, and <protein> ABCA1 </protein>-dependent <chemical> cholesterol </chemical> efflux and serum lipid and lipoprotein levels were assessed.",
    "original_text": "[H]-Cholesterol-labeled J774 macrophage cells, with and without ABCA1 up-regulation, were incubated with the samples, and  ABCA1 -dependent  cholesterol  efflux and serum lipid and lipoprotein levels were assessed.",
    "entity1": "ABCA1",
    "entity2": "cholesterol"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Thus, isoflavone supplementation did not affect <protein> ABCA1 </protein>-dependent <chemical> cholesterol </chemical> efflux to serum.",
    "original_text": "Thus, isoflavone supplementation did not affect  ABCA1 -dependent  cholesterol  efflux to serum.",
    "entity1": "ABCA1",
    "entity2": "cholesterol"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "<protein> ABCA1 </protein>-facilitated <chemical> cholesterol </chemical> efflux and lipid parameters did not differ between equol-producing and non-equol-producing women.",
    "original_text": " ABCA1 -facilitated  cholesterol  efflux and lipid parameters did not differ between equol-producing and non-equol-producing women.",
    "entity1": "ABCA1",
    "entity2": "cholesterol"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "CONCLUSION: In postmenopausal women, isolated isoflavone treatment does not affect <protein> ABCA1 </protein>-dependent <chemical> cholesterol </chemical> efflux potential from macrophages but increases circulating pre-beta high-density lipoprotein level, which could provide beneficial vascular effects.",
    "original_text": "CONCLUSION: In postmenopausal women, isolated isoflavone treatment does not affect  ABCA1 -dependent  cholesterol  efflux potential from macrophages but increases circulating pre-beta high-density lipoprotein level, which could provide beneficial vascular effects.",
    "entity1": "ABCA1",
    "entity2": "cholesterol"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Exposure to <protein> mifepristone </protein> (a <chemical> glucocorticoid receptor </chemical> antagonist), but not spironolactone (a mineralocorticoid receptor antagonist), precluded both the corticosteroid-induced elevation in amiloride-sensitive I(sc) and the induced changes in beta- and gamma-ENaC mRNA.",
    "original_text": "Exposure to  mifepristone  (a  glucocorticoid receptor  antagonist), but not spironolactone (a mineralocorticoid receptor antagonist), precluded both the corticosteroid-induced elevation in amiloride-sensitive I(sc) and the induced changes in beta- and gamma-ENaC mRNA.",
    "entity1": "mifepristone",
    "entity2": "glucocorticoid receptor"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Exposure to mifepristone (a glucocorticoid receptor antagonist), but not <protein> spironolactone </protein> (a <chemical> mineralocorticoid receptor </chemical> antagonist), precluded both the corticosteroid-induced elevation in amiloride-sensitive I(sc) and the induced changes in beta- and gamma-ENaC mRNA.",
    "original_text": "Exposure to mifepristone (a glucocorticoid receptor antagonist), but not  spironolactone  (a  mineralocorticoid receptor  antagonist), precluded both the corticosteroid-induced elevation in amiloride-sensitive I(sc) and the induced changes in beta- and gamma-ENaC mRNA.",
    "entity1": "spironolactone",
    "entity2": "mineralocorticoid receptor"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "We found that <protein> simvastatin </protein> abolishes anti-<chemical> CD11a </chemical> mAb-induced increases in lymphocytic cholinergic activity in a manner independent of its cholesterol-lowering activity.",
    "original_text": "We found that  simvastatin  abolishes anti- CD11a  mAb-induced increases in lymphocytic cholinergic activity in a manner independent of its cholesterol-lowering activity.",
    "entity1": "simvastatin",
    "entity2": "CD11a"
  },
  {
    "_id": 1,
    "label": "Upregulator",
    "text": "INTRODUCTION: Medroxyprogesterone acetate (<protein> MPA </protein>) induces estrogen receptor (ER)-positive and progesterone receptor (<chemical> PR </chemical>)-positive ductal invasive mammary carcinomas in BALB/c mice.",
    "original_text": "INTRODUCTION: Medroxyprogesterone acetate ( MPA ) induces estrogen receptor (ER)-positive and progesterone receptor ( PR )-positive ductal invasive mammary carcinomas in BALB/c mice.",
    "entity1": "MPA",
    "entity2": "PR"
  },
  {
    "_id": 1,
    "label": "Upregulator",
    "text": "INTRODUCTION: Medroxyprogesterone acetate (<protein> MPA </protein>) induces <chemical> estrogen receptor </chemical> (ER)-positive and progesterone receptor (PR)-positive ductal invasive mammary carcinomas in BALB/c mice.",
    "original_text": "INTRODUCTION: Medroxyprogesterone acetate ( MPA ) induces  estrogen receptor  (ER)-positive and progesterone receptor (PR)-positive ductal invasive mammary carcinomas in BALB/c mice.",
    "entity1": "MPA",
    "entity2": "estrogen receptor"
  },
  {
    "_id": 1,
    "label": "Upregulator",
    "text": "INTRODUCTION: Medroxyprogesterone acetate (<protein> MPA </protein>) induces estrogen receptor (<chemical> ER </chemical>)-positive and progesterone receptor (PR)-positive ductal invasive mammary carcinomas in BALB/c mice.",
    "original_text": "INTRODUCTION: Medroxyprogesterone acetate ( MPA ) induces estrogen receptor ( ER )-positive and progesterone receptor (PR)-positive ductal invasive mammary carcinomas in BALB/c mice.",
    "entity1": "MPA",
    "entity2": "ER"
  },
  {
    "_id": 1,
    "label": "Upregulator",
    "text": "INTRODUCTION: <protein> Medroxyprogesterone acetate </protein> (MPA) induces estrogen receptor (ER)-positive and progesterone receptor (<chemical> PR </chemical>)-positive ductal invasive mammary carcinomas in BALB/c mice.",
    "original_text": "INTRODUCTION:  Medroxyprogesterone acetate  (MPA) induces estrogen receptor (ER)-positive and progesterone receptor ( PR )-positive ductal invasive mammary carcinomas in BALB/c mice.",
    "entity1": "Medroxyprogesterone acetate",
    "entity2": "PR"
  },
  {
    "_id": 1,
    "label": "Upregulator",
    "text": "INTRODUCTION: <protein> Medroxyprogesterone acetate </protein> (MPA) induces <chemical> estrogen receptor </chemical> (ER)-positive and progesterone receptor (PR)-positive ductal invasive mammary carcinomas in BALB/c mice.",
    "original_text": "INTRODUCTION:  Medroxyprogesterone acetate  (MPA) induces  estrogen receptor  (ER)-positive and progesterone receptor (PR)-positive ductal invasive mammary carcinomas in BALB/c mice.",
    "entity1": "Medroxyprogesterone acetate",
    "entity2": "estrogen receptor"
  },
  {
    "_id": 1,
    "label": "Upregulator",
    "text": "INTRODUCTION: <protein> Medroxyprogesterone acetate </protein> (MPA) induces estrogen receptor (<chemical> ER </chemical>)-positive and progesterone receptor (PR)-positive ductal invasive mammary carcinomas in BALB/c mice.",
    "original_text": "INTRODUCTION:  Medroxyprogesterone acetate  (MPA) induces estrogen receptor ( ER )-positive and progesterone receptor (PR)-positive ductal invasive mammary carcinomas in BALB/c mice.",
    "entity1": "Medroxyprogesterone acetate",
    "entity2": "ER"
  },
  {
    "_id": 1,
    "label": "Upregulator",
    "text": "INTRODUCTION: <protein> Medroxyprogesterone acetate </protein> (MPA) induces estrogen receptor (ER)-positive and <chemical> progesterone receptor </chemical> (PR)-positive ductal invasive mammary carcinomas in BALB/c mice.",
    "original_text": "INTRODUCTION:  Medroxyprogesterone acetate  (MPA) induces estrogen receptor (ER)-positive and  progesterone receptor  (PR)-positive ductal invasive mammary carcinomas in BALB/c mice.",
    "entity1": "Medroxyprogesterone acetate",
    "entity2": "progesterone receptor"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "In humans, <protein> methionine synthase </protein> deficiency results in the accumulation of <chemical> methyltetrahydrofolate </chemical> at the expense of folate derivatives required for purine and thymidylate biosynthesis.",
    "original_text": "In humans,  methionine synthase  deficiency results in the accumulation of  methyltetrahydrofolate  at the expense of folate derivatives required for purine and thymidylate biosynthesis.",
    "entity1": "methionine synthase",
    "entity2": "methyltetrahydrofolate"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "It is currently not known how much this <protein> H(1) </protein> antagonism of <chemical> clozapine </chemical> contributes to the therapeutic or adverse side effects of clozapine.",
    "original_text": "It is currently not known how much this  H(1)  antagonism of  clozapine  contributes to the therapeutic or adverse side effects of clozapine.",
    "entity1": "H(1)",
    "entity2": "clozapine"
  },
  {
    "_id": 1,
    "label": "Upregulator",
    "text": "In the current project, we found that the selective <protein> H(1) </protein> antagonist pyrilamine also reversed the <chemical> dizocilpine </chemical>-induced impairment in PPI of tactile startle with an auditory prepulse.",
    "original_text": "In the current project, we found that the selective  H(1)  antagonist pyrilamine also reversed the  dizocilpine -induced impairment in PPI of tactile startle with an auditory prepulse.",
    "entity1": "H(1)",
    "entity2": "dizocilpine"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "In the current project, we found that the selective <protein> H(1) </protein> antagonist <chemical> pyrilamine </chemical> also reversed the dizocilpine-induced impairment in PPI of tactile startle with an auditory prepulse.",
    "original_text": "In the current project, we found that the selective  H(1)  antagonist  pyrilamine  also reversed the dizocilpine-induced impairment in PPI of tactile startle with an auditory prepulse.",
    "entity1": "H(1)",
    "entity2": "pyrilamine"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "In summary, the therapeutic effect of <protein> clozapine </protein> in reversing PPI impairment was mimicked by the <chemical> H(1) </chemical> antagonist pyrilamine, while pyrilamine had a mixed effect on cognition.",
    "original_text": "In summary, the therapeutic effect of  clozapine  in reversing PPI impairment was mimicked by the  H(1)  antagonist pyrilamine, while pyrilamine had a mixed effect on cognition.",
    "entity1": "clozapine",
    "entity2": "H(1)"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "In summary, the therapeutic effect of clozapine in reversing PPI impairment was mimicked by the <protein> H(1) </protein> antagonist <chemical> pyrilamine </chemical>, while pyrilamine had a mixed effect on cognition.",
    "original_text": "In summary, the therapeutic effect of clozapine in reversing PPI impairment was mimicked by the  H(1)  antagonist  pyrilamine , while pyrilamine had a mixed effect on cognition.",
    "entity1": "H(1)",
    "entity2": "pyrilamine"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "In summary, the therapeutic effect of clozapine in reversing PPI impairment was mimicked by the <protein> H(1) </protein> antagonist pyrilamine, while <chemical> pyrilamine </chemical> had a mixed effect on cognition.",
    "original_text": "In summary, the therapeutic effect of clozapine in reversing PPI impairment was mimicked by the  H(1)  antagonist pyrilamine, while  pyrilamine  had a mixed effect on cognition.",
    "entity1": "H(1)",
    "entity2": "pyrilamine"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Thus, <protein> H(1) </protein> antagonism seems to play a role in part of the beneficial actions of antipsychotics, such as <chemical> clozapine </chemical>.",
    "original_text": "Thus,  H(1)  antagonism seems to play a role in part of the beneficial actions of antipsychotics, such as  clozapine .",
    "entity1": "H(1)",
    "entity2": "clozapine"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Furthermore, the enzymatic activity of <protein> alanine aminotransferase </protein> (ALT), which converts the critical gluconeogenic <chemical> amino acid </chemical> alanine into pyruvate, is decreased (approximately 50%) in KLF15-/- hepatocytes.",
    "original_text": "Furthermore, the enzymatic activity of  alanine aminotransferase  (ALT), which converts the critical gluconeogenic  amino acid  alanine into pyruvate, is decreased (approximately 50%) in KLF15-/- hepatocytes.",
    "entity1": "alanine aminotransferase",
    "entity2": "amino acid"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Furthermore, the enzymatic activity of alanine aminotransferase (<protein> ALT </protein>), which converts the critical gluconeogenic <chemical> amino acid </chemical> alanine into pyruvate, is decreased (approximately 50%) in KLF15-/- hepatocytes.",
    "original_text": "Furthermore, the enzymatic activity of alanine aminotransferase ( ALT ), which converts the critical gluconeogenic  amino acid  alanine into pyruvate, is decreased (approximately 50%) in KLF15-/- hepatocytes.",
    "entity1": "ALT",
    "entity2": "amino acid"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Furthermore, the enzymatic activity of <protein> alanine aminotransferase </protein> (ALT), which converts the critical gluconeogenic amino acid <chemical> alanine </chemical> into pyruvate, is decreased (approximately 50%) in KLF15-/- hepatocytes.",
    "original_text": "Furthermore, the enzymatic activity of  alanine aminotransferase  (ALT), which converts the critical gluconeogenic amino acid  alanine  into pyruvate, is decreased (approximately 50%) in KLF15-/- hepatocytes.",
    "entity1": "alanine aminotransferase",
    "entity2": "alanine"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Furthermore, the enzymatic activity of alanine aminotransferase (<protein> ALT </protein>), which converts the critical gluconeogenic amino acid <chemical> alanine </chemical> into pyruvate, is decreased (approximately 50%) in KLF15-/- hepatocytes.",
    "original_text": "Furthermore, the enzymatic activity of alanine aminotransferase ( ALT ), which converts the critical gluconeogenic amino acid  alanine  into pyruvate, is decreased (approximately 50%) in KLF15-/- hepatocytes.",
    "entity1": "ALT",
    "entity2": "alanine"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "The inhibitory effects of <protein> GW9662 </protein> and T0070907 (<chemical> PPARgamma </chemical> antagonists), on COX-2 expression and on stimulation of COX-2 promoter activity by EPA and GLA suggest that PPARgamma is implicated in COX-2 induction.",
    "original_text": "The inhibitory effects of  GW9662  and T0070907 ( PPARgamma  antagonists), on COX-2 expression and on stimulation of COX-2 promoter activity by EPA and GLA suggest that PPARgamma is implicated in COX-2 induction.",
    "entity1": "GW9662",
    "entity2": "PPARgamma"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "The inhibitory effects of GW9662 and <protein> T0070907 </protein> (<chemical> PPARgamma </chemical> antagonists), on COX-2 expression and on stimulation of COX-2 promoter activity by EPA and GLA suggest that PPARgamma is implicated in COX-2 induction.",
    "original_text": "The inhibitory effects of GW9662 and  T0070907  ( PPARgamma  antagonists), on COX-2 expression and on stimulation of COX-2 promoter activity by EPA and GLA suggest that PPARgamma is implicated in COX-2 induction.",
    "entity1": "T0070907",
    "entity2": "PPARgamma"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "OBJECTIVE: The aim of this study was to assess the efficacy and tolerability of nebulized arformoterol tartrate (a selective, long-acting <protein> beta(2)-adrenergic </protein> agonist that is the <chemical> [R,R] isomer of formoterol </chemical>) and salmeterol xinafoate versus placebo in patients with chronic obstructive pulmonary disease (COPD).",
    "original_text": "OBJECTIVE: The aim of this study was to assess the efficacy and tolerability of nebulized arformoterol tartrate (a selective, long-acting  beta(2)-adrenergic  agonist that is the  [R,R] isomer of formoterol ) and salmeterol xinafoate versus placebo in patients with chronic obstructive pulmonary disease (COPD).",
    "entity1": "beta(2)-adrenergic",
    "entity2": "[R,R] isomer of formoterol"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "OBJECTIVE: The aim of this study was to assess the efficacy and tolerability of nebulized <protein> arformoterol tartrate </protein> (a selective, long-acting <chemical> beta(2)-adrenergic </chemical> agonist that is the [R,R] isomer of formoterol) and salmeterol xinafoate versus placebo in patients with chronic obstructive pulmonary disease (COPD).",
    "original_text": "OBJECTIVE: The aim of this study was to assess the efficacy and tolerability of nebulized  arformoterol tartrate  (a selective, long-acting  beta(2)-adrenergic  agonist that is the [R,R] isomer of formoterol) and salmeterol xinafoate versus placebo in patients with chronic obstructive pulmonary disease (COPD).",
    "entity1": "arformoterol tartrate",
    "entity2": "beta(2)-adrenergic"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "In contrast, the <protein> RA </protein> catabolising enzymes <chemical> Cyp26A1 </chemical> and Cyp26B1 which are known to be RA-responsive were not expressed at all in the developing eye.",
    "original_text": "In contrast, the  RA  catabolising enzymes  Cyp26A1  and Cyp26B1 which are known to be RA-responsive were not expressed at all in the developing eye.",
    "entity1": "RA",
    "entity2": "Cyp26A1"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "In contrast, the <protein> RA </protein> catabolising enzymes Cyp26A1 and <chemical> Cyp26B1 </chemical> which are known to be RA-responsive were not expressed at all in the developing eye.",
    "original_text": "In contrast, the  RA  catabolising enzymes Cyp26A1 and  Cyp26B1  which are known to be RA-responsive were not expressed at all in the developing eye.",
    "entity1": "RA",
    "entity2": "Cyp26B1"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "This report reviews published and unpublished data that suggest that <protein> aripiprazole </protein> acts as a selective partial agonist at the <chemical> dopamine D(2) receptor </chemical> and does not affect 5-HT receptors at therapeutic doses.",
    "original_text": "This report reviews published and unpublished data that suggest that  aripiprazole  acts as a selective partial agonist at the  dopamine D(2) receptor  and does not affect 5-HT receptors at therapeutic doses.",
    "entity1": "aripiprazole",
    "entity2": "dopamine D(2) receptor"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "[N-(piperidin-1-yl)-5-(4-chlorophenyl)-4-methyl-1H-pyrazole-3-carboxyamide] (<protein> SR 141716A </protein>), a selective <chemical> cannabinoid CB1 receptor </chemical> antagonist, injected into the paraventricular nucleus of the hypothalamus (PVN) of male rats, induces penile erection.",
    "original_text": "[N-(piperidin-1-yl)-5-(4-chlorophenyl)-4-methyl-1H-pyrazole-3-carboxyamide] ( SR 141716A ), a selective  cannabinoid CB1 receptor  antagonist, injected into the paraventricular nucleus of the hypothalamus (PVN) of male rats, induces penile erection.",
    "entity1": "SR 141716A",
    "entity2": "cannabinoid CB1 receptor"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "[<protein> N-(piperidin-1-yl)-5-(4-chlorophenyl)-4-methyl-1H-pyrazole-3-carboxyamide </protein>] (SR 141716A), a selective <chemical> cannabinoid CB1 receptor </chemical> antagonist, injected into the paraventricular nucleus of the hypothalamus (PVN) of male rats, induces penile erection.",
    "original_text": "[ N-(piperidin-1-yl)-5-(4-chlorophenyl)-4-methyl-1H-pyrazole-3-carboxyamide ] (SR 141716A), a selective  cannabinoid CB1 receptor  antagonist, injected into the paraventricular nucleus of the hypothalamus (PVN) of male rats, induces penile erection.",
    "entity1": "N-(piperidin-1-yl)-5-(4-chlorophenyl)-4-methyl-1H-pyrazole-3-carboxyamide",
    "entity2": "cannabinoid CB1 receptor"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "An investigation of the absolute configuration of the potent <protein> histamine H3 receptor </protein> antagonist <chemical> GT-2331 </chemical> using vibrational circular dichroism.",
    "original_text": "An investigation of the absolute configuration of the potent  histamine H3 receptor  antagonist  GT-2331  using vibrational circular dichroism.",
    "entity1": "histamine H3 receptor",
    "entity2": "GT-2331"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "In this study the neuromuscular blocking drug <protein> vecuronium </protein> and the controls gallamine and pancuronium slowed the rate of atropine induced [(3)H]N-methylscopolamine dissociation from Chinese hamster ovary cells expressing recombinant <chemical> human muscarinic M2 receptors </chemical> K(off) values min(-1); vecuronium (125 nM), atropine 0.45+/-0.07+blocker 0.04+/-0.02; gallamine (21 nM), atropine 0.42+/-0.05+blocker 0.15+/-0.04; pancuronium(21 nM), atropine 0.36+/-0.03+blocker 0.03+/-0.01).",
    "original_text": "In this study the neuromuscular blocking drug  vecuronium  and the controls gallamine and pancuronium slowed the rate of atropine induced [(3)H]N-methylscopolamine dissociation from Chinese hamster ovary cells expressing recombinant  human muscarinic M2 receptors  K(off) values min(-1); vecuronium (125 nM), atropine 0.45+/-0.07+blocker 0.04+/-0.02; gallamine (21 nM), atropine 0.42+/-0.05+blocker 0.15+/-0.04; pancuronium(21 nM), atropine 0.36+/-0.03+blocker 0.03+/-0.01).",
    "entity1": "vecuronium",
    "entity2": "human muscarinic M2 receptors"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "In this study the neuromuscular blocking drug vecuronium and the controls <protein> gallamine </protein> and pancuronium slowed the rate of atropine induced [(3)H]N-methylscopolamine dissociation from Chinese hamster ovary cells expressing recombinant <chemical> human muscarinic M2 receptors </chemical> K(off) values min(-1); vecuronium (125 nM), atropine 0.45+/-0.07+blocker 0.04+/-0.02; gallamine (21 nM), atropine 0.42+/-0.05+blocker 0.15+/-0.04; pancuronium(21 nM), atropine 0.36+/-0.03+blocker 0.03+/-0.01).",
    "original_text": "In this study the neuromuscular blocking drug vecuronium and the controls  gallamine  and pancuronium slowed the rate of atropine induced [(3)H]N-methylscopolamine dissociation from Chinese hamster ovary cells expressing recombinant  human muscarinic M2 receptors  K(off) values min(-1); vecuronium (125 nM), atropine 0.45+/-0.07+blocker 0.04+/-0.02; gallamine (21 nM), atropine 0.42+/-0.05+blocker 0.15+/-0.04; pancuronium(21 nM), atropine 0.36+/-0.03+blocker 0.03+/-0.01).",
    "entity1": "gallamine",
    "entity2": "human muscarinic M2 receptors"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "In this study the neuromuscular blocking drug vecuronium and the controls gallamine and <protein> pancuronium </protein> slowed the rate of atropine induced [(3)H]N-methylscopolamine dissociation from Chinese hamster ovary cells expressing recombinant <chemical> human muscarinic M2 receptors </chemical> K(off) values min(-1); vecuronium (125 nM), atropine 0.45+/-0.07+blocker 0.04+/-0.02; gallamine (21 nM), atropine 0.42+/-0.05+blocker 0.15+/-0.04; pancuronium(21 nM), atropine 0.36+/-0.03+blocker 0.03+/-0.01).",
    "original_text": "In this study the neuromuscular blocking drug vecuronium and the controls gallamine and  pancuronium  slowed the rate of atropine induced [(3)H]N-methylscopolamine dissociation from Chinese hamster ovary cells expressing recombinant  human muscarinic M2 receptors  K(off) values min(-1); vecuronium (125 nM), atropine 0.45+/-0.07+blocker 0.04+/-0.02; gallamine (21 nM), atropine 0.42+/-0.05+blocker 0.15+/-0.04; pancuronium(21 nM), atropine 0.36+/-0.03+blocker 0.03+/-0.01).",
    "entity1": "pancuronium",
    "entity2": "human muscarinic M2 receptors"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Patients with acute vitiligo have low epidermal <protein> catalase </protein> expression/activities and accumulate 10(-3) M <chemical> H(2)O(2) </chemical>.",
    "original_text": "Patients with acute vitiligo have low epidermal  catalase  expression/activities and accumulate 10(-3) M  H(2)O(2) .",
    "entity1": "catalase",
    "entity2": "H(2)O(2)"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "<protein> Mammalian cysteine dioxygenase </protein> (CDO) is a non-heme iron metalloenzyme that catalyzes the first committed step in oxidative <chemical> cysteine </chemical> catabolism.",
    "original_text": " Mammalian cysteine dioxygenase  (CDO) is a non-heme iron metalloenzyme that catalyzes the first committed step in oxidative  cysteine  catabolism.",
    "entity1": "Mammalian cysteine dioxygenase",
    "entity2": "cysteine"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Mammalian cysteine dioxygenase (<protein> CDO </protein>) is a non-heme iron metalloenzyme that catalyzes the first committed step in oxidative <chemical> cysteine </chemical> catabolism.",
    "original_text": "Mammalian cysteine dioxygenase ( CDO ) is a non-heme iron metalloenzyme that catalyzes the first committed step in oxidative  cysteine  catabolism.",
    "entity1": "CDO",
    "entity2": "cysteine"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "However, upon addition of NO to <protein> CDO </protein> in the presence of substrate <chemical> l-cysteine </chemical>, a low-spin {FeNO}7 (S = 1/2) signal that accounts for approximately 85% of the iron within the enzyme develops.",
    "original_text": "However, upon addition of NO to  CDO  in the presence of substrate  l-cysteine , a low-spin {FeNO}7 (S = 1/2) signal that accounts for approximately 85% of the iron within the enzyme develops.",
    "entity1": "CDO",
    "entity2": "l-cysteine"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Combination chemotherapy with a <protein> substance P receptor </protein> antagonist (<chemical> aprepitant </chemical>) and melarsoprol in a mouse model of human African trypanosomiasis.",
    "original_text": "Combination chemotherapy with a  substance P receptor  antagonist ( aprepitant ) and melarsoprol in a mouse model of human African trypanosomiasis.",
    "entity1": "substance P receptor",
    "entity2": "aprepitant"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Combination chemotherapy with a <protein> substance P receptor </protein> antagonist (aprepitant) and <chemical> melarsoprol </chemical> in a mouse model of human African trypanosomiasis.",
    "original_text": "Combination chemotherapy with a  substance P receptor  antagonist (aprepitant) and  melarsoprol  in a mouse model of human African trypanosomiasis.",
    "entity1": "substance P receptor",
    "entity2": "melarsoprol"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "In this study we investigated the effects of combination chemotherapy with melarsoprol and a <protein> humanised SP receptor </protein> antagonist <chemical> aprepitant </chemical> (EMEND) in this mouse model.",
    "original_text": "In this study we investigated the effects of combination chemotherapy with melarsoprol and a  humanised SP receptor  antagonist  aprepitant  (EMEND) in this mouse model.",
    "entity1": "humanised SP receptor",
    "entity2": "aprepitant"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "In this study we investigated the effects of combination chemotherapy with melarsoprol and a <protein> humanised SP receptor </protein> antagonist aprepitant (<chemical> EMEND </chemical>) in this mouse model.",
    "original_text": "In this study we investigated the effects of combination chemotherapy with melarsoprol and a  humanised SP receptor  antagonist aprepitant ( EMEND ) in this mouse model.",
    "entity1": "humanised SP receptor",
    "entity2": "EMEND"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "<protein> Dimethylarginine dimethylaminohydrolase </protein> (DDAH) metabolizes asymmetric <chemical> dimethylarginine </chemical> to generate L-citrulline and is present in large quantities in the kidney.",
    "original_text": " Dimethylarginine dimethylaminohydrolase  (DDAH) metabolizes asymmetric  dimethylarginine  to generate L-citrulline and is present in large quantities in the kidney.",
    "entity1": "Dimethylarginine dimethylaminohydrolase",
    "entity2": "dimethylarginine"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Dimethylarginine dimethylaminohydrolase (<protein> DDAH </protein>) metabolizes asymmetric <chemical> dimethylarginine </chemical> to generate L-citrulline and is present in large quantities in the kidney.",
    "original_text": "Dimethylarginine dimethylaminohydrolase ( DDAH ) metabolizes asymmetric  dimethylarginine  to generate L-citrulline and is present in large quantities in the kidney.",
    "entity1": "DDAH",
    "entity2": "dimethylarginine"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "We found that the removal of <protein> urea </protein> with <chemical> urease </chemical> is necessary since urea also produces a positive reaction.",
    "original_text": "We found that the removal of  urea  with  urease  is necessary since urea also produces a positive reaction.",
    "entity1": "urea",
    "entity2": "urease"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Our optimized L-citrulline production assay to measure <protein> DDAH </protein> activity correlated closely with the direct measure of the rate of asymmetric <chemical> dimethylarginine </chemical> consumption.",
    "original_text": "Our optimized L-citrulline production assay to measure  DDAH  activity correlated closely with the direct measure of the rate of asymmetric  dimethylarginine  consumption.",
    "entity1": "DDAH",
    "entity2": "dimethylarginine"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Exposure of Jurkat cells to either <protein> (5S,10R)-(+)-5-methyl-10,11-dihydro-5H-dibenzo[a,b]cyclohepten-5,10-imine </protein> [(+)-MK 801] or D-(-)-2-amino-5-phosphonopentanoic acid (D-AP5), two selective <chemical> NMDA receptor </chemical> antagonists, limited cell growth by inhibiting cell cycle progression and inducing apoptosis, whereas l-glutamate (1 microM) and NMDA (10 microM) significantly increased (137.2+/-22.0%; P<0.01) Jurkat T cell adhesion to fibronectin.",
    "original_text": "Exposure of Jurkat cells to either  (5S,10R)-(+)-5-methyl-10,11-dihydro-5H-dibenzo[a,b]cyclohepten-5,10-imine  [(+)-MK 801] or D-(-)-2-amino-5-phosphonopentanoic acid (D-AP5), two selective  NMDA receptor  antagonists, limited cell growth by inhibiting cell cycle progression and inducing apoptosis, whereas l-glutamate (1 microM) and NMDA (10 microM) significantly increased (137.2+/-22.0%; P<0.01) Jurkat T cell adhesion to fibronectin.",
    "entity1": "(5S,10R)-(+)-5-methyl-10,11-dihydro-5H-dibenzo[a,b]cyclohepten-5,10-imine",
    "entity2": "NMDA receptor"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Exposure of Jurkat cells to either (5S,10R)-(+)-5-methyl-10,11-dihydro-5H-dibenzo[a,b]cyclohepten-5,10-imine [<protein> (+)-MK 801 </protein>] or D-(-)-2-amino-5-phosphonopentanoic acid (D-AP5), two selective <chemical> NMDA receptor </chemical> antagonists, limited cell growth by inhibiting cell cycle progression and inducing apoptosis, whereas l-glutamate (1 microM) and NMDA (10 microM) significantly increased (137.2+/-22.0%; P<0.01) Jurkat T cell adhesion to fibronectin.",
    "original_text": "Exposure of Jurkat cells to either (5S,10R)-(+)-5-methyl-10,11-dihydro-5H-dibenzo[a,b]cyclohepten-5,10-imine [ (+)-MK 801 ] or D-(-)-2-amino-5-phosphonopentanoic acid (D-AP5), two selective  NMDA receptor  antagonists, limited cell growth by inhibiting cell cycle progression and inducing apoptosis, whereas l-glutamate (1 microM) and NMDA (10 microM) significantly increased (137.2+/-22.0%; P<0.01) Jurkat T cell adhesion to fibronectin.",
    "entity1": "(+)-MK 801",
    "entity2": "NMDA receptor"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Exposure of Jurkat cells to either (5S,10R)-(+)-5-methyl-10,11-dihydro-5H-dibenzo[a,b]cyclohepten-5,10-imine [(+)-MK 801] or <protein> D-(-)-2-amino-5-phosphonopentanoic acid </protein> (D-AP5), two selective <chemical> NMDA receptor </chemical> antagonists, limited cell growth by inhibiting cell cycle progression and inducing apoptosis, whereas l-glutamate (1 microM) and NMDA (10 microM) significantly increased (137.2+/-22.0%; P<0.01) Jurkat T cell adhesion to fibronectin.",
    "original_text": "Exposure of Jurkat cells to either (5S,10R)-(+)-5-methyl-10,11-dihydro-5H-dibenzo[a,b]cyclohepten-5,10-imine [(+)-MK 801] or  D-(-)-2-amino-5-phosphonopentanoic acid  (D-AP5), two selective  NMDA receptor  antagonists, limited cell growth by inhibiting cell cycle progression and inducing apoptosis, whereas l-glutamate (1 microM) and NMDA (10 microM) significantly increased (137.2+/-22.0%; P<0.01) Jurkat T cell adhesion to fibronectin.",
    "entity1": "D-(-)-2-amino-5-phosphonopentanoic acid",
    "entity2": "NMDA receptor"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Exposure of Jurkat cells to either (5S,10R)-(+)-5-methyl-10,11-dihydro-5H-dibenzo[a,b]cyclohepten-5,10-imine [(+)-MK 801] or D-(-)-2-amino-5-phosphonopentanoic acid (<protein> D-AP5 </protein>), two selective <chemical> NMDA receptor </chemical> antagonists, limited cell growth by inhibiting cell cycle progression and inducing apoptosis, whereas l-glutamate (1 microM) and NMDA (10 microM) significantly increased (137.2+/-22.0%; P<0.01) Jurkat T cell adhesion to fibronectin.",
    "original_text": "Exposure of Jurkat cells to either (5S,10R)-(+)-5-methyl-10,11-dihydro-5H-dibenzo[a,b]cyclohepten-5,10-imine [(+)-MK 801] or D-(-)-2-amino-5-phosphonopentanoic acid ( D-AP5 ), two selective  NMDA receptor  antagonists, limited cell growth by inhibiting cell cycle progression and inducing apoptosis, whereas l-glutamate (1 microM) and NMDA (10 microM) significantly increased (137.2+/-22.0%; P<0.01) Jurkat T cell adhesion to fibronectin.",
    "entity1": "D-AP5",
    "entity2": "NMDA receptor"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "<protein> Desvenlafaxine succinate </protein> identifies novel antagonist binding determinants in the <chemical> human norepinephrine transporter </chemical>.",
    "original_text": " Desvenlafaxine succinate  identifies novel antagonist binding determinants in the  human norepinephrine transporter .",
    "entity1": "Desvenlafaxine succinate",
    "entity2": "human norepinephrine transporter"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "<protein> Desvenlafaxine succinate </protein> (DVS) is a recently introduced antagonist of the human norepinephrine and serotonin transporters (<chemical> hNET </chemical> and hSERT, respectively), currently in clinical development for use in the treatment of major depressive disorder and vasomotor symptoms associated with menopause.",
    "original_text": " Desvenlafaxine succinate  (DVS) is a recently introduced antagonist of the human norepinephrine and serotonin transporters ( hNET  and hSERT, respectively), currently in clinical development for use in the treatment of major depressive disorder and vasomotor symptoms associated with menopause.",
    "entity1": "Desvenlafaxine succinate",
    "entity2": "hNET"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "<protein> Desvenlafaxine succinate </protein> (DVS) is a recently introduced antagonist of the human norepinephrine and serotonin transporters (hNET and <chemical> hSERT </chemical>, respectively), currently in clinical development for use in the treatment of major depressive disorder and vasomotor symptoms associated with menopause.",
    "original_text": " Desvenlafaxine succinate  (DVS) is a recently introduced antagonist of the human norepinephrine and serotonin transporters (hNET and  hSERT , respectively), currently in clinical development for use in the treatment of major depressive disorder and vasomotor symptoms associated with menopause.",
    "entity1": "Desvenlafaxine succinate",
    "entity2": "hSERT"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Desvenlafaxine succinate (<protein> DVS </protein>) is a recently introduced antagonist of the human norepinephrine and serotonin transporters (<chemical> hNET </chemical> and hSERT, respectively), currently in clinical development for use in the treatment of major depressive disorder and vasomotor symptoms associated with menopause.",
    "original_text": "Desvenlafaxine succinate ( DVS ) is a recently introduced antagonist of the human norepinephrine and serotonin transporters ( hNET  and hSERT, respectively), currently in clinical development for use in the treatment of major depressive disorder and vasomotor symptoms associated with menopause.",
    "entity1": "DVS",
    "entity2": "hNET"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Desvenlafaxine succinate (<protein> DVS </protein>) is a recently introduced antagonist of the human norepinephrine and serotonin transporters (hNET and <chemical> hSERT </chemical>, respectively), currently in clinical development for use in the treatment of major depressive disorder and vasomotor symptoms associated with menopause.",
    "original_text": "Desvenlafaxine succinate ( DVS ) is a recently introduced antagonist of the human norepinephrine and serotonin transporters (hNET and  hSERT , respectively), currently in clinical development for use in the treatment of major depressive disorder and vasomotor symptoms associated with menopause.",
    "entity1": "DVS",
    "entity2": "hSERT"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Using <protein> hNET </protein> in transfected human embryonic kidney-293 cells, this difference in potency for DVS at sites labeled by [(3)H]NIS was found to distinguish DVS, the <chemical> DVS </chemical> analog rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol (WY-46824), methylphenidate, and the cocaine analog 3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester (RTI-55) from other hNET antagonists, such as NIS, mazindol, tricyclic antidepressants, and cocaine.",
    "original_text": "Using  hNET  in transfected human embryonic kidney-293 cells, this difference in potency for DVS at sites labeled by [(3)H]NIS was found to distinguish DVS, the  DVS  analog rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol (WY-46824), methylphenidate, and the cocaine analog 3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester (RTI-55) from other hNET antagonists, such as NIS, mazindol, tricyclic antidepressants, and cocaine.",
    "entity1": "hNET",
    "entity2": "DVS"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Using <protein> hNET </protein> in transfected human embryonic kidney-293 cells, this difference in potency for DVS at sites labeled by [(3)H]NIS was found to distinguish DVS, the DVS analog <chemical> rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol </chemical> (WY-46824), methylphenidate, and the cocaine analog 3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester (RTI-55) from other hNET antagonists, such as NIS, mazindol, tricyclic antidepressants, and cocaine.",
    "original_text": "Using  hNET  in transfected human embryonic kidney-293 cells, this difference in potency for DVS at sites labeled by [(3)H]NIS was found to distinguish DVS, the DVS analog  rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol  (WY-46824), methylphenidate, and the cocaine analog 3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester (RTI-55) from other hNET antagonists, such as NIS, mazindol, tricyclic antidepressants, and cocaine.",
    "entity1": "hNET",
    "entity2": "rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Using <protein> hNET </protein> in transfected human embryonic kidney-293 cells, this difference in potency for DVS at sites labeled by [(3)H]NIS was found to distinguish DVS, the DVS analog rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol (<chemical> WY-46824 </chemical>), methylphenidate, and the cocaine analog 3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester (RTI-55) from other hNET antagonists, such as NIS, mazindol, tricyclic antidepressants, and cocaine.",
    "original_text": "Using  hNET  in transfected human embryonic kidney-293 cells, this difference in potency for DVS at sites labeled by [(3)H]NIS was found to distinguish DVS, the DVS analog rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol ( WY-46824 ), methylphenidate, and the cocaine analog 3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester (RTI-55) from other hNET antagonists, such as NIS, mazindol, tricyclic antidepressants, and cocaine.",
    "entity1": "hNET",
    "entity2": "WY-46824"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Using <protein> hNET </protein> in transfected human embryonic kidney-293 cells, this difference in potency for DVS at sites labeled by [(3)H]NIS was found to distinguish DVS, the DVS analog rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol (WY-46824), <chemical> methylphenidate </chemical>, and the cocaine analog 3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester (RTI-55) from other hNET antagonists, such as NIS, mazindol, tricyclic antidepressants, and cocaine.",
    "original_text": "Using  hNET  in transfected human embryonic kidney-293 cells, this difference in potency for DVS at sites labeled by [(3)H]NIS was found to distinguish DVS, the DVS analog rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol (WY-46824),  methylphenidate , and the cocaine analog 3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester (RTI-55) from other hNET antagonists, such as NIS, mazindol, tricyclic antidepressants, and cocaine.",
    "entity1": "hNET",
    "entity2": "methylphenidate"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Using <protein> hNET </protein> in transfected human embryonic kidney-293 cells, this difference in potency for DVS at sites labeled by [(3)H]NIS was found to distinguish DVS, the DVS analog rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol (WY-46824), methylphenidate, and the <chemical> cocaine </chemical> analog 3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester (RTI-55) from other hNET antagonists, such as NIS, mazindol, tricyclic antidepressants, and cocaine.",
    "original_text": "Using  hNET  in transfected human embryonic kidney-293 cells, this difference in potency for DVS at sites labeled by [(3)H]NIS was found to distinguish DVS, the DVS analog rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol (WY-46824), methylphenidate, and the  cocaine  analog 3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester (RTI-55) from other hNET antagonists, such as NIS, mazindol, tricyclic antidepressants, and cocaine.",
    "entity1": "hNET",
    "entity2": "cocaine"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Using <protein> hNET </protein> in transfected human embryonic kidney-293 cells, this difference in potency for DVS at sites labeled by [(3)H]NIS was found to distinguish DVS, the DVS analog rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol (WY-46824), methylphenidate, and the cocaine analog <chemical> 3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester </chemical> (RTI-55) from other hNET antagonists, such as NIS, mazindol, tricyclic antidepressants, and cocaine.",
    "original_text": "Using  hNET  in transfected human embryonic kidney-293 cells, this difference in potency for DVS at sites labeled by [(3)H]NIS was found to distinguish DVS, the DVS analog rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol (WY-46824), methylphenidate, and the cocaine analog  3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester  (RTI-55) from other hNET antagonists, such as NIS, mazindol, tricyclic antidepressants, and cocaine.",
    "entity1": "hNET",
    "entity2": "3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Using <protein> hNET </protein> in transfected human embryonic kidney-293 cells, this difference in potency for DVS at sites labeled by [(3)H]NIS was found to distinguish DVS, the DVS analog rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol (WY-46824), methylphenidate, and the cocaine analog 3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester (<chemical> RTI-55 </chemical>) from other hNET antagonists, such as NIS, mazindol, tricyclic antidepressants, and cocaine.",
    "original_text": "Using  hNET  in transfected human embryonic kidney-293 cells, this difference in potency for DVS at sites labeled by [(3)H]NIS was found to distinguish DVS, the DVS analog rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol (WY-46824), methylphenidate, and the cocaine analog 3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester ( RTI-55 ) from other hNET antagonists, such as NIS, mazindol, tricyclic antidepressants, and cocaine.",
    "entity1": "hNET",
    "entity2": "RTI-55"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Using hNET in transfected human embryonic kidney-293 cells, this difference in potency for DVS at sites labeled by [(3)H]NIS was found to distinguish DVS, the DVS analog rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol (WY-46824), methylphenidate, and the cocaine analog 3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester (RTI-55) from other <protein> hNET </protein> antagonists, such as <chemical> NIS </chemical>, mazindol, tricyclic antidepressants, and cocaine.",
    "original_text": "Using hNET in transfected human embryonic kidney-293 cells, this difference in potency for DVS at sites labeled by [(3)H]NIS was found to distinguish DVS, the DVS analog rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol (WY-46824), methylphenidate, and the cocaine analog 3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester (RTI-55) from other  hNET  antagonists, such as  NIS , mazindol, tricyclic antidepressants, and cocaine.",
    "entity1": "hNET",
    "entity2": "NIS"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Using hNET in transfected human embryonic kidney-293 cells, this difference in potency for DVS at sites labeled by [(3)H]NIS was found to distinguish DVS, the DVS analog rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol (WY-46824), methylphenidate, and the cocaine analog 3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester (RTI-55) from other <protein> hNET </protein> antagonists, such as NIS, <chemical> mazindol </chemical>, tricyclic antidepressants, and cocaine.",
    "original_text": "Using hNET in transfected human embryonic kidney-293 cells, this difference in potency for DVS at sites labeled by [(3)H]NIS was found to distinguish DVS, the DVS analog rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol (WY-46824), methylphenidate, and the cocaine analog 3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester (RTI-55) from other  hNET  antagonists, such as NIS,  mazindol , tricyclic antidepressants, and cocaine.",
    "entity1": "hNET",
    "entity2": "mazindol"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Using hNET in transfected human embryonic kidney-293 cells, this difference in potency for DVS at sites labeled by [(3)H]NIS was found to distinguish DVS, the DVS analog rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol (WY-46824), methylphenidate, and the cocaine analog 3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester (RTI-55) from other <protein> hNET </protein> antagonists, such as NIS, mazindol, <chemical> tricyclic </chemical> antidepressants, and cocaine.",
    "original_text": "Using hNET in transfected human embryonic kidney-293 cells, this difference in potency for DVS at sites labeled by [(3)H]NIS was found to distinguish DVS, the DVS analog rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol (WY-46824), methylphenidate, and the cocaine analog 3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester (RTI-55) from other  hNET  antagonists, such as NIS, mazindol,  tricyclic  antidepressants, and cocaine.",
    "entity1": "hNET",
    "entity2": "tricyclic"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Using hNET in transfected human embryonic kidney-293 cells, this difference in potency for DVS at sites labeled by [(3)H]NIS was found to distinguish DVS, the DVS analog rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol (WY-46824), methylphenidate, and the cocaine analog 3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester (RTI-55) from other <protein> hNET </protein> antagonists, such as NIS, mazindol, tricyclic antidepressants, and <chemical> cocaine </chemical>.",
    "original_text": "Using hNET in transfected human embryonic kidney-293 cells, this difference in potency for DVS at sites labeled by [(3)H]NIS was found to distinguish DVS, the DVS analog rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol (WY-46824), methylphenidate, and the cocaine analog 3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester (RTI-55) from other  hNET  antagonists, such as NIS, mazindol, tricyclic antidepressants, and  cocaine .",
    "entity1": "hNET",
    "entity2": "cocaine"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Using <protein> hNET </protein> in transfected human embryonic kidney-293 cells, this difference in potency for DVS at sites labeled by [(3)H]NIS was found to distinguish <chemical> DVS </chemical>, the DVS analog rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol (WY-46824), methylphenidate, and the cocaine analog 3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester (RTI-55) from other hNET antagonists, such as NIS, mazindol, tricyclic antidepressants, and cocaine.",
    "original_text": "Using  hNET  in transfected human embryonic kidney-293 cells, this difference in potency for DVS at sites labeled by [(3)H]NIS was found to distinguish  DVS , the DVS analog rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol (WY-46824), methylphenidate, and the cocaine analog 3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester (RTI-55) from other hNET antagonists, such as NIS, mazindol, tricyclic antidepressants, and cocaine.",
    "entity1": "hNET",
    "entity2": "DVS"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "<protein> Irbesartan </protein> (Aprovel, Avapro, Irbetan, Karvea), an <chemical> angiotensin II receptor type 1 </chemical> antagonist, is approved in many countries worldwide for the treatment of hypertension.",
    "original_text": " Irbesartan  (Aprovel, Avapro, Irbetan, Karvea), an  angiotensin II receptor type 1  antagonist, is approved in many countries worldwide for the treatment of hypertension.",
    "entity1": "Irbesartan",
    "entity2": "angiotensin II receptor type 1"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Irbesartan (<protein> Aprovel </protein>, Avapro, Irbetan, Karvea), an <chemical> angiotensin II receptor type 1 </chemical> antagonist, is approved in many countries worldwide for the treatment of hypertension.",
    "original_text": "Irbesartan ( Aprovel , Avapro, Irbetan, Karvea), an  angiotensin II receptor type 1  antagonist, is approved in many countries worldwide for the treatment of hypertension.",
    "entity1": "Aprovel",
    "entity2": "angiotensin II receptor type 1"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Irbesartan (Aprovel, <protein> Avapro </protein>, Irbetan, Karvea), an <chemical> angiotensin II receptor type 1 </chemical> antagonist, is approved in many countries worldwide for the treatment of hypertension.",
    "original_text": "Irbesartan (Aprovel,  Avapro , Irbetan, Karvea), an  angiotensin II receptor type 1  antagonist, is approved in many countries worldwide for the treatment of hypertension.",
    "entity1": "Avapro",
    "entity2": "angiotensin II receptor type 1"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Irbesartan (Aprovel, Avapro, <protein> Irbetan </protein>, Karvea), an <chemical> angiotensin II receptor type 1 </chemical> antagonist, is approved in many countries worldwide for the treatment of hypertension.",
    "original_text": "Irbesartan (Aprovel, Avapro,  Irbetan , Karvea), an  angiotensin II receptor type 1  antagonist, is approved in many countries worldwide for the treatment of hypertension.",
    "entity1": "Irbetan",
    "entity2": "angiotensin II receptor type 1"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Irbesartan (Aprovel, Avapro, Irbetan, <protein> Karvea </protein>), an <chemical> angiotensin II receptor type 1 </chemical> antagonist, is approved in many countries worldwide for the treatment of hypertension.",
    "original_text": "Irbesartan (Aprovel, Avapro, Irbetan,  Karvea ), an  angiotensin II receptor type 1  antagonist, is approved in many countries worldwide for the treatment of hypertension.",
    "entity1": "Karvea",
    "entity2": "angiotensin II receptor type 1"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "<protein> Nicotinamide N-methyltransferase </protein> (NNMT) catalyses the conversion of <chemical> nicotinamide </chemical> to 1-methylnicotinamide and plays an important role in hepatic detoxification reactions.",
    "original_text": " Nicotinamide N-methyltransferase  (NNMT) catalyses the conversion of  nicotinamide  to 1-methylnicotinamide and plays an important role in hepatic detoxification reactions.",
    "entity1": "Nicotinamide N-methyltransferase",
    "entity2": "nicotinamide"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Nicotinamide N-methyltransferase (<protein> NNMT </protein>) catalyses the conversion of <chemical> nicotinamide </chemical> to 1-methylnicotinamide and plays an important role in hepatic detoxification reactions.",
    "original_text": "Nicotinamide N-methyltransferase ( NNMT ) catalyses the conversion of  nicotinamide  to 1-methylnicotinamide and plays an important role in hepatic detoxification reactions.",
    "entity1": "NNMT",
    "entity2": "nicotinamide"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Affinity alkylation with 2 alpha-bromoacetoxyprogesterone suggests that the <protein> dehydrogenase </protein> and isomerase substrate <chemical> steroids </chemical> bind at different sites on the same protein.",
    "original_text": "Affinity alkylation with 2 alpha-bromoacetoxyprogesterone suggests that the  dehydrogenase  and isomerase substrate  steroids  bind at different sites on the same protein.",
    "entity1": "dehydrogenase",
    "entity2": "steroids"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "It undergoes extensive biotransformation, which is affected by poor metabolism by <protein> cytochrome P450 (CYP) 2D6 </protein> in a small percentage of the population; these patients have greater exposure to and slower elimination of <chemical> atomoxetine </chemical> than extensive metabolizers.",
    "original_text": "It undergoes extensive biotransformation, which is affected by poor metabolism by  cytochrome P450 (CYP) 2D6  in a small percentage of the population; these patients have greater exposure to and slower elimination of  atomoxetine  than extensive metabolizers.",
    "entity1": "cytochrome P450 (CYP) 2D6",
    "entity2": "atomoxetine"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "CYP2D6 inhibitors, such as paroxetine, are associated with changes in <protein> atomoxetine </protein> pharmacokinetics similar to those observed among poor <chemical> CYP2D6 </chemical> metabolizers.",
    "original_text": "CYP2D6 inhibitors, such as paroxetine, are associated with changes in  atomoxetine  pharmacokinetics similar to those observed among poor  CYP2D6  metabolizers.",
    "entity1": "atomoxetine",
    "entity2": "CYP2D6"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "<protein> Atomoxetine </protein> appeared better tolerated among extensive <chemical> CYP2D6 </chemical> metabolizers than among poor metabolizers.",
    "original_text": " Atomoxetine  appeared better tolerated among extensive  CYP2D6  metabolizers than among poor metabolizers.",
    "entity1": "Atomoxetine",
    "entity2": "CYP2D6"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "<protein> Mammalian glutamate dehydrogenase </protein> (GDH) is a homohexameric enzyme that catalyzes the reversible oxidative deamination of <chemical> l-glutamate </chemical> to 2-oxoglutarate using NAD(P)(+) as coenzyme.",
    "original_text": " Mammalian glutamate dehydrogenase  (GDH) is a homohexameric enzyme that catalyzes the reversible oxidative deamination of  l-glutamate  to 2-oxoglutarate using NAD(P)(+) as coenzyme.",
    "entity1": "Mammalian glutamate dehydrogenase",
    "entity2": "l-glutamate"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Mammalian glutamate dehydrogenase (<protein> GDH </protein>) is a homohexameric enzyme that catalyzes the reversible oxidative deamination of <chemical> l-glutamate </chemical> to 2-oxoglutarate using NAD(P)(+) as coenzyme.",
    "original_text": "Mammalian glutamate dehydrogenase ( GDH ) is a homohexameric enzyme that catalyzes the reversible oxidative deamination of  l-glutamate  to 2-oxoglutarate using NAD(P)(+) as coenzyme.",
    "entity1": "GDH",
    "entity2": "l-glutamate"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Using the <protein> alpha 1-adrenoceptor </protein> subtype-selective antagonists chlorethylclonidine (CEC), WB4101, and <chemical> 5-methyl-urapidil </chemical>, we have examined the possible heterogeneity in the alpha 1-adrenoceptor populations in rabbit aorta.",
    "original_text": "Using the  alpha 1-adrenoceptor  subtype-selective antagonists chlorethylclonidine (CEC), WB4101, and  5-methyl-urapidil , we have examined the possible heterogeneity in the alpha 1-adrenoceptor populations in rabbit aorta.",
    "entity1": "alpha 1-adrenoceptor",
    "entity2": "5-methyl-urapidil"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Using the <protein> alpha 1-adrenoceptor </protein> subtype-selective antagonists <chemical> chlorethylclonidine </chemical> (CEC), WB4101, and 5-methyl-urapidil, we have examined the possible heterogeneity in the alpha 1-adrenoceptor populations in rabbit aorta.",
    "original_text": "Using the  alpha 1-adrenoceptor  subtype-selective antagonists  chlorethylclonidine  (CEC), WB4101, and 5-methyl-urapidil, we have examined the possible heterogeneity in the alpha 1-adrenoceptor populations in rabbit aorta.",
    "entity1": "alpha 1-adrenoceptor",
    "entity2": "chlorethylclonidine"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Using the <protein> alpha 1-adrenoceptor </protein> subtype-selective antagonists chlorethylclonidine (<chemical> CEC </chemical>), WB4101, and 5-methyl-urapidil, we have examined the possible heterogeneity in the alpha 1-adrenoceptor populations in rabbit aorta.",
    "original_text": "Using the  alpha 1-adrenoceptor  subtype-selective antagonists chlorethylclonidine ( CEC ), WB4101, and 5-methyl-urapidil, we have examined the possible heterogeneity in the alpha 1-adrenoceptor populations in rabbit aorta.",
    "entity1": "alpha 1-adrenoceptor",
    "entity2": "CEC"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Using the <protein> alpha 1-adrenoceptor </protein> subtype-selective antagonists chlorethylclonidine (CEC), <chemical> WB4101 </chemical>, and 5-methyl-urapidil, we have examined the possible heterogeneity in the alpha 1-adrenoceptor populations in rabbit aorta.",
    "original_text": "Using the  alpha 1-adrenoceptor  subtype-selective antagonists chlorethylclonidine (CEC),  WB4101 , and 5-methyl-urapidil, we have examined the possible heterogeneity in the alpha 1-adrenoceptor populations in rabbit aorta.",
    "entity1": "alpha 1-adrenoceptor",
    "entity2": "WB4101"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Radioligand binding studies with the nonselective <protein> alpha 1-adrenoceptor </protein> antagonist radioligand <chemical> 125I-BE2254 </chemical> showed that 73-87% of the binding sites in rabbit aorta are CEC sensitive and they are predominantly low affinity sites both for WB4101 (pKd = 8.1) and for 5-methylurapidil (pKd = 7.1).",
    "original_text": "Radioligand binding studies with the nonselective  alpha 1-adrenoceptor  antagonist radioligand  125I-BE2254  showed that 73-87% of the binding sites in rabbit aorta are CEC sensitive and they are predominantly low affinity sites both for WB4101 (pKd = 8.1) and for 5-methylurapidil (pKd = 7.1).",
    "entity1": "alpha 1-adrenoceptor",
    "entity2": "125I-BE2254"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "The Schild plots for the competitive antagonists WB4101 and 5-methyl-urapidil against <protein> alpha 1a-adrenoceptor </protein>-selective agonist <chemical> methoxamine </chemical>-induced contraction were linear and had slopes not significantly different from unity, with a pA2 of 9.07 +/- 0.07 (n = 5) for WB4101 and 9.09 +/- 0.05 (n = 3) for 5-methyl-urapidil.",
    "original_text": "The Schild plots for the competitive antagonists WB4101 and 5-methyl-urapidil against  alpha 1a-adrenoceptor -selective agonist  methoxamine -induced contraction were linear and had slopes not significantly different from unity, with a pA2 of 9.07 +/- 0.07 (n = 5) for WB4101 and 9.09 +/- 0.05 (n = 3) for 5-methyl-urapidil.",
    "entity1": "alpha 1a-adrenoceptor",
    "entity2": "methoxamine"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "The Schild plots for the competitive antagonists WB4101 and 5-methyl-urapidil against <protein> alpha 1a-adrenoceptor </protein>-selective agonist methoxamine-induced contraction were linear and had slopes not significantly different from unity, with a pA2 of 9.07 +/- 0.07 (n = 5) for <chemical> WB4101 </chemical> and 9.09 +/- 0.05 (n = 3) for 5-methyl-urapidil.",
    "original_text": "The Schild plots for the competitive antagonists WB4101 and 5-methyl-urapidil against  alpha 1a-adrenoceptor -selective agonist methoxamine-induced contraction were linear and had slopes not significantly different from unity, with a pA2 of 9.07 +/- 0.07 (n = 5) for  WB4101  and 9.09 +/- 0.05 (n = 3) for 5-methyl-urapidil.",
    "entity1": "alpha 1a-adrenoceptor",
    "entity2": "WB4101"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "The Schild plots for the competitive antagonists WB4101 and 5-methyl-urapidil against <protein> alpha 1a-adrenoceptor </protein>-selective agonist methoxamine-induced contraction were linear and had slopes not significantly different from unity, with a pA2 of 9.07 +/- 0.07 (n = 5) for WB4101 and 9.09 +/- 0.05 (n = 3) for <chemical> 5-methyl-urapidil </chemical>.",
    "original_text": "The Schild plots for the competitive antagonists WB4101 and 5-methyl-urapidil against  alpha 1a-adrenoceptor -selective agonist methoxamine-induced contraction were linear and had slopes not significantly different from unity, with a pA2 of 9.07 +/- 0.07 (n = 5) for WB4101 and 9.09 +/- 0.05 (n = 3) for  5-methyl-urapidil .",
    "entity1": "alpha 1a-adrenoceptor",
    "entity2": "5-methyl-urapidil"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "The Schild plots for the competitive antagonists <protein> WB4101 </protein> and 5-methyl-urapidil against <chemical> alpha 1a-adrenoceptor </chemical>-selective agonist methoxamine-induced contraction were linear and had slopes not significantly different from unity, with a pA2 of 9.07 +/- 0.07 (n = 5) for WB4101 and 9.09 +/- 0.05 (n = 3) for 5-methyl-urapidil.",
    "original_text": "The Schild plots for the competitive antagonists  WB4101  and 5-methyl-urapidil against  alpha 1a-adrenoceptor -selective agonist methoxamine-induced contraction were linear and had slopes not significantly different from unity, with a pA2 of 9.07 +/- 0.07 (n = 5) for WB4101 and 9.09 +/- 0.05 (n = 3) for 5-methyl-urapidil.",
    "entity1": "WB4101",
    "entity2": "alpha 1a-adrenoceptor"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "The Schild plots for the competitive antagonists WB4101 and <protein> 5-methyl-urapidil </protein> against <chemical> alpha 1a-adrenoceptor </chemical>-selective agonist methoxamine-induced contraction were linear and had slopes not significantly different from unity, with a pA2 of 9.07 +/- 0.07 (n = 5) for WB4101 and 9.09 +/- 0.05 (n = 3) for 5-methyl-urapidil.",
    "original_text": "The Schild plots for the competitive antagonists WB4101 and  5-methyl-urapidil  against  alpha 1a-adrenoceptor -selective agonist methoxamine-induced contraction were linear and had slopes not significantly different from unity, with a pA2 of 9.07 +/- 0.07 (n = 5) for WB4101 and 9.09 +/- 0.05 (n = 3) for 5-methyl-urapidil.",
    "entity1": "5-methyl-urapidil",
    "entity2": "alpha 1a-adrenoceptor"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Computer-assisted analysis of these curvilinear Schild plots in a two-receptor system indicated that <protein> alpha 1-adrenoceptor </protein> populations responsible for the constrictive response are predominantly (approximately 80-90%) low affinity sites for the two antagonists (pKd approximately 8.1 for <chemical> WB4101 </chemical> and pKd approximately 7.1 for 5-methyl-urapidil) and a small population (approximately 10-20%) are high affinity sites (pKd approximately 9.1 for both WB4101 and 5-methyl-urapidil), which was in good agreement with radioligand binding studies.(ABSTRACT TRUNCATED AT 400 WORDS)",
    "original_text": "Computer-assisted analysis of these curvilinear Schild plots in a two-receptor system indicated that  alpha 1-adrenoceptor  populations responsible for the constrictive response are predominantly (approximately 80-90%) low affinity sites for the two antagonists (pKd approximately 8.1 for  WB4101  and pKd approximately 7.1 for 5-methyl-urapidil) and a small population (approximately 10-20%) are high affinity sites (pKd approximately 9.1 for both WB4101 and 5-methyl-urapidil), which was in good agreement with radioligand binding studies.(ABSTRACT TRUNCATED AT 400 WORDS)",
    "entity1": "alpha 1-adrenoceptor",
    "entity2": "WB4101"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Computer-assisted analysis of these curvilinear Schild plots in a two-receptor system indicated that <protein> alpha 1-adrenoceptor </protein> populations responsible for the constrictive response are predominantly (approximately 80-90%) low affinity sites for the two antagonists (pKd approximately 8.1 for WB4101 and pKd approximately 7.1 for <chemical> 5-methyl-urapidil </chemical>) and a small population (approximately 10-20%) are high affinity sites (pKd approximately 9.1 for both WB4101 and 5-methyl-urapidil), which was in good agreement with radioligand binding studies.(ABSTRACT TRUNCATED AT 400 WORDS)",
    "original_text": "Computer-assisted analysis of these curvilinear Schild plots in a two-receptor system indicated that  alpha 1-adrenoceptor  populations responsible for the constrictive response are predominantly (approximately 80-90%) low affinity sites for the two antagonists (pKd approximately 8.1 for WB4101 and pKd approximately 7.1 for  5-methyl-urapidil ) and a small population (approximately 10-20%) are high affinity sites (pKd approximately 9.1 for both WB4101 and 5-methyl-urapidil), which was in good agreement with radioligand binding studies.(ABSTRACT TRUNCATED AT 400 WORDS)",
    "entity1": "alpha 1-adrenoceptor",
    "entity2": "5-methyl-urapidil"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "<protein> Ambrisentan </protein> is an <chemical> endothelin receptor </chemical> antagonist (ERA) that was recently approved for treatment of pulmonary arterial hypertension (PAH).",
    "original_text": " Ambrisentan  is an  endothelin receptor  antagonist (ERA) that was recently approved for treatment of pulmonary arterial hypertension (PAH).",
    "entity1": "Ambrisentan",
    "entity2": "endothelin receptor"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "<protein> Ambrisentan </protein> is the first <chemical> ET(A) </chemical> selective ERA approved for use in the US.",
    "original_text": " Ambrisentan  is the first  ET(A)  selective ERA approved for use in the US.",
    "entity1": "Ambrisentan",
    "entity2": "ET(A)"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "As discussed in this review, various progestogens including dydrogesterone and its 20alpha-dihydro-derivative, medrogestone, promegestone, nomegestrol acetate and norelgestromin can reduce intratissular levels of <protein> estradiol </protein> in breast cancer by blocking <chemical> sulfatase </chemical> and 17beta-hydroxysteroid-dehydrogenase type 1 activities.",
    "original_text": "As discussed in this review, various progestogens including dydrogesterone and its 20alpha-dihydro-derivative, medrogestone, promegestone, nomegestrol acetate and norelgestromin can reduce intratissular levels of  estradiol  in breast cancer by blocking  sulfatase  and 17beta-hydroxysteroid-dehydrogenase type 1 activities.",
    "entity1": "estradiol",
    "entity2": "sulfatase"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "As discussed in this review, various progestogens including dydrogesterone and its 20alpha-dihydro-derivative, medrogestone, promegestone, nomegestrol acetate and norelgestromin can reduce intratissular levels of <protein> estradiol </protein> in breast cancer by blocking sulfatase and <chemical> 17beta-hydroxysteroid-dehydrogenase type 1 </chemical> activities.",
    "original_text": "As discussed in this review, various progestogens including dydrogesterone and its 20alpha-dihydro-derivative, medrogestone, promegestone, nomegestrol acetate and norelgestromin can reduce intratissular levels of  estradiol  in breast cancer by blocking sulfatase and  17beta-hydroxysteroid-dehydrogenase type 1  activities.",
    "entity1": "estradiol",
    "entity2": "17beta-hydroxysteroid-dehydrogenase type 1"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "<protein> Phenformin </protein> reduced the open probability of <chemical> Kir6.1 </chemical>/SUR2B channels by approximately 90% in inside-out patches.",
    "original_text": " Phenformin  reduced the open probability of  Kir6.1 /SUR2B channels by approximately 90% in inside-out patches.",
    "entity1": "Phenformin",
    "entity2": "Kir6.1"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "<protein> Phenformin </protein> reduced the open probability of Kir6.1/<chemical> SUR2B </chemical> channels by approximately 90% in inside-out patches.",
    "original_text": " Phenformin  reduced the open probability of Kir6.1/ SUR2B  channels by approximately 90% in inside-out patches.",
    "entity1": "Phenformin",
    "entity2": "SUR2B"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "Both drugs at the tested doses (0.042-0.33 mug/kg) suppressed PTH mRNA expression and serum <protein> PTH </protein> effectively in the 5/6 NX rats, but <chemical> paricalcitol </chemical> was less potent in raising serum Ca than doxercalciferol.",
    "original_text": "Both drugs at the tested doses (0.042-0.33 mug/kg) suppressed PTH mRNA expression and serum  PTH  effectively in the 5/6 NX rats, but  paricalcitol  was less potent in raising serum Ca than doxercalciferol.",
    "entity1": "PTH",
    "entity2": "paricalcitol"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "Both drugs at the tested doses (0.042-0.33 mug/kg) suppressed PTH mRNA expression and serum <protein> PTH </protein> effectively in the 5/6 NX rats, but paricalcitol was less potent in raising serum Ca than <chemical> doxercalciferol </chemical>.",
    "original_text": "Both drugs at the tested doses (0.042-0.33 mug/kg) suppressed PTH mRNA expression and serum  PTH  effectively in the 5/6 NX rats, but paricalcitol was less potent in raising serum Ca than  doxercalciferol .",
    "entity1": "PTH",
    "entity2": "doxercalciferol"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "Recent studies indicate that <protein> tamoxifen </protein> initially acts as an antagonist, but later functions as an <chemical> ER </chemical> agonist, promoting tumor growth.",
    "original_text": "Recent studies indicate that  tamoxifen  initially acts as an antagonist, but later functions as an  ER  agonist, promoting tumor growth.",
    "entity1": "tamoxifen",
    "entity2": "ER"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Recent studies indicate that <protein> tamoxifen </protein> initially acts as an antagonist, but later functions as an <chemical> ER </chemical> agonist, promoting tumor growth.",
    "original_text": "Recent studies indicate that  tamoxifen  initially acts as an antagonist, but later functions as an  ER  agonist, promoting tumor growth.",
    "entity1": "tamoxifen",
    "entity2": "ER"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "With the pentapeptide linked through the C7alpha position of <protein> estradiol </protein>, the resulting PROTAC shows the most effective <chemical> ER </chemical> degradation and highest affinity for the estrogen receptor.",
    "original_text": "With the pentapeptide linked through the C7alpha position of  estradiol , the resulting PROTAC shows the most effective  ER  degradation and highest affinity for the estrogen receptor.",
    "entity1": "estradiol",
    "entity2": "ER"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "KEY RESULTS: Several agonists were found to be highly subtype selective because of selective affinity (e.g. <protein> salmeterol </protein> and formoterol, for the <chemical> beta(2)-adrenoceptor </chemical> over the beta(1) or beta(3)), while others (e.g. isoprenaline) had little affinity-selectivity.",
    "original_text": "KEY RESULTS: Several agonists were found to be highly subtype selective because of selective affinity (e.g.  salmeterol  and formoterol, for the  beta(2)-adrenoceptor  over the beta(1) or beta(3)), while others (e.g. isoprenaline) had little affinity-selectivity.",
    "entity1": "salmeterol",
    "entity2": "beta(2)-adrenoceptor"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "KEY RESULTS: Several agonists were found to be highly subtype selective because of selective affinity (e.g. <protein> salmeterol </protein> and formoterol, for the beta(2)-adrenoceptor over the <chemical> beta(1) </chemical> or beta(3)), while others (e.g. isoprenaline) had little affinity-selectivity.",
    "original_text": "KEY RESULTS: Several agonists were found to be highly subtype selective because of selective affinity (e.g.  salmeterol  and formoterol, for the beta(2)-adrenoceptor over the  beta(1)  or beta(3)), while others (e.g. isoprenaline) had little affinity-selectivity.",
    "entity1": "salmeterol",
    "entity2": "beta(1)"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "KEY RESULTS: Several agonists were found to be highly subtype selective because of selective affinity (e.g. salmeterol and <protein> formoterol </protein>, for the <chemical> beta(2)-adrenoceptor </chemical> over the beta(1) or beta(3)), while others (e.g. isoprenaline) had little affinity-selectivity.",
    "original_text": "KEY RESULTS: Several agonists were found to be highly subtype selective because of selective affinity (e.g. salmeterol and  formoterol , for the  beta(2)-adrenoceptor  over the beta(1) or beta(3)), while others (e.g. isoprenaline) had little affinity-selectivity.",
    "entity1": "formoterol",
    "entity2": "beta(2)-adrenoceptor"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "KEY RESULTS: Several agonists were found to be highly subtype selective because of selective affinity (e.g. salmeterol and <protein> formoterol </protein>, for the beta(2)-adrenoceptor over the beta(1) or <chemical> beta(3) </chemical>), while others (e.g. isoprenaline) had little affinity-selectivity.",
    "original_text": "KEY RESULTS: Several agonists were found to be highly subtype selective because of selective affinity (e.g. salmeterol and  formoterol , for the beta(2)-adrenoceptor over the beta(1) or  beta(3) ), while others (e.g. isoprenaline) had little affinity-selectivity.",
    "entity1": "formoterol",
    "entity2": "beta(3)"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "KEY RESULTS: Several agonists were found to be highly subtype selective because of selective affinity (e.g. salmeterol and formoterol, for the <protein> beta(2)-adrenoceptor </protein> over the beta(1) or beta(3)), while others (e.g. <chemical> isoprenaline </chemical>) had little affinity-selectivity.",
    "original_text": "KEY RESULTS: Several agonists were found to be highly subtype selective because of selective affinity (e.g. salmeterol and formoterol, for the  beta(2)-adrenoceptor  over the beta(1) or beta(3)), while others (e.g.  isoprenaline ) had little affinity-selectivity.",
    "entity1": "beta(2)-adrenoceptor",
    "entity2": "isoprenaline"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "KEY RESULTS: Several agonists were found to be highly subtype selective because of selective affinity (e.g. salmeterol and formoterol, for the beta(2)-adrenoceptor over the <protein> beta(1) </protein> or beta(3)), while others (e.g. <chemical> isoprenaline </chemical>) had little affinity-selectivity.",
    "original_text": "KEY RESULTS: Several agonists were found to be highly subtype selective because of selective affinity (e.g. salmeterol and formoterol, for the beta(2)-adrenoceptor over the  beta(1)  or beta(3)), while others (e.g.  isoprenaline ) had little affinity-selectivity.",
    "entity1": "beta(1)",
    "entity2": "isoprenaline"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "KEY RESULTS: Several agonists were found to be highly subtype selective because of selective affinity (e.g. salmeterol and formoterol, for the beta(2)-adrenoceptor over the beta(1) or <protein> beta(3) </protein>), while others (e.g. <chemical> isoprenaline </chemical>) had little affinity-selectivity.",
    "original_text": "KEY RESULTS: Several agonists were found to be highly subtype selective because of selective affinity (e.g. salmeterol and formoterol, for the beta(2)-adrenoceptor over the beta(1) or  beta(3) ), while others (e.g.  isoprenaline ) had little affinity-selectivity.",
    "entity1": "beta(3)",
    "entity2": "isoprenaline"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "The suppressive effect of <protein> ceruletide </protein> on barrel rotation could be partially countered by MK-329, a selective peripheral <chemical> CCK </chemical> (CCK-A) receptor antagonist.",
    "original_text": "The suppressive effect of  ceruletide  on barrel rotation could be partially countered by MK-329, a selective peripheral  CCK  (CCK-A) receptor antagonist.",
    "entity1": "ceruletide",
    "entity2": "CCK"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "The suppressive effect of <protein> ceruletide </protein> on barrel rotation could be partially countered by MK-329, a selective peripheral CCK <chemical> (CCK-A) receptor </chemical> antagonist.",
    "original_text": "The suppressive effect of  ceruletide  on barrel rotation could be partially countered by MK-329, a selective peripheral CCK  (CCK-A) receptor  antagonist.",
    "entity1": "ceruletide",
    "entity2": "(CCK-A) receptor"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "The suppressive effect of ceruletide on barrel rotation could be partially countered by <protein> MK-329 </protein>, a selective peripheral <chemical> CCK </chemical> (CCK-A) receptor antagonist.",
    "original_text": "The suppressive effect of ceruletide on barrel rotation could be partially countered by  MK-329 , a selective peripheral  CCK  (CCK-A) receptor antagonist.",
    "entity1": "MK-329",
    "entity2": "CCK"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "The suppressive effect of ceruletide on barrel rotation could be partially countered by <protein> MK-329 </protein>, a selective peripheral CCK <chemical> (CCK-A) receptor </chemical> antagonist.",
    "original_text": "The suppressive effect of ceruletide on barrel rotation could be partially countered by  MK-329 , a selective peripheral CCK  (CCK-A) receptor  antagonist.",
    "entity1": "MK-329",
    "entity2": "(CCK-A) receptor"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "These findings suggest that <protein> ceruletide </protein> specifically suppresses the barrel rotation evoked by SMS 201-995 in a long-lasting manner possibly acting through <chemical> CCK-A receptor </chemical>.",
    "original_text": "These findings suggest that  ceruletide  specifically suppresses the barrel rotation evoked by SMS 201-995 in a long-lasting manner possibly acting through  CCK-A receptor .",
    "entity1": "ceruletide",
    "entity2": "CCK-A receptor"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Effects of the <protein> histamine H1 </protein> antagonist <chemical> chlorcyclizine </chemical> on rat fetal palate development.",
    "original_text": "Effects of the  histamine H1  antagonist  chlorcyclizine  on rat fetal palate development.",
    "entity1": "histamine H1",
    "entity2": "chlorcyclizine"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "BACKGROUND: The effects of <protein> histamine H1 </protein> antagonist <chemical> chlorcyclizine </chemical> on rat palate development were characterized following in utero exposure.",
    "original_text": "BACKGROUND: The effects of  histamine H1  antagonist  chlorcyclizine  on rat palate development were characterized following in utero exposure.",
    "entity1": "histamine H1",
    "entity2": "chlorcyclizine"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "Unexpectedly, both the <protein> mGluR(5) </protein>specific agonist, <chemical> CHPG </chemical>, and the group II mGluR (mGlu(2/3)) agonist, LY379268 (LY), induced a TTX-insensitive outward current/hyperpolarization.",
    "original_text": "Unexpectedly, both the  mGluR(5) specific agonist,  CHPG , and the group II mGluR (mGlu(2/3)) agonist, LY379268 (LY), induced a TTX-insensitive outward current/hyperpolarization.",
    "entity1": "mGluR(5)",
    "entity2": "CHPG"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "Unexpectedly, both the mGluR(5)specific agonist, CHPG, and the <protein> group II mGluR </protein> (mGlu(2/3)) agonist, <chemical> LY379268 </chemical> (LY), induced a TTX-insensitive outward current/hyperpolarization.",
    "original_text": "Unexpectedly, both the mGluR(5)specific agonist, CHPG, and the  group II mGluR  (mGlu(2/3)) agonist,  LY379268  (LY), induced a TTX-insensitive outward current/hyperpolarization.",
    "entity1": "group II mGluR",
    "entity2": "LY379268"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Both outward currents were significantly reduced by the <protein> mGluR </protein> antagonist <chemical> MCPG </chemical> and the CHPG-induced current was blocked by the specific mGluR(5) antagonist MTEP.",
    "original_text": "Both outward currents were significantly reduced by the  mGluR  antagonist  MCPG  and the CHPG-induced current was blocked by the specific mGluR(5) antagonist MTEP.",
    "entity1": "mGluR",
    "entity2": "MCPG"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Both outward currents were significantly reduced by the mGluR antagonist MCPG and the CHPG-induced current was blocked by the specific <protein> mGluR(5) </protein> antagonist <chemical> MTEP </chemical>.",
    "original_text": "Both outward currents were significantly reduced by the mGluR antagonist MCPG and the CHPG-induced current was blocked by the specific  mGluR(5)  antagonist  MTEP .",
    "entity1": "mGluR(5)",
    "entity2": "MTEP"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "To clarify if the behavioral interaction between ethanol and adenosine reported previously occur centrally or due to a peripheral hemodynamic change, the effect of i.c.v. <protein> adenosine </protein> agonists, <chemical> N6-(R-phenylisopropyl)adenosine </chemical> (R-PIA), N6-(S-phenylisopropyl)adenosine, 5'-(N-cyclopropyl)-carboxamidoadenosine, antagonists, theophylline and 8-p-(sulfophenyl)theophylline as well as enprofylline on ethanol-(i.p.)-induced motor incoordination was evaluated by rotorod.",
    "original_text": "To clarify if the behavioral interaction between ethanol and adenosine reported previously occur centrally or due to a peripheral hemodynamic change, the effect of i.c.v.  adenosine  agonists,  N6-(R-phenylisopropyl)adenosine  (R-PIA), N6-(S-phenylisopropyl)adenosine, 5'-(N-cyclopropyl)-carboxamidoadenosine, antagonists, theophylline and 8-p-(sulfophenyl)theophylline as well as enprofylline on ethanol-(i.p.)-induced motor incoordination was evaluated by rotorod.",
    "entity1": "adenosine",
    "entity2": "N6-(R-phenylisopropyl)adenosine"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "To clarify if the behavioral interaction between ethanol and adenosine reported previously occur centrally or due to a peripheral hemodynamic change, the effect of i.c.v. <protein> adenosine </protein> agonists, N6-(R-phenylisopropyl)adenosine (<chemical> R-PIA </chemical>), N6-(S-phenylisopropyl)adenosine, 5'-(N-cyclopropyl)-carboxamidoadenosine, antagonists, theophylline and 8-p-(sulfophenyl)theophylline as well as enprofylline on ethanol-(i.p.)-induced motor incoordination was evaluated by rotorod.",
    "original_text": "To clarify if the behavioral interaction between ethanol and adenosine reported previously occur centrally or due to a peripheral hemodynamic change, the effect of i.c.v.  adenosine  agonists, N6-(R-phenylisopropyl)adenosine ( R-PIA ), N6-(S-phenylisopropyl)adenosine, 5'-(N-cyclopropyl)-carboxamidoadenosine, antagonists, theophylline and 8-p-(sulfophenyl)theophylline as well as enprofylline on ethanol-(i.p.)-induced motor incoordination was evaluated by rotorod.",
    "entity1": "adenosine",
    "entity2": "R-PIA"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "To clarify if the behavioral interaction between ethanol and adenosine reported previously occur centrally or due to a peripheral hemodynamic change, the effect of i.c.v. <protein> adenosine </protein> agonists, N6-(R-phenylisopropyl)adenosine (R-PIA), <chemical> N6-(S-phenylisopropyl)adenosine </chemical>, 5'-(N-cyclopropyl)-carboxamidoadenosine, antagonists, theophylline and 8-p-(sulfophenyl)theophylline as well as enprofylline on ethanol-(i.p.)-induced motor incoordination was evaluated by rotorod.",
    "original_text": "To clarify if the behavioral interaction between ethanol and adenosine reported previously occur centrally or due to a peripheral hemodynamic change, the effect of i.c.v.  adenosine  agonists, N6-(R-phenylisopropyl)adenosine (R-PIA),  N6-(S-phenylisopropyl)adenosine , 5'-(N-cyclopropyl)-carboxamidoadenosine, antagonists, theophylline and 8-p-(sulfophenyl)theophylline as well as enprofylline on ethanol-(i.p.)-induced motor incoordination was evaluated by rotorod.",
    "entity1": "adenosine",
    "entity2": "N6-(S-phenylisopropyl)adenosine"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "To clarify if the behavioral interaction between ethanol and adenosine reported previously occur centrally or due to a peripheral hemodynamic change, the effect of i.c.v. <protein> adenosine </protein> agonists, N6-(R-phenylisopropyl)adenosine (R-PIA), N6-(S-phenylisopropyl)adenosine, <chemical> 5'-(N-cyclopropyl)-carboxamidoadenosine </chemical>, antagonists, theophylline and 8-p-(sulfophenyl)theophylline as well as enprofylline on ethanol-(i.p.)-induced motor incoordination was evaluated by rotorod.",
    "original_text": "To clarify if the behavioral interaction between ethanol and adenosine reported previously occur centrally or due to a peripheral hemodynamic change, the effect of i.c.v.  adenosine  agonists, N6-(R-phenylisopropyl)adenosine (R-PIA), N6-(S-phenylisopropyl)adenosine,  5'-(N-cyclopropyl)-carboxamidoadenosine , antagonists, theophylline and 8-p-(sulfophenyl)theophylline as well as enprofylline on ethanol-(i.p.)-induced motor incoordination was evaluated by rotorod.",
    "entity1": "adenosine",
    "entity2": "5'-(N-cyclopropyl)-carboxamidoadenosine"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "To clarify if the behavioral interaction between ethanol and adenosine reported previously occur centrally or due to a peripheral hemodynamic change, the effect of i.c.v. <protein> adenosine </protein> agonists, N6-(R-phenylisopropyl)adenosine (R-PIA), N6-(S-phenylisopropyl)adenosine, 5'-(N-cyclopropyl)-carboxamidoadenosine, antagonists, <chemical> theophylline </chemical> and 8-p-(sulfophenyl)theophylline as well as enprofylline on ethanol-(i.p.)-induced motor incoordination was evaluated by rotorod.",
    "original_text": "To clarify if the behavioral interaction between ethanol and adenosine reported previously occur centrally or due to a peripheral hemodynamic change, the effect of i.c.v.  adenosine  agonists, N6-(R-phenylisopropyl)adenosine (R-PIA), N6-(S-phenylisopropyl)adenosine, 5'-(N-cyclopropyl)-carboxamidoadenosine, antagonists,  theophylline  and 8-p-(sulfophenyl)theophylline as well as enprofylline on ethanol-(i.p.)-induced motor incoordination was evaluated by rotorod.",
    "entity1": "adenosine",
    "entity2": "theophylline"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "To clarify if the behavioral interaction between ethanol and adenosine reported previously occur centrally or due to a peripheral hemodynamic change, the effect of i.c.v. <protein> adenosine </protein> agonists, N6-(R-phenylisopropyl)adenosine (R-PIA), N6-(S-phenylisopropyl)adenosine, 5'-(N-cyclopropyl)-carboxamidoadenosine, antagonists, theophylline and <chemical> 8-p-(sulfophenyl)theophylline </chemical> as well as enprofylline on ethanol-(i.p.)-induced motor incoordination was evaluated by rotorod.",
    "original_text": "To clarify if the behavioral interaction between ethanol and adenosine reported previously occur centrally or due to a peripheral hemodynamic change, the effect of i.c.v.  adenosine  agonists, N6-(R-phenylisopropyl)adenosine (R-PIA), N6-(S-phenylisopropyl)adenosine, 5'-(N-cyclopropyl)-carboxamidoadenosine, antagonists, theophylline and  8-p-(sulfophenyl)theophylline  as well as enprofylline on ethanol-(i.p.)-induced motor incoordination was evaluated by rotorod.",
    "entity1": "adenosine",
    "entity2": "8-p-(sulfophenyl)theophylline"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "To clarify if the behavioral interaction between ethanol and adenosine reported previously occur centrally or due to a peripheral hemodynamic change, the effect of i.c.v. <protein> adenosine </protein> agonists, N6-(R-phenylisopropyl)adenosine (R-PIA), N6-(S-phenylisopropyl)adenosine, 5'-(N-cyclopropyl)-carboxamidoadenosine, antagonists, theophylline and 8-p-(sulfophenyl)theophylline as well as <chemical> enprofylline </chemical> on ethanol-(i.p.)-induced motor incoordination was evaluated by rotorod.",
    "original_text": "To clarify if the behavioral interaction between ethanol and adenosine reported previously occur centrally or due to a peripheral hemodynamic change, the effect of i.c.v.  adenosine  agonists, N6-(R-phenylisopropyl)adenosine (R-PIA), N6-(S-phenylisopropyl)adenosine, 5'-(N-cyclopropyl)-carboxamidoadenosine, antagonists, theophylline and 8-p-(sulfophenyl)theophylline as well as  enprofylline  on ethanol-(i.p.)-induced motor incoordination was evaluated by rotorod.",
    "entity1": "adenosine",
    "entity2": "enprofylline"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "<protein> Enprofylline </protein>, a weak <chemical> adenosine </chemical> antagonist but potent inhibitor of cyclic AMP phosphodiesterase, did not alter ethanol's motor incoordination, further supporting involvement of brain adenosine receptor mechanism(s) in ethanol-adenosine interactions.",
    "original_text": " Enprofylline , a weak  adenosine  antagonist but potent inhibitor of cyclic AMP phosphodiesterase, did not alter ethanol's motor incoordination, further supporting involvement of brain adenosine receptor mechanism(s) in ethanol-adenosine interactions.",
    "entity1": "Enprofylline",
    "entity2": "adenosine"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "<protein> Celastrol </protein>, a TAK1 inhibitor and anti-inflammatory compound used in traditional Chinese medicine, also decreased <chemical> TGF-\u03b21 </chemical>-induced phosphorylation of TAK1 and RELA, and suppressed basal, TGF-\u03b21- and tumor necrosis factor-alpha (TNF-\u03b1)-induced NF-\u03baB reporter gene activity.",
    "original_text": " Celastrol , a TAK1 inhibitor and anti-inflammatory compound used in traditional Chinese medicine, also decreased  TGF-\u03b21 -induced phosphorylation of TAK1 and RELA, and suppressed basal, TGF-\u03b21- and tumor necrosis factor-alpha (TNF-\u03b1)-induced NF-\u03baB reporter gene activity.",
    "entity1": "Celastrol",
    "entity2": "TGF-\u03b21"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "<protein> Celastrol </protein>, a TAK1 inhibitor and anti-inflammatory compound used in traditional Chinese medicine, also decreased TGF-\u03b21-induced phosphorylation of TAK1 and RELA, and suppressed basal, <chemical> TGF-\u03b21 </chemical>- and tumor necrosis factor-alpha (TNF-\u03b1)-induced NF-\u03baB reporter gene activity.",
    "original_text": " Celastrol , a TAK1 inhibitor and anti-inflammatory compound used in traditional Chinese medicine, also decreased TGF-\u03b21-induced phosphorylation of TAK1 and RELA, and suppressed basal,  TGF-\u03b21 - and tumor necrosis factor-alpha (TNF-\u03b1)-induced NF-\u03baB reporter gene activity.",
    "entity1": "Celastrol",
    "entity2": "TGF-\u03b21"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "<protein> Celastrol </protein>, a TAK1 inhibitor and anti-inflammatory compound used in traditional Chinese medicine, also decreased TGF-\u03b21-induced phosphorylation of TAK1 and RELA, and suppressed basal, TGF-\u03b21- and <chemical> tumor necrosis factor-alpha </chemical> (TNF-\u03b1)-induced NF-\u03baB reporter gene activity.",
    "original_text": " Celastrol , a TAK1 inhibitor and anti-inflammatory compound used in traditional Chinese medicine, also decreased TGF-\u03b21-induced phosphorylation of TAK1 and RELA, and suppressed basal, TGF-\u03b21- and  tumor necrosis factor-alpha  (TNF-\u03b1)-induced NF-\u03baB reporter gene activity.",
    "entity1": "Celastrol",
    "entity2": "tumor necrosis factor-alpha"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "The atypical antidepressant <protein> mianserin </protein> exhibits agonist activity at <chemical> kappa-opioid receptors </chemical>.",
    "original_text": "The atypical antidepressant  mianserin  exhibits agonist activity at  kappa-opioid receptors .",
    "entity1": "mianserin",
    "entity2": "kappa-opioid receptors"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "We previously reported that <protein> tricyclic </protein> antidepressants act as agonists at distinct <chemical> opioid receptors </chemical>.",
    "original_text": "We previously reported that  tricyclic  antidepressants act as agonists at distinct  opioid receptors .",
    "entity1": "tricyclic",
    "entity2": "opioid receptors"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "The agonist activity was antagonized by the selective <protein> kappa-opioid </protein> blocker <chemical> nor-binaltorphimine </chemical> (nor-BNI).",
    "original_text": "The agonist activity was antagonized by the selective  kappa-opioid  blocker  nor-binaltorphimine  (nor-BNI).",
    "entity1": "kappa-opioid",
    "entity2": "nor-binaltorphimine"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "The agonist activity was antagonized by the selective <protein> kappa-opioid </protein> blocker nor-binaltorphimine (<chemical> nor-BNI </chemical>).",
    "original_text": "The agonist activity was antagonized by the selective  kappa-opioid  blocker nor-binaltorphimine ( nor-BNI ).",
    "entity1": "kappa-opioid",
    "entity2": "nor-BNI"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "The <protein> mianserin </protein> analogue mirtazapine also displayed <chemical> kappa-opioid </chemical> agonist activity.",
    "original_text": "The  mianserin  analogue mirtazapine also displayed  kappa-opioid  agonist activity.",
    "entity1": "mianserin",
    "entity2": "kappa-opioid"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "The mianserin analogue <protein> mirtazapine </protein> also displayed <chemical> kappa-opioid </chemical> agonist activity.",
    "original_text": "The mianserin analogue  mirtazapine  also displayed  kappa-opioid  agonist activity.",
    "entity1": "mirtazapine",
    "entity2": "kappa-opioid"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "In rat striatum and nucleus accumbens, mianserin stimulated [35S]GTPgammaS binding in a nor-BNI-sensitive manner with maximal effects lower than those of the full <protein> kappa-opioid </protein> agonists <chemical> (-)-U50,488 </chemical> and dynorphin A.",
    "original_text": "In rat striatum and nucleus accumbens, mianserin stimulated [35S]GTPgammaS binding in a nor-BNI-sensitive manner with maximal effects lower than those of the full  kappa-opioid  agonists  (-)-U50,488  and dynorphin A.",
    "entity1": "kappa-opioid",
    "entity2": "(-)-U50,488"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "In rat striatum and nucleus accumbens, mianserin stimulated [35S]GTPgammaS binding in a nor-BNI-sensitive manner with maximal effects lower than those of the full <protein> kappa-opioid </protein> agonists (-)-U50,488 and <chemical> dynorphin A </chemical>.",
    "original_text": "In rat striatum and nucleus accumbens, mianserin stimulated [35S]GTPgammaS binding in a nor-BNI-sensitive manner with maximal effects lower than those of the full  kappa-opioid  agonists (-)-U50,488 and  dynorphin A .",
    "entity1": "kappa-opioid",
    "entity2": "dynorphin A"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "When combined, <protein> mianserin </protein> antagonized the effects of the full <chemical> kappa-opioid receptor </chemical> agonists in [(35)S]GTPgammaS assays and reduced the stimulation of p38 MAPK and ERK1/2 phosphorylation by dynorphin A.",
    "original_text": "When combined,  mianserin  antagonized the effects of the full  kappa-opioid receptor  agonists in [(35)S]GTPgammaS assays and reduced the stimulation of p38 MAPK and ERK1/2 phosphorylation by dynorphin A.",
    "entity1": "mianserin",
    "entity2": "kappa-opioid receptor"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "CONCLUSIONS AND IMPLICATIONS: In different cell systems, <protein> mianserin </protein> directly activates <chemical> kappa-opioid receptors </chemical>, displaying partial agonist activity at brain receptors.",
    "original_text": "CONCLUSIONS AND IMPLICATIONS: In different cell systems,  mianserin  directly activates  kappa-opioid receptors , displaying partial agonist activity at brain receptors.",
    "entity1": "mianserin",
    "entity2": "kappa-opioid receptors"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "In the present study we tested whether <protein> propranolol </protein>, a <chemical> \u03b2-receptor </chemical> antagonist commonly used as antihypertensive drug, could ameliorate the cognitive impairments and increases in AD-related markers shown by the senescence-accelerated mouse prone-8 (SAMP8).",
    "original_text": "In the present study we tested whether  propranolol , a  \u03b2-receptor  antagonist commonly used as antihypertensive drug, could ameliorate the cognitive impairments and increases in AD-related markers shown by the senescence-accelerated mouse prone-8 (SAMP8).",
    "entity1": "propranolol",
    "entity2": "\u03b2-receptor"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of oestradiol, a selective ER\u03b1 agonist-PPT [4,4',4\u2033-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol], a selective <protein> ER\u03b2 </protein> agonist-<chemical> DPN </chemical> [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective ER\u03b1 antagonist-MPP [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride] or a selective ER\u03b2 antagonist-PHTPP (4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol).",
    "original_text": "Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of oestradiol, a selective ER\u03b1 agonist-PPT [4,4',4\u2033-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol], a selective  ER\u03b2  agonist- DPN  [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective ER\u03b1 antagonist-MPP [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride] or a selective ER\u03b2 antagonist-PHTPP (4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol).",
    "entity1": "ER\u03b2",
    "entity2": "DPN"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of oestradiol, a selective ER\u03b1 agonist-PPT [4,4',4\u2033-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol], a selective <protein> ER\u03b2 </protein> agonist-DPN <chemical>[ 2,3-bis(4-hydroxyphenyl)-propionitrile </chemical>], a selective ER\u03b1 antagonist-MPP [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride] or a selective ER\u03b2 antagonist-PHTPP (4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol).",
    "original_text": "Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of oestradiol, a selective ER\u03b1 agonist-PPT [4,4',4\u2033-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol], a selective  ER\u03b2  agonist-DPN [ 2,3-bis(4-hydroxyphenyl)-propionitrile ], a selective ER\u03b1 antagonist-MPP [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride] or a selective ER\u03b2 antagonist-PHTPP (4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol).",
    "entity1": "ER\u03b2",
    "entity2": "[ 2,3-bis(4-hydroxyphenyl)-propionitrile"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of oestradiol, a selective <protein> ER\u03b1 </protein> agonist-<chemical> PPT </chemical> [4,4',4\u2033-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol], a selective ER\u03b2 agonist-DPN [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective ER\u03b1 antagonist-MPP [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride] or a selective ER\u03b2 antagonist-PHTPP (4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol).",
    "original_text": "Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of oestradiol, a selective  ER\u03b1  agonist- PPT  [4,4',4\u2033-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol], a selective ER\u03b2 agonist-DPN [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective ER\u03b1 antagonist-MPP [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride] or a selective ER\u03b2 antagonist-PHTPP (4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol).",
    "entity1": "ER\u03b1",
    "entity2": "PPT"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of oestradiol, a selective <protein> ER\u03b1 </protein> agonist-PPT <chemical>[ 4,4',4\u2033-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol </chemical>], a selective ER\u03b2 agonist-DPN [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective ER\u03b1 antagonist-MPP [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride] or a selective ER\u03b2 antagonist-PHTPP (4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol).",
    "original_text": "Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of oestradiol, a selective  ER\u03b1  agonist-PPT [ 4,4',4\u2033-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol ], a selective ER\u03b2 agonist-DPN [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective ER\u03b1 antagonist-MPP [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride] or a selective ER\u03b2 antagonist-PHTPP (4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol).",
    "entity1": "ER\u03b1",
    "entity2": "[ 4,4',4\u2033-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of oestradiol, a selective ER\u03b1 agonist-PPT [4,4',4\u2033-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol], a selective ER\u03b2 agonist-DPN [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective <protein> ER\u03b1 </protein> antagonist-<chemical> MPP </chemical> [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride] or a selective ER\u03b2 antagonist-PHTPP (4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol).",
    "original_text": "Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of oestradiol, a selective ER\u03b1 agonist-PPT [4,4',4\u2033-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol], a selective ER\u03b2 agonist-DPN [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective  ER\u03b1  antagonist- MPP  [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride] or a selective ER\u03b2 antagonist-PHTPP (4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol).",
    "entity1": "ER\u03b1",
    "entity2": "MPP"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of oestradiol, a selective ER\u03b1 agonist-PPT [4,4',4\u2033-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol], a selective ER\u03b2 agonist-DPN [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective <protein> ER\u03b1 </protein> antagonist-MPP <chemical>[ 1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol </chemical>]-1H-pyrazole dihydrochloride] or a selective ER\u03b2 antagonist-PHTPP (4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol).",
    "original_text": "Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of oestradiol, a selective ER\u03b1 agonist-PPT [4,4',4\u2033-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol], a selective ER\u03b2 agonist-DPN [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective  ER\u03b1  antagonist-MPP [ 1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol ]-1H-pyrazole dihydrochloride] or a selective ER\u03b2 antagonist-PHTPP (4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol).",
    "entity1": "ER\u03b1",
    "entity2": "[ 1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of oestradiol, a selective ER\u03b1 agonist-PPT [4,4',4\u2033-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol], a selective ER\u03b2 agonist-DPN [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective <protein> ER\u03b1 </protein> antagonist-MPP [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-<chemical> 1H-pyrazole dihydrochloride </chemical>] or a selective ER\u03b2 antagonist-PHTPP (4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol).",
    "original_text": "Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of oestradiol, a selective ER\u03b1 agonist-PPT [4,4',4\u2033-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol], a selective ER\u03b2 agonist-DPN [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective  ER\u03b1  antagonist-MPP [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]- 1H-pyrazole dihydrochloride ] or a selective ER\u03b2 antagonist-PHTPP (4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol).",
    "entity1": "ER\u03b1",
    "entity2": "1H-pyrazole dihydrochloride"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of oestradiol, a selective ER\u03b1 agonist-PPT [4,4',4\u2033-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol], a selective ER\u03b2 agonist-DPN [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective ER\u03b1 antagonist-MPP [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride] or a selective <protein> ER\u03b2 </protein> antagonist-<chemical> PHTPP </chemical> (4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol).",
    "original_text": "Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of oestradiol, a selective ER\u03b1 agonist-PPT [4,4',4\u2033-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol], a selective ER\u03b2 agonist-DPN [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective ER\u03b1 antagonist-MPP [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride] or a selective  ER\u03b2  antagonist- PHTPP  (4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol).",
    "entity1": "ER\u03b2",
    "entity2": "PHTPP"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of oestradiol, a selective ER\u03b1 agonist-PPT [4,4',4\u2033-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol], a selective ER\u03b2 agonist-DPN [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective ER\u03b1 antagonist-MPP [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride] or a selective <protein> ER\u03b2 </protein> antagonist-PHTPP (<chemical> 4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol </chemical>).",
    "original_text": "Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of oestradiol, a selective ER\u03b1 agonist-PPT [4,4',4\u2033-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol], a selective ER\u03b2 agonist-DPN [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective ER\u03b1 antagonist-MPP [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride] or a selective  ER\u03b2  antagonist-PHTPP ( 4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol ).",
    "entity1": "ER\u03b2",
    "entity2": "4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Disruption of microtubule prevented insulin-induced actin remodeling and distal insulin signal transduction, with reduction in surface <protein> glucose transporter isoform 4 </protein> (GLUT4) and <chemical> glucose </chemical> uptake.",
    "original_text": "Disruption of microtubule prevented insulin-induced actin remodeling and distal insulin signal transduction, with reduction in surface  glucose transporter isoform 4  (GLUT4) and  glucose  uptake.",
    "entity1": "glucose transporter isoform 4",
    "entity2": "glucose"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Disruption of microtubule prevented insulin-induced actin remodeling and distal insulin signal transduction, with reduction in surface glucose transporter isoform 4 (<protein> GLUT4 </protein>) and <chemical> glucose </chemical> uptake.",
    "original_text": "Disruption of microtubule prevented insulin-induced actin remodeling and distal insulin signal transduction, with reduction in surface glucose transporter isoform 4 ( GLUT4 ) and  glucose  uptake.",
    "entity1": "GLUT4",
    "entity2": "glucose"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Other groups received either an infusion of the selective <protein> NMDA receptor </protein> antagonist (<chemical> AP7 </chemical>; 10 nmol; intra-mPFC) or vehicle, 10 min prior to PILO preceding LFS600, or prior to a supra-threshold LTD protocol (900 pulses, 1 Hz; LFS900).",
    "original_text": "Other groups received either an infusion of the selective  NMDA receptor  antagonist ( AP7 ; 10 nmol; intra-mPFC) or vehicle, 10 min prior to PILO preceding LFS600, or prior to a supra-threshold LTD protocol (900 pulses, 1 Hz; LFS900).",
    "entity1": "NMDA receptor",
    "entity2": "AP7"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Metabolism of <protein> triethylenetetramine </protein> and 1,12-diamino-3,6,9-triazadodecane by the spermidine/spermine-N(1)-acetyltransferase and <chemical> thialysine acetyltransferase </chemical>.",
    "original_text": "Metabolism of  triethylenetetramine  and 1,12-diamino-3,6,9-triazadodecane by the spermidine/spermine-N(1)-acetyltransferase and  thialysine acetyltransferase .",
    "entity1": "triethylenetetramine",
    "entity2": "thialysine acetyltransferase"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Metabolism of <protein> triethylenetetramine </protein> and 1,12-diamino-3,6,9-triazadodecane by the <chemical> spermidine/spermine-N(1)-acetyltransferase </chemical> and thialysine acetyltransferase.",
    "original_text": "Metabolism of  triethylenetetramine  and 1,12-diamino-3,6,9-triazadodecane by the  spermidine/spermine-N(1)-acetyltransferase  and thialysine acetyltransferase.",
    "entity1": "triethylenetetramine",
    "entity2": "spermidine/spermine-N(1)-acetyltransferase"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Metabolism of triethylenetetramine and <protein> 1,12-diamino-3,6,9-triazadodecane </protein> by the spermidine/spermine-N(1)-acetyltransferase and <chemical> thialysine acetyltransferase </chemical>.",
    "original_text": "Metabolism of triethylenetetramine and  1,12-diamino-3,6,9-triazadodecane  by the spermidine/spermine-N(1)-acetyltransferase and  thialysine acetyltransferase .",
    "entity1": "1,12-diamino-3,6,9-triazadodecane",
    "entity2": "thialysine acetyltransferase"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Metabolism of triethylenetetramine and <protein> 1,12-diamino-3,6,9-triazadodecane </protein> by the <chemical> spermidine/spermine-N(1)-acetyltransferase </chemical> and thialysine acetyltransferase.",
    "original_text": "Metabolism of triethylenetetramine and  1,12-diamino-3,6,9-triazadodecane  by the  spermidine/spermine-N(1)-acetyltransferase  and thialysine acetyltransferase.",
    "entity1": "1,12-diamino-3,6,9-triazadodecane",
    "entity2": "spermidine/spermine-N(1)-acetyltransferase"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "We recently showed that <protein> TETA </protein> is metabolized in vitro by polyamine catabolic enzyme <chemical> spermidine/spermine-N(1)-acetyltransferase </chemical> (SSAT1) and by thialysine acetyltransferase (SSAT2) to its monoacetylated derivative (MAT).",
    "original_text": "We recently showed that  TETA  is metabolized in vitro by polyamine catabolic enzyme  spermidine/spermine-N(1)-acetyltransferase  (SSAT1) and by thialysine acetyltransferase (SSAT2) to its monoacetylated derivative (MAT).",
    "entity1": "TETA",
    "entity2": "spermidine/spermine-N(1)-acetyltransferase"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "We recently showed that <protein> TETA </protein> is metabolized in vitro by polyamine catabolic enzyme spermidine/spermine-N(1)-acetyltransferase (<chemical> SSAT1 </chemical>) and by thialysine acetyltransferase (SSAT2) to its monoacetylated derivative (MAT).",
    "original_text": "We recently showed that  TETA  is metabolized in vitro by polyamine catabolic enzyme spermidine/spermine-N(1)-acetyltransferase ( SSAT1 ) and by thialysine acetyltransferase (SSAT2) to its monoacetylated derivative (MAT).",
    "entity1": "TETA",
    "entity2": "SSAT1"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "We recently showed that <protein> TETA </protein> is metabolized in vitro by polyamine catabolic enzyme spermidine/spermine-N(1)-acetyltransferase (SSAT1) and by <chemical> thialysine acetyltransferase </chemical> (SSAT2) to its monoacetylated derivative (MAT).",
    "original_text": "We recently showed that  TETA  is metabolized in vitro by polyamine catabolic enzyme spermidine/spermine-N(1)-acetyltransferase (SSAT1) and by  thialysine acetyltransferase  (SSAT2) to its monoacetylated derivative (MAT).",
    "entity1": "TETA",
    "entity2": "thialysine acetyltransferase"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "We recently showed that <protein> TETA </protein> is metabolized in vitro by polyamine catabolic enzyme spermidine/spermine-N(1)-acetyltransferase (SSAT1) and by thialysine acetyltransferase (<chemical> SSAT2 </chemical>) to its monoacetylated derivative (MAT).",
    "original_text": "We recently showed that  TETA  is metabolized in vitro by polyamine catabolic enzyme spermidine/spermine-N(1)-acetyltransferase (SSAT1) and by thialysine acetyltransferase ( SSAT2 ) to its monoacetylated derivative (MAT).",
    "entity1": "TETA",
    "entity2": "SSAT2"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "We recently showed that TETA is metabolized in vitro by <protein> polyamine </protein> catabolic enzyme <chemical> spermidine/spermine-N(1)-acetyltransferase </chemical> (SSAT1) and by thialysine acetyltransferase (SSAT2) to its monoacetylated derivative (MAT).",
    "original_text": "We recently showed that TETA is metabolized in vitro by  polyamine  catabolic enzyme  spermidine/spermine-N(1)-acetyltransferase  (SSAT1) and by thialysine acetyltransferase (SSAT2) to its monoacetylated derivative (MAT).",
    "entity1": "polyamine",
    "entity2": "spermidine/spermine-N(1)-acetyltransferase"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "We recently showed that TETA is metabolized in vitro by <protein> polyamine </protein> catabolic enzyme spermidine/spermine-N(1)-acetyltransferase (<chemical> SSAT1 </chemical>) and by thialysine acetyltransferase (SSAT2) to its monoacetylated derivative (MAT).",
    "original_text": "We recently showed that TETA is metabolized in vitro by  polyamine  catabolic enzyme spermidine/spermine-N(1)-acetyltransferase ( SSAT1 ) and by thialysine acetyltransferase (SSAT2) to its monoacetylated derivative (MAT).",
    "entity1": "polyamine",
    "entity2": "SSAT1"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "The acetylation of <protein> TETA </protein> is increased in <chemical> SSAT1 </chemical>-overexpressing mice compared with wild-type mice.",
    "original_text": "The acetylation of  TETA  is increased in  SSAT1 -overexpressing mice compared with wild-type mice.",
    "entity1": "TETA",
    "entity2": "SSAT1"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "However, SSAT1-deficient mice metabolize <protein> TETA </protein> at the same rate as the wild-type mice, indicating the existence of another <chemical> N-acetylase </chemical> respons 2ible for its metabolism in mice.",
    "original_text": "However, SSAT1-deficient mice metabolize  TETA  at the same rate as the wild-type mice, indicating the existence of another  N-acetylase  respons 2ible for its metabolism in mice.",
    "entity1": "TETA",
    "entity2": "N-acetylase"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Here, we show that siRNA-mediated knockdown of <protein> SSAT2 </protein> in HEPG2 cells and in primary hepatocytes from the SSAT1-deficient or wild-type mice reduced the metabolism of <chemical> TETA </chemical> to MAT.",
    "original_text": "Here, we show that siRNA-mediated knockdown of  SSAT2  in HEPG2 cells and in primary hepatocytes from the SSAT1-deficient or wild-type mice reduced the metabolism of  TETA  to MAT.",
    "entity1": "SSAT2",
    "entity2": "TETA"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "By contrast, <protein> 1,12-diamino-3,6,9-triazadodecane </protein>(SpmTrien), a charge-deficient spermine analog, was an extremely poor substrate of human recombinant SSAT2 and was metabolized by <chemical> SSAT1 </chemical> in HEPG2 cells and in wild-type primary hepatocytes.",
    "original_text": "By contrast,  1,12-diamino-3,6,9-triazadodecane (SpmTrien), a charge-deficient spermine analog, was an extremely poor substrate of human recombinant SSAT2 and was metabolized by  SSAT1  in HEPG2 cells and in wild-type primary hepatocytes.",
    "entity1": "1,12-diamino-3,6,9-triazadodecane",
    "entity2": "SSAT1"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "By contrast, <protein> 1,12-diamino-3,6,9-triazadodecane </protein>(SpmTrien), a charge-deficient spermine analog, was an extremely poor substrate of <chemical> human recombinant SSAT2 </chemical> and was metabolized by SSAT1 in HEPG2 cells and in wild-type primary hepatocytes.",
    "original_text": "By contrast,  1,12-diamino-3,6,9-triazadodecane (SpmTrien), a charge-deficient spermine analog, was an extremely poor substrate of  human recombinant SSAT2  and was metabolized by SSAT1 in HEPG2 cells and in wild-type primary hepatocytes.",
    "entity1": "1,12-diamino-3,6,9-triazadodecane",
    "entity2": "human recombinant SSAT2"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "By contrast, 1,12-diamino-3,6,9-triazadodecane(<protein> SpmTrien </protein>), a charge-deficient spermine analog, was an extremely poor substrate of human recombinant SSAT2 and was metabolized by <chemical> SSAT1 </chemical> in HEPG2 cells and in wild-type primary hepatocytes.",
    "original_text": "By contrast, 1,12-diamino-3,6,9-triazadodecane( SpmTrien ), a charge-deficient spermine analog, was an extremely poor substrate of human recombinant SSAT2 and was metabolized by  SSAT1  in HEPG2 cells and in wild-type primary hepatocytes.",
    "entity1": "SpmTrien",
    "entity2": "SSAT1"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "By contrast, 1,12-diamino-3,6,9-triazadodecane(<protein> SpmTrien </protein>), a charge-deficient spermine analog, was an extremely poor substrate of <chemical> human recombinant SSAT2 </chemical> and was metabolized by SSAT1 in HEPG2 cells and in wild-type primary hepatocytes.",
    "original_text": "By contrast, 1,12-diamino-3,6,9-triazadodecane( SpmTrien ), a charge-deficient spermine analog, was an extremely poor substrate of  human recombinant SSAT2  and was metabolized by SSAT1 in HEPG2 cells and in wild-type primary hepatocytes.",
    "entity1": "SpmTrien",
    "entity2": "human recombinant SSAT2"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "By contrast, 1,12-diamino-3,6,9-triazadodecane(SpmTrien), a charge-deficient <protein> spermine </protein> analog, was an extremely poor substrate of human recombinant SSAT2 and was metabolized by <chemical> SSAT1 </chemical> in HEPG2 cells and in wild-type primary hepatocytes.",
    "original_text": "By contrast, 1,12-diamino-3,6,9-triazadodecane(SpmTrien), a charge-deficient  spermine  analog, was an extremely poor substrate of human recombinant SSAT2 and was metabolized by  SSAT1  in HEPG2 cells and in wild-type primary hepatocytes.",
    "entity1": "spermine",
    "entity2": "SSAT1"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "By contrast, 1,12-diamino-3,6,9-triazadodecane(SpmTrien), a charge-deficient <protein> spermine </protein> analog, was an extremely poor substrate of <chemical> human recombinant SSAT2 </chemical> and was metabolized by SSAT1 in HEPG2 cells and in wild-type primary hepatocytes.",
    "original_text": "By contrast, 1,12-diamino-3,6,9-triazadodecane(SpmTrien), a charge-deficient  spermine  analog, was an extremely poor substrate of  human recombinant SSAT2  and was metabolized by SSAT1 in HEPG2 cells and in wild-type primary hepatocytes.",
    "entity1": "spermine",
    "entity2": "human recombinant SSAT2"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Thus, despite the similar structures of TETA and SpmTrien, <protein> SSAT2 </protein> is the main acetylator of <chemical> TETA </chemical>, whereas SpmTrien is primarily acetylated by SSAT1.",
    "original_text": "Thus, despite the similar structures of TETA and SpmTrien,  SSAT2  is the main acetylator of  TETA , whereas SpmTrien is primarily acetylated by SSAT1.",
    "entity1": "SSAT2",
    "entity2": "TETA"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Thus, despite the similar structures of TETA and SpmTrien, SSAT2 is the main acetylator of TETA, whereas <protein> SpmTrien </protein> is primarily acetylated by <chemical> SSAT1 </chemical>.",
    "original_text": "Thus, despite the similar structures of TETA and SpmTrien, SSAT2 is the main acetylator of TETA, whereas  SpmTrien  is primarily acetylated by  SSAT1 .",
    "entity1": "SpmTrien",
    "entity2": "SSAT1"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "In vitro metabolism of the <protein> 5-hydroxytryptamine1B </protein> receptor antagonist <chemical> elzasonan </chemical>.",
    "original_text": "In vitro metabolism of the  5-hydroxytryptamine1B  receptor antagonist  elzasonan .",
    "entity1": "5-hydroxytryptamine1B",
    "entity2": "elzasonan"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "The rCYP data was normalized relative to the levels of each CYP form in native human liver microsomes to better assess the contribution of each <protein> rCYP </protein> in the metabolism of <chemical> elzasonan </chemical>.",
    "original_text": "The rCYP data was normalized relative to the levels of each CYP form in native human liver microsomes to better assess the contribution of each  rCYP  in the metabolism of  elzasonan .",
    "entity1": "rCYP",
    "entity2": "elzasonan"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Human serum butyrylcholinesterase (<protein> HuBChE </protein>) is currently the most suitable bioscavenger for the prophylaxis of highly toxic <chemical> organophosphate </chemical> (OP) nerve agents.",
    "original_text": "Human serum butyrylcholinesterase ( HuBChE ) is currently the most suitable bioscavenger for the prophylaxis of highly toxic  organophosphate  (OP) nerve agents.",
    "entity1": "HuBChE",
    "entity2": "organophosphate"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "<protein> Human serum butyrylcholinesterase </protein> (HuBChE) is currently the most suitable bioscavenger for the prophylaxis of highly toxic <chemical> organophosphate </chemical> (OP) nerve agents.",
    "original_text": " Human serum butyrylcholinesterase  (HuBChE) is currently the most suitable bioscavenger for the prophylaxis of highly toxic  organophosphate  (OP) nerve agents.",
    "entity1": "Human serum butyrylcholinesterase",
    "entity2": "organophosphate"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Cu-dependent <protein> tyrosinase </protein> activity was also markedly reduced in both types of CLDN knockdown cells when incubated with the substrate <chemical> l-DOPA </chemical>.",
    "original_text": "Cu-dependent  tyrosinase  activity was also markedly reduced in both types of CLDN knockdown cells when incubated with the substrate  l-DOPA .",
    "entity1": "tyrosinase",
    "entity2": "l-DOPA"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "Additionally, <protein> DMF </protein> and Ad-Nrf2 repressed <chemical> TGF-beta </chemical>-stimulated Smad3 activity by inhibiting Smad3 phosphorylation, which was restored by siRNA-mediated knockdown of Nrf2 expression.",
    "original_text": "Additionally,  DMF  and Ad-Nrf2 repressed  TGF-beta -stimulated Smad3 activity by inhibiting Smad3 phosphorylation, which was restored by siRNA-mediated knockdown of Nrf2 expression.",
    "entity1": "DMF",
    "entity2": "TGF-beta"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "However, downregulation of the antioxidant response element (ARE)-driven Nrf2 target genes such as NQO1, HO-1 and glutathione S-transferase (GST) did not reverse the inhibitory effect of <protein> DMF </protein> on <chemical> TGF-beta </chemical>-induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an ARE-independent anti-fibrotic activity of DMF.",
    "original_text": "However, downregulation of the antioxidant response element (ARE)-driven Nrf2 target genes such as NQO1, HO-1 and glutathione S-transferase (GST) did not reverse the inhibitory effect of  DMF  on  TGF-beta -induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an ARE-independent anti-fibrotic activity of DMF.",
    "entity1": "DMF",
    "entity2": "TGF-beta"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Our results showed that bone remodeling was significantly decreased in CCL3(-/-) and CCR1(-/-) mice and in animals treated with <protein> Met </protein>-RANTES (an antagonist of <chemical> CCR5 </chemical> and CCR1).",
    "original_text": "Our results showed that bone remodeling was significantly decreased in CCL3(-/-) and CCR1(-/-) mice and in animals treated with  Met -RANTES (an antagonist of  CCR5  and CCR1).",
    "entity1": "Met",
    "entity2": "CCR5"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Our results showed that bone remodeling was significantly decreased in CCL3(-/-) and CCR1(-/-) mice and in animals treated with <protein> Met </protein>-RANTES (an antagonist of CCR5 and <chemical> CCR1 </chemical>).",
    "original_text": "Our results showed that bone remodeling was significantly decreased in CCL3(-/-) and CCR1(-/-) mice and in animals treated with  Met -RANTES (an antagonist of CCR5 and  CCR1 ).",
    "entity1": "Met",
    "entity2": "CCR1"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "<protein> NFD </protein> suppressed <chemical> EGF </chemical>-mediated protein levels of c-Jun and c-Fos, and reduced MMP-9 expression and activity, concomitantly with a marked inhibition on cell migration and invasion without obvious cellular cytotoxicity.",
    "original_text": " NFD  suppressed  EGF -mediated protein levels of c-Jun and c-Fos, and reduced MMP-9 expression and activity, concomitantly with a marked inhibition on cell migration and invasion without obvious cellular cytotoxicity.",
    "entity1": "NFD",
    "entity2": "EGF"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "<protein> NFD </protein> abrogated <chemical> EGF </chemical>-induced phosphorylation of EGF receptor (EGFR) and phosphatidylinositol 3-kinase (PI3K)/Akt.",
    "original_text": " NFD  abrogated  EGF -induced phosphorylation of EGF receptor (EGFR) and phosphatidylinositol 3-kinase (PI3K)/Akt.",
    "entity1": "NFD",
    "entity2": "EGF"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Herein, we report the identification and characterization of <protein> 3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile </protein> (ESI-09), a novel noncyclic nucleotide <chemical> EPAC </chemical> antagonist that is capable of specifically blocking intracellular EPAC-mediated Rap1 activation and Akt phosphorylation, as well as EPAC-mediated insulin secretion in pancreatic \u03b2 cells.",
    "original_text": "Herein, we report the identification and characterization of  3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile  (ESI-09), a novel noncyclic nucleotide  EPAC  antagonist that is capable of specifically blocking intracellular EPAC-mediated Rap1 activation and Akt phosphorylation, as well as EPAC-mediated insulin secretion in pancreatic \u03b2 cells.",
    "entity1": "3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile",
    "entity2": "EPAC"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Herein, we report the identification and characterization of 3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile (<protein> ESI-09 </protein>), a novel noncyclic nucleotide <chemical> EPAC </chemical> antagonist that is capable of specifically blocking intracellular EPAC-mediated Rap1 activation and Akt phosphorylation, as well as EPAC-mediated insulin secretion in pancreatic \u03b2 cells.",
    "original_text": "Herein, we report the identification and characterization of 3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile ( ESI-09 ), a novel noncyclic nucleotide  EPAC  antagonist that is capable of specifically blocking intracellular EPAC-mediated Rap1 activation and Akt phosphorylation, as well as EPAC-mediated insulin secretion in pancreatic \u03b2 cells.",
    "entity1": "ESI-09",
    "entity2": "EPAC"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Herein, we report the identification and characterization of 3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile (ESI-09), a novel noncyclic <protein> nucleotide </protein> <chemical> EPAC </chemical> antagonist that is capable of specifically blocking intracellular EPAC-mediated Rap1 activation and Akt phosphorylation, as well as EPAC-mediated insulin secretion in pancreatic \u03b2 cells.",
    "original_text": "Herein, we report the identification and characterization of 3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile (ESI-09), a novel noncyclic  nucleotide   EPAC  antagonist that is capable of specifically blocking intracellular EPAC-mediated Rap1 activation and Akt phosphorylation, as well as EPAC-mediated insulin secretion in pancreatic \u03b2 cells.",
    "entity1": "nucleotide",
    "entity2": "EPAC"
  },
  {
    "_id": 1,
    "label": "Upregulator",
    "text": "Fungicide <protein> prochloraz </protein> and environmental pollutant dioxin induce the <chemical> ABCG2 </chemical> transporter in bovine mammary epithelial cells by the arylhydrocarbon receptor signaling pathway.",
    "original_text": "Fungicide  prochloraz  and environmental pollutant dioxin induce the  ABCG2  transporter in bovine mammary epithelial cells by the arylhydrocarbon receptor signaling pathway.",
    "entity1": "prochloraz",
    "entity2": "ABCG2"
  },
  {
    "_id": 1,
    "label": "Upregulator",
    "text": "Fungicide prochloraz and environmental pollutant <protein> dioxin </protein> induce the <chemical> ABCG2 </chemical> transporter in bovine mammary epithelial cells by the arylhydrocarbon receptor signaling pathway.",
    "original_text": "Fungicide prochloraz and environmental pollutant  dioxin  induce the  ABCG2  transporter in bovine mammary epithelial cells by the arylhydrocarbon receptor signaling pathway.",
    "entity1": "dioxin",
    "entity2": "ABCG2"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "As these regulatory motifs mediate regulation of target genes by <protein> AhR </protein> agonists including <chemical> TCDD </chemical> and prochloraz, we have systematically investigated the effect of both contaminants on functional ABCG2 transport activity in primary bovine mammary epithelial cells.",
    "original_text": "As these regulatory motifs mediate regulation of target genes by  AhR  agonists including  TCDD  and prochloraz, we have systematically investigated the effect of both contaminants on functional ABCG2 transport activity in primary bovine mammary epithelial cells.",
    "entity1": "AhR",
    "entity2": "TCDD"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "As these regulatory motifs mediate regulation of target genes by <protein> AhR </protein> agonists including TCDD and <chemical> prochloraz </chemical>, we have systematically investigated the effect of both contaminants on functional ABCG2 transport activity in primary bovine mammary epithelial cells.",
    "original_text": "As these regulatory motifs mediate regulation of target genes by  AhR  agonists including TCDD and  prochloraz , we have systematically investigated the effect of both contaminants on functional ABCG2 transport activity in primary bovine mammary epithelial cells.",
    "entity1": "AhR",
    "entity2": "prochloraz"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "TCDD or prochloraz doubled <protein> ABCG2 </protein>-mediated <chemical> Hoechst H33342 </chemical> secretion.",
    "original_text": "TCDD or prochloraz doubled  ABCG2 -mediated  Hoechst H33342  secretion.",
    "entity1": "ABCG2",
    "entity2": "Hoechst H33342"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Receptor binding was significantly reduced by specific <protein> AhR </protein> antagonist <chemical> salicyl amide </chemical>.",
    "original_text": "Receptor binding was significantly reduced by specific  AhR  antagonist  salicyl amide .",
    "entity1": "AhR",
    "entity2": "salicyl amide"
  },
  {
    "_id": 1,
    "label": "Upregulator",
    "text": "Induction of <protein> AhR </protein> by <chemical> TCDD </chemical> and prochloraz resulted in a time- and dose-dependent increase of ABCG2 gene expression and transporter protein levels.",
    "original_text": "Induction of  AhR  by  TCDD  and prochloraz resulted in a time- and dose-dependent increase of ABCG2 gene expression and transporter protein levels.",
    "entity1": "AhR",
    "entity2": "TCDD"
  },
  {
    "_id": 1,
    "label": "Upregulator",
    "text": "Induction of <protein> AhR </protein> by TCDD and <chemical> prochloraz </chemical> resulted in a time- and dose-dependent increase of ABCG2 gene expression and transporter protein levels.",
    "original_text": "Induction of  AhR  by TCDD and  prochloraz  resulted in a time- and dose-dependent increase of ABCG2 gene expression and transporter protein levels.",
    "entity1": "AhR",
    "entity2": "prochloraz"
  },
  {
    "_id": 1,
    "label": "Upregulator",
    "text": "Following <protein> CdCl\u2082 </protein> treatment, <chemical> ICAM2 </chemical> was found to be upregulated during restructuring of the seminiferous epithelium, with round spermatids becoming increasingly immunoreactive for ICAM2 by 6-16 h.",
    "original_text": "Following  CdCl\u2082  treatment,  ICAM2  was found to be upregulated during restructuring of the seminiferous epithelium, with round spermatids becoming increasingly immunoreactive for ICAM2 by 6-16 h.",
    "entity1": "CdCl\u2082",
    "entity2": "ICAM2"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "The catalytic competence of <protein> cytochrome P450 </protein> in the synthesis of serotonin from <chemical> 5-methoxytryptamine </chemical> in the brain: an in vitro study.",
    "original_text": "The catalytic competence of  cytochrome P450  in the synthesis of serotonin from  5-methoxytryptamine  in the brain: an in vitro study.",
    "entity1": "cytochrome P450",
    "entity2": "5-methoxytryptamine"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Of the rat CYP isoforms studied, <protein> CYP2D </protein> isoforms were the most efficient in catalyzing the <chemical> O </chemical>-demethylation of 5-methoxytryptamine to serotonin, but they were less effective than the human isoform CYP2D6.",
    "original_text": "Of the rat CYP isoforms studied,  CYP2D  isoforms were the most efficient in catalyzing the  O -demethylation of 5-methoxytryptamine to serotonin, but they were less effective than the human isoform CYP2D6.",
    "entity1": "CYP2D",
    "entity2": "O"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Of the rat CYP isoforms studied, CYP2D isoforms were the most efficient in catalyzing the <protein> O </protein>-demethylation of 5-methoxytryptamine to serotonin, but they were less effective than the <chemical> human isoform CYP2D6 </chemical>.",
    "original_text": "Of the rat CYP isoforms studied, CYP2D isoforms were the most efficient in catalyzing the  O -demethylation of 5-methoxytryptamine to serotonin, but they were less effective than the  human isoform CYP2D6 .",
    "entity1": "O",
    "entity2": "human isoform CYP2D6"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Of the rat CYP isoforms studied, <protein> CYP2D </protein> isoforms were the most efficient in catalyzing the O-demethylation of <chemical> 5-methoxytryptamine </chemical> to serotonin, but they were less effective than the human isoform CYP2D6.",
    "original_text": "Of the rat CYP isoforms studied,  CYP2D  isoforms were the most efficient in catalyzing the O-demethylation of  5-methoxytryptamine  to serotonin, but they were less effective than the human isoform CYP2D6.",
    "entity1": "CYP2D",
    "entity2": "5-methoxytryptamine"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Of the rat CYP isoforms studied, CYP2D isoforms were the most efficient in catalyzing the O-demethylation of <protein> 5-methoxytryptamine </protein> to serotonin, but they were less effective than the <chemical> human isoform CYP2D6 </chemical>.",
    "original_text": "Of the rat CYP isoforms studied, CYP2D isoforms were the most efficient in catalyzing the O-demethylation of  5-methoxytryptamine  to serotonin, but they were less effective than the  human isoform CYP2D6 .",
    "entity1": "5-methoxytryptamine",
    "entity2": "human isoform CYP2D6"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Human liver microsomes of the wild-type <protein> CYP2D6 </protein> metabolized <chemical> 5-methoxytryptamine </chemical> to serotonin more effectively than did the defective CYP2D6*4*4 ones.",
    "original_text": "Human liver microsomes of the wild-type  CYP2D6  metabolized  5-methoxytryptamine  to serotonin more effectively than did the defective CYP2D6*4*4 ones.",
    "entity1": "CYP2D6",
    "entity2": "5-methoxytryptamine"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Human liver microsomes of the wild-type CYP2D6 metabolized <protein> 5-methoxytryptamine </protein> to serotonin more effectively than did the defective <chemical> CYP2D6 </chemical>*4*4 ones.",
    "original_text": "Human liver microsomes of the wild-type CYP2D6 metabolized  5-methoxytryptamine  to serotonin more effectively than did the defective  CYP2D6 *4*4 ones.",
    "entity1": "5-methoxytryptamine",
    "entity2": "CYP2D6"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "The obtained results indicate that <protein> rat brain CYP2D </protein> isoforms catalyze the formation of serotonin from <chemical> 5-methoxytryptamine </chemical>, and that the deficit or genetic defect of CYP2D may affect serotonin metabolism in the brain.",
    "original_text": "The obtained results indicate that  rat brain CYP2D  isoforms catalyze the formation of serotonin from  5-methoxytryptamine , and that the deficit or genetic defect of CYP2D may affect serotonin metabolism in the brain.",
    "entity1": "rat brain CYP2D",
    "entity2": "5-methoxytryptamine"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Small interfering RNA directed BDNF, orexin-A, and <protein> SB334867 </protein> [N-(2-methyl-6-benzoxazolyl)-N'-1,5-naphthyridin-4-yl urea; a specific <chemical> orexin-1 receptor </chemical> antagonist] were administered directly into the hypothalamus.",
    "original_text": "Small interfering RNA directed BDNF, orexin-A, and  SB334867  [N-(2-methyl-6-benzoxazolyl)-N'-1,5-naphthyridin-4-yl urea; a specific  orexin-1 receptor  antagonist] were administered directly into the hypothalamus.",
    "entity1": "SB334867",
    "entity2": "orexin-1 receptor"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Small interfering RNA directed BDNF, orexin-A, and SB334867 [<protein> N-(2-methyl-6-benzoxazolyl)-N'-1,5-naphthyridin-4-yl urea </protein>; a specific <chemical> orexin-1 receptor </chemical> antagonist] were administered directly into the hypothalamus.",
    "original_text": "Small interfering RNA directed BDNF, orexin-A, and SB334867 [ N-(2-methyl-6-benzoxazolyl)-N'-1,5-naphthyridin-4-yl urea ; a specific  orexin-1 receptor  antagonist] were administered directly into the hypothalamus.",
    "entity1": "N-(2-methyl-6-benzoxazolyl)-N'-1,5-naphthyridin-4-yl urea",
    "entity2": "orexin-1 receptor"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "The MCAO-induced decrease in insulin receptor levels in the liver and skeletal muscle on day 1 was recovered to control levels by orexin-A, and this effect of <protein> orexin-A </protein> was reversed by the administration of <chemical> SB334867 </chemical> as well as by hypothalamic BDNF knockdown.",
    "original_text": "The MCAO-induced decrease in insulin receptor levels in the liver and skeletal muscle on day 1 was recovered to control levels by orexin-A, and this effect of  orexin-A  was reversed by the administration of  SB334867  as well as by hypothalamic BDNF knockdown.",
    "entity1": "orexin-A",
    "entity2": "SB334867"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "In contrast, <protein> EGCG </protein> markedly downregulated major <chemical> bile acid transporters </chemical> (Asbt and Ost\u03b1) and regulatory molecules (Shp and Fgf15) in the ileum.",
    "original_text": "In contrast,  EGCG  markedly downregulated major  bile acid transporters  (Asbt and Ost\u03b1) and regulatory molecules (Shp and Fgf15) in the ileum.",
    "entity1": "EGCG",
    "entity2": "bile acid transporters"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "In contrast, <protein> EGCG </protein> markedly downregulated major bile acid transporters (<chemical> Asbt </chemical> and Ost\u03b1) and regulatory molecules (Shp and Fgf15) in the ileum.",
    "original_text": "In contrast,  EGCG  markedly downregulated major bile acid transporters ( Asbt  and Ost\u03b1) and regulatory molecules (Shp and Fgf15) in the ileum.",
    "entity1": "EGCG",
    "entity2": "Asbt"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "In contrast, <protein> EGCG </protein> markedly downregulated major bile acid transporters (Asbt and <chemical> Ost\u03b1 </chemical>) and regulatory molecules (Shp and Fgf15) in the ileum.",
    "original_text": "In contrast,  EGCG  markedly downregulated major bile acid transporters (Asbt and  Ost\u03b1 ) and regulatory molecules (Shp and Fgf15) in the ileum.",
    "entity1": "EGCG",
    "entity2": "Ost\u03b1"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Fluorescence of the reporter dye is turned on by rapid removal of the quinone quencher, an event that immediately occurs only after highly selective, two-electron reduction of the sterically and conformationally restricted <protein> quinone </protein> substrate by the cancer-associated <chemical> human NAD(P)H:quinone oxidoreductase isozyme 1 </chemical> (hNQO1).",
    "original_text": "Fluorescence of the reporter dye is turned on by rapid removal of the quinone quencher, an event that immediately occurs only after highly selective, two-electron reduction of the sterically and conformationally restricted  quinone  substrate by the cancer-associated  human NAD(P)H:quinone oxidoreductase isozyme 1  (hNQO1).",
    "entity1": "quinone",
    "entity2": "human NAD(P)H:quinone oxidoreductase isozyme 1"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Fluorescence of the reporter dye is turned on by rapid removal of the quinone quencher, an event that immediately occurs only after highly selective, two-electron reduction of the sterically and conformationally restricted <protein> quinone </protein> substrate by the cancer-associated human NAD(P)H:quinone oxidoreductase isozyme 1 (<chemical> hNQO1 </chemical>).",
    "original_text": "Fluorescence of the reporter dye is turned on by rapid removal of the quinone quencher, an event that immediately occurs only after highly selective, two-electron reduction of the sterically and conformationally restricted  quinone  substrate by the cancer-associated human NAD(P)H:quinone oxidoreductase isozyme 1 ( hNQO1 ).",
    "entity1": "quinone",
    "entity2": "hNQO1"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Within the <protein> TPBP </protein> scaffold, either electronic or steric perturbations to the central piperidine ring led to a loss of selective M(1) allosteric agonism and afforded pan-<chemical> mAChR </chemical> antagonism, which was demonstrated to be mediated via the orthosteric site.",
    "original_text": "Within the  TPBP  scaffold, either electronic or steric perturbations to the central piperidine ring led to a loss of selective M(1) allosteric agonism and afforded pan- mAChR  antagonism, which was demonstrated to be mediated via the orthosteric site.",
    "entity1": "TPBP",
    "entity2": "mAChR"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Within the TPBP scaffold, either electronic or steric perturbations to the central <protein> piperidine </protein> ring led to a loss of selective M(1) allosteric agonism and afforded pan-<chemical> mAChR </chemical> antagonism, which was demonstrated to be mediated via the orthosteric site.",
    "original_text": "Within the TPBP scaffold, either electronic or steric perturbations to the central  piperidine  ring led to a loss of selective M(1) allosteric agonism and afforded pan- mAChR  antagonism, which was demonstrated to be mediated via the orthosteric site.",
    "entity1": "piperidine",
    "entity2": "mAChR"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Additional SAR around a related M(1) allosteric agonist family (<protein> VU0357017 </protein>) identified similar, subtle 'molecular switches' that modulated modes of pharmacology from allosteric agonism to pan-<chemical> mAChR </chemical> orthosteric antagonism.",
    "original_text": "Additional SAR around a related M(1) allosteric agonist family ( VU0357017 ) identified similar, subtle 'molecular switches' that modulated modes of pharmacology from allosteric agonism to pan- mAChR  orthosteric antagonism.",
    "entity1": "VU0357017",
    "entity2": "mAChR"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "2.\u2002The objective of this article is to examine the effects of single and repeated administrations of silymarin on pharmacokinetics of a <protein> P-gp </protein> substrate, <chemical> risperidone </chemical>, and its major metabolite, 9-hydroxyrisperidone, in rats.",
    "original_text": "2.\u2002The objective of this article is to examine the effects of single and repeated administrations of silymarin on pharmacokinetics of a  P-gp  substrate,  risperidone , and its major metabolite, 9-hydroxyrisperidone, in rats.",
    "entity1": "P-gp",
    "entity2": "risperidone"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "2.\u2002The objective of this article is to examine the effects of single and repeated administrations of silymarin on pharmacokinetics of a <protein> P-gp </protein> substrate, risperidone, and its major metabolite, <chemical> 9-hydroxyrisperidone </chemical>, in rats.",
    "original_text": "2.\u2002The objective of this article is to examine the effects of single and repeated administrations of silymarin on pharmacokinetics of a  P-gp  substrate, risperidone, and its major metabolite,  9-hydroxyrisperidone , in rats.",
    "entity1": "P-gp",
    "entity2": "9-hydroxyrisperidone"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "On the other hand, peptides modified with <protein> (2S,4R)-4-(naphthalene-2-ylmethyl)pyrrolidine-2-carboxylic acid </protein>, apart from their moderate antioxytocic activity, turned out to be weak antagonists of the pressor response to <chemical> arginine vasopressin </chemical>.",
    "original_text": "On the other hand, peptides modified with  (2S,4R)-4-(naphthalene-2-ylmethyl)pyrrolidine-2-carboxylic acid , apart from their moderate antioxytocic activity, turned out to be weak antagonists of the pressor response to  arginine vasopressin .",
    "entity1": "(2S,4R)-4-(naphthalene-2-ylmethyl)pyrrolidine-2-carboxylic acid",
    "entity2": "arginine vasopressin"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "The herbicide <protein> paraquat </protein> (PQ) is a <chemical> P-gp </chemical> substrate responsible for thousands of fatal intoxications worldwide that still lacks an effective antidote.",
    "original_text": "The herbicide  paraquat  (PQ) is a  P-gp  substrate responsible for thousands of fatal intoxications worldwide that still lacks an effective antidote.",
    "entity1": "paraquat",
    "entity2": "P-gp"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "<protein> Gemcitabine </protein> (dFdC, 2',2'-difluorodeoxycytidine) is metabolized by cytidine deaminase (CDA) and deoxycytidine kinase (<chemical> DCK </chemical>), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear.",
    "original_text": " Gemcitabine  (dFdC, 2',2'-difluorodeoxycytidine) is metabolized by cytidine deaminase (CDA) and deoxycytidine kinase ( DCK ), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear.",
    "entity1": "Gemcitabine",
    "entity2": "DCK"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "<protein> Gemcitabine </protein> (dFdC, 2',2'-difluorodeoxycytidine) is metabolized by <chemical> cytidine deaminase </chemical> (CDA) and deoxycytidine kinase (DCK), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear.",
    "original_text": " Gemcitabine  (dFdC, 2',2'-difluorodeoxycytidine) is metabolized by  cytidine deaminase  (CDA) and deoxycytidine kinase (DCK), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear.",
    "entity1": "Gemcitabine",
    "entity2": "cytidine deaminase"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "<protein> Gemcitabine </protein> (dFdC, 2',2'-difluorodeoxycytidine) is metabolized by cytidine deaminase (<chemical> CDA </chemical>) and deoxycytidine kinase (DCK), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear.",
    "original_text": " Gemcitabine  (dFdC, 2',2'-difluorodeoxycytidine) is metabolized by cytidine deaminase ( CDA ) and deoxycytidine kinase (DCK), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear.",
    "entity1": "Gemcitabine",
    "entity2": "CDA"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "<protein> Gemcitabine </protein> (dFdC, 2',2'-difluorodeoxycytidine) is metabolized by cytidine deaminase (CDA) and <chemical> deoxycytidine kinase </chemical> (DCK), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear.",
    "original_text": " Gemcitabine  (dFdC, 2',2'-difluorodeoxycytidine) is metabolized by cytidine deaminase (CDA) and  deoxycytidine kinase  (DCK), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear.",
    "entity1": "Gemcitabine",
    "entity2": "deoxycytidine kinase"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Gemcitabine (<protein> dFdC </protein>, 2',2'-difluorodeoxycytidine) is metabolized by cytidine deaminase (CDA) and deoxycytidine kinase (<chemical> DCK </chemical>), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear.",
    "original_text": "Gemcitabine ( dFdC , 2',2'-difluorodeoxycytidine) is metabolized by cytidine deaminase (CDA) and deoxycytidine kinase ( DCK ), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear.",
    "entity1": "dFdC",
    "entity2": "DCK"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Gemcitabine (<protein> dFdC </protein>, 2',2'-difluorodeoxycytidine) is metabolized by <chemical> cytidine deaminase </chemical> (CDA) and deoxycytidine kinase (DCK), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear.",
    "original_text": "Gemcitabine ( dFdC , 2',2'-difluorodeoxycytidine) is metabolized by  cytidine deaminase  (CDA) and deoxycytidine kinase (DCK), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear.",
    "entity1": "dFdC",
    "entity2": "cytidine deaminase"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Gemcitabine (<protein> dFdC </protein>, 2',2'-difluorodeoxycytidine) is metabolized by cytidine deaminase (<chemical> CDA </chemical>) and deoxycytidine kinase (DCK), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear.",
    "original_text": "Gemcitabine ( dFdC , 2',2'-difluorodeoxycytidine) is metabolized by cytidine deaminase ( CDA ) and deoxycytidine kinase (DCK), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear.",
    "entity1": "dFdC",
    "entity2": "CDA"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Gemcitabine (<protein> dFdC </protein>, 2',2'-difluorodeoxycytidine) is metabolized by cytidine deaminase (CDA) and <chemical> deoxycytidine kinase </chemical> (DCK), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear.",
    "original_text": "Gemcitabine ( dFdC , 2',2'-difluorodeoxycytidine) is metabolized by cytidine deaminase (CDA) and  deoxycytidine kinase  (DCK), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear.",
    "entity1": "dFdC",
    "entity2": "deoxycytidine kinase"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Gemcitabine (dFdC, <protein> 2',2'-difluorodeoxycytidine </protein>) is metabolized by cytidine deaminase (CDA) and deoxycytidine kinase (<chemical> DCK </chemical>), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear.",
    "original_text": "Gemcitabine (dFdC,  2',2'-difluorodeoxycytidine ) is metabolized by cytidine deaminase (CDA) and deoxycytidine kinase ( DCK ), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear.",
    "entity1": "2',2'-difluorodeoxycytidine",
    "entity2": "DCK"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Gemcitabine (dFdC, <protein> 2',2'-difluorodeoxycytidine </protein>) is metabolized by <chemical> cytidine deaminase </chemical> (CDA) and deoxycytidine kinase (DCK), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear.",
    "original_text": "Gemcitabine (dFdC,  2',2'-difluorodeoxycytidine ) is metabolized by  cytidine deaminase  (CDA) and deoxycytidine kinase (DCK), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear.",
    "entity1": "2',2'-difluorodeoxycytidine",
    "entity2": "cytidine deaminase"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Gemcitabine (dFdC, <protein> 2',2'-difluorodeoxycytidine </protein>) is metabolized by cytidine deaminase (<chemical> CDA </chemical>) and deoxycytidine kinase (DCK), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear.",
    "original_text": "Gemcitabine (dFdC,  2',2'-difluorodeoxycytidine ) is metabolized by cytidine deaminase ( CDA ) and deoxycytidine kinase (DCK), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear.",
    "entity1": "2',2'-difluorodeoxycytidine",
    "entity2": "CDA"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Gemcitabine (dFdC, <protein> 2',2'-difluorodeoxycytidine </protein>) is metabolized by cytidine deaminase (CDA) and <chemical> deoxycytidine kinase </chemical> (DCK), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear.",
    "original_text": "Gemcitabine (dFdC,  2',2'-difluorodeoxycytidine ) is metabolized by cytidine deaminase (CDA) and  deoxycytidine kinase  (DCK), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear.",
    "entity1": "2',2'-difluorodeoxycytidine",
    "entity2": "deoxycytidine kinase"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Wild-type enzymes and variants of <protein> CDA </protein> (Lys27Gln and Ala70Thr) and DCK (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (<chemical> Ara-C </chemical>), dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates.",
    "original_text": "Wild-type enzymes and variants of  CDA  (Lys27Gln and Ala70Thr) and DCK (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine ( Ara-C ), dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates.",
    "entity1": "CDA",
    "entity2": "Ara-C"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Wild-type enzymes and variants of CDA (<protein> Lys27Gln </protein> and Ala70Thr) and DCK (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (<chemical> Ara-C </chemical>), dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates.",
    "original_text": "Wild-type enzymes and variants of CDA ( Lys27Gln  and Ala70Thr) and DCK (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine ( Ara-C ), dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates.",
    "entity1": "Lys27Gln",
    "entity2": "Ara-C"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Wild-type enzymes and variants of CDA (Lys27Gln and <protein> Ala70Thr </protein>) and DCK (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (<chemical> Ara-C </chemical>), dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates.",
    "original_text": "Wild-type enzymes and variants of CDA (Lys27Gln and  Ala70Thr ) and DCK (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine ( Ara-C ), dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates.",
    "entity1": "Ala70Thr",
    "entity2": "Ara-C"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and <protein> DCK </protein> (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (<chemical> Ara-C </chemical>), dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates.",
    "original_text": "Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and  DCK  (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine ( Ara-C ), dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates.",
    "entity1": "DCK",
    "entity2": "Ara-C"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and DCK (<protein> Ile24Val </protein>, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (<chemical> Ara-C </chemical>), dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates.",
    "original_text": "Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and DCK ( Ile24Val , Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine ( Ara-C ), dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates.",
    "entity1": "Ile24Val",
    "entity2": "Ara-C"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and DCK (Ile24Val, <protein> Ala119Gly </protein>, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (<chemical> Ara-C </chemical>), dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates.",
    "original_text": "Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and DCK (Ile24Val,  Ala119Gly , and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine ( Ara-C ), dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates.",
    "entity1": "Ala119Gly",
    "entity2": "Ara-C"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and DCK (Ile24Val, Ala119Gly, and <protein> Pro122Ser </protein>) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (<chemical> Ara-C </chemical>), dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates.",
    "original_text": "Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and DCK (Ile24Val, Ala119Gly, and  Pro122Ser ) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine ( Ara-C ), dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates.",
    "entity1": "Pro122Ser",
    "entity2": "Ara-C"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Wild-type enzymes and variants of <protein> CDA </protein> (Lys27Gln and Ala70Thr) and DCK (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C), <chemical> dFdC </chemical>, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates.",
    "original_text": "Wild-type enzymes and variants of  CDA  (Lys27Gln and Ala70Thr) and DCK (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C),  dFdC , and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates.",
    "entity1": "CDA",
    "entity2": "dFdC"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Wild-type enzymes and variants of CDA (<protein> Lys27Gln </protein> and Ala70Thr) and DCK (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C), <chemical> dFdC </chemical>, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates.",
    "original_text": "Wild-type enzymes and variants of CDA ( Lys27Gln  and Ala70Thr) and DCK (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C),  dFdC , and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates.",
    "entity1": "Lys27Gln",
    "entity2": "dFdC"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Wild-type enzymes and variants of CDA (Lys27Gln and <protein> Ala70Thr </protein>) and DCK (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C), <chemical> dFdC </chemical>, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates.",
    "original_text": "Wild-type enzymes and variants of CDA (Lys27Gln and  Ala70Thr ) and DCK (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C),  dFdC , and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates.",
    "entity1": "Ala70Thr",
    "entity2": "dFdC"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and <protein> DCK </protein> (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C), <chemical> dFdC </chemical>, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates.",
    "original_text": "Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and  DCK  (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C),  dFdC , and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates.",
    "entity1": "DCK",
    "entity2": "dFdC"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and DCK (<protein> Ile24Val </protein>, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C), <chemical> dFdC </chemical>, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates.",
    "original_text": "Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and DCK ( Ile24Val , Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C),  dFdC , and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates.",
    "entity1": "Ile24Val",
    "entity2": "dFdC"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and DCK (Ile24Val, <protein> Ala119Gly </protein>, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C), <chemical> dFdC </chemical>, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates.",
    "original_text": "Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and DCK (Ile24Val,  Ala119Gly , and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C),  dFdC , and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates.",
    "entity1": "Ala119Gly",
    "entity2": "dFdC"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and DCK (Ile24Val, Ala119Gly, and <protein> Pro122Ser </protein>) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C), <chemical> dFdC </chemical>, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates.",
    "original_text": "Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and DCK (Ile24Val, Ala119Gly, and  Pro122Ser ) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C),  dFdC , and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates.",
    "entity1": "Pro122Ser",
    "entity2": "dFdC"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Wild-type enzymes and variants of <protein> CDA </protein> (Lys27Gln and Ala70Thr) and DCK (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C), dFdC, and its metabolite <chemical> 2',2'-difluorodeoxyuridine </chemical> (dFdU) as substrates.",
    "original_text": "Wild-type enzymes and variants of  CDA  (Lys27Gln and Ala70Thr) and DCK (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C), dFdC, and its metabolite  2',2'-difluorodeoxyuridine  (dFdU) as substrates.",
    "entity1": "CDA",
    "entity2": "2',2'-difluorodeoxyuridine"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Wild-type enzymes and variants of CDA (<protein> Lys27Gln </protein> and Ala70Thr) and DCK (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C), dFdC, and its metabolite <chemical> 2',2'-difluorodeoxyuridine </chemical> (dFdU) as substrates.",
    "original_text": "Wild-type enzymes and variants of CDA ( Lys27Gln  and Ala70Thr) and DCK (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C), dFdC, and its metabolite  2',2'-difluorodeoxyuridine  (dFdU) as substrates.",
    "entity1": "Lys27Gln",
    "entity2": "2',2'-difluorodeoxyuridine"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Wild-type enzymes and variants of CDA (Lys27Gln and <protein> Ala70Thr </protein>) and DCK (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C), dFdC, and its metabolite <chemical> 2',2'-difluorodeoxyuridine </chemical> (dFdU) as substrates.",
    "original_text": "Wild-type enzymes and variants of CDA (Lys27Gln and  Ala70Thr ) and DCK (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C), dFdC, and its metabolite  2',2'-difluorodeoxyuridine  (dFdU) as substrates.",
    "entity1": "Ala70Thr",
    "entity2": "2',2'-difluorodeoxyuridine"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and <protein> DCK </protein> (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C), dFdC, and its metabolite <chemical> 2',2'-difluorodeoxyuridine </chemical> (dFdU) as substrates.",
    "original_text": "Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and  DCK  (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C), dFdC, and its metabolite  2',2'-difluorodeoxyuridine  (dFdU) as substrates.",
    "entity1": "DCK",
    "entity2": "2',2'-difluorodeoxyuridine"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and DCK (<protein> Ile24Val </protein>, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C), dFdC, and its metabolite <chemical> 2',2'-difluorodeoxyuridine </chemical> (dFdU) as substrates.",
    "original_text": "Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and DCK ( Ile24Val , Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C), dFdC, and its metabolite  2',2'-difluorodeoxyuridine  (dFdU) as substrates.",
    "entity1": "Ile24Val",
    "entity2": "2',2'-difluorodeoxyuridine"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and DCK (Ile24Val, <protein> Ala119Gly </protein>, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C), dFdC, and its metabolite <chemical> 2',2'-difluorodeoxyuridine </chemical> (dFdU) as substrates.",
    "original_text": "Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and DCK (Ile24Val,  Ala119Gly , and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C), dFdC, and its metabolite  2',2'-difluorodeoxyuridine  (dFdU) as substrates.",
    "entity1": "Ala119Gly",
    "entity2": "2',2'-difluorodeoxyuridine"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and DCK (Ile24Val, Ala119Gly, and <protein> Pro122Ser </protein>) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C), dFdC, and its metabolite <chemical> 2',2'-difluorodeoxyuridine </chemical> (dFdU) as substrates.",
    "original_text": "Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and DCK (Ile24Val, Ala119Gly, and  Pro122Ser ) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C), dFdC, and its metabolite  2',2'-difluorodeoxyuridine  (dFdU) as substrates.",
    "entity1": "Pro122Ser",
    "entity2": "2',2'-difluorodeoxyuridine"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Wild-type enzymes and variants of <protein> CDA </protein> (Lys27Gln and Ala70Thr) and DCK (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C), dFdC, and its metabolite 2',2'-difluorodeoxyuridine (<chemical> dFdU </chemical>) as substrates.",
    "original_text": "Wild-type enzymes and variants of  CDA  (Lys27Gln and Ala70Thr) and DCK (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C), dFdC, and its metabolite 2',2'-difluorodeoxyuridine ( dFdU ) as substrates.",
    "entity1": "CDA",
    "entity2": "dFdU"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Wild-type enzymes and variants of <protein> CDA </protein> (Lys27Gln and Ala70Thr) and DCK (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for <chemical> cytarabine </chemical> (Ara-C), dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates.",
    "original_text": "Wild-type enzymes and variants of  CDA  (Lys27Gln and Ala70Thr) and DCK (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for  cytarabine  (Ara-C), dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates.",
    "entity1": "CDA",
    "entity2": "cytarabine"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Wild-type enzymes and variants of CDA (<protein> Lys27Gln </protein> and Ala70Thr) and DCK (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for <chemical> cytarabine </chemical> (Ara-C), dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates.",
    "original_text": "Wild-type enzymes and variants of CDA ( Lys27Gln  and Ala70Thr) and DCK (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for  cytarabine  (Ara-C), dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates.",
    "entity1": "Lys27Gln",
    "entity2": "cytarabine"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Wild-type enzymes and variants of CDA (Lys27Gln and <protein> Ala70Thr </protein>) and DCK (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for <chemical> cytarabine </chemical> (Ara-C), dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates.",
    "original_text": "Wild-type enzymes and variants of CDA (Lys27Gln and  Ala70Thr ) and DCK (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for  cytarabine  (Ara-C), dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates.",
    "entity1": "Ala70Thr",
    "entity2": "cytarabine"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and <protein> DCK </protein> (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for <chemical> cytarabine </chemical> (Ara-C), dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates.",
    "original_text": "Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and  DCK  (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for  cytarabine  (Ara-C), dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates.",
    "entity1": "DCK",
    "entity2": "cytarabine"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and DCK (<protein> Ile24Val </protein>, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for <chemical> cytarabine </chemical> (Ara-C), dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates.",
    "original_text": "Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and DCK ( Ile24Val , Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for  cytarabine  (Ara-C), dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates.",
    "entity1": "Ile24Val",
    "entity2": "cytarabine"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and DCK (Ile24Val, <protein> Ala119Gly </protein>, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for <chemical> cytarabine </chemical> (Ara-C), dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates.",
    "original_text": "Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and DCK (Ile24Val,  Ala119Gly , and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for  cytarabine  (Ara-C), dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates.",
    "entity1": "Ala119Gly",
    "entity2": "cytarabine"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and DCK (Ile24Val, Ala119Gly, and <protein> Pro122Ser </protein>) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for <chemical> cytarabine </chemical> (Ara-C), dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates.",
    "original_text": "Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and DCK (Ile24Val, Ala119Gly, and  Pro122Ser ) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for  cytarabine  (Ara-C), dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates.",
    "entity1": "Pro122Ser",
    "entity2": "cytarabine"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "All three <protein> CDA </protein> proteins showed similar K(m) and V(max) for <chemical> Ara-C </chemical> and dFdC deamination, except for CDA70Thr, which had a 2.5-fold lower K(m) and 6-fold lower V(max) for Ara-C deamination.",
    "original_text": "All three  CDA  proteins showed similar K(m) and V(max) for  Ara-C  and dFdC deamination, except for CDA70Thr, which had a 2.5-fold lower K(m) and 6-fold lower V(max) for Ara-C deamination.",
    "entity1": "CDA",
    "entity2": "Ara-C"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "All three <protein> CDA </protein> proteins showed similar K(m) and V(max) for Ara-C and <chemical> dFdC </chemical> deamination, except for CDA70Thr, which had a 2.5-fold lower K(m) and 6-fold lower V(max) for Ara-C deamination.",
    "original_text": "All three  CDA  proteins showed similar K(m) and V(max) for Ara-C and  dFdC  deamination, except for CDA70Thr, which had a 2.5-fold lower K(m) and 6-fold lower V(max) for Ara-C deamination.",
    "entity1": "CDA",
    "entity2": "dFdC"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "All three CDA proteins showed similar K(m) and V(max) for Ara-C and dFdC deamination, except for <protein> CDA </protein>70Thr, which had a 2.5-fold lower K(m) and 6-fold lower V(max) for <chemical> Ara-C </chemical> deamination.",
    "original_text": "All three CDA proteins showed similar K(m) and V(max) for Ara-C and dFdC deamination, except for  CDA 70Thr, which had a 2.5-fold lower K(m) and 6-fold lower V(max) for  Ara-C  deamination.",
    "entity1": "CDA",
    "entity2": "Ara-C"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "All four <protein> DCK </protein> proteins yielded comparable metabolic activity for <chemical> Ara-C </chemical> and dFdC monophosphorylation, except for DCK24Val, which demonstrated an approximately 2-fold increase (P < 0.05) in the intrinsic clearance of dFdC monophosphorylation due to a 40% decrease in K(m) (P < 0.05).",
    "original_text": "All four  DCK  proteins yielded comparable metabolic activity for  Ara-C  and dFdC monophosphorylation, except for DCK24Val, which demonstrated an approximately 2-fold increase (P < 0.05) in the intrinsic clearance of dFdC monophosphorylation due to a 40% decrease in K(m) (P < 0.05).",
    "entity1": "DCK",
    "entity2": "Ara-C"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "All four <protein> DCK </protein> proteins yielded comparable metabolic activity for Ara-C and <chemical> dFdC </chemical> monophosphorylation, except for DCK24Val, which demonstrated an approximately 2-fold increase (P < 0.05) in the intrinsic clearance of dFdC monophosphorylation due to a 40% decrease in K(m) (P < 0.05).",
    "original_text": "All four  DCK  proteins yielded comparable metabolic activity for Ara-C and  dFdC  monophosphorylation, except for DCK24Val, which demonstrated an approximately 2-fold increase (P < 0.05) in the intrinsic clearance of dFdC monophosphorylation due to a 40% decrease in K(m) (P < 0.05).",
    "entity1": "DCK",
    "entity2": "dFdC"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "All four DCK proteins yielded comparable metabolic activity for Ara-C and dFdC monophosphorylation, except for <protein> DCK </protein>24Val, which demonstrated an approximately 2-fold increase (P < 0.05) in the intrinsic clearance of <chemical> dFdC </chemical> monophosphorylation due to a 40% decrease in K(m) (P < 0.05).",
    "original_text": "All four DCK proteins yielded comparable metabolic activity for Ara-C and dFdC monophosphorylation, except for  DCK 24Val, which demonstrated an approximately 2-fold increase (P < 0.05) in the intrinsic clearance of  dFdC  monophosphorylation due to a 40% decrease in K(m) (P < 0.05).",
    "entity1": "DCK",
    "entity2": "dFdC"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "In conclusion, the <protein> Lys27Gln </protein> substitution does not significantly modulate CDA activity toward <chemical> dFdC </chemical>, and therefore would not contribute to interindividual variability in response to gemcitabine.",
    "original_text": "In conclusion, the  Lys27Gln  substitution does not significantly modulate CDA activity toward  dFdC , and therefore would not contribute to interindividual variability in response to gemcitabine.",
    "entity1": "Lys27Gln",
    "entity2": "dFdC"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "In conclusion, the Lys27Gln substitution does not significantly modulate <protein> CDA </protein> activity toward <chemical> dFdC </chemical>, and therefore would not contribute to interindividual variability in response to gemcitabine.",
    "original_text": "In conclusion, the Lys27Gln substitution does not significantly modulate  CDA  activity toward  dFdC , and therefore would not contribute to interindividual variability in response to gemcitabine.",
    "entity1": "CDA",
    "entity2": "dFdC"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "The higher in vitro catalytic efficiency of <protein> DCK </protein>24Val toward <chemical> dFdC </chemical> monophosphorylation may be relevant to dFdC clinical response.",
    "original_text": "The higher in vitro catalytic efficiency of  DCK 24Val toward  dFdC  monophosphorylation may be relevant to dFdC clinical response.",
    "entity1": "DCK",
    "entity2": "dFdC"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "The higher in vitro catalytic efficiency of <protein> DCK </protein>24Val toward dFdC monophosphorylation may be relevant to <chemical> dFdC </chemical> clinical response.",
    "original_text": "The higher in vitro catalytic efficiency of  DCK 24Val toward dFdC monophosphorylation may be relevant to  dFdC  clinical response.",
    "entity1": "DCK",
    "entity2": "dFdC"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "Evaluation of drug interactions of <protein> GSK1292263 </protein> (a <chemical> GPR119 </chemical> agonist) with statins: from in vitro data to clinical study design.",
    "original_text": "Evaluation of drug interactions of  GSK1292263  (a  GPR119  agonist) with statins: from in vitro data to clinical study design.",
    "entity1": "GSK1292263",
    "entity2": "GPR119"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "1.\u2002This work investigated the drug interaction potential of <protein> GSK1292263 </protein>, a novel <chemical> GPR119 </chemical> agonist, with the HMG-coA reductase inhibitors simvastatin and rosuvastatin.",
    "original_text": "1.\u2002This work investigated the drug interaction potential of  GSK1292263 , a novel  GPR119  agonist, with the HMG-coA reductase inhibitors simvastatin and rosuvastatin.",
    "entity1": "GSK1292263",
    "entity2": "GPR119"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "Pharmacological inhibition of MTORC1 with <protein> rapamycin </protein> abrogated the <chemical> insulin </chemical>-induced phosphorylation of EIF4EBP1, RPS6KB1 and its downstream effector, RPS6.",
    "original_text": "Pharmacological inhibition of MTORC1 with  rapamycin  abrogated the  insulin -induced phosphorylation of EIF4EBP1, RPS6KB1 and its downstream effector, RPS6.",
    "entity1": "rapamycin",
    "entity2": "insulin"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "Synthesis and evaluation of <protein> 8-oxoadenine </protein> derivatives as potent <chemical> Toll-like receptor 7 </chemical> agonists with high water solubility.",
    "original_text": "Synthesis and evaluation of  8-oxoadenine  derivatives as potent  Toll-like receptor 7  agonists with high water solubility.",
    "entity1": "8-oxoadenine",
    "entity2": "Toll-like receptor 7"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "We report the discovery of novel series of highly potent <protein> TLR7 </protein> agonists based on 8-oxoadenines, 1 and 2 by introducing and optimizing various <chemical> tertiary amines </chemical> onto the N(9)-position of the adenine moiety.",
    "original_text": "We report the discovery of novel series of highly potent  TLR7  agonists based on 8-oxoadenines, 1 and 2 by introducing and optimizing various  tertiary amines  onto the N(9)-position of the adenine moiety.",
    "entity1": "TLR7",
    "entity2": "tertiary amines"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "We report the discovery of novel series of highly potent <protein> TLR7 </protein> agonists based on 8-oxoadenines, 1 and 2 by introducing and optimizing various tertiary amines onto the <chemical> N </chemical>(9)-position of the adenine moiety.",
    "original_text": "We report the discovery of novel series of highly potent  TLR7  agonists based on 8-oxoadenines, 1 and 2 by introducing and optimizing various tertiary amines onto the  N (9)-position of the adenine moiety.",
    "entity1": "TLR7",
    "entity2": "N"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "We report the discovery of novel series of highly potent <protein> TLR7 </protein> agonists based on 8-oxoadenines, 1 and 2 by introducing and optimizing various tertiary amines onto the N(9)-position of the <chemical> adenine </chemical> moiety.",
    "original_text": "We report the discovery of novel series of highly potent  TLR7  agonists based on 8-oxoadenines, 1 and 2 by introducing and optimizing various tertiary amines onto the N(9)-position of the  adenine  moiety.",
    "entity1": "TLR7",
    "entity2": "adenine"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "We report the discovery of novel series of highly potent <protein> TLR7 </protein> agonists based on <chemical> 8-oxoadenines </chemical>, 1 and 2 by introducing and optimizing various tertiary amines onto the N(9)-position of the adenine moiety.",
    "original_text": "We report the discovery of novel series of highly potent  TLR7  agonists based on  8-oxoadenines , 1 and 2 by introducing and optimizing various tertiary amines onto the N(9)-position of the adenine moiety.",
    "entity1": "TLR7",
    "entity2": "8-oxoadenines"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "The introduction of the <protein> amino </protein> group resulted in not only improved water solubility but also enhanced <chemical> TLR7 </chemical> agonistic activity.",
    "original_text": "The introduction of the  amino  group resulted in not only improved water solubility but also enhanced  TLR7  agonistic activity.",
    "entity1": "amino",
    "entity2": "TLR7"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Apocynin and <protein> raisanberine </protein> alleviate intermittent hypoxia induced abnormal StAR and <chemical> 3\u03b2-HSD </chemical> and low testosterone by suppressing endoplasmic reticulum stress and activated p66Shc in rat testes.",
    "original_text": "Apocynin and  raisanberine  alleviate intermittent hypoxia induced abnormal StAR and  3\u03b2-HSD  and low testosterone by suppressing endoplasmic reticulum stress and activated p66Shc in rat testes.",
    "entity1": "raisanberine",
    "entity2": "3\u03b2-HSD"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Electrical Stimuli Release ATP to Increase <protein> GLUT4 </protein> Translocation and <chemical> Glucose </chemical> Uptake via PI3K\u03b3-Akt-AS160 in Skeletal Muscle Cells.",
    "original_text": "Electrical Stimuli Release ATP to Increase  GLUT4  Translocation and  Glucose  Uptake via PI3K\u03b3-Akt-AS160 in Skeletal Muscle Cells.",
    "entity1": "GLUT4",
    "entity2": "Glucose"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "In the present studies, the CB(1) inverse agonist SR141716A (rimonabant) and the <protein> CB(1) </protein> neutral antagonist <chemical> AM4113 </chemical> were compared for their ability to modify CB(1) receptor-mediated discriminative stimulus effects in nonhuman primates trained to discriminate the novel CB(1) full agonist AM4054.",
    "original_text": "In the present studies, the CB(1) inverse agonist SR141716A (rimonabant) and the  CB(1)  neutral antagonist  AM4113  were compared for their ability to modify CB(1) receptor-mediated discriminative stimulus effects in nonhuman primates trained to discriminate the novel CB(1) full agonist AM4054.",
    "entity1": "CB(1)",
    "entity2": "AM4113"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "Results indicate that AM4054 serves as an effective CB(1) discriminative stimulus, with an onset and time course of action comparable with that of the <protein> CB(1) </protein> agonist <chemical> \u0394(9)-tetrahydrocannabinol </chemical>, and that the inverse agonist rimonabant and the neutral antagonist AM4113 produce dose-related rightward shifts in the AM4054 dose-effect curve, indicating that both drugs surmountably antagonize the discriminative stimulus effects of AM4054.",
    "original_text": "Results indicate that AM4054 serves as an effective CB(1) discriminative stimulus, with an onset and time course of action comparable with that of the  CB(1)  agonist  \u0394(9)-tetrahydrocannabinol , and that the inverse agonist rimonabant and the neutral antagonist AM4113 produce dose-related rightward shifts in the AM4054 dose-effect curve, indicating that both drugs surmountably antagonize the discriminative stimulus effects of AM4054.",
    "entity1": "CB(1)",
    "entity2": "\u0394(9)-tetrahydrocannabinol"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "Results indicate that AM4054 serves as an effective CB(1) discriminative stimulus, with an onset and time course of action comparable with that of the <protein> CB(1) </protein> agonist \u0394(9)-tetrahydrocannabinol, and that the inverse agonist rimonabant and the neutral antagonist AM4113 produce dose-related rightward shifts in the <chemical> AM4054 </chemical> dose-effect curve, indicating that both drugs surmountably antagonize the discriminative stimulus effects of AM4054.",
    "original_text": "Results indicate that AM4054 serves as an effective CB(1) discriminative stimulus, with an onset and time course of action comparable with that of the  CB(1)  agonist \u0394(9)-tetrahydrocannabinol, and that the inverse agonist rimonabant and the neutral antagonist AM4113 produce dose-related rightward shifts in the  AM4054  dose-effect curve, indicating that both drugs surmountably antagonize the discriminative stimulus effects of AM4054.",
    "entity1": "CB(1)",
    "entity2": "AM4054"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "Results indicate that AM4054 serves as an effective CB(1) discriminative stimulus, with an onset and time course of action comparable with that of the <protein> CB(1) </protein> agonist \u0394(9)-tetrahydrocannabinol, and that the inverse agonist rimonabant and the neutral antagonist AM4113 produce dose-related rightward shifts in the AM4054 dose-effect curve, indicating that both drugs surmountably antagonize the discriminative stimulus effects of <chemical> AM4054 </chemical>.",
    "original_text": "Results indicate that AM4054 serves as an effective CB(1) discriminative stimulus, with an onset and time course of action comparable with that of the  CB(1)  agonist \u0394(9)-tetrahydrocannabinol, and that the inverse agonist rimonabant and the neutral antagonist AM4113 produce dose-related rightward shifts in the AM4054 dose-effect curve, indicating that both drugs surmountably antagonize the discriminative stimulus effects of  AM4054 .",
    "entity1": "CB(1)",
    "entity2": "AM4054"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Results indicate that AM4054 serves as an effective CB(1) discriminative stimulus, with an onset and time course of action comparable with that of the <protein> CB(1) </protein> agonist \u0394(9)-tetrahydrocannabinol, and that the inverse agonist rimonabant and the neutral antagonist <chemical> AM4113 </chemical> produce dose-related rightward shifts in the AM4054 dose-effect curve, indicating that both drugs surmountably antagonize the discriminative stimulus effects of AM4054.",
    "original_text": "Results indicate that AM4054 serves as an effective CB(1) discriminative stimulus, with an onset and time course of action comparable with that of the  CB(1)  agonist \u0394(9)-tetrahydrocannabinol, and that the inverse agonist rimonabant and the neutral antagonist  AM4113  produce dose-related rightward shifts in the AM4054 dose-effect curve, indicating that both drugs surmountably antagonize the discriminative stimulus effects of AM4054.",
    "entity1": "CB(1)",
    "entity2": "AM4113"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Although parenteral oral direct thrombin inhibitors (DTIs), such as argatroban and bivalirudin, have been on the market for years, DTIs such as <protein> dabigatran </protein> are novel synthetic <chemical> thrombin </chemical> antagonists.",
    "original_text": "Although parenteral oral direct thrombin inhibitors (DTIs), such as argatroban and bivalirudin, have been on the market for years, DTIs such as  dabigatran  are novel synthetic  thrombin  antagonists.",
    "entity1": "dabigatran",
    "entity2": "thrombin"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "<protein> Aldehyde dehydrogenase 1 </protein> (ALDH1A1) catalyzes the oxidation of toxic <chemical> aldehydes </chemical> to carboxylic acids.",
    "original_text": " Aldehyde dehydrogenase 1  (ALDH1A1) catalyzes the oxidation of toxic  aldehydes  to carboxylic acids.",
    "entity1": "Aldehyde dehydrogenase 1",
    "entity2": "aldehydes"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Aldehyde dehydrogenase 1 (<protein> ALDH1A1 </protein>) catalyzes the oxidation of toxic <chemical> aldehydes </chemical> to carboxylic acids.",
    "original_text": "Aldehyde dehydrogenase 1 ( ALDH1A1 ) catalyzes the oxidation of toxic  aldehydes  to carboxylic acids.",
    "entity1": "ALDH1A1",
    "entity2": "aldehydes"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "As the <protein> Mg(2+) </protein> ion concentration was increased, there was a consistent decrease of the enzyme catalytic turnover from 0.31 s(-1) (0 \u03bcM Mg(2+)) to 0.050 s(-1) (6000 \u03bcM Mg(2+)) and a distinct shift in steady-state conformational population from one that favors the <chemical> ALDH1 </chemical>-NADH complex with the shorter fluorescence lifetime (33% excess) in the absence of magnesium ion to one that favors the ALDH1-NADH complex with the longer fluorescence lifetime (13% excess) at 6000 \u03bcM Mg(2+).",
    "original_text": "As the  Mg(2+)  ion concentration was increased, there was a consistent decrease of the enzyme catalytic turnover from 0.31 s(-1) (0 \u03bcM Mg(2+)) to 0.050 s(-1) (6000 \u03bcM Mg(2+)) and a distinct shift in steady-state conformational population from one that favors the  ALDH1 -NADH complex with the shorter fluorescence lifetime (33% excess) in the absence of magnesium ion to one that favors the ALDH1-NADH complex with the longer fluorescence lifetime (13% excess) at 6000 \u03bcM Mg(2+).",
    "entity1": "Mg(2+)",
    "entity2": "ALDH1"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "This shift in conformational population at higher <protein> Mg(2+) </protein> ion concentrations and to lower enzyme activity may be due to longer residence time of the NADH in the <chemical> ALDH1 </chemical> pocket.",
    "original_text": "This shift in conformational population at higher  Mg(2+)  ion concentrations and to lower enzyme activity may be due to longer residence time of the NADH in the  ALDH1  pocket.",
    "entity1": "Mg(2+)",
    "entity2": "ALDH1"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Insertion of ER\u03b1 was blocked by the <protein> ER </protein> antagonist <chemical> ICI 182,780 </chemical> or with the protein kinase C (PKC) pathway inhibitor bisindolylmaleimide (BIS).",
    "original_text": "Insertion of ER\u03b1 was blocked by the  ER  antagonist  ICI 182,780  or with the protein kinase C (PKC) pathway inhibitor bisindolylmaleimide (BIS).",
    "entity1": "ER",
    "entity2": "ICI 182,780"
  },
  {
    "_id": 1,
    "label": "Upregulator",
    "text": "Additionally, in SH-SY5Y cells, MPP(+)-induced demethylation of <protein> phosphoprotein phosphatase 2A </protein> (PP2A), the master regulator of the cellular phosphoregulatory network, and cytotoxicity were ameliorated by <chemical> EHT </chemical>.",
    "original_text": "Additionally, in SH-SY5Y cells, MPP(+)-induced demethylation of  phosphoprotein phosphatase 2A  (PP2A), the master regulator of the cellular phosphoregulatory network, and cytotoxicity were ameliorated by  EHT .",
    "entity1": "phosphoprotein phosphatase 2A",
    "entity2": "EHT"
  },
  {
    "_id": 1,
    "label": "Upregulator",
    "text": "Additionally, in SH-SY5Y cells, MPP(+)-induced demethylation of phosphoprotein phosphatase 2A (<protein> PP2A </protein>), the master regulator of the cellular phosphoregulatory network, and cytotoxicity were ameliorated by <chemical> EHT </chemical>.",
    "original_text": "Additionally, in SH-SY5Y cells, MPP(+)-induced demethylation of phosphoprotein phosphatase 2A ( PP2A ), the master regulator of the cellular phosphoregulatory network, and cytotoxicity were ameliorated by  EHT .",
    "entity1": "PP2A",
    "entity2": "EHT"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "Additionally, in SH-SY5Y cells, <protein> MPP(+) </protein>-induced demethylation of <chemical> phosphoprotein phosphatase 2A </chemical> (PP2A), the master regulator of the cellular phosphoregulatory network, and cytotoxicity were ameliorated by EHT.",
    "original_text": "Additionally, in SH-SY5Y cells,  MPP(+) -induced demethylation of  phosphoprotein phosphatase 2A  (PP2A), the master regulator of the cellular phosphoregulatory network, and cytotoxicity were ameliorated by EHT.",
    "entity1": "MPP(+)",
    "entity2": "phosphoprotein phosphatase 2A"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "Additionally, in SH-SY5Y cells, <protein> MPP(+) </protein>-induced demethylation of phosphoprotein phosphatase 2A (<chemical> PP2A </chemical>), the master regulator of the cellular phosphoregulatory network, and cytotoxicity were ameliorated by EHT.",
    "original_text": "Additionally, in SH-SY5Y cells,  MPP(+) -induced demethylation of phosphoprotein phosphatase 2A ( PP2A ), the master regulator of the cellular phosphoregulatory network, and cytotoxicity were ameliorated by EHT.",
    "entity1": "MPP(+)",
    "entity2": "PP2A"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "We demonstrate that two <protein> flavin mono-oxygenase </protein> family members, FMO1 and FMO3, oxidize <chemical> trimethylamine </chemical> (TMA), derived from gut flora metabolism of choline, to TMAO.",
    "original_text": "We demonstrate that two  flavin mono-oxygenase  family members, FMO1 and FMO3, oxidize  trimethylamine  (TMA), derived from gut flora metabolism of choline, to TMAO.",
    "entity1": "flavin mono-oxygenase",
    "entity2": "trimethylamine"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "We demonstrate that two flavin mono-oxygenase family members, <protein> FMO1 </protein> and FMO3, oxidize <chemical> trimethylamine </chemical> (TMA), derived from gut flora metabolism of choline, to TMAO.",
    "original_text": "We demonstrate that two flavin mono-oxygenase family members,  FMO1  and FMO3, oxidize  trimethylamine  (TMA), derived from gut flora metabolism of choline, to TMAO.",
    "entity1": "FMO1",
    "entity2": "trimethylamine"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "We demonstrate that two flavin mono-oxygenase family members, FMO1 and <protein> FMO3 </protein>, oxidize <chemical> trimethylamine </chemical> (TMA), derived from gut flora metabolism of choline, to TMAO.",
    "original_text": "We demonstrate that two flavin mono-oxygenase family members, FMO1 and  FMO3 , oxidize  trimethylamine  (TMA), derived from gut flora metabolism of choline, to TMAO.",
    "entity1": "FMO3",
    "entity2": "trimethylamine"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "We demonstrate that two <protein> flavin mono-oxygenase </protein> family members, FMO1 and FMO3, oxidize trimethylamine (<chemical> TMA </chemical>), derived from gut flora metabolism of choline, to TMAO.",
    "original_text": "We demonstrate that two  flavin mono-oxygenase  family members, FMO1 and FMO3, oxidize trimethylamine ( TMA ), derived from gut flora metabolism of choline, to TMAO.",
    "entity1": "flavin mono-oxygenase",
    "entity2": "TMA"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "We demonstrate that two flavin mono-oxygenase family members, <protein> FMO1 </protein> and FMO3, oxidize trimethylamine (<chemical> TMA </chemical>), derived from gut flora metabolism of choline, to TMAO.",
    "original_text": "We demonstrate that two flavin mono-oxygenase family members,  FMO1  and FMO3, oxidize trimethylamine ( TMA ), derived from gut flora metabolism of choline, to TMAO.",
    "entity1": "FMO1",
    "entity2": "TMA"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "We demonstrate that two flavin mono-oxygenase family members, FMO1 and <protein> FMO3 </protein>, oxidize trimethylamine (<chemical> TMA </chemical>), derived from gut flora metabolism of choline, to TMAO.",
    "original_text": "We demonstrate that two flavin mono-oxygenase family members, FMO1 and  FMO3 , oxidize trimethylamine ( TMA ), derived from gut flora metabolism of choline, to TMAO.",
    "entity1": "FMO3",
    "entity2": "TMA"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "We demonstrate that two <protein> flavin mono-oxygenase </protein> family members, FMO1 and FMO3, oxidize trimethylamine (TMA), derived from gut flora metabolism of <chemical> choline </chemical>, to TMAO.",
    "original_text": "We demonstrate that two  flavin mono-oxygenase  family members, FMO1 and FMO3, oxidize trimethylamine (TMA), derived from gut flora metabolism of  choline , to TMAO.",
    "entity1": "flavin mono-oxygenase",
    "entity2": "choline"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "We demonstrate that two flavin mono-oxygenase family members, <protein> FMO1 </protein> and FMO3, oxidize trimethylamine (TMA), derived from gut flora metabolism of <chemical> choline </chemical>, to TMAO.",
    "original_text": "We demonstrate that two flavin mono-oxygenase family members,  FMO1  and FMO3, oxidize trimethylamine (TMA), derived from gut flora metabolism of  choline , to TMAO.",
    "entity1": "FMO1",
    "entity2": "choline"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "We demonstrate that two flavin mono-oxygenase family members, FMO1 and <protein> FMO3 </protein>, oxidize trimethylamine (TMA), derived from gut flora metabolism of <chemical> choline </chemical>, to TMAO.",
    "original_text": "We demonstrate that two flavin mono-oxygenase family members, FMO1 and  FMO3 , oxidize trimethylamine (TMA), derived from gut flora metabolism of  choline , to TMAO.",
    "entity1": "FMO3",
    "entity2": "choline"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "FMO3 overexpression in mice significantly increases plasma TMAO levels while silencing <protein> FMO3 </protein> decreases <chemical> TMAO </chemical> levels.",
    "original_text": "FMO3 overexpression in mice significantly increases plasma TMAO levels while silencing  FMO3  decreases  TMAO  levels.",
    "entity1": "FMO3",
    "entity2": "TMAO"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "<protein> FMO3 </protein> overexpression in mice significantly increases plasma <chemical> TMAO </chemical> levels while silencing FMO3 decreases TMAO levels.",
    "original_text": " FMO3  overexpression in mice significantly increases plasma  TMAO  levels while silencing FMO3 decreases TMAO levels.",
    "entity1": "FMO3",
    "entity2": "TMAO"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Phosphodiesterase type 5 (<protein> PDE5 </protein>) mediates the degradation of <chemical> cGMP </chemical> in a variety of tissues including brain.",
    "original_text": "Phosphodiesterase type 5 ( PDE5 ) mediates the degradation of  cGMP  in a variety of tissues including brain.",
    "entity1": "PDE5",
    "entity2": "cGMP"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "<protein> Phosphodiesterase type 5 </protein> (PDE5) mediates the degradation of <chemical> cGMP </chemical> in a variety of tissues including brain.",
    "original_text": " Phosphodiesterase type 5  (PDE5) mediates the degradation of  cGMP  in a variety of tissues including brain.",
    "entity1": "Phosphodiesterase type 5",
    "entity2": "cGMP"
  },
  {
    "_id": 1,
    "label": "Upregulator",
    "text": "In monocytes, both <protein> EPA </protein> and DHA increased <chemical> interleukin (IL)-10 </chemical> without affecting tumor necrosis factor (TNF)-\u03b1 and IL-6.",
    "original_text": "In monocytes, both  EPA  and DHA increased  interleukin (IL)-10  without affecting tumor necrosis factor (TNF)-\u03b1 and IL-6.",
    "entity1": "EPA",
    "entity2": "interleukin (IL)-10"
  },
  {
    "_id": 1,
    "label": "Upregulator",
    "text": "In monocytes, both EPA and <protein> DHA </protein> increased <chemical> interleukin (IL)-10 </chemical> without affecting tumor necrosis factor (TNF)-\u03b1 and IL-6.",
    "original_text": "In monocytes, both EPA and  DHA  increased  interleukin (IL)-10  without affecting tumor necrosis factor (TNF)-\u03b1 and IL-6.",
    "entity1": "DHA",
    "entity2": "interleukin (IL)-10"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "In the in vitro model we observed high permeability of <protein> imperatorin </protein> and isoimperatorin with the <chemical> P-gp </chemical>-mediated efflux ratios of 0.53 and 0.06, as well as medium permeability of cnidilin with 0.82.",
    "original_text": "In the in vitro model we observed high permeability of  imperatorin  and isoimperatorin with the  P-gp -mediated efflux ratios of 0.53 and 0.06, as well as medium permeability of cnidilin with 0.82.",
    "entity1": "imperatorin",
    "entity2": "P-gp"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "In the in vitro model we observed high permeability of imperatorin and <protein> isoimperatorin </protein> with the <chemical> P-gp </chemical>-mediated efflux ratios of 0.53 and 0.06, as well as medium permeability of cnidilin with 0.82.",
    "original_text": "In the in vitro model we observed high permeability of imperatorin and  isoimperatorin  with the  P-gp -mediated efflux ratios of 0.53 and 0.06, as well as medium permeability of cnidilin with 0.82.",
    "entity1": "isoimperatorin",
    "entity2": "P-gp"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "In the in vitro model we observed high permeability of imperatorin and isoimperatorin with the <protein> P-gp </protein>-mediated efflux ratios of 0.53 and 0.06, as well as medium permeability of <chemical> cnidilin </chemical> with 0.82.",
    "original_text": "In the in vitro model we observed high permeability of imperatorin and isoimperatorin with the  P-gp -mediated efflux ratios of 0.53 and 0.06, as well as medium permeability of  cnidilin  with 0.82.",
    "entity1": "P-gp",
    "entity2": "cnidilin"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Treatment with adenosine dialdehyde (AdOx), an inhibitor of transmethylation-suppressive <protein> adenosylhomocysteine (SAH) hydrolase </protein> (SAHH), enhanced the level of <chemical> SAH </chemical> and effectively blocked the proliferation, migration, and invasion of cancer cells; the treatment also induced the differentiation of C6 glioma cells and suppressed the neovascular genesis of eggs in a dose-dependent manner.",
    "original_text": "Treatment with adenosine dialdehyde (AdOx), an inhibitor of transmethylation-suppressive  adenosylhomocysteine (SAH) hydrolase  (SAHH), enhanced the level of  SAH  and effectively blocked the proliferation, migration, and invasion of cancer cells; the treatment also induced the differentiation of C6 glioma cells and suppressed the neovascular genesis of eggs in a dose-dependent manner.",
    "entity1": "adenosylhomocysteine (SAH) hydrolase",
    "entity2": "SAH"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Treatment with adenosine dialdehyde (AdOx), an inhibitor of transmethylation-suppressive adenosylhomocysteine (SAH) hydrolase (<protein> SAHH </protein>), enhanced the level of <chemical> SAH </chemical> and effectively blocked the proliferation, migration, and invasion of cancer cells; the treatment also induced the differentiation of C6 glioma cells and suppressed the neovascular genesis of eggs in a dose-dependent manner.",
    "original_text": "Treatment with adenosine dialdehyde (AdOx), an inhibitor of transmethylation-suppressive adenosylhomocysteine (SAH) hydrolase ( SAHH ), enhanced the level of  SAH  and effectively blocked the proliferation, migration, and invasion of cancer cells; the treatment also induced the differentiation of C6 glioma cells and suppressed the neovascular genesis of eggs in a dose-dependent manner.",
    "entity1": "SAHH",
    "entity2": "SAH"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "In agreement with these data, the exogenous treatment of <protein> SAH </protein> or inhibition of SAHH by specific siRNA or another type of inhibitor, 3-deazaadenosine (DAZA), similarly resulted in antitumorigenic responses, suppressive activity on <chemical> Src </chemical>, the alteration of actin cytoskeleton, and a change of the colocalization pattern between actin and Src.",
    "original_text": "In agreement with these data, the exogenous treatment of  SAH  or inhibition of SAHH by specific siRNA or another type of inhibitor, 3-deazaadenosine (DAZA), similarly resulted in antitumorigenic responses, suppressive activity on  Src , the alteration of actin cytoskeleton, and a change of the colocalization pattern between actin and Src.",
    "entity1": "SAH",
    "entity2": "Src"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Its head-space aroma displayed new volatile phytomolecules and also had higher levels of green volatiles from the <protein> lipoxygenase </protein> (LOX)-pathway (one having as precursors the <chemical> polyunsaturated fatty acids </chemical> containing a cis-cis-1,4-pentadiene system).",
    "original_text": "Its head-space aroma displayed new volatile phytomolecules and also had higher levels of green volatiles from the  lipoxygenase  (LOX)-pathway (one having as precursors the  polyunsaturated fatty acids  containing a cis-cis-1,4-pentadiene system).",
    "entity1": "lipoxygenase",
    "entity2": "polyunsaturated fatty acids"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Its head-space aroma displayed new volatile phytomolecules and also had higher levels of green volatiles from the lipoxygenase (<protein> LOX </protein>)-pathway (one having as precursors the <chemical> polyunsaturated fatty acids </chemical> containing a cis-cis-1,4-pentadiene system).",
    "original_text": "Its head-space aroma displayed new volatile phytomolecules and also had higher levels of green volatiles from the lipoxygenase ( LOX )-pathway (one having as precursors the  polyunsaturated fatty acids  containing a cis-cis-1,4-pentadiene system).",
    "entity1": "LOX",
    "entity2": "polyunsaturated fatty acids"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Its head-space aroma displayed new volatile phytomolecules and also had higher levels of green volatiles from the <protein> lipoxygenase </protein> (LOX)-pathway (one having as precursors the polyunsaturated fatty acids containing a <chemical> cis-cis-1,4-pentadiene </chemical> system).",
    "original_text": "Its head-space aroma displayed new volatile phytomolecules and also had higher levels of green volatiles from the  lipoxygenase  (LOX)-pathway (one having as precursors the polyunsaturated fatty acids containing a  cis-cis-1,4-pentadiene  system).",
    "entity1": "lipoxygenase",
    "entity2": "cis-cis-1,4-pentadiene"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Its head-space aroma displayed new volatile phytomolecules and also had higher levels of green volatiles from the lipoxygenase (<protein> LOX </protein>)-pathway (one having as precursors the polyunsaturated fatty acids containing a <chemical> cis-cis-1,4-pentadiene </chemical> system).",
    "original_text": "Its head-space aroma displayed new volatile phytomolecules and also had higher levels of green volatiles from the lipoxygenase ( LOX )-pathway (one having as precursors the polyunsaturated fatty acids containing a  cis-cis-1,4-pentadiene  system).",
    "entity1": "LOX",
    "entity2": "cis-cis-1,4-pentadiene"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Cellular <protein> zinc </protein> is controlled by <chemical> zinc-chelating proteins </chemical> and by zinc transporters.",
    "original_text": "Cellular  zinc  is controlled by  zinc-chelating proteins  and by zinc transporters.",
    "entity1": "zinc",
    "entity2": "zinc-chelating proteins"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Cellular <protein> zinc </protein> is controlled by zinc-chelating proteins and by <chemical> zinc transporters </chemical>.",
    "original_text": "Cellular  zinc  is controlled by zinc-chelating proteins and by  zinc transporters .",
    "entity1": "zinc",
    "entity2": "zinc transporters"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "The recent identification of <protein> zinc </protein> permeability of the lysosomal ion channel <chemical> TRPML1 </chemical> (transient receptor potential mucolipin 1), and the evidence of abnormal zinc levels in cells deficient in TRPML1, suggested a role for TRPML1\u00a0in zinc transport.",
    "original_text": "The recent identification of  zinc  permeability of the lysosomal ion channel  TRPML1  (transient receptor potential mucolipin 1), and the evidence of abnormal zinc levels in cells deficient in TRPML1, suggested a role for TRPML1\u00a0in zinc transport.",
    "entity1": "zinc",
    "entity2": "TRPML1"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "The recent identification of <protein> zinc </protein> permeability of the lysosomal ion channel TRPML1 (<chemical> transient receptor potential mucolipin 1 </chemical>), and the evidence of abnormal zinc levels in cells deficient in TRPML1, suggested a role for TRPML1\u00a0in zinc transport.",
    "original_text": "The recent identification of  zinc  permeability of the lysosomal ion channel TRPML1 ( transient receptor potential mucolipin 1 ), and the evidence of abnormal zinc levels in cells deficient in TRPML1, suggested a role for TRPML1\u00a0in zinc transport.",
    "entity1": "zinc",
    "entity2": "transient receptor potential mucolipin 1"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "The recent identification of zinc permeability of the lysosomal ion channel TRPML1 (transient receptor potential mucolipin 1), and the evidence of abnormal zinc levels in cells deficient in TRPML1, suggested a role for <protein> TRPML1 </protein>\u00a0in <chemical> zinc </chemical> transport.",
    "original_text": "The recent identification of zinc permeability of the lysosomal ion channel TRPML1 (transient receptor potential mucolipin 1), and the evidence of abnormal zinc levels in cells deficient in TRPML1, suggested a role for  TRPML1 \u00a0in  zinc  transport.",
    "entity1": "TRPML1",
    "entity2": "zinc"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "These results underscore a role for <protein> TRPML1 </protein>\u00a0in <chemical> zinc </chemical> metabolism.",
    "original_text": "These results underscore a role for  TRPML1 \u00a0in  zinc  metabolism.",
    "entity1": "TRPML1",
    "entity2": "zinc"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Furthermore, they suggest that <protein> TRPML1 </protein> works in concert with ZnT4 to regulate <chemical> zinc </chemical> translocation between the cytoplasm and lysosomes.",
    "original_text": "Furthermore, they suggest that  TRPML1  works in concert with ZnT4 to regulate  zinc  translocation between the cytoplasm and lysosomes.",
    "entity1": "TRPML1",
    "entity2": "zinc"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Furthermore, they suggest that TRPML1 works in concert with <protein> ZnT4 </protein> to regulate <chemical> zinc </chemical> translocation between the cytoplasm and lysosomes.",
    "original_text": "Furthermore, they suggest that TRPML1 works in concert with  ZnT4  to regulate  zinc  translocation between the cytoplasm and lysosomes.",
    "entity1": "ZnT4",
    "entity2": "zinc"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "<protein> BCRP </protein> appeared to play a more important role for absorption and intestinal and renal elimination of <chemical> apixaban </chemical> than P-gp in transporter-KO rats after oral and i.v. dosing, which led to a higher level of active renal excretion in rat than other species.",
    "original_text": " BCRP  appeared to play a more important role for absorption and intestinal and renal elimination of  apixaban  than P-gp in transporter-KO rats after oral and i.v. dosing, which led to a higher level of active renal excretion in rat than other species.",
    "entity1": "BCRP",
    "entity2": "apixaban"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "BCRP appeared to play a more important role for absorption and intestinal and renal elimination of <protein> apixaban </protein> than <chemical> P-gp </chemical> in transporter-KO rats after oral and i.v. dosing, which led to a higher level of active renal excretion in rat than other species.",
    "original_text": "BCRP appeared to play a more important role for absorption and intestinal and renal elimination of  apixaban  than  P-gp  in transporter-KO rats after oral and i.v. dosing, which led to a higher level of active renal excretion in rat than other species.",
    "entity1": "apixaban",
    "entity2": "P-gp"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "The enzyme (TcCA) has a very high catalytic activity for the <protein> CO(2) </protein> hydration reaction, being similar kinetically to the human (h) isoform <chemical> hCA II </chemical>, although it is devoid of the His64 proton shuttle.",
    "original_text": "The enzyme (TcCA) has a very high catalytic activity for the  CO(2)  hydration reaction, being similar kinetically to the human (h) isoform  hCA II , although it is devoid of the His64 proton shuttle.",
    "entity1": "CO(2)",
    "entity2": "hCA II"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "The enzyme (<protein> TcCA </protein>) has a very high catalytic activity for the <chemical> CO(2) </chemical> hydration reaction, being similar kinetically to the human (h) isoform hCA II, although it is devoid of the His64 proton shuttle.",
    "original_text": "The enzyme ( TcCA ) has a very high catalytic activity for the  CO(2)  hydration reaction, being similar kinetically to the human (h) isoform hCA II, although it is devoid of the His64 proton shuttle.",
    "entity1": "TcCA",
    "entity2": "CO(2)"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "To evaluate to what extent the regional differences in expression of <protein> P-gp </protein> and P450 enzymes affect the absorption of a dual substrate, we investigated the transport of <chemical> darunavir </chemical> across different small intestinal segments (duodenum, proximal jejunum and ileum).",
    "original_text": "To evaluate to what extent the regional differences in expression of  P-gp  and P450 enzymes affect the absorption of a dual substrate, we investigated the transport of  darunavir  across different small intestinal segments (duodenum, proximal jejunum and ileum).",
    "entity1": "P-gp",
    "entity2": "darunavir"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "To evaluate to what extent the regional differences in expression of P-gp and <protein> P450 enzymes </protein> affect the absorption of a dual substrate, we investigated the transport of <chemical> darunavir </chemical> across different small intestinal segments (duodenum, proximal jejunum and ileum).",
    "original_text": "To evaluate to what extent the regional differences in expression of P-gp and  P450 enzymes  affect the absorption of a dual substrate, we investigated the transport of  darunavir  across different small intestinal segments (duodenum, proximal jejunum and ileum).",
    "entity1": "P450 enzymes",
    "entity2": "darunavir"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "The involvement of <protein> P-gp </protein> in the absorption of <chemical> darunavir </chemical> was clearly shown by coperfusion of darunavir with the P-gp inhibitor zosuquidar.",
    "original_text": "The involvement of  P-gp  in the absorption of  darunavir  was clearly shown by coperfusion of darunavir with the P-gp inhibitor zosuquidar.",
    "entity1": "P-gp",
    "entity2": "darunavir"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Involvement of <protein> P450 </protein> mediated metabolism in the absorption of <chemical> darunavir </chemical> could not be demonstrated in this rat model.",
    "original_text": "Involvement of  P450  mediated metabolism in the absorption of  darunavir  could not be demonstrated in this rat model.",
    "entity1": "P450",
    "entity2": "darunavir"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Upon studying the drug-drug interaction of darunavir with ketoconazole, data were indicative for an inhibitory effect of ketoconazole on <protein> P-gp </protein> as the main mechanism for the increased transport of <chemical> darunavir </chemical> across the small intestine.",
    "original_text": "Upon studying the drug-drug interaction of darunavir with ketoconazole, data were indicative for an inhibitory effect of ketoconazole on  P-gp  as the main mechanism for the increased transport of  darunavir  across the small intestine.",
    "entity1": "P-gp",
    "entity2": "darunavir"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "In overexpressing cell lines, <protein> OATP1B1 </protein>- and OATP1B3-mediated <chemical> estradiol-17\u03b2-glucuronide </chemical> uptake and OATP2B1-mediated estrone-3-sulfate uptake were inhibited by most of the silymarin flavonolignans investigated.",
    "original_text": "In overexpressing cell lines,  OATP1B1 - and OATP1B3-mediated  estradiol-17\u03b2-glucuronide  uptake and OATP2B1-mediated estrone-3-sulfate uptake were inhibited by most of the silymarin flavonolignans investigated.",
    "entity1": "OATP1B1",
    "entity2": "estradiol-17\u03b2-glucuronide"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "In overexpressing cell lines, OATP1B1- and <protein> OATP1B3 </protein>-mediated <chemical> estradiol-17\u03b2-glucuronide </chemical> uptake and OATP2B1-mediated estrone-3-sulfate uptake were inhibited by most of the silymarin flavonolignans investigated.",
    "original_text": "In overexpressing cell lines, OATP1B1- and  OATP1B3 -mediated  estradiol-17\u03b2-glucuronide  uptake and OATP2B1-mediated estrone-3-sulfate uptake were inhibited by most of the silymarin flavonolignans investigated.",
    "entity1": "OATP1B3",
    "entity2": "estradiol-17\u03b2-glucuronide"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "In overexpressing cell lines, OATP1B1- and OATP1B3-mediated estradiol-17\u03b2-glucuronide uptake and <protein> OATP2B1 </protein>-mediated <chemical> estrone-3-sulfate </chemical> uptake were inhibited by most of the silymarin flavonolignans investigated.",
    "original_text": "In overexpressing cell lines, OATP1B1- and OATP1B3-mediated estradiol-17\u03b2-glucuronide uptake and  OATP2B1 -mediated  estrone-3-sulfate  uptake were inhibited by most of the silymarin flavonolignans investigated.",
    "entity1": "OATP2B1",
    "entity2": "estrone-3-sulfate"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Furthermore, silymarin, silybin A, and silybin B (100 \u00b5M) significantly inhibited <protein> OATP </protein>-mediated <chemical> estradiol-17\u03b2-glucuronide </chemical> and rosuvastatin uptake into human hepatocytes.",
    "original_text": "Furthermore, silymarin, silybin A, and silybin B (100 \u00b5M) significantly inhibited  OATP -mediated  estradiol-17\u03b2-glucuronide  and rosuvastatin uptake into human hepatocytes.",
    "entity1": "OATP",
    "entity2": "estradiol-17\u03b2-glucuronide"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Furthermore, silymarin, silybin A, and silybin B (100 \u00b5M) significantly inhibited <protein> OATP </protein>-mediated estradiol-17\u03b2-glucuronide and <chemical> rosuvastatin </chemical> uptake into human hepatocytes.",
    "original_text": "Furthermore, silymarin, silybin A, and silybin B (100 \u00b5M) significantly inhibited  OATP -mediated estradiol-17\u03b2-glucuronide and  rosuvastatin  uptake into human hepatocytes.",
    "entity1": "OATP",
    "entity2": "rosuvastatin"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "The <protein> CRF(1) receptor </protein> antagonist <chemical> SSR125543 </chemical> prevents stress-induced cognitive deficit associated with hippocampal dysfunction: Comparison with paroxetine and D-cycloserine.",
    "original_text": "The  CRF(1) receptor  antagonist  SSR125543  prevents stress-induced cognitive deficit associated with hippocampal dysfunction: Comparison with paroxetine and D-cycloserine.",
    "entity1": "CRF(1) receptor",
    "entity2": "SSR125543"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "RATIONALE: The selective <protein> CRF(1) (corticotropin releasing factor type 1) receptor </protein> antagonist <chemical> SSR125543 </chemical> has been previously shown to attenuate the long-term cognitive deficit produced by traumatic stress exposure.",
    "original_text": "RATIONALE: The selective  CRF(1) (corticotropin releasing factor type 1) receptor  antagonist  SSR125543  has been previously shown to attenuate the long-term cognitive deficit produced by traumatic stress exposure.",
    "entity1": "CRF(1) (corticotropin releasing factor type 1) receptor",
    "entity2": "SSR125543"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "Effects of SSR125543 were compared to those of the 5-HT reuptake inhibitor, paroxetine (10\u00a0mg/kg/day), and the partial <protein> N-methyl-D-aspartate (NMDA) receptor </protein> agonist, <chemical> D-cycloserine </chemical> (10\u00a0mg/kg/day), two compounds which have demonstrated clinical efficacy against PTSD.",
    "original_text": "Effects of SSR125543 were compared to those of the 5-HT reuptake inhibitor, paroxetine (10\u00a0mg/kg/day), and the partial  N-methyl-D-aspartate (NMDA) receptor  agonist,  D-cycloserine  (10\u00a0mg/kg/day), two compounds which have demonstrated clinical efficacy against PTSD.",
    "entity1": "N-methyl-D-aspartate (NMDA) receptor",
    "entity2": "D-cycloserine"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "CONCLUSIONS: These findings confirm that the <protein> CRF(1) receptor </protein> antagonist <chemical> SSR125543 </chemical> is able to attenuate the behavioral effects of traumatic stress exposure and indicate that these effects are associated with a normalization of hippocampal neuronal excitability impaired by stress.",
    "original_text": "CONCLUSIONS: These findings confirm that the  CRF(1) receptor  antagonist  SSR125543  is able to attenuate the behavioral effects of traumatic stress exposure and indicate that these effects are associated with a normalization of hippocampal neuronal excitability impaired by stress.",
    "entity1": "CRF(1) receptor",
    "entity2": "SSR125543"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "A series of <protein> indazole arylsulfonamides </protein> were synthesized and examined as <chemical> human CCR4 </chemical> antagonists.",
    "original_text": "A series of  indazole arylsulfonamides  were synthesized and examined as  human CCR4  antagonists.",
    "entity1": "indazole arylsulfonamides",
    "entity2": "human CCR4"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "Mice given daily injections of high dose <protein> JZL184 </protein> (\u226516 mg/kg) for six days displayed decreased <chemical> CB(1) </chemical> receptor density and function in brain, as assessed in [(3)H]SR141716A binding and CP55,940-stimulated [(35)S]GTP\u03b3S binding assays, respectively.",
    "original_text": "Mice given daily injections of high dose  JZL184  (\u226516 mg/kg) for six days displayed decreased  CB(1)  receptor density and function in brain, as assessed in [(3)H]SR141716A binding and CP55,940-stimulated [(35)S]GTP\u03b3S binding assays, respectively.",
    "entity1": "JZL184",
    "entity2": "CB(1)"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "Cardiac hypertrophy, structural remodeling, and expression of the genes associated with fatty acid metabolism were examined in rats treated with triiodothyronine (T3) alone (8\u200a\u03bcg/100\u200ag body weight (BW), i.p.) for 15 days or along with a <protein> peroxisome proliferator-activated receptor alpha </protein> agonist <chemical> bezafibrate </chemical> (Bzf; 30\u200a\u03bcg/100\u200ag BW, oral) and were found to improve in the Bzf co-treated condition.",
    "original_text": "Cardiac hypertrophy, structural remodeling, and expression of the genes associated with fatty acid metabolism were examined in rats treated with triiodothyronine (T3) alone (8\u200a\u03bcg/100\u200ag body weight (BW), i.p.) for 15 days or along with a  peroxisome proliferator-activated receptor alpha  agonist  bezafibrate  (Bzf; 30\u200a\u03bcg/100\u200ag BW, oral) and were found to improve in the Bzf co-treated condition.",
    "entity1": "peroxisome proliferator-activated receptor alpha",
    "entity2": "bezafibrate"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "Cardiac hypertrophy, structural remodeling, and expression of the genes associated with fatty acid metabolism were examined in rats treated with triiodothyronine (T3) alone (8\u200a\u03bcg/100\u200ag body weight (BW), i.p.) for 15 days or along with a <protein> peroxisome proliferator-activated receptor alpha </protein> agonist bezafibrate (<chemical> Bzf </chemical>; 30\u200a\u03bcg/100\u200ag BW, oral) and were found to improve in the Bzf co-treated condition.",
    "original_text": "Cardiac hypertrophy, structural remodeling, and expression of the genes associated with fatty acid metabolism were examined in rats treated with triiodothyronine (T3) alone (8\u200a\u03bcg/100\u200ag body weight (BW), i.p.) for 15 days or along with a  peroxisome proliferator-activated receptor alpha  agonist bezafibrate ( Bzf ; 30\u200a\u03bcg/100\u200ag BW, oral) and were found to improve in the Bzf co-treated condition.",
    "entity1": "peroxisome proliferator-activated receptor alpha",
    "entity2": "Bzf"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "Moreover, the effects of the <protein> DRD3 </protein> agonist <chemical> 7-hydroxy-N,N-dipropyl-2-aminotetralin </chemical> (7-OH-DPAT)-induced locomotor hypoactivity were significantly increased when DRD3 proteins were abundant.",
    "original_text": "Moreover, the effects of the  DRD3  agonist  7-hydroxy-N,N-dipropyl-2-aminotetralin  (7-OH-DPAT)-induced locomotor hypoactivity were significantly increased when DRD3 proteins were abundant.",
    "entity1": "DRD3",
    "entity2": "7-hydroxy-N,N-dipropyl-2-aminotetralin"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "Moreover, the effects of the DRD3 agonist <protein> 7-hydroxy-N,N-dipropyl-2-aminotetralin </protein> (7-OH-DPAT)-induced locomotor hypoactivity were significantly increased when <chemical> DRD3 </chemical> proteins were abundant.",
    "original_text": "Moreover, the effects of the DRD3 agonist  7-hydroxy-N,N-dipropyl-2-aminotetralin  (7-OH-DPAT)-induced locomotor hypoactivity were significantly increased when  DRD3  proteins were abundant.",
    "entity1": "7-hydroxy-N,N-dipropyl-2-aminotetralin",
    "entity2": "DRD3"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "Moreover, the effects of the <protein> DRD3 </protein> agonist 7-hydroxy-N,N-dipropyl-2-aminotetralin (<chemical> 7-OH-DPAT </chemical>)-induced locomotor hypoactivity were significantly increased when DRD3 proteins were abundant.",
    "original_text": "Moreover, the effects of the  DRD3  agonist 7-hydroxy-N,N-dipropyl-2-aminotetralin ( 7-OH-DPAT )-induced locomotor hypoactivity were significantly increased when DRD3 proteins were abundant.",
    "entity1": "DRD3",
    "entity2": "7-OH-DPAT"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "Moreover, the effects of the DRD3 agonist 7-hydroxy-N,N-dipropyl-2-aminotetralin (<protein> 7-OH-DPAT </protein>)-induced locomotor hypoactivity were significantly increased when <chemical> DRD3 </chemical> proteins were abundant.",
    "original_text": "Moreover, the effects of the DRD3 agonist 7-hydroxy-N,N-dipropyl-2-aminotetralin ( 7-OH-DPAT )-induced locomotor hypoactivity were significantly increased when  DRD3  proteins were abundant.",
    "entity1": "7-OH-DPAT",
    "entity2": "DRD3"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Studies on an (S)-2-amino-3-(3-hydroxy-5-methyl-4-isoxazolyl)propionic acid <protein> (AMPA) receptor </protein> antagonist <chemical> IKM-159 </chemical>: asymmetric synthesis, neuroactivity, and structural characterization.",
    "original_text": "Studies on an (S)-2-amino-3-(3-hydroxy-5-methyl-4-isoxazolyl)propionic acid  (AMPA) receptor  antagonist  IKM-159 : asymmetric synthesis, neuroactivity, and structural characterization.",
    "entity1": "(AMPA) receptor",
    "entity2": "IKM-159"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "<protein> IKM-159 </protein> was developed and identified as a member of a new class of heterotricyclic glutamate analogues that act as <chemical> AMPA receptor </chemical>-selective antagonists.",
    "original_text": " IKM-159  was developed and identified as a member of a new class of heterotricyclic glutamate analogues that act as  AMPA receptor -selective antagonists.",
    "entity1": "IKM-159",
    "entity2": "AMPA receptor"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "IKM-159 was developed and identified as a member of a new class of heterotricyclic <protein> glutamate </protein> analogues that act as <chemical> AMPA receptor </chemical>-selective antagonists.",
    "original_text": "IKM-159 was developed and identified as a member of a new class of heterotricyclic  glutamate  analogues that act as  AMPA receptor -selective antagonists.",
    "entity1": "glutamate",
    "entity2": "AMPA receptor"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "<protein> (2R)-IKM-159 </protein> locks the GluA2 in an open form, consistent with a pharmacological action as competitive antagonist of <chemical> AMPA receptors </chemical>.",
    "original_text": " (2R)-IKM-159  locks the GluA2 in an open form, consistent with a pharmacological action as competitive antagonist of  AMPA receptors .",
    "entity1": "(2R)-IKM-159",
    "entity2": "AMPA receptors"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "<protein> Coumarin </protein> 7-hydroxylation, catalyzed by <chemical> P450 2A13 </chemical>, was strongly inhibited by 2'-methoxy-5,7-dihydroxyflavone, 2-ethynylnaphthalene, 2'-methoxyflavone, 2-naphththalene propargyl ether, acenaphthene, acenaphthylene, naphthalene, 1-acetylpyrene, flavanone, chrysin, 3-ethynylphenanthrene, flavone, and 7-hydroxyflavone; these chemicals induced Type I spectral changes with low Ks values.",
    "original_text": " Coumarin  7-hydroxylation, catalyzed by  P450 2A13 , was strongly inhibited by 2'-methoxy-5,7-dihydroxyflavone, 2-ethynylnaphthalene, 2'-methoxyflavone, 2-naphththalene propargyl ether, acenaphthene, acenaphthylene, naphthalene, 1-acetylpyrene, flavanone, chrysin, 3-ethynylphenanthrene, flavone, and 7-hydroxyflavone; these chemicals induced Type I spectral changes with low Ks values.",
    "entity1": "Coumarin",
    "entity2": "P450 2A13"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "The <protein> (R)-omeprazole </protein> hydroxylation index reflects <chemical> CYP2C19 </chemical> activity in healthy Japanese volunteers.",
    "original_text": "The  (R)-omeprazole  hydroxylation index reflects  CYP2C19  activity in healthy Japanese volunteers.",
    "entity1": "(R)-omeprazole",
    "entity2": "CYP2C19"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "PURPOSE: <protein> Omeprazole </protein> has (R)- and (S)-enantiomers, which exhibit different pharmacokinetics (PK) among patients with <chemical> cytochrome P450 (CYP) 2C19 </chemical> genotype groups.",
    "original_text": "PURPOSE:  Omeprazole  has (R)- and (S)-enantiomers, which exhibit different pharmacokinetics (PK) among patients with  cytochrome P450 (CYP) 2C19  genotype groups.",
    "entity1": "Omeprazole",
    "entity2": "cytochrome P450 (CYP) 2C19"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Additionally, there was a significant difference in plasma concentrations of <protein> (R)-5-hydroxyomeprazole </protein> among <chemical> CYP2C19 </chemical> genotype groups, whereas no significant differences were observed in that of (S)-5-hydroxyomeprazole.",
    "original_text": "Additionally, there was a significant difference in plasma concentrations of  (R)-5-hydroxyomeprazole  among  CYP2C19  genotype groups, whereas no significant differences were observed in that of (S)-5-hydroxyomeprazole.",
    "entity1": "(R)-5-hydroxyomeprazole",
    "entity2": "CYP2C19"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Additionally, there was a significant difference in plasma concentrations of (R)-5-hydroxyomeprazole among <protein> CYP2C19 </protein> genotype groups, whereas no significant differences were observed in that of <chemical> (S)-5-hydroxyomeprazole </chemical>.",
    "original_text": "Additionally, there was a significant difference in plasma concentrations of (R)-5-hydroxyomeprazole among  CYP2C19  genotype groups, whereas no significant differences were observed in that of  (S)-5-hydroxyomeprazole .",
    "entity1": "CYP2C19",
    "entity2": "(S)-5-hydroxyomeprazole"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "CONCLUSION: Our findings demonstrate that <protein> (R)-omeprazole </protein> HI correlated better with <chemical> CYP2C19 </chemical> genotype groups than racemic-omeprazole HI, and these results may be useful for classification among patients in CYP2C19 genotype groups prior to omeprazole treatment.",
    "original_text": "CONCLUSION: Our findings demonstrate that  (R)-omeprazole  HI correlated better with  CYP2C19  genotype groups than racemic-omeprazole HI, and these results may be useful for classification among patients in CYP2C19 genotype groups prior to omeprazole treatment.",
    "entity1": "(R)-omeprazole",
    "entity2": "CYP2C19"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "CONCLUSION: Our findings demonstrate that (R)-omeprazole HI correlated better with <protein> CYP2C19 </protein> genotype groups than <chemical> racemic-omeprazole </chemical> HI, and these results may be useful for classification among patients in CYP2C19 genotype groups prior to omeprazole treatment.",
    "original_text": "CONCLUSION: Our findings demonstrate that (R)-omeprazole HI correlated better with  CYP2C19  genotype groups than  racemic-omeprazole  HI, and these results may be useful for classification among patients in CYP2C19 genotype groups prior to omeprazole treatment.",
    "entity1": "CYP2C19",
    "entity2": "racemic-omeprazole"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "The <protein> human cytosolic sulfotransferase hSULT2A1 </protein> catalyzes the sulfation of a broad range of xenobiotics, as well as endogenous <chemical> hydroxysteroids </chemical> and bile acids.",
    "original_text": "The  human cytosolic sulfotransferase hSULT2A1  catalyzes the sulfation of a broad range of xenobiotics, as well as endogenous  hydroxysteroids  and bile acids.",
    "entity1": "human cytosolic sulfotransferase hSULT2A1",
    "entity2": "hydroxysteroids"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "The <protein> human cytosolic sulfotransferase hSULT2A1 </protein> catalyzes the sulfation of a broad range of xenobiotics, as well as endogenous hydroxysteroids and <chemical> bile acids </chemical>.",
    "original_text": "The  human cytosolic sulfotransferase hSULT2A1  catalyzes the sulfation of a broad range of xenobiotics, as well as endogenous hydroxysteroids and  bile acids .",
    "entity1": "human cytosolic sulfotransferase hSULT2A1",
    "entity2": "bile acids"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Studies on the kinetics of the <protein> hSULT2A1 </protein>-catalyzed sulfation of <chemical> dehydroepiandrosterone </chemical> (DHEA) showed the effects of disulfide bond formation on the substrate inhibition characteristics of the enzyme.",
    "original_text": "Studies on the kinetics of the  hSULT2A1 -catalyzed sulfation of  dehydroepiandrosterone  (DHEA) showed the effects of disulfide bond formation on the substrate inhibition characteristics of the enzyme.",
    "entity1": "hSULT2A1",
    "entity2": "dehydroepiandrosterone"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Studies on the kinetics of the <protein> hSULT2A1 </protein>-catalyzed sulfation of dehydroepiandrosterone (<chemical> DHEA </chemical>) showed the effects of disulfide bond formation on the substrate inhibition characteristics of the enzyme.",
    "original_text": "Studies on the kinetics of the  hSULT2A1 -catalyzed sulfation of dehydroepiandrosterone ( DHEA ) showed the effects of disulfide bond formation on the substrate inhibition characteristics of the enzyme.",
    "entity1": "hSULT2A1",
    "entity2": "DHEA"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Computational docking analysis was conducted to model the interaction of these antagonists with the human ER\u03b1 and showed that they could tightly bind to the ER\u03b1 in a manner similar to that of <protein> ICI-182,780 </protein>, a pure <chemical> ER </chemical> antagonist.",
    "original_text": "Computational docking analysis was conducted to model the interaction of these antagonists with the human ER\u03b1 and showed that they could tightly bind to the ER\u03b1 in a manner similar to that of  ICI-182,780 , a pure  ER  antagonist.",
    "entity1": "ICI-182,780",
    "entity2": "ER"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "These results provide an example that attachment of a bulky side chain to the C-7\u03b1 position of E2 can produce ER antagonists with <protein> ER </protein> affinity comparable to that of <chemical> ICI-182,780 </chemical>.",
    "original_text": "These results provide an example that attachment of a bulky side chain to the C-7\u03b1 position of E2 can produce ER antagonists with  ER  affinity comparable to that of  ICI-182,780 .",
    "entity1": "ER",
    "entity2": "ICI-182,780"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "In non-pre-treated cells, only <protein> efflux transporters </protein> were down-regulated by <chemical> 7-ketosterols </chemical>, showing a greater influence upon ABCG5 expression.",
    "original_text": "In non-pre-treated cells, only  efflux transporters  were down-regulated by  7-ketosterols , showing a greater influence upon ABCG5 expression.",
    "entity1": "efflux transporters",
    "entity2": "7-ketosterols"
  },
  {
    "_id": 1,
    "label": "Upregulator",
    "text": "In non-pre-treated cells, <protein> HMG-CoA </protein> was up-regulated by both <chemical> 7-ketosterols </chemical>.",
    "original_text": "In non-pre-treated cells,  HMG-CoA  was up-regulated by both  7-ketosterols .",
    "entity1": "HMG-CoA",
    "entity2": "7-ketosterols"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Currently, the most important insecticides are <protein> neonicotinoids </protein>, which are metabolized in vitro by <chemical> AOX </chemical> on reduction of the nitroimino group and by CYPs via oxidation reactions.",
    "original_text": "Currently, the most important insecticides are  neonicotinoids , which are metabolized in vitro by  AOX  on reduction of the nitroimino group and by CYPs via oxidation reactions.",
    "entity1": "neonicotinoids",
    "entity2": "AOX"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Currently, the most important insecticides are <protein> neonicotinoids </protein>, which are metabolized in vitro by AOX on reduction of the nitroimino group and by <chemical> CYPs </chemical> via oxidation reactions.",
    "original_text": "Currently, the most important insecticides are  neonicotinoids , which are metabolized in vitro by AOX on reduction of the nitroimino group and by  CYPs  via oxidation reactions.",
    "entity1": "neonicotinoids",
    "entity2": "CYPs"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Currently, the most important insecticides are neonicotinoids, which are metabolized in vitro by <protein> AOX </protein> on reduction of the <chemical> nitroimino </chemical> group and by CYPs via oxidation reactions.",
    "original_text": "Currently, the most important insecticides are neonicotinoids, which are metabolized in vitro by  AOX  on reduction of the  nitroimino  group and by CYPs via oxidation reactions.",
    "entity1": "AOX",
    "entity2": "nitroimino"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Thus, decreasing liver <protein> AOX </protein> activity by three quite different procedures gave a corresponding decrease for in vivo reductive metabolites in the liver of <chemical> IMI </chemical>-treated mice.",
    "original_text": "Thus, decreasing liver  AOX  activity by three quite different procedures gave a corresponding decrease for in vivo reductive metabolites in the liver of  IMI -treated mice.",
    "entity1": "AOX",
    "entity2": "IMI"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Possible <protein> AOX </protein> involvement in <chemical> IMI </chemical> metabolism in insects was evaluated using AOX-expressing and AOX-deficient Drosophila, but no differences were found in IMI nitroreduction or sensitivity between the two strains.",
    "original_text": "Possible  AOX  involvement in  IMI  metabolism in insects was evaluated using AOX-expressing and AOX-deficient Drosophila, but no differences were found in IMI nitroreduction or sensitivity between the two strains.",
    "entity1": "AOX",
    "entity2": "IMI"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Possible AOX involvement in <protein> IMI </protein> metabolism in insects was evaluated using <chemical> AOX </chemical>-expressing and AOX-deficient Drosophila, but no differences were found in IMI nitroreduction or sensitivity between the two strains.",
    "original_text": "Possible AOX involvement in  IMI  metabolism in insects was evaluated using  AOX -expressing and AOX-deficient Drosophila, but no differences were found in IMI nitroreduction or sensitivity between the two strains.",
    "entity1": "IMI",
    "entity2": "AOX"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "This is the first study to establish the in vivo relevance of <protein> AOX </protein> in <chemical> neonicotinoid </chemical> metabolism in mammals and one of the first for xenobiotics in general.",
    "original_text": "This is the first study to establish the in vivo relevance of  AOX  in  neonicotinoid  metabolism in mammals and one of the first for xenobiotics in general.",
    "entity1": "AOX",
    "entity2": "neonicotinoid"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "Of the compounds active in the present assay system, the most potent compound 7, platyphyllonol-5-O-\u03b2-d-xylopyranoside, significantly suppressed the induction of peroxisome proliferator activated receptor \u03b3 (PPAR\u03b3 and CCAAT/enhancer binding protein \u03b1 (C/EBP\u03b1) protein expression, and inhibited adipocyte differentiation induced by <protein> troglitazone </protein>, a <chemical> PPAR\u03b3 </chemical> agonist.",
    "original_text": "Of the compounds active in the present assay system, the most potent compound 7, platyphyllonol-5-O-\u03b2-d-xylopyranoside, significantly suppressed the induction of peroxisome proliferator activated receptor \u03b3 (PPAR\u03b3 and CCAAT/enhancer binding protein \u03b1 (C/EBP\u03b1) protein expression, and inhibited adipocyte differentiation induced by  troglitazone , a  PPAR\u03b3  agonist.",
    "entity1": "troglitazone",
    "entity2": "PPAR\u03b3"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Measurement of Transport Activities of <protein> 3\u03b2-Hydroxy-\u0394(5)-bile Acids </protein> in <chemical> Bile Salt Export Pump </chemical> and Multidrug Resistance-Associated Proteins Using LC-MS/MS.",
    "original_text": "Measurement of Transport Activities of  3\u03b2-Hydroxy-\u0394(5)-bile Acids  in  Bile Salt Export Pump  and Multidrug Resistance-Associated Proteins Using LC-MS/MS.",
    "entity1": "3\u03b2-Hydroxy-\u0394(5)-bile Acids",
    "entity2": "Bile Salt Export Pump"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Measurement of Transport Activities of <protein> 3\u03b2-Hydroxy-\u0394(5)-bile Acids </protein> in Bile Salt Export Pump and <chemical> Multidrug Resistance-Associated Proteins </chemical> Using LC-MS/MS.",
    "original_text": "Measurement of Transport Activities of  3\u03b2-Hydroxy-\u0394(5)-bile Acids  in Bile Salt Export Pump and  Multidrug Resistance-Associated Proteins  Using LC-MS/MS.",
    "entity1": "3\u03b2-Hydroxy-\u0394(5)-bile Acids",
    "entity2": "Multidrug Resistance-Associated Proteins"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "The analytical method was applied to measurements of transport activities in membrane vesicles obtained from human multidrug resistance-associated protein 2-, 3-, and <protein> human bile salt export pump </protein>-expressing Sf9 cells for conjugated <chemical> 3\u03b2-hydroxy-\u0394(5)-bile acids </chemical>.",
    "original_text": "The analytical method was applied to measurements of transport activities in membrane vesicles obtained from human multidrug resistance-associated protein 2-, 3-, and  human bile salt export pump -expressing Sf9 cells for conjugated  3\u03b2-hydroxy-\u0394(5)-bile acids .",
    "entity1": "human bile salt export pump",
    "entity2": "3\u03b2-hydroxy-\u0394(5)-bile acids"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "The present study demonstrated that <protein> human multidrug resistance-associated protein 3 </protein> vesicles accepted conjugated <chemical> 3\u03b2-hydroxy-\u0394(5)-bile acids </chemical> along with common bile acids such as glycocholic acid and taurolithocholic acid 3-sulfate.",
    "original_text": "The present study demonstrated that  human multidrug resistance-associated protein 3  vesicles accepted conjugated  3\u03b2-hydroxy-\u0394(5)-bile acids  along with common bile acids such as glycocholic acid and taurolithocholic acid 3-sulfate.",
    "entity1": "human multidrug resistance-associated protein 3",
    "entity2": "3\u03b2-hydroxy-\u0394(5)-bile acids"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "The present study demonstrated that <protein> human multidrug resistance-associated protein 3 </protein> vesicles accepted conjugated 3\u03b2-hydroxy-\u0394(5)-bile acids along with common <chemical> bile acids </chemical> such as glycocholic acid and taurolithocholic acid 3-sulfate.",
    "original_text": "The present study demonstrated that  human multidrug resistance-associated protein 3  vesicles accepted conjugated 3\u03b2-hydroxy-\u0394(5)-bile acids along with common  bile acids  such as glycocholic acid and taurolithocholic acid 3-sulfate.",
    "entity1": "human multidrug resistance-associated protein 3",
    "entity2": "bile acids"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "The present study demonstrated that <protein> human multidrug resistance-associated protein 3 </protein> vesicles accepted conjugated 3\u03b2-hydroxy-\u0394(5)-bile acids along with common bile acids such as <chemical> glycocholic acid </chemical> and taurolithocholic acid 3-sulfate.",
    "original_text": "The present study demonstrated that  human multidrug resistance-associated protein 3  vesicles accepted conjugated 3\u03b2-hydroxy-\u0394(5)-bile acids along with common bile acids such as  glycocholic acid  and taurolithocholic acid 3-sulfate.",
    "entity1": "human multidrug resistance-associated protein 3",
    "entity2": "glycocholic acid"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "The present study demonstrated that <protein> human multidrug resistance-associated protein 3 </protein> vesicles accepted conjugated 3\u03b2-hydroxy-\u0394(5)-bile acids along with common bile acids such as glycocholic acid and <chemical> taurolithocholic acid 3-sulfate </chemical>.",
    "original_text": "The present study demonstrated that  human multidrug resistance-associated protein 3  vesicles accepted conjugated 3\u03b2-hydroxy-\u0394(5)-bile acids along with common bile acids such as glycocholic acid and  taurolithocholic acid 3-sulfate .",
    "entity1": "human multidrug resistance-associated protein 3",
    "entity2": "taurolithocholic acid 3-sulfate"
  },
  {
    "_id": 1,
    "label": "Upregulator",
    "text": "Upon <protein> nicotine </protein> pre-exposure, brain <chemical> acetylcholinesterase </chemical> increased, while monoamine oxidase (MAO) decreased.",
    "original_text": "Upon  nicotine  pre-exposure, brain  acetylcholinesterase  increased, while monoamine oxidase (MAO) decreased.",
    "entity1": "nicotine",
    "entity2": "acetylcholinesterase"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "Upon <protein> nicotine </protein> pre-exposure, brain acetylcholinesterase increased, while <chemical> monoamine oxidase </chemical> (MAO) decreased.",
    "original_text": "Upon  nicotine  pre-exposure, brain acetylcholinesterase increased, while  monoamine oxidase  (MAO) decreased.",
    "entity1": "nicotine",
    "entity2": "monoamine oxidase"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "Upon <protein> nicotine </protein> pre-exposure, brain acetylcholinesterase increased, while monoamine oxidase (<chemical> MAO </chemical>) decreased.",
    "original_text": "Upon  nicotine  pre-exposure, brain acetylcholinesterase increased, while monoamine oxidase ( MAO ) decreased.",
    "entity1": "nicotine",
    "entity2": "MAO"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "The toxic effects of <protein> MAO </protein> significantly attenuated with <chemical> nicotine </chemical> pre-exposure.",
    "original_text": "The toxic effects of  MAO  significantly attenuated with  nicotine  pre-exposure.",
    "entity1": "MAO",
    "entity2": "nicotine"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "Although naturally occurring electrophilic plant compounds, such as mustard oil and <protein> cinnamaldehyde </protein>, are <chemical> TRPA1 </chemical> agonists, it is unknown whether arthropod-produced electrophiles activate mammalian TRPA1.",
    "original_text": "Although naturally occurring electrophilic plant compounds, such as mustard oil and  cinnamaldehyde , are  TRPA1  agonists, it is unknown whether arthropod-produced electrophiles activate mammalian TRPA1.",
    "entity1": "cinnamaldehyde",
    "entity2": "TRPA1"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "Interestingly, following pBQN desensitization, wild-type <protein> TRPA1 </protein> had dramatically reduced response to the nonelectrophile agonist <chemical> carvacrol </chemical>, whereas the triple cysteine mutant TRPA1 retained its full response.",
    "original_text": "Interestingly, following pBQN desensitization, wild-type  TRPA1  had dramatically reduced response to the nonelectrophile agonist  carvacrol , whereas the triple cysteine mutant TRPA1 retained its full response.",
    "entity1": "TRPA1",
    "entity2": "carvacrol"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "A series of N-substituted lobelane analogues was synthesized and evaluated for their [(3)H]dihydrotetrabenazine binding affinity at the <protein> vesicular monoamine transporter </protein> and for their inhibition of vesicular <chemical> [(3)H]dopamine </chemical> uptake.",
    "original_text": "A series of N-substituted lobelane analogues was synthesized and evaluated for their [(3)H]dihydrotetrabenazine binding affinity at the  vesicular monoamine transporter  and for their inhibition of vesicular  [(3)H]dopamine  uptake.",
    "entity1": "vesicular monoamine transporter",
    "entity2": "[(3)H]dopamine"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "<protein> IPI-926 </protein> is both a substrate and inhibitor (IC50\u2009=\u20091.9\u2009\u00b5M) of <chemical> P-glycoprotein </chemical>.",
    "original_text": " IPI-926  is both a substrate and inhibitor (IC50\u2009=\u20091.9\u2009\u00b5M) of  P-glycoprotein .",
    "entity1": "IPI-926",
    "entity2": "P-glycoprotein"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "Oral <protein> lorcaserin </protein> (BELVIQ(\u00ae)), a selective serotonin <chemical> 5-HT2C </chemical> receptor agonist, is indicated in the US as an adjunct to diet and exercise in the chronic weight management of obese adults, or overweight adults with at least one weight-related comorbidity (e.g. dyslipidaemia, hypertension, type 2 diabetes).",
    "original_text": "Oral  lorcaserin  (BELVIQ(\u00ae)), a selective serotonin  5-HT2C  receptor agonist, is indicated in the US as an adjunct to diet and exercise in the chronic weight management of obese adults, or overweight adults with at least one weight-related comorbidity (e.g. dyslipidaemia, hypertension, type 2 diabetes).",
    "entity1": "lorcaserin",
    "entity2": "5-HT2C"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "Oral lorcaserin (<protein> BELVIQ </protein>(\u00ae)), a selective serotonin <chemical> 5-HT2C </chemical> receptor agonist, is indicated in the US as an adjunct to diet and exercise in the chronic weight management of obese adults, or overweight adults with at least one weight-related comorbidity (e.g. dyslipidaemia, hypertension, type 2 diabetes).",
    "original_text": "Oral lorcaserin ( BELVIQ (\u00ae)), a selective serotonin  5-HT2C  receptor agonist, is indicated in the US as an adjunct to diet and exercise in the chronic weight management of obese adults, or overweight adults with at least one weight-related comorbidity (e.g. dyslipidaemia, hypertension, type 2 diabetes).",
    "entity1": "BELVIQ",
    "entity2": "5-HT2C"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "Furthermore, <protein> galangin </protein> attenuated <chemical> IgE </chemical>-mediated passive cutaneous anaphylaxis and the expression of histamine receptor 1 at the inflamed tissue.",
    "original_text": "Furthermore,  galangin  attenuated  IgE -mediated passive cutaneous anaphylaxis and the expression of histamine receptor 1 at the inflamed tissue.",
    "entity1": "galangin",
    "entity2": "IgE"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "<protein> Cholesterol </protein> also increases <chemical> Amyloid \u03b2 </chemical> (A\u03b2) deposition and tau pathology.",
    "original_text": " Cholesterol  also increases  Amyloid \u03b2  (A\u03b2) deposition and tau pathology.",
    "entity1": "Cholesterol",
    "entity2": "Amyloid \u03b2"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "<protein> Cholesterol </protein> also increases Amyloid \u03b2 (<chemical> A\u03b2 </chemical>) deposition and tau pathology.",
    "original_text": " Cholesterol  also increases Amyloid \u03b2 ( A\u03b2 ) deposition and tau pathology.",
    "entity1": "Cholesterol",
    "entity2": "A\u03b2"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "<protein> Cholesterol </protein> also increases Amyloid \u03b2 (A\u03b2) deposition and <chemical> tau </chemical> pathology.",
    "original_text": " Cholesterol  also increases Amyloid \u03b2 (A\u03b2) deposition and  tau  pathology.",
    "entity1": "Cholesterol",
    "entity2": "tau"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "In the current study, we extend these findings to show that the ability of astrocytes to buffer extracellular <protein> glutamate </protein> is reduced when <chemical> CaMKII </chemical> is inhibited.",
    "original_text": "In the current study, we extend these findings to show that the ability of astrocytes to buffer extracellular  glutamate  is reduced when  CaMKII  is inhibited.",
    "entity1": "glutamate",
    "entity2": "CaMKII"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "4-Hydroxypyridazin-3(2H)-one Derivatives as Novel d-Amino Acid Oxidase Inhibitors. d-Amino acid oxidase (DAAO) catalyzes the oxidation of d-amino acids including <protein> d-serine </protein>, a coagonist of the <chemical> N-methyl-d-aspartate receptor </chemical>.",
    "original_text": "4-Hydroxypyridazin-3(2H)-one Derivatives as Novel d-Amino Acid Oxidase Inhibitors. d-Amino acid oxidase (DAAO) catalyzes the oxidation of d-amino acids including  d-serine , a coagonist of the  N-methyl-d-aspartate receptor .",
    "entity1": "d-serine",
    "entity2": "N-methyl-d-aspartate receptor"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "4-Hydroxypyridazin-3(2H)-one Derivatives as Novel d-Amino Acid Oxidase Inhibitors. <protein> d-Amino acid oxidase </protein> (DAAO) catalyzes the oxidation of d-amino acids including <chemical> d-serine </chemical>, a coagonist of the N-methyl-d-aspartate receptor.",
    "original_text": "4-Hydroxypyridazin-3(2H)-one Derivatives as Novel d-Amino Acid Oxidase Inhibitors.  d-Amino acid oxidase  (DAAO) catalyzes the oxidation of d-amino acids including  d-serine , a coagonist of the N-methyl-d-aspartate receptor.",
    "entity1": "d-Amino acid oxidase",
    "entity2": "d-serine"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "4-Hydroxypyridazin-3(2H)-one Derivatives as Novel d-Amino Acid Oxidase Inhibitors. d-Amino acid oxidase (<protein> DAAO </protein>) catalyzes the oxidation of d-amino acids including <chemical> d-serine </chemical>, a coagonist of the N-methyl-d-aspartate receptor.",
    "original_text": "4-Hydroxypyridazin-3(2H)-one Derivatives as Novel d-Amino Acid Oxidase Inhibitors. d-Amino acid oxidase ( DAAO ) catalyzes the oxidation of d-amino acids including  d-serine , a coagonist of the N-methyl-d-aspartate receptor.",
    "entity1": "DAAO",
    "entity2": "d-serine"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "4-Hydroxypyridazin-3(2H)-one Derivatives as Novel d-Amino Acid Oxidase Inhibitors. <protein> d-Amino acid oxidase </protein> (DAAO) catalyzes the oxidation of <chemical> d-amino acids </chemical> including d-serine, a coagonist of the N-methyl-d-aspartate receptor.",
    "original_text": "4-Hydroxypyridazin-3(2H)-one Derivatives as Novel d-Amino Acid Oxidase Inhibitors.  d-Amino acid oxidase  (DAAO) catalyzes the oxidation of  d-amino acids  including d-serine, a coagonist of the N-methyl-d-aspartate receptor.",
    "entity1": "d-Amino acid oxidase",
    "entity2": "d-amino acids"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "4-Hydroxypyridazin-3(2H)-one Derivatives as Novel d-Amino Acid Oxidase Inhibitors. d-Amino acid oxidase (<protein> DAAO </protein>) catalyzes the oxidation of <chemical> d-amino acids </chemical> including d-serine, a coagonist of the N-methyl-d-aspartate receptor.",
    "original_text": "4-Hydroxypyridazin-3(2H)-one Derivatives as Novel d-Amino Acid Oxidase Inhibitors. d-Amino acid oxidase ( DAAO ) catalyzes the oxidation of  d-amino acids  including d-serine, a coagonist of the N-methyl-d-aspartate receptor.",
    "entity1": "DAAO",
    "entity2": "d-amino acids"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "Fourteen of 17 <protein> parabens </protein> exhibited <chemical> hER\u03b1 </chemical> and/or hER\u03b2 agonistic activity at concentrations of \u2a7d1\u00d710(-5)M, whereas none of the 17 parabens showed AR agonistic or antagonistic activity.",
    "original_text": "Fourteen of 17  parabens  exhibited  hER\u03b1  and/or hER\u03b2 agonistic activity at concentrations of \u2a7d1\u00d710(-5)M, whereas none of the 17 parabens showed AR agonistic or antagonistic activity.",
    "entity1": "parabens",
    "entity2": "hER\u03b1"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "Fourteen of 17 <protein> parabens </protein> exhibited hER\u03b1 and/or <chemical> hER\u03b2 </chemical> agonistic activity at concentrations of \u2a7d1\u00d710(-5)M, whereas none of the 17 parabens showed AR agonistic or antagonistic activity.",
    "original_text": "Fourteen of 17  parabens  exhibited hER\u03b1 and/or  hER\u03b2  agonistic activity at concentrations of \u2a7d1\u00d710(-5)M, whereas none of the 17 parabens showed AR agonistic or antagonistic activity.",
    "entity1": "parabens",
    "entity2": "hER\u03b2"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "Among 12 parabens with linear alkyl chains ranging in length from C1 to C12, <protein> heptylparaben </protein> (C7) and pentylparaben (C5) showed the most potent <chemical> ER\u03b1 </chemical> and ER\u03b2 agonistic activity in the order of 10(-7)M and 10(-8)M, respectively, and the activities decreased in a stepwise manner as the alkyl chain was shortened to C1 or lengthened to C12.",
    "original_text": "Among 12 parabens with linear alkyl chains ranging in length from C1 to C12,  heptylparaben  (C7) and pentylparaben (C5) showed the most potent  ER\u03b1  and ER\u03b2 agonistic activity in the order of 10(-7)M and 10(-8)M, respectively, and the activities decreased in a stepwise manner as the alkyl chain was shortened to C1 or lengthened to C12.",
    "entity1": "heptylparaben",
    "entity2": "ER\u03b1"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "Among 12 parabens with linear alkyl chains ranging in length from C1 to C12, <protein> heptylparaben </protein> (C7) and pentylparaben (C5) showed the most potent ER\u03b1 and <chemical> ER\u03b2 </chemical> agonistic activity in the order of 10(-7)M and 10(-8)M, respectively, and the activities decreased in a stepwise manner as the alkyl chain was shortened to C1 or lengthened to C12.",
    "original_text": "Among 12 parabens with linear alkyl chains ranging in length from C1 to C12,  heptylparaben  (C7) and pentylparaben (C5) showed the most potent ER\u03b1 and  ER\u03b2  agonistic activity in the order of 10(-7)M and 10(-8)M, respectively, and the activities decreased in a stepwise manner as the alkyl chain was shortened to C1 or lengthened to C12.",
    "entity1": "heptylparaben",
    "entity2": "ER\u03b2"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "Among 12 parabens with linear alkyl chains ranging in length from C1 to C12, heptylparaben (C7) and <protein> pentylparaben </protein> (C5) showed the most potent <chemical> ER\u03b1 </chemical> and ER\u03b2 agonistic activity in the order of 10(-7)M and 10(-8)M, respectively, and the activities decreased in a stepwise manner as the alkyl chain was shortened to C1 or lengthened to C12.",
    "original_text": "Among 12 parabens with linear alkyl chains ranging in length from C1 to C12, heptylparaben (C7) and  pentylparaben  (C5) showed the most potent  ER\u03b1  and ER\u03b2 agonistic activity in the order of 10(-7)M and 10(-8)M, respectively, and the activities decreased in a stepwise manner as the alkyl chain was shortened to C1 or lengthened to C12.",
    "entity1": "pentylparaben",
    "entity2": "ER\u03b1"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "Among 12 parabens with linear alkyl chains ranging in length from C1 to C12, heptylparaben (C7) and <protein> pentylparaben </protein> (C5) showed the most potent ER\u03b1 and <chemical> ER\u03b2 </chemical> agonistic activity in the order of 10(-7)M and 10(-8)M, respectively, and the activities decreased in a stepwise manner as the alkyl chain was shortened to C1 or lengthened to C12.",
    "original_text": "Among 12 parabens with linear alkyl chains ranging in length from C1 to C12, heptylparaben (C7) and  pentylparaben  (C5) showed the most potent ER\u03b1 and  ER\u03b2  agonistic activity in the order of 10(-7)M and 10(-8)M, respectively, and the activities decreased in a stepwise manner as the alkyl chain was shortened to C1 or lengthened to C12.",
    "entity1": "pentylparaben",
    "entity2": "ER\u03b2"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "Among 12 <protein> parabens </protein> with linear alkyl chains ranging in length from C1 to C12, heptylparaben (C7) and pentylparaben (C5) showed the most potent <chemical> ER\u03b1 </chemical> and ER\u03b2 agonistic activity in the order of 10(-7)M and 10(-8)M, respectively, and the activities decreased in a stepwise manner as the alkyl chain was shortened to C1 or lengthened to C12.",
    "original_text": "Among 12  parabens  with linear alkyl chains ranging in length from C1 to C12, heptylparaben (C7) and pentylparaben (C5) showed the most potent  ER\u03b1  and ER\u03b2 agonistic activity in the order of 10(-7)M and 10(-8)M, respectively, and the activities decreased in a stepwise manner as the alkyl chain was shortened to C1 or lengthened to C12.",
    "entity1": "parabens",
    "entity2": "ER\u03b1"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "Among 12 <protein> parabens </protein> with linear alkyl chains ranging in length from C1 to C12, heptylparaben (C7) and pentylparaben (C5) showed the most potent ER\u03b1 and <chemical> ER\u03b2 </chemical> agonistic activity in the order of 10(-7)M and 10(-8)M, respectively, and the activities decreased in a stepwise manner as the alkyl chain was shortened to C1 or lengthened to C12.",
    "original_text": "Among 12  parabens  with linear alkyl chains ranging in length from C1 to C12, heptylparaben (C7) and pentylparaben (C5) showed the most potent ER\u03b1 and  ER\u03b2  agonistic activity in the order of 10(-7)M and 10(-8)M, respectively, and the activities decreased in a stepwise manner as the alkyl chain was shortened to C1 or lengthened to C12.",
    "entity1": "parabens",
    "entity2": "ER\u03b2"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "Among 12 parabens with linear <protein> alkyl </protein> chains ranging in length from C1 to C12, heptylparaben (C7) and pentylparaben (C5) showed the most potent <chemical> ER\u03b1 </chemical> and ER\u03b2 agonistic activity in the order of 10(-7)M and 10(-8)M, respectively, and the activities decreased in a stepwise manner as the alkyl chain was shortened to C1 or lengthened to C12.",
    "original_text": "Among 12 parabens with linear  alkyl  chains ranging in length from C1 to C12, heptylparaben (C7) and pentylparaben (C5) showed the most potent  ER\u03b1  and ER\u03b2 agonistic activity in the order of 10(-7)M and 10(-8)M, respectively, and the activities decreased in a stepwise manner as the alkyl chain was shortened to C1 or lengthened to C12.",
    "entity1": "alkyl",
    "entity2": "ER\u03b1"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "Among 12 parabens with linear <protein> alkyl </protein> chains ranging in length from C1 to C12, heptylparaben (C7) and pentylparaben (C5) showed the most potent ER\u03b1 and <chemical> ER\u03b2 </chemical> agonistic activity in the order of 10(-7)M and 10(-8)M, respectively, and the activities decreased in a stepwise manner as the alkyl chain was shortened to C1 or lengthened to C12.",
    "original_text": "Among 12 parabens with linear  alkyl  chains ranging in length from C1 to C12, heptylparaben (C7) and pentylparaben (C5) showed the most potent ER\u03b1 and  ER\u03b2  agonistic activity in the order of 10(-7)M and 10(-8)M, respectively, and the activities decreased in a stepwise manner as the alkyl chain was shortened to C1 or lengthened to C12.",
    "entity1": "alkyl",
    "entity2": "ER\u03b2"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "Most <protein> parabens </protein> showing estrogenic activity exhibited <chemical> ER\u03b2 </chemical>-agonistic activity at lower concentrations than those inducing ER\u03b1-agonistic activity.",
    "original_text": "Most  parabens  showing estrogenic activity exhibited  ER\u03b2 -agonistic activity at lower concentrations than those inducing ER\u03b1-agonistic activity.",
    "entity1": "parabens",
    "entity2": "ER\u03b2"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "Most <protein> parabens </protein> showing estrogenic activity exhibited ER\u03b2-agonistic activity at lower concentrations than those inducing <chemical> ER\u03b1 </chemical>-agonistic activity.",
    "original_text": "Most  parabens  showing estrogenic activity exhibited ER\u03b2-agonistic activity at lower concentrations than those inducing  ER\u03b1 -agonistic activity.",
    "entity1": "parabens",
    "entity2": "ER\u03b1"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "These results indicate that <protein> parabens </protein> are selective agonists for <chemical> ER\u03b2 </chemical> over ER\u03b1; their interactions with ER\u03b1/\u03b2 are dependent on the size and bulkiness of the alkyl groups; and they are metabolized by carboxylesterases, leading to attenuation of their estrogenic activity.",
    "original_text": "These results indicate that  parabens  are selective agonists for  ER\u03b2  over ER\u03b1; their interactions with ER\u03b1/\u03b2 are dependent on the size and bulkiness of the alkyl groups; and they are metabolized by carboxylesterases, leading to attenuation of their estrogenic activity.",
    "entity1": "parabens",
    "entity2": "ER\u03b2"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "These results indicate that <protein> parabens </protein> are selective agonists for ER\u03b2 over <chemical> ER\u03b1 </chemical>; their interactions with ER\u03b1/\u03b2 are dependent on the size and bulkiness of the alkyl groups; and they are metabolized by carboxylesterases, leading to attenuation of their estrogenic activity.",
    "original_text": "These results indicate that  parabens  are selective agonists for ER\u03b2 over  ER\u03b1 ; their interactions with ER\u03b1/\u03b2 are dependent on the size and bulkiness of the alkyl groups; and they are metabolized by carboxylesterases, leading to attenuation of their estrogenic activity.",
    "entity1": "parabens",
    "entity2": "ER\u03b1"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "These results indicate that <protein> parabens </protein> are selective agonists for ER\u03b2 over ER\u03b1; their interactions with ER\u03b1/\u03b2 are dependent on the size and bulkiness of the alkyl groups; and they are metabolized by <chemical> carboxylesterases </chemical>, leading to attenuation of their estrogenic activity.",
    "original_text": "These results indicate that  parabens  are selective agonists for ER\u03b2 over ER\u03b1; their interactions with ER\u03b1/\u03b2 are dependent on the size and bulkiness of the alkyl groups; and they are metabolized by  carboxylesterases , leading to attenuation of their estrogenic activity.",
    "entity1": "parabens",
    "entity2": "carboxylesterases"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "<protein> Quercetin </protein> suppressed <chemical> CYP2E1 </chemical>-dependent ethanol hepatotoxicity via depleting heme pool and releasing CO.",
    "original_text": " Quercetin  suppressed  CYP2E1 -dependent ethanol hepatotoxicity via depleting heme pool and releasing CO.",
    "entity1": "Quercetin",
    "entity2": "CYP2E1"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "However, the precise mechanism by which <protein> quercetin </protein> counteracts <chemical> CYP2E1 </chemical>-mediated ethanol hepatotoxicity through HO-1 system is still remained unclear.",
    "original_text": "However, the precise mechanism by which  quercetin  counteracts  CYP2E1 -mediated ethanol hepatotoxicity through HO-1 system is still remained unclear.",
    "entity1": "quercetin",
    "entity2": "CYP2E1"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "Our data showed that chronic <protein> ethanol </protein> over-activated CYP2E1 but suppressed <chemical> HO-1 </chemical> with concurrent hepatic oxidative damage, which was partially normalized by quercetin (100mg/kg.bw.).",
    "original_text": "Our data showed that chronic  ethanol  over-activated CYP2E1 but suppressed  HO-1  with concurrent hepatic oxidative damage, which was partially normalized by quercetin (100mg/kg.bw.).",
    "entity1": "ethanol",
    "entity2": "HO-1"
  },
  {
    "_id": 1,
    "label": "Upregulator",
    "text": "<protein> Quercetin </protein> (100\u03bcM) induced <chemical> HO-1 </chemical> and depleted heme pool when incubated to human hepatocytes.",
    "original_text": " Quercetin  (100\u03bcM) induced  HO-1  and depleted heme pool when incubated to human hepatocytes.",
    "entity1": "Quercetin",
    "entity2": "HO-1"
  },
  {
    "_id": 1,
    "label": "Upregulator",
    "text": "<protein> Ethanol </protein>-stimulated (100mM) <chemical> CYP2E1 </chemical> upregulation was suppressed by quercetin but further enhanced by HO-1 inhibition with resultant heme accumulation.",
    "original_text": " Ethanol -stimulated (100mM)  CYP2E1  upregulation was suppressed by quercetin but further enhanced by HO-1 inhibition with resultant heme accumulation.",
    "entity1": "Ethanol",
    "entity2": "CYP2E1"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "Ethanol-stimulated (100mM) <protein> CYP2E1 </protein> upregulation was suppressed by <chemical> quercetin </chemical> but further enhanced by HO-1 inhibition with resultant heme accumulation.",
    "original_text": "Ethanol-stimulated (100mM)  CYP2E1  upregulation was suppressed by  quercetin  but further enhanced by HO-1 inhibition with resultant heme accumulation.",
    "entity1": "CYP2E1",
    "entity2": "quercetin"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Ethanol-stimulated (100mM) CYP2E1 upregulation was suppressed by quercetin but further enhanced by <protein> HO-1 </protein> inhibition with resultant <chemical> heme </chemical> accumulation.",
    "original_text": "Ethanol-stimulated (100mM) CYP2E1 upregulation was suppressed by quercetin but further enhanced by  HO-1  inhibition with resultant  heme  accumulation.",
    "entity1": "HO-1",
    "entity2": "heme"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "<protein> CO </protein> scavenging blocked the suppression of quercetin only on <chemical> CYP2E1 </chemical> activity.",
    "original_text": " CO  scavenging blocked the suppression of quercetin only on  CYP2E1  activity.",
    "entity1": "CO",
    "entity2": "CYP2E1"
  },
  {
    "_id": 1,
    "label": "Upregulator",
    "text": "CO donor dose-dependently inactivated <protein> CYP2E1 </protein> of <chemical> ethanol </chemical>-incubated microsome, which was mimicked by HO-1 substrate but abolished by CO scavenger.",
    "original_text": "CO donor dose-dependently inactivated  CYP2E1  of  ethanol -incubated microsome, which was mimicked by HO-1 substrate but abolished by CO scavenger.",
    "entity1": "CYP2E1",
    "entity2": "ethanol"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "<protein> CO </protein> donor dose-dependently inactivated <chemical> CYP2E1 </chemical> of ethanol-incubated microsome, which was mimicked by HO-1 substrate but abolished by CO scavenger.",
    "original_text": " CO  donor dose-dependently inactivated  CYP2E1  of ethanol-incubated microsome, which was mimicked by HO-1 substrate but abolished by CO scavenger.",
    "entity1": "CO",
    "entity2": "CYP2E1"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "CO donor dose-dependently inactivated <protein> CYP2E1 </protein> of ethanol-incubated microsome, which was mimicked by HO-1 substrate but abolished by <chemical> CO </chemical> scavenger.",
    "original_text": "CO donor dose-dependently inactivated  CYP2E1  of ethanol-incubated microsome, which was mimicked by HO-1 substrate but abolished by  CO  scavenger.",
    "entity1": "CYP2E1",
    "entity2": "CO"
  },
  {
    "_id": 1,
    "label": "Upregulator",
    "text": "Thus, CYP2E1-mediated ethanol hepatotoxicity was alleviated by <protein> quercetin </protein> through <chemical> HO-1 </chemical> induction.",
    "original_text": "Thus, CYP2E1-mediated ethanol hepatotoxicity was alleviated by  quercetin  through  HO-1  induction.",
    "entity1": "quercetin",
    "entity2": "HO-1"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "Agonistic activity of <protein> ICI 182 780 </protein> on activation of <chemical> GSK 3\u03b2 </chemical>/AKT pathway in the rat uterus during the estrous cycle.",
    "original_text": "Agonistic activity of  ICI 182 780  on activation of  GSK 3\u03b2 /AKT pathway in the rat uterus during the estrous cycle.",
    "entity1": "ICI 182 780",
    "entity2": "GSK 3\u03b2"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "A series of aminopropylindenes, designed as mimics of a cationic high energy intermediate in the oxidosqualene cyclase(1) (<protein> OSC </protein>)-mediated cyclization of <chemical> 2,3-oxidosqualen </chemical> to lanosterol was prepared from Grundmann's ketone.",
    "original_text": "A series of aminopropylindenes, designed as mimics of a cationic high energy intermediate in the oxidosqualene cyclase(1) ( OSC )-mediated cyclization of  2,3-oxidosqualen  to lanosterol was prepared from Grundmann's ketone.",
    "entity1": "OSC",
    "entity2": "2,3-oxidosqualen"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "A series of aminopropylindenes, designed as mimics of a cationic high energy intermediate in the <protein> oxidosqualene cyclase(1) </protein> (OSC)-mediated cyclization of <chemical> 2,3-oxidosqualen </chemical> to lanosterol was prepared from Grundmann's ketone.",
    "original_text": "A series of aminopropylindenes, designed as mimics of a cationic high energy intermediate in the  oxidosqualene cyclase(1)  (OSC)-mediated cyclization of  2,3-oxidosqualen  to lanosterol was prepared from Grundmann's ketone.",
    "entity1": "oxidosqualene cyclase(1)",
    "entity2": "2,3-oxidosqualen"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "The <protein> ATP </protein> required for potentiation of skeletal muscle contraction is released via <chemical> pannexin </chemical> hemichannels.",
    "original_text": "The  ATP  required for potentiation of skeletal muscle contraction is released via  pannexin  hemichannels.",
    "entity1": "ATP",
    "entity2": "pannexin"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Consistent with two <protein> glucose </protein> uptake pathways, induced uptake of 2-NBDG, a fluorescent glucose derivative, was decreased by inhibition of HCs or <chemical> glucose transporter </chemical> (GLUT4), and blocked by dual blockade.",
    "original_text": "Consistent with two  glucose  uptake pathways, induced uptake of 2-NBDG, a fluorescent glucose derivative, was decreased by inhibition of HCs or  glucose transporter  (GLUT4), and blocked by dual blockade.",
    "entity1": "glucose",
    "entity2": "glucose transporter"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Consistent with two <protein> glucose </protein> uptake pathways, induced uptake of 2-NBDG, a fluorescent glucose derivative, was decreased by inhibition of HCs or glucose transporter (<chemical> GLUT4 </chemical>), and blocked by dual blockade.",
    "original_text": "Consistent with two  glucose  uptake pathways, induced uptake of 2-NBDG, a fluorescent glucose derivative, was decreased by inhibition of HCs or glucose transporter ( GLUT4 ), and blocked by dual blockade.",
    "entity1": "glucose",
    "entity2": "GLUT4"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Consistent with two glucose uptake pathways, induced uptake of <protein> 2-NBDG </protein>, a fluorescent glucose derivative, was decreased by inhibition of HCs or <chemical> glucose transporter </chemical> (GLUT4), and blocked by dual blockade.",
    "original_text": "Consistent with two glucose uptake pathways, induced uptake of  2-NBDG , a fluorescent glucose derivative, was decreased by inhibition of HCs or  glucose transporter  (GLUT4), and blocked by dual blockade.",
    "entity1": "2-NBDG",
    "entity2": "glucose transporter"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Consistent with two glucose uptake pathways, induced uptake of <protein> 2-NBDG </protein>, a fluorescent glucose derivative, was decreased by inhibition of HCs or glucose transporter (<chemical> GLUT4 </chemical>), and blocked by dual blockade.",
    "original_text": "Consistent with two glucose uptake pathways, induced uptake of  2-NBDG , a fluorescent glucose derivative, was decreased by inhibition of HCs or glucose transporter ( GLUT4 ), and blocked by dual blockade.",
    "entity1": "2-NBDG",
    "entity2": "GLUT4"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Opening of <protein> Panx1 </protein> HCs during repetitive activation allows efflux of <chemical> ATP </chemical>, influx of glucose and possibly Ca(2+) too, which are required for potentiation of contraction.",
    "original_text": "Opening of  Panx1  HCs during repetitive activation allows efflux of  ATP , influx of glucose and possibly Ca(2+) too, which are required for potentiation of contraction.",
    "entity1": "Panx1",
    "entity2": "ATP"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Opening of <protein> Panx1 </protein> HCs during repetitive activation allows efflux of ATP, influx of <chemical> glucose </chemical> and possibly Ca(2+) too, which are required for potentiation of contraction.",
    "original_text": "Opening of  Panx1  HCs during repetitive activation allows efflux of ATP, influx of  glucose  and possibly Ca(2+) too, which are required for potentiation of contraction.",
    "entity1": "Panx1",
    "entity2": "glucose"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Opening of <protein> Panx1 </protein> HCs during repetitive activation allows efflux of ATP, influx of glucose and possibly <chemical> Ca(2+) </chemical> too, which are required for potentiation of contraction.",
    "original_text": "Opening of  Panx1  HCs during repetitive activation allows efflux of ATP, influx of glucose and possibly  Ca(2+)  too, which are required for potentiation of contraction.",
    "entity1": "Panx1",
    "entity2": "Ca(2+)"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Discovery of <protein> aryl ureas </protein> and aryl amides as potent and selective <chemical> histamine H3 receptor </chemical> antagonists for the treatment of obesity (Part I).",
    "original_text": "Discovery of  aryl ureas  and aryl amides as potent and selective  histamine H3 receptor  antagonists for the treatment of obesity (Part I).",
    "entity1": "aryl ureas",
    "entity2": "histamine H3 receptor"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Discovery of aryl ureas and <protein> aryl amides </protein> as potent and selective <chemical> histamine H3 receptor </chemical> antagonists for the treatment of obesity (Part I).",
    "original_text": "Discovery of aryl ureas and  aryl amides  as potent and selective  histamine H3 receptor  antagonists for the treatment of obesity (Part I).",
    "entity1": "aryl amides",
    "entity2": "histamine H3 receptor"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "A series of structurally novel <protein> aryl ureas </protein> was derived from optimization of the HTS lead as selective <chemical> histamine H3 receptor </chemical> (H3R) antagonists.",
    "original_text": "A series of structurally novel  aryl ureas  was derived from optimization of the HTS lead as selective  histamine H3 receptor  (H3R) antagonists.",
    "entity1": "aryl ureas",
    "entity2": "histamine H3 receptor"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "A series of structurally novel <protein> aryl ureas </protein> was derived from optimization of the HTS lead as selective histamine H3 receptor (<chemical> H3R </chemical>) antagonists.",
    "original_text": "A series of structurally novel  aryl ureas  was derived from optimization of the HTS lead as selective histamine H3 receptor ( H3R ) antagonists.",
    "entity1": "aryl ureas",
    "entity2": "H3R"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "In terms of the mechanisms, we found that fatty acid amide hydrolase (<protein> FAAH </protein>) which degrades <chemical> anandamide </chemical>, was upregulated after nerve injury at both ages, so that this upregulation likely did not account for the age-dependent differences.",
    "original_text": "In terms of the mechanisms, we found that fatty acid amide hydrolase ( FAAH ) which degrades  anandamide , was upregulated after nerve injury at both ages, so that this upregulation likely did not account for the age-dependent differences.",
    "entity1": "FAAH",
    "entity2": "anandamide"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "In terms of the mechanisms, we found that <protein> fatty acid amide hydrolase </protein> (FAAH) which degrades <chemical> anandamide </chemical>, was upregulated after nerve injury at both ages, so that this upregulation likely did not account for the age-dependent differences.",
    "original_text": "In terms of the mechanisms, we found that  fatty acid amide hydrolase  (FAAH) which degrades  anandamide , was upregulated after nerve injury at both ages, so that this upregulation likely did not account for the age-dependent differences.",
    "entity1": "fatty acid amide hydrolase",
    "entity2": "anandamide"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "However, enzymes contributing to oxidative metabolism of <protein> anandamide </protein>, namely <chemical> cyclooxygenase-1 </chemical> and Cyp2D6, were increased in the brain of aged mice, possibly enhancing the oxidative breakdown of anandamide.",
    "original_text": "However, enzymes contributing to oxidative metabolism of  anandamide , namely  cyclooxygenase-1  and Cyp2D6, were increased in the brain of aged mice, possibly enhancing the oxidative breakdown of anandamide.",
    "entity1": "anandamide",
    "entity2": "cyclooxygenase-1"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "However, enzymes contributing to oxidative metabolism of <protein> anandamide </protein>, namely cyclooxygenase-1 and <chemical> Cyp2D6 </chemical>, were increased in the brain of aged mice, possibly enhancing the oxidative breakdown of anandamide.",
    "original_text": "However, enzymes contributing to oxidative metabolism of  anandamide , namely cyclooxygenase-1 and  Cyp2D6 , were increased in the brain of aged mice, possibly enhancing the oxidative breakdown of anandamide.",
    "entity1": "anandamide",
    "entity2": "Cyp2D6"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "However, enzymes contributing to oxidative metabolism of anandamide, namely <protein> cyclooxygenase-1 </protein> and Cyp2D6, were increased in the brain of aged mice, possibly enhancing the oxidative breakdown of <chemical> anandamide </chemical>.",
    "original_text": "However, enzymes contributing to oxidative metabolism of anandamide, namely  cyclooxygenase-1  and Cyp2D6, were increased in the brain of aged mice, possibly enhancing the oxidative breakdown of  anandamide .",
    "entity1": "cyclooxygenase-1",
    "entity2": "anandamide"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "However, enzymes contributing to oxidative metabolism of anandamide, namely cyclooxygenase-1 and <protein> Cyp2D6 </protein>, were increased in the brain of aged mice, possibly enhancing the oxidative breakdown of <chemical> anandamide </chemical>.",
    "original_text": "However, enzymes contributing to oxidative metabolism of anandamide, namely cyclooxygenase-1 and  Cyp2D6 , were increased in the brain of aged mice, possibly enhancing the oxidative breakdown of  anandamide .",
    "entity1": "Cyp2D6",
    "entity2": "anandamide"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "<protein> 24(S)-hydroxycholesterol </protein> is actively eliminated from neuronal cells by <chemical> ABCA1 </chemical>.",
    "original_text": " 24(S)-hydroxycholesterol  is actively eliminated from neuronal cells by  ABCA1 .",
    "entity1": "24(S)-hydroxycholesterol",
    "entity2": "ABCA1"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "High <protein> cholesterol </protein> turnover catalyzed by <chemical> cholesterol 24-hydroxylase </chemical> is essential for neural functions, especially learning.",
    "original_text": "High  cholesterol  turnover catalyzed by  cholesterol 24-hydroxylase  is essential for neural functions, especially learning.",
    "entity1": "cholesterol",
    "entity2": "cholesterol 24-hydroxylase"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "To confirm the role of each transporter, we analyzed HEK293 cells stably expressing <protein> human ABCA1 </protein> or ABCG1; we clearly observed <chemical> 24-OHC </chemical> efflux in the presence of HDL, whereas efflux in the presence of apolipoprotein A-I was marginal.",
    "original_text": "To confirm the role of each transporter, we analyzed HEK293 cells stably expressing  human ABCA1  or ABCG1; we clearly observed  24-OHC  efflux in the presence of HDL, whereas efflux in the presence of apolipoprotein A-I was marginal.",
    "entity1": "human ABCA1",
    "entity2": "24-OHC"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "To confirm the role of each transporter, we analyzed HEK293 cells stably expressing human ABCA1 or <protein> ABCG1 </protein>; we clearly observed <chemical> 24-OHC </chemical> efflux in the presence of HDL, whereas efflux in the presence of apolipoprotein A-I was marginal.",
    "original_text": "To confirm the role of each transporter, we analyzed HEK293 cells stably expressing human ABCA1 or  ABCG1 ; we clearly observed  24-OHC  efflux in the presence of HDL, whereas efflux in the presence of apolipoprotein A-I was marginal.",
    "entity1": "ABCG1",
    "entity2": "24-OHC"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "These results suggest that <protein> ABCA1 </protein> actively eliminates <chemical> 24-OHC </chemical> in the presence of HDL as a lipid acceptor and protects neuronal cells.",
    "original_text": "These results suggest that  ABCA1  actively eliminates  24-OHC  in the presence of HDL as a lipid acceptor and protects neuronal cells.",
    "entity1": "ABCA1",
    "entity2": "24-OHC"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "In the presence of this inhibitor, the selective <protein> D3 </protein> agonist <chemical> PD 128,907 </chemical> reduced the ED50 for the D1 agonist SKF 38393 from 56 to 4\u00a0nM.",
    "original_text": "In the presence of this inhibitor, the selective  D3  agonist  PD 128,907  reduced the ED50 for the D1 agonist SKF 38393 from 56 to 4\u00a0nM.",
    "entity1": "D3",
    "entity2": "PD 128,907"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "In the presence of this inhibitor, the selective D3 agonist PD 128,907 reduced the ED50 for the <protein> D1 </protein> agonist <chemical> SKF 38393 </chemical> from 56 to 4\u00a0nM.",
    "original_text": "In the presence of this inhibitor, the selective D3 agonist PD 128,907 reduced the ED50 for the  D1  agonist  SKF 38393  from 56 to 4\u00a0nM.",
    "entity1": "D1",
    "entity2": "SKF 38393"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "This includes nonribosomal peptide synthetases (NRPS) and polyketide synthases (PKS) required for the formation of the <protein> benzopyranopyrrole </protein> core unit, as well as a suite of tailoring enzymes (e.g., four <chemical> halogenases </chemical>, an O-methyltransferase, and an N-glycosyltransferase) necessary for further modifications of the core structure.",
    "original_text": "This includes nonribosomal peptide synthetases (NRPS) and polyketide synthases (PKS) required for the formation of the  benzopyranopyrrole  core unit, as well as a suite of tailoring enzymes (e.g., four  halogenases , an O-methyltransferase, and an N-glycosyltransferase) necessary for further modifications of the core structure.",
    "entity1": "benzopyranopyrrole",
    "entity2": "halogenases"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "This includes nonribosomal peptide synthetases (NRPS) and polyketide synthases (PKS) required for the formation of the <protein> benzopyranopyrrole </protein> core unit, as well as a suite of tailoring enzymes (e.g., four halogenases, an <chemical> O-methyltransferase </chemical>, and an N-glycosyltransferase) necessary for further modifications of the core structure.",
    "original_text": "This includes nonribosomal peptide synthetases (NRPS) and polyketide synthases (PKS) required for the formation of the  benzopyranopyrrole  core unit, as well as a suite of tailoring enzymes (e.g., four halogenases, an  O-methyltransferase , and an N-glycosyltransferase) necessary for further modifications of the core structure.",
    "entity1": "benzopyranopyrrole",
    "entity2": "O-methyltransferase"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "This includes nonribosomal peptide synthetases (NRPS) and polyketide synthases (PKS) required for the formation of the <protein> benzopyranopyrrole </protein> core unit, as well as a suite of tailoring enzymes (e.g., four halogenases, an O-methyltransferase, and an <chemical> N-glycosyltransferase </chemical>) necessary for further modifications of the core structure.",
    "original_text": "This includes nonribosomal peptide synthetases (NRPS) and polyketide synthases (PKS) required for the formation of the  benzopyranopyrrole  core unit, as well as a suite of tailoring enzymes (e.g., four halogenases, an O-methyltransferase, and an  N-glycosyltransferase ) necessary for further modifications of the core structure.",
    "entity1": "benzopyranopyrrole",
    "entity2": "N-glycosyltransferase"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "To examine receptor mediation of estradiol effects, Ovx mice replaced for 2 days with either the <protein> ER\u03b1 </protein>-selective agonist <chemical> PPT </chemical> or the ER\u03b2-selective agonist DPN were compared to Sham mice, and mice lacking either ER\u03b1 (\u03b1ERKO) or ER\u03b2 (\u03b2ERKO) were compared to WT littermates.",
    "original_text": "To examine receptor mediation of estradiol effects, Ovx mice replaced for 2 days with either the  ER\u03b1 -selective agonist  PPT  or the ER\u03b2-selective agonist DPN were compared to Sham mice, and mice lacking either ER\u03b1 (\u03b1ERKO) or ER\u03b2 (\u03b2ERKO) were compared to WT littermates.",
    "entity1": "ER\u03b1",
    "entity2": "PPT"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "To examine receptor mediation of estradiol effects, Ovx mice replaced for 2 days with either the ER\u03b1-selective agonist PPT or the <protein> ER\u03b2 </protein>-selective agonist <chemical> DPN </chemical> were compared to Sham mice, and mice lacking either ER\u03b1 (\u03b1ERKO) or ER\u03b2 (\u03b2ERKO) were compared to WT littermates.",
    "original_text": "To examine receptor mediation of estradiol effects, Ovx mice replaced for 2 days with either the ER\u03b1-selective agonist PPT or the  ER\u03b2 -selective agonist  DPN  were compared to Sham mice, and mice lacking either ER\u03b1 (\u03b1ERKO) or ER\u03b2 (\u03b2ERKO) were compared to WT littermates.",
    "entity1": "ER\u03b2",
    "entity2": "DPN"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "The <protein> Intermediate-conductance Calcium-activated Potassium Channel KCa3.1 </protein> Regulates Vascular Smooth Muscle Cell Proliferation via Controlling <chemical> Calcium </chemical>-dependent Signaling.",
    "original_text": "The  Intermediate-conductance Calcium-activated Potassium Channel KCa3.1  Regulates Vascular Smooth Muscle Cell Proliferation via Controlling  Calcium -dependent Signaling.",
    "entity1": "Intermediate-conductance Calcium-activated Potassium Channel KCa3.1",
    "entity2": "Calcium"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "We have recently reported that a mono-hydroxylated metabolite of the synthetic <protein> aminoalkylindole </protein> cannabinoid JHW-073 (3) exhibits neutral antagonist activity at <chemical> CB1Rs </chemical> and thus may serve as a promising lead for the development of novel alcohol abuse therapies.",
    "original_text": "We have recently reported that a mono-hydroxylated metabolite of the synthetic  aminoalkylindole  cannabinoid JHW-073 (3) exhibits neutral antagonist activity at  CB1Rs  and thus may serve as a promising lead for the development of novel alcohol abuse therapies.",
    "entity1": "aminoalkylindole",
    "entity2": "CB1Rs"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "We have recently reported that a mono-hydroxylated metabolite of the synthetic aminoalkylindole cannabinoid <protein> JHW-073 </protein> (3) exhibits neutral antagonist activity at <chemical> CB1Rs </chemical> and thus may serve as a promising lead for the development of novel alcohol abuse therapies.",
    "original_text": "We have recently reported that a mono-hydroxylated metabolite of the synthetic aminoalkylindole cannabinoid  JHW-073  (3) exhibits neutral antagonist activity at  CB1Rs  and thus may serve as a promising lead for the development of novel alcohol abuse therapies.",
    "entity1": "JHW-073",
    "entity2": "CB1Rs"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "In the current study, we show that systematic modification of an <protein> aminoalkylindole </protein> scaffold identifies two new compounds with dual CB1R antagonist/<chemical> CB2R </chemical> agonist activity.",
    "original_text": "In the current study, we show that systematic modification of an  aminoalkylindole  scaffold identifies two new compounds with dual CB1R antagonist/ CB2R  agonist activity.",
    "entity1": "aminoalkylindole",
    "entity2": "CB2R"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "In the current study, we show that systematic modification of an <protein> aminoalkylindole </protein> scaffold identifies two new compounds with dual <chemical> CB1R </chemical> antagonist/CB2R agonist activity.",
    "original_text": "In the current study, we show that systematic modification of an  aminoalkylindole  scaffold identifies two new compounds with dual  CB1R  antagonist/CB2R agonist activity.",
    "entity1": "aminoalkylindole",
    "entity2": "CB1R"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "Collectively, these initial findings suggest that design and systematic modification of <protein> aminoalkylindoles </protein> such as 3 may lead to development of novel cannabinoid ligands with dual CB1R antagonist/<chemical> CB2R </chemical> agonist activity with potential for use as treatments of alcohol abuse.",
    "original_text": "Collectively, these initial findings suggest that design and systematic modification of  aminoalkylindoles  such as 3 may lead to development of novel cannabinoid ligands with dual CB1R antagonist/ CB2R  agonist activity with potential for use as treatments of alcohol abuse.",
    "entity1": "aminoalkylindoles",
    "entity2": "CB2R"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Collectively, these initial findings suggest that design and systematic modification of <protein> aminoalkylindoles </protein> such as 3 may lead to development of novel cannabinoid ligands with dual <chemical> CB1R </chemical> antagonist/CB2R agonist activity with potential for use as treatments of alcohol abuse.",
    "original_text": "Collectively, these initial findings suggest that design and systematic modification of  aminoalkylindoles  such as 3 may lead to development of novel cannabinoid ligands with dual  CB1R  antagonist/CB2R agonist activity with potential for use as treatments of alcohol abuse.",
    "entity1": "aminoalkylindoles",
    "entity2": "CB1R"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Protein levels of the <protein> glucose transporter </protein> (GLUT4) involved in <chemical> glucose </chemical> transport via these two pathways were also increased.",
    "original_text": "Protein levels of the  glucose transporter  (GLUT4) involved in  glucose  transport via these two pathways were also increased.",
    "entity1": "glucose transporter",
    "entity2": "glucose"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Protein levels of the glucose transporter (<protein> GLUT4 </protein>) involved in <chemical> glucose </chemical> transport via these two pathways were also increased.",
    "original_text": "Protein levels of the glucose transporter ( GLUT4 ) involved in  glucose  transport via these two pathways were also increased.",
    "entity1": "GLUT4",
    "entity2": "glucose"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Treatment with the <protein> ER </protein> antagonist <chemical> ICI 182,780 </chemical> abolishes the above actions of puerarin on osteoblast-derived cells.",
    "original_text": "Treatment with the  ER  antagonist  ICI 182,780  abolishes the above actions of puerarin on osteoblast-derived cells.",
    "entity1": "ER",
    "entity2": "ICI 182,780"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "The involvement of the various DA receptor subtypes in the motor effects of N/OFQ and NOP receptor antagonists was evaluated pharmacologically, using <protein> D1 </protein>/D5 (<chemical> SCH23390 </chemical>), D2/D3 (raclopride, amisulpride) and D3 (S33084) receptor antagonists, and by using D2 receptor knockout mice.",
    "original_text": "The involvement of the various DA receptor subtypes in the motor effects of N/OFQ and NOP receptor antagonists was evaluated pharmacologically, using  D1 /D5 ( SCH23390 ), D2/D3 (raclopride, amisulpride) and D3 (S33084) receptor antagonists, and by using D2 receptor knockout mice.",
    "entity1": "D1",
    "entity2": "SCH23390"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "The involvement of the various DA receptor subtypes in the motor effects of N/OFQ and NOP receptor antagonists was evaluated pharmacologically, using D1/<protein> D5 </protein> (<chemical> SCH23390 </chemical>), D2/D3 (raclopride, amisulpride) and D3 (S33084) receptor antagonists, and by using D2 receptor knockout mice.",
    "original_text": "The involvement of the various DA receptor subtypes in the motor effects of N/OFQ and NOP receptor antagonists was evaluated pharmacologically, using D1/ D5  ( SCH23390 ), D2/D3 (raclopride, amisulpride) and D3 (S33084) receptor antagonists, and by using D2 receptor knockout mice.",
    "entity1": "D5",
    "entity2": "SCH23390"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "The involvement of the various DA receptor subtypes in the motor effects of N/OFQ and NOP receptor antagonists was evaluated pharmacologically, using D1/D5 (SCH23390), <protein> D2 </protein>/D3 (<chemical> raclopride </chemical>, amisulpride) and D3 (S33084) receptor antagonists, and by using D2 receptor knockout mice.",
    "original_text": "The involvement of the various DA receptor subtypes in the motor effects of N/OFQ and NOP receptor antagonists was evaluated pharmacologically, using D1/D5 (SCH23390),  D2 /D3 ( raclopride , amisulpride) and D3 (S33084) receptor antagonists, and by using D2 receptor knockout mice.",
    "entity1": "D2",
    "entity2": "raclopride"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "The involvement of the various DA receptor subtypes in the motor effects of N/OFQ and NOP receptor antagonists was evaluated pharmacologically, using D1/D5 (SCH23390), D2/<protein> D3 </protein> (<chemical> raclopride </chemical>, amisulpride) and D3 (S33084) receptor antagonists, and by using D2 receptor knockout mice.",
    "original_text": "The involvement of the various DA receptor subtypes in the motor effects of N/OFQ and NOP receptor antagonists was evaluated pharmacologically, using D1/D5 (SCH23390), D2/ D3  ( raclopride , amisulpride) and D3 (S33084) receptor antagonists, and by using D2 receptor knockout mice.",
    "entity1": "D3",
    "entity2": "raclopride"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "The involvement of the various DA receptor subtypes in the motor effects of N/OFQ and NOP receptor antagonists was evaluated pharmacologically, using D1/D5 (SCH23390), <protein> D2 </protein>/D3 (raclopride, <chemical> amisulpride </chemical>) and D3 (S33084) receptor antagonists, and by using D2 receptor knockout mice.",
    "original_text": "The involvement of the various DA receptor subtypes in the motor effects of N/OFQ and NOP receptor antagonists was evaluated pharmacologically, using D1/D5 (SCH23390),  D2 /D3 (raclopride,  amisulpride ) and D3 (S33084) receptor antagonists, and by using D2 receptor knockout mice.",
    "entity1": "D2",
    "entity2": "amisulpride"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "The involvement of the various DA receptor subtypes in the motor effects of N/OFQ and NOP receptor antagonists was evaluated pharmacologically, using D1/D5 (SCH23390), D2/<protein> D3 </protein> (raclopride, <chemical> amisulpride </chemical>) and D3 (S33084) receptor antagonists, and by using D2 receptor knockout mice.",
    "original_text": "The involvement of the various DA receptor subtypes in the motor effects of N/OFQ and NOP receptor antagonists was evaluated pharmacologically, using D1/D5 (SCH23390), D2/ D3  (raclopride,  amisulpride ) and D3 (S33084) receptor antagonists, and by using D2 receptor knockout mice.",
    "entity1": "D3",
    "entity2": "amisulpride"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "The involvement of the various DA receptor subtypes in the motor effects of N/OFQ and NOP receptor antagonists was evaluated pharmacologically, using D1/D5 (SCH23390), D2/D3 (raclopride, amisulpride) and <protein> D3 </protein> (<chemical> S33084 </chemical>) receptor antagonists, and by using D2 receptor knockout mice.",
    "original_text": "The involvement of the various DA receptor subtypes in the motor effects of N/OFQ and NOP receptor antagonists was evaluated pharmacologically, using D1/D5 (SCH23390), D2/D3 (raclopride, amisulpride) and  D3  ( S33084 ) receptor antagonists, and by using D2 receptor knockout mice.",
    "entity1": "D3",
    "entity2": "S33084"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "Rats intoxicated with <protein> Cd </protein> for 30 days, significantly increased tissue malondialdehyde (MDA) levels and significantly decreased enzymatic antioxidants <chemical> superoxide dismutase </chemical>, glutathione peroxidase and catalase in the frontal cortex tissue.",
    "original_text": "Rats intoxicated with  Cd  for 30 days, significantly increased tissue malondialdehyde (MDA) levels and significantly decreased enzymatic antioxidants  superoxide dismutase , glutathione peroxidase and catalase in the frontal cortex tissue.",
    "entity1": "Cd",
    "entity2": "superoxide dismutase"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "Rats intoxicated with <protein> Cd </protein> for 30 days, significantly increased tissue malondialdehyde (MDA) levels and significantly decreased enzymatic antioxidants superoxide dismutase, <chemical> glutathione peroxidase </chemical> and catalase in the frontal cortex tissue.",
    "original_text": "Rats intoxicated with  Cd  for 30 days, significantly increased tissue malondialdehyde (MDA) levels and significantly decreased enzymatic antioxidants superoxide dismutase,  glutathione peroxidase  and catalase in the frontal cortex tissue.",
    "entity1": "Cd",
    "entity2": "glutathione peroxidase"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "Rats intoxicated with <protein> Cd </protein> for 30 days, significantly increased tissue malondialdehyde (MDA) levels and significantly decreased enzymatic antioxidants superoxide dismutase, glutathione peroxidase and <chemical> catalase </chemical> in the frontal cortex tissue.",
    "original_text": "Rats intoxicated with  Cd  for 30 days, significantly increased tissue malondialdehyde (MDA) levels and significantly decreased enzymatic antioxidants superoxide dismutase, glutathione peroxidase and  catalase  in the frontal cortex tissue.",
    "entity1": "Cd",
    "entity2": "catalase"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Drug-drug interactions are dependent on statins' pharmacokinetic profile: <protein> simvastatin </protein>, lovastatin and atorvastatin are metabolized through <chemical> cytochrome P450 (CYP) 3A </chemical>, while the metabolism of the other statins is independent of this CYP.",
    "original_text": "Drug-drug interactions are dependent on statins' pharmacokinetic profile:  simvastatin , lovastatin and atorvastatin are metabolized through  cytochrome P450 (CYP) 3A , while the metabolism of the other statins is independent of this CYP.",
    "entity1": "simvastatin",
    "entity2": "cytochrome P450 (CYP) 3A"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Drug-drug interactions are dependent on statins' pharmacokinetic profile: simvastatin, <protein> lovastatin </protein> and atorvastatin are metabolized through <chemical> cytochrome P450 (CYP) 3A </chemical>, while the metabolism of the other statins is independent of this CYP.",
    "original_text": "Drug-drug interactions are dependent on statins' pharmacokinetic profile: simvastatin,  lovastatin  and atorvastatin are metabolized through  cytochrome P450 (CYP) 3A , while the metabolism of the other statins is independent of this CYP.",
    "entity1": "lovastatin",
    "entity2": "cytochrome P450 (CYP) 3A"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Drug-drug interactions are dependent on statins' pharmacokinetic profile: simvastatin, lovastatin and <protein> atorvastatin </protein> are metabolized through <chemical> cytochrome P450 (CYP) 3A </chemical>, while the metabolism of the other statins is independent of this CYP.",
    "original_text": "Drug-drug interactions are dependent on statins' pharmacokinetic profile: simvastatin, lovastatin and  atorvastatin  are metabolized through  cytochrome P450 (CYP) 3A , while the metabolism of the other statins is independent of this CYP.",
    "entity1": "atorvastatin",
    "entity2": "cytochrome P450 (CYP) 3A"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "<protein> Simvastatin </protein> and lovastatin metabolized through <chemical> CYP3A </chemical> have the highest potency for drug-drug interaction with potent CYP3A inhibitors such as ritonavir- or cobicistat-boosted HIV-PI or the hepatitis C virus (HCV) PI, telaprevir or boceprevir, and therefore their coadministration is contraindicated.",
    "original_text": " Simvastatin  and lovastatin metabolized through  CYP3A  have the highest potency for drug-drug interaction with potent CYP3A inhibitors such as ritonavir- or cobicistat-boosted HIV-PI or the hepatitis C virus (HCV) PI, telaprevir or boceprevir, and therefore their coadministration is contraindicated.",
    "entity1": "Simvastatin",
    "entity2": "CYP3A"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Simvastatin and <protein> lovastatin </protein> metabolized through <chemical> CYP3A </chemical> have the highest potency for drug-drug interaction with potent CYP3A inhibitors such as ritonavir- or cobicistat-boosted HIV-PI or the hepatitis C virus (HCV) PI, telaprevir or boceprevir, and therefore their coadministration is contraindicated.",
    "original_text": "Simvastatin and  lovastatin  metabolized through  CYP3A  have the highest potency for drug-drug interaction with potent CYP3A inhibitors such as ritonavir- or cobicistat-boosted HIV-PI or the hepatitis C virus (HCV) PI, telaprevir or boceprevir, and therefore their coadministration is contraindicated.",
    "entity1": "lovastatin",
    "entity2": "CYP3A"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "<protein> Atorvastatin </protein> is also a <chemical> CYP3A </chemical> substrate, but less potent drug-drug interactions have been reported with CYP3A inhibitors.",
    "original_text": " Atorvastatin  is also a  CYP3A  substrate, but less potent drug-drug interactions have been reported with CYP3A inhibitors.",
    "entity1": "Atorvastatin",
    "entity2": "CYP3A"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "Limitation of SRF was produced by the anticonvulsant BDZs (diazepam, clonazepam, nitrazepam and lorazepam) at low to mid nanomolar concentrations, by a convulsant BDZ which does not bind to high affinity BDZ receptors (Ro 5-4864) at high nanomolar concentrations and by a <protein> BDZ receptor </protein> weak partial agonist (<chemical> Ro 15-1788 </chemical>) at micromolar concentrations.",
    "original_text": "Limitation of SRF was produced by the anticonvulsant BDZs (diazepam, clonazepam, nitrazepam and lorazepam) at low to mid nanomolar concentrations, by a convulsant BDZ which does not bind to high affinity BDZ receptors (Ro 5-4864) at high nanomolar concentrations and by a  BDZ receptor  weak partial agonist ( Ro 15-1788 ) at micromolar concentrations.",
    "entity1": "BDZ receptor",
    "entity2": "Ro 15-1788"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "The limitation of SRF by diazepam was not prevented by inverse or partial agonists at the <protein> BDZ receptor </protein>, including <chemical> Ro 15-1788 </chemical> and the beta CCs.",
    "original_text": "The limitation of SRF by diazepam was not prevented by inverse or partial agonists at the  BDZ receptor , including  Ro 15-1788  and the beta CCs.",
    "entity1": "BDZ receptor",
    "entity2": "Ro 15-1788"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "The limitation of SRF by diazepam was not prevented by inverse or partial agonists at the <protein> BDZ receptor </protein>, including Ro 15-1788 and the <chemical> beta CCs </chemical>.",
    "original_text": "The limitation of SRF by diazepam was not prevented by inverse or partial agonists at the  BDZ receptor , including Ro 15-1788 and the  beta CCs .",
    "entity1": "BDZ receptor",
    "entity2": "beta CCs"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "The effect of <protein> histamine-H1 receptor </protein> antagonism with <chemical> terfenadine </chemical> on concentration-related AMP-induced bronchoconstriction in asthma.",
    "original_text": "The effect of  histamine-H1 receptor  antagonism with  terfenadine  on concentration-related AMP-induced bronchoconstriction in asthma.",
    "entity1": "histamine-H1 receptor",
    "entity2": "terfenadine"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "To study the mechanism underlying this phenomenon, the effects of the nonselective <protein> beta-adrenoceptor </protein> antagonists <chemical> propranolol </chemical> [no intrinsic sympathomimetic activity (ISA)], alprenolol (weak ISA) and mepindolol (strong ISA) on lymphocyte beta 2-adrenoceptor density--assessed by (+/-)-[125I]-iodocyanopindolol (ICYP) binding--and plasma renin activity (PRA) were investigated in male healthy volunteers aged 23-35 years.",
    "original_text": "To study the mechanism underlying this phenomenon, the effects of the nonselective  beta-adrenoceptor  antagonists  propranolol  [no intrinsic sympathomimetic activity (ISA)], alprenolol (weak ISA) and mepindolol (strong ISA) on lymphocyte beta 2-adrenoceptor density--assessed by (+/-)-[125I]-iodocyanopindolol (ICYP) binding--and plasma renin activity (PRA) were investigated in male healthy volunteers aged 23-35 years.",
    "entity1": "beta-adrenoceptor",
    "entity2": "propranolol"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "To study the mechanism underlying this phenomenon, the effects of the nonselective <protein> beta-adrenoceptor </protein> antagonists propranolol [no intrinsic sympathomimetic activity (ISA)], <chemical> alprenolol </chemical> (weak ISA) and mepindolol (strong ISA) on lymphocyte beta 2-adrenoceptor density--assessed by (+/-)-[125I]-iodocyanopindolol (ICYP) binding--and plasma renin activity (PRA) were investigated in male healthy volunteers aged 23-35 years.",
    "original_text": "To study the mechanism underlying this phenomenon, the effects of the nonselective  beta-adrenoceptor  antagonists propranolol [no intrinsic sympathomimetic activity (ISA)],  alprenolol  (weak ISA) and mepindolol (strong ISA) on lymphocyte beta 2-adrenoceptor density--assessed by (+/-)-[125I]-iodocyanopindolol (ICYP) binding--and plasma renin activity (PRA) were investigated in male healthy volunteers aged 23-35 years.",
    "entity1": "beta-adrenoceptor",
    "entity2": "alprenolol"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "To study the mechanism underlying this phenomenon, the effects of the nonselective <protein> beta-adrenoceptor </protein> antagonists propranolol [no intrinsic sympathomimetic activity (ISA)], alprenolol (weak ISA) and <chemical> mepindolol </chemical> (strong ISA) on lymphocyte beta 2-adrenoceptor density--assessed by (+/-)-[125I]-iodocyanopindolol (ICYP) binding--and plasma renin activity (PRA) were investigated in male healthy volunteers aged 23-35 years.",
    "original_text": "To study the mechanism underlying this phenomenon, the effects of the nonselective  beta-adrenoceptor  antagonists propranolol [no intrinsic sympathomimetic activity (ISA)], alprenolol (weak ISA) and  mepindolol  (strong ISA) on lymphocyte beta 2-adrenoceptor density--assessed by (+/-)-[125I]-iodocyanopindolol (ICYP) binding--and plasma renin activity (PRA) were investigated in male healthy volunteers aged 23-35 years.",
    "entity1": "beta-adrenoceptor",
    "entity2": "mepindolol"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Inhibition of <protein> 5-lipoxygenase </protein> pathway of <chemical> arachidonic acid </chemical> metabolism in human neutrophils by sulfasalazine and 5-aminosalicylic acid.",
    "original_text": "Inhibition of  5-lipoxygenase  pathway of  arachidonic acid  metabolism in human neutrophils by sulfasalazine and 5-aminosalicylic acid.",
    "entity1": "5-lipoxygenase",
    "entity2": "arachidonic acid"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Interference with <protein> lipoxygenase </protein> enzymes, rather than a steroid-like inhibition of <chemical> arachidonic acid </chemical> release from intracellular phospholipids, seems to be the mode of action.",
    "original_text": "Interference with  lipoxygenase  enzymes, rather than a steroid-like inhibition of  arachidonic acid  release from intracellular phospholipids, seems to be the mode of action.",
    "entity1": "lipoxygenase",
    "entity2": "arachidonic acid"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "<protein> Bevantolol </protein>: a <chemical> beta-1 adrenoceptor </chemical> antagonist with unique additional actions.",
    "original_text": " Bevantolol : a  beta-1 adrenoceptor  antagonist with unique additional actions.",
    "entity1": "Bevantolol",
    "entity2": "beta-1 adrenoceptor"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "UNLABELLED: <protein> Bevantolol </protein> is a <chemical> beta-1 adrenoceptor </chemical> antagonist that has been shown to be as effective as other beta blockers for the treatment of angina pectoris and hypertension.",
    "original_text": "UNLABELLED:  Bevantolol  is a  beta-1 adrenoceptor  antagonist that has been shown to be as effective as other beta blockers for the treatment of angina pectoris and hypertension.",
    "entity1": "Bevantolol",
    "entity2": "beta-1 adrenoceptor"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "It is suggested that all the additional actions of <protein> bevantolol </protein> can be attributed to a partial agonist action on <chemical> alpha-adrenoceptors </chemical>.",
    "original_text": "It is suggested that all the additional actions of  bevantolol  can be attributed to a partial agonist action on  alpha-adrenoceptors .",
    "entity1": "bevantolol",
    "entity2": "alpha-adrenoceptors"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Similar concentrations also inhibited the formation of leukotriene C4 (LTC4) by <protein> LTC synthetase </protein>, a detergent-solubilized cell free particulate enzyme from RBL cells which is capable of coupling <chemical> LTA4 </chemical> to glutathione.",
    "original_text": "Similar concentrations also inhibited the formation of leukotriene C4 (LTC4) by  LTC synthetase , a detergent-solubilized cell free particulate enzyme from RBL cells which is capable of coupling  LTA4  to glutathione.",
    "entity1": "LTC synthetase",
    "entity2": "LTA4"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "The EC50 for inhibition of the <protein> leukotriene C synthetase </protein> of RBL cells was directly proportional to the <chemical> LTA4 </chemical> concentration in the incubations, ranging from 1.5 mM at 10 microM LTA4 to over 40 mM at 500 microM LTA4.",
    "original_text": "The EC50 for inhibition of the  leukotriene C synthetase  of RBL cells was directly proportional to the  LTA4  concentration in the incubations, ranging from 1.5 mM at 10 microM LTA4 to over 40 mM at 500 microM LTA4.",
    "entity1": "leukotriene C synthetase",
    "entity2": "LTA4"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "These results are consistent with the interpretation that both piriprost and diethylcarbamazine inhibit leukotriene formation but that they act on sequential steps in the biosynthetic pathway in such a manner as to synergistically interfere with the availability or utilization of <protein> LTA4 </protein> in the <chemical> leukotriene C synthetase </chemical> reaction.",
    "original_text": "These results are consistent with the interpretation that both piriprost and diethylcarbamazine inhibit leukotriene formation but that they act on sequential steps in the biosynthetic pathway in such a manner as to synergistically interfere with the availability or utilization of  LTA4  in the  leukotriene C synthetase  reaction.",
    "entity1": "LTA4",
    "entity2": "leukotriene C synthetase"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "The test procedure was verified with respect to intestinal <protein> lactose </protein> hydrolysis by demonstrating a linear relationship between lactose/lactulose excretion and log jejunal mucosal <chemical> lactase </chemical> activity by in vitro assay (R2 = 0.95) in a further group of subjects.",
    "original_text": "The test procedure was verified with respect to intestinal  lactose  hydrolysis by demonstrating a linear relationship between lactose/lactulose excretion and log jejunal mucosal  lactase  activity by in vitro assay (R2 = 0.95) in a further group of subjects.",
    "entity1": "lactose",
    "entity2": "lactase"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "The test procedure was verified with respect to intestinal lactose hydrolysis by demonstrating a linear relationship between <protein> lactose </protein>/lactulose excretion and log jejunal mucosal <chemical> lactase </chemical> activity by in vitro assay (R2 = 0.95) in a further group of subjects.",
    "original_text": "The test procedure was verified with respect to intestinal lactose hydrolysis by demonstrating a linear relationship between  lactose /lactulose excretion and log jejunal mucosal  lactase  activity by in vitro assay (R2 = 0.95) in a further group of subjects.",
    "entity1": "lactose",
    "entity2": "lactase"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "The test procedure was verified with respect to intestinal lactose hydrolysis by demonstrating a linear relationship between lactose/<protein> lactulose </protein> excretion and log jejunal mucosal <chemical> lactase </chemical> activity by in vitro assay (R2 = 0.95) in a further group of subjects.",
    "original_text": "The test procedure was verified with respect to intestinal lactose hydrolysis by demonstrating a linear relationship between lactose/ lactulose  excretion and log jejunal mucosal  lactase  activity by in vitro assay (R2 = 0.95) in a further group of subjects.",
    "entity1": "lactulose",
    "entity2": "lactase"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Differential <protein> lactose </protein>/lactulose/L-rhamnose absorption provides a non-invasive and sensitive index of small intestinal integrity of value for the interpretation of prolonged or otherwise complicated enteritis and the distinction of primary secondary intestinal <chemical> lactase </chemical> deficiency.",
    "original_text": "Differential  lactose /lactulose/L-rhamnose absorption provides a non-invasive and sensitive index of small intestinal integrity of value for the interpretation of prolonged or otherwise complicated enteritis and the distinction of primary secondary intestinal  lactase  deficiency.",
    "entity1": "lactose",
    "entity2": "lactase"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Differential lactose/<protein> lactulose </protein>/L-rhamnose absorption provides a non-invasive and sensitive index of small intestinal integrity of value for the interpretation of prolonged or otherwise complicated enteritis and the distinction of primary secondary intestinal <chemical> lactase </chemical> deficiency.",
    "original_text": "Differential lactose/ lactulose /L-rhamnose absorption provides a non-invasive and sensitive index of small intestinal integrity of value for the interpretation of prolonged or otherwise complicated enteritis and the distinction of primary secondary intestinal  lactase  deficiency.",
    "entity1": "lactulose",
    "entity2": "lactase"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Differential lactose/lactulose/<protein> L-rhamnose </protein> absorption provides a non-invasive and sensitive index of small intestinal integrity of value for the interpretation of prolonged or otherwise complicated enteritis and the distinction of primary secondary intestinal <chemical> lactase </chemical> deficiency.",
    "original_text": "Differential lactose/lactulose/ L-rhamnose  absorption provides a non-invasive and sensitive index of small intestinal integrity of value for the interpretation of prolonged or otherwise complicated enteritis and the distinction of primary secondary intestinal  lactase  deficiency.",
    "entity1": "L-rhamnose",
    "entity2": "lactase"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "<protein> Xanthines </protein> are classical antagonists for <chemical> adenosine receptors </chemical> for many of their pharmacological actions may be due to blockade of adenosine receptors.",
    "original_text": " Xanthines  are classical antagonists for  adenosine receptors  for many of their pharmacological actions may be due to blockade of adenosine receptors.",
    "entity1": "Xanthines",
    "entity2": "adenosine receptors"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Gossypol and its isomers were non-competitive inhibitors of human and hamster LDH-X with respect to the coenzyme NADH, competitive inhibitors of human LDH-X and noncompetitive-competitive inhibitors of <protein> hamster LDH-X </protein> with respect to the substrate <chemical> alpha-ketobutyrate </chemical>.",
    "original_text": "Gossypol and its isomers were non-competitive inhibitors of human and hamster LDH-X with respect to the coenzyme NADH, competitive inhibitors of human LDH-X and noncompetitive-competitive inhibitors of  hamster LDH-X  with respect to the substrate  alpha-ketobutyrate .",
    "entity1": "hamster LDH-X",
    "entity2": "alpha-ketobutyrate"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Chromatographic analysis of the metabolism of <protein> 14C-labeled arachidonic acid </protein> in this system revealed that PB-dependent inactivation of <chemical> PHS </chemical> is markedly increased in the presence of 100 microM H2O2.",
    "original_text": "Chromatographic analysis of the metabolism of  14C-labeled arachidonic acid  in this system revealed that PB-dependent inactivation of  PHS  is markedly increased in the presence of 100 microM H2O2.",
    "entity1": "14C-labeled arachidonic acid",
    "entity2": "PHS"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Positive staining of mitochondria was achieved in the presence of the <protein> MAO </protein> substrate, <chemical> tryptamine </chemical>.",
    "original_text": "Positive staining of mitochondria was achieved in the presence of the  MAO  substrate,  tryptamine .",
    "entity1": "MAO",
    "entity2": "tryptamine"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Staining around the edges of the brown fat cells was observed with the <protein> SSAO </protein> substrates, <chemical> tyramine </chemical> and benzylamine.",
    "original_text": "Staining around the edges of the brown fat cells was observed with the  SSAO  substrates,  tyramine  and benzylamine.",
    "entity1": "SSAO",
    "entity2": "tyramine"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Staining around the edges of the brown fat cells was observed with the <protein> SSAO </protein> substrates, tyramine and <chemical> benzylamine </chemical>.",
    "original_text": "Staining around the edges of the brown fat cells was observed with the  SSAO  substrates, tyramine and  benzylamine .",
    "entity1": "SSAO",
    "entity2": "benzylamine"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "From these results, it is proposed that <protein> tyrosine hydroxylase </protein> activity determines p-HPAA concentrations by regulating <chemical> p-tyrosine </chemical> availability.",
    "original_text": "From these results, it is proposed that  tyrosine hydroxylase  activity determines p-HPAA concentrations by regulating  p-tyrosine  availability.",
    "entity1": "tyrosine hydroxylase",
    "entity2": "p-tyrosine"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "The binding of FHA-HIS was inhibited on 35-79% of the platelets by the <protein> histamine H1 receptor </protein> antagonists <chemical> diphenhydramine </chemical> and clemastine.",
    "original_text": "The binding of FHA-HIS was inhibited on 35-79% of the platelets by the  histamine H1 receptor  antagonists  diphenhydramine  and clemastine.",
    "entity1": "histamine H1 receptor",
    "entity2": "diphenhydramine"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "The binding of FHA-HIS was inhibited on 35-79% of the platelets by the <protein> histamine H1 receptor </protein> antagonists diphenhydramine and <chemical> clemastine </chemical>.",
    "original_text": "The binding of FHA-HIS was inhibited on 35-79% of the platelets by the  histamine H1 receptor  antagonists diphenhydramine and  clemastine .",
    "entity1": "histamine H1 receptor",
    "entity2": "clemastine"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "The <protein> histamine H2 receptor </protein> antagonist <chemical> cimetidine </chemical> blocked the FHA-HIS binding on 14-37% of the platelets.",
    "original_text": "The  histamine H2 receptor  antagonist  cimetidine  blocked the FHA-HIS binding on 14-37% of the platelets.",
    "entity1": "histamine H2 receptor",
    "entity2": "cimetidine"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "<protein> Alanine:glyoxylate aminotransferase </protein> (AGT) in the liver catalyzes most of the <chemical> glyoxylate </chemical> transamination in mammalian tissues (E. V. Rowsell, K. Snell, J. A. Carnie, and K. V. Rowsell (1972) Biochem. J. 127, 155-165).",
    "original_text": " Alanine:glyoxylate aminotransferase  (AGT) in the liver catalyzes most of the  glyoxylate  transamination in mammalian tissues (E. V. Rowsell, K. Snell, J. A. Carnie, and K. V. Rowsell (1972) Biochem. J. 127, 155-165).",
    "entity1": "Alanine:glyoxylate aminotransferase",
    "entity2": "glyoxylate"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Alanine:glyoxylate aminotransferase (<protein> AGT </protein>) in the liver catalyzes most of the <chemical> glyoxylate </chemical> transamination in mammalian tissues (E. V. Rowsell, K. Snell, J. A. Carnie, and K. V. Rowsell (1972) Biochem. J. 127, 155-165).",
    "original_text": "Alanine:glyoxylate aminotransferase ( AGT ) in the liver catalyzes most of the  glyoxylate  transamination in mammalian tissues (E. V. Rowsell, K. Snell, J. A. Carnie, and K. V. Rowsell (1972) Biochem. J. 127, 155-165).",
    "entity1": "AGT",
    "entity2": "glyoxylate"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "The holo activity of combined peroxisomal and mitochondrial <protein> AGT 1 </protein> with a low Km for <chemical> L-alanine </chemical> rapidly decreased after a lag time of about 2 days during feeding of the vitamin B6-deficient diet (by 50% in 5 days, by 86% in 14 days).",
    "original_text": "The holo activity of combined peroxisomal and mitochondrial  AGT 1  with a low Km for  L-alanine  rapidly decreased after a lag time of about 2 days during feeding of the vitamin B6-deficient diet (by 50% in 5 days, by 86% in 14 days).",
    "entity1": "AGT 1",
    "entity2": "L-alanine"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "The holo activity of AGT 2 with a high Km for <protein> L-alanine </protein> decreased more slowly than <chemical> AGT 1 </chemical> (by 33% in 14 days, by 60% in 28 days).",
    "original_text": "The holo activity of AGT 2 with a high Km for  L-alanine  decreased more slowly than  AGT 1  (by 33% in 14 days, by 60% in 28 days).",
    "entity1": "L-alanine",
    "entity2": "AGT 1"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "The holo activity of <protein> AGT 2 </protein> with a high Km for <chemical> L-alanine </chemical> decreased more slowly than AGT 1 (by 33% in 14 days, by 60% in 28 days).",
    "original_text": "The holo activity of  AGT 2  with a high Km for  L-alanine  decreased more slowly than AGT 1 (by 33% in 14 days, by 60% in 28 days).",
    "entity1": "AGT 2",
    "entity2": "L-alanine"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Hence, triclosan has the ability to inhibit both the <protein> cyclo-oxygenase </protein> and lipoxygenase pathways of <chemical> arachidonic acid </chemical> metabolism with similar efficacy.",
    "original_text": "Hence, triclosan has the ability to inhibit both the  cyclo-oxygenase  and lipoxygenase pathways of  arachidonic acid  metabolism with similar efficacy.",
    "entity1": "cyclo-oxygenase",
    "entity2": "arachidonic acid"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Hence, triclosan has the ability to inhibit both the cyclo-oxygenase and <protein> lipoxygenase </protein> pathways of <chemical> arachidonic acid </chemical> metabolism with similar efficacy.",
    "original_text": "Hence, triclosan has the ability to inhibit both the cyclo-oxygenase and  lipoxygenase  pathways of  arachidonic acid  metabolism with similar efficacy.",
    "entity1": "lipoxygenase",
    "entity2": "arachidonic acid"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Inhibition of cyclic AMP production by ergovaline was blocked by the <protein> dopamine receptor </protein> antagonist, <chemical> (-)-sulpiride </chemical> (IC50, 300 +/- 150 nM).",
    "original_text": "Inhibition of cyclic AMP production by ergovaline was blocked by the  dopamine receptor  antagonist,  (-)-sulpiride  (IC50, 300 +/- 150 nM).",
    "entity1": "dopamine receptor",
    "entity2": "(-)-sulpiride"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Incubation of rat aortic membranes with the irreversible <protein> alpha 1B-adrenoceptor </protein> antagonist, <chemical> chloroethylclonidine </chemical> (CEC: 10 microM) did not change the KD of [3H]-prazosin binding in comparison to untreated membranes, but reduced by 88% the total number of binding sites (Bmax).",
    "original_text": "Incubation of rat aortic membranes with the irreversible  alpha 1B-adrenoceptor  antagonist,  chloroethylclonidine  (CEC: 10 microM) did not change the KD of [3H]-prazosin binding in comparison to untreated membranes, but reduced by 88% the total number of binding sites (Bmax).",
    "entity1": "alpha 1B-adrenoceptor",
    "entity2": "chloroethylclonidine"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Incubation of rat aortic membranes with the irreversible <protein> alpha 1B-adrenoceptor </protein> antagonist, chloroethylclonidine (<chemical> CEC </chemical>: 10 microM) did not change the KD of [3H]-prazosin binding in comparison to untreated membranes, but reduced by 88% the total number of binding sites (Bmax).",
    "original_text": "Incubation of rat aortic membranes with the irreversible  alpha 1B-adrenoceptor  antagonist, chloroethylclonidine ( CEC : 10 microM) did not change the KD of [3H]-prazosin binding in comparison to untreated membranes, but reduced by 88% the total number of binding sites (Bmax).",
    "entity1": "alpha 1B-adrenoceptor",
    "entity2": "CEC"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Intraperitoneal administration of <protein> (+/- )propranolol HCl </protein> (2.5-10 mg/kg), a nonselective <chemical> beta-adrenoceptor </chemical> antagonist, dose dependently attenuated the desipramine-induced enhancement of aggressive behavior without significantly affecting the basal aggressive responses.",
    "original_text": "Intraperitoneal administration of  (+/- )propranolol HCl  (2.5-10 mg/kg), a nonselective  beta-adrenoceptor  antagonist, dose dependently attenuated the desipramine-induced enhancement of aggressive behavior without significantly affecting the basal aggressive responses.",
    "entity1": "(+/- )propranolol HCl",
    "entity2": "beta-adrenoceptor"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "<protein> ICI118,551 HCl </protein> (1.25-5 mg/kg, IP), a selective <chemical> beta 2-adrenoceptor </chemical> antagonist, also blocked the desipramine-induced enhancement of aggressive behavior in a dose-dependent manner, whereas metoprolol tartrate (5-20 mg/kg, IP), a selective beta 1-adrenoceptor antagonist, did not affect it.",
    "original_text": " ICI118,551 HCl  (1.25-5 mg/kg, IP), a selective  beta 2-adrenoceptor  antagonist, also blocked the desipramine-induced enhancement of aggressive behavior in a dose-dependent manner, whereas metoprolol tartrate (5-20 mg/kg, IP), a selective beta 1-adrenoceptor antagonist, did not affect it.",
    "entity1": "ICI118,551 HCl",
    "entity2": "beta 2-adrenoceptor"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "ICI118,551 HCl (1.25-5 mg/kg, IP), a selective beta 2-adrenoceptor antagonist, also blocked the desipramine-induced enhancement of aggressive behavior in a dose-dependent manner, whereas <protein> metoprolol tartrate </protein> (5-20 mg/kg, IP), a selective <chemical> beta 1-adrenoceptor </chemical> antagonist, did not affect it.",
    "original_text": "ICI118,551 HCl (1.25-5 mg/kg, IP), a selective beta 2-adrenoceptor antagonist, also blocked the desipramine-induced enhancement of aggressive behavior in a dose-dependent manner, whereas  metoprolol tartrate  (5-20 mg/kg, IP), a selective  beta 1-adrenoceptor  antagonist, did not affect it.",
    "entity1": "metoprolol tartrate",
    "entity2": "beta 1-adrenoceptor"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "Moreover, <protein> clenbuterol HCl </protein> (0.1-0.5 mg/kg, IP), a lipophilic <chemical> beta 2-adrenoceptor </chemical> agonist, significantly increased the duration of basal aggressive behavior.",
    "original_text": "Moreover,  clenbuterol HCl  (0.1-0.5 mg/kg, IP), a lipophilic  beta 2-adrenoceptor  agonist, significantly increased the duration of basal aggressive behavior.",
    "entity1": "clenbuterol HCl",
    "entity2": "beta 2-adrenoceptor"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Taken together with our previous finding that the desipramine-induced enhancement of aggressive behavior can be blocked by <protein> yohimbine </protein>, an <chemical> alpha 2-adrenoceptor </chemical> antagonist, the present results indicate that not only alpha 2- but also beta 2-adrenoceptor stimulation plays important roles in modulation of aggressive behavior in long-term isolated mice.",
    "original_text": "Taken together with our previous finding that the desipramine-induced enhancement of aggressive behavior can be blocked by  yohimbine , an  alpha 2-adrenoceptor  antagonist, the present results indicate that not only alpha 2- but also beta 2-adrenoceptor stimulation plays important roles in modulation of aggressive behavior in long-term isolated mice.",
    "entity1": "yohimbine",
    "entity2": "alpha 2-adrenoceptor"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "In beta-escin-skinned strips of chloroethylclonidine-pretreated smooth muscle, the enhancement of Ca2+ contraction produced by norepinephrine was significantly decreased, whereas the amplitude was the same as that produced by methoxamine or clonidine; this enhancement was inhibited by the selective <protein> alpha 1A-adrenoceptor </protein> antagonist <chemical> WB 4101 </chemical> (100 nM).",
    "original_text": "In beta-escin-skinned strips of chloroethylclonidine-pretreated smooth muscle, the enhancement of Ca2+ contraction produced by norepinephrine was significantly decreased, whereas the amplitude was the same as that produced by methoxamine or clonidine; this enhancement was inhibited by the selective  alpha 1A-adrenoceptor  antagonist  WB 4101  (100 nM).",
    "entity1": "alpha 1A-adrenoceptor",
    "entity2": "WB 4101"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "The drug had a potent cytotoxic effect on RIN cells expressing <protein> GLUT2 </protein>, but had no effect on cells lacking GLUT2 expression, as indicated by histological analysis and measurement of the blood <chemical> glucose </chemical> levels of treated animals.",
    "original_text": "The drug had a potent cytotoxic effect on RIN cells expressing  GLUT2 , but had no effect on cells lacking GLUT2 expression, as indicated by histological analysis and measurement of the blood  glucose  levels of treated animals.",
    "entity1": "GLUT2",
    "entity2": "glucose"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Consistent with these data, only <protein> GLUT2 </protein>-expressing RIN or AtT-20ins cells transported <chemical> STZ </chemical> efficiently.",
    "original_text": "Consistent with these data, only  GLUT2 -expressing RIN or AtT-20ins cells transported  STZ  efficiently.",
    "entity1": "GLUT2",
    "entity2": "STZ"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "We conclude that expression of <protein> GLUT2 </protein> is required for efficient killing of neuroendocrine cells by <chemical> STZ </chemical>, and this effect is related to specific recognition of the drug as a transported substrate by GLUT2 but not GLUT1.",
    "original_text": "We conclude that expression of  GLUT2  is required for efficient killing of neuroendocrine cells by  STZ , and this effect is related to specific recognition of the drug as a transported substrate by GLUT2 but not GLUT1.",
    "entity1": "GLUT2",
    "entity2": "STZ"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "We conclude that expression of GLUT2 is required for efficient killing of neuroendocrine cells by <protein> STZ </protein>, and this effect is related to specific recognition of the drug as a transported substrate by <chemical> GLUT2 </chemical> but not GLUT1.",
    "original_text": "We conclude that expression of GLUT2 is required for efficient killing of neuroendocrine cells by  STZ , and this effect is related to specific recognition of the drug as a transported substrate by  GLUT2  but not GLUT1.",
    "entity1": "STZ",
    "entity2": "GLUT2"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "The enhancement of the depolarizing afterpotential by histamine was mimicked by the <protein> histamine H1-receptor </protein> agonist <chemical> 2-thiazolylethylamine </chemical> and was reduced or blocked by the H1-receptor antagonist promethazine, but was not blocked or reduced in the presence of the histamine H2-receptor antagonist, cimetidine.",
    "original_text": "The enhancement of the depolarizing afterpotential by histamine was mimicked by the  histamine H1-receptor  agonist  2-thiazolylethylamine  and was reduced or blocked by the H1-receptor antagonist promethazine, but was not blocked or reduced in the presence of the histamine H2-receptor antagonist, cimetidine.",
    "entity1": "histamine H1-receptor",
    "entity2": "2-thiazolylethylamine"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "The enhancement of the depolarizing afterpotential by histamine was mimicked by the histamine H1-receptor agonist 2-thiazolylethylamine and was reduced or blocked by the <protein> H1-receptor </protein> antagonist <chemical> promethazine </chemical>, but was not blocked or reduced in the presence of the histamine H2-receptor antagonist, cimetidine.",
    "original_text": "The enhancement of the depolarizing afterpotential by histamine was mimicked by the histamine H1-receptor agonist 2-thiazolylethylamine and was reduced or blocked by the  H1-receptor  antagonist  promethazine , but was not blocked or reduced in the presence of the histamine H2-receptor antagonist, cimetidine.",
    "entity1": "H1-receptor",
    "entity2": "promethazine"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "The enhancement of the depolarizing afterpotential by histamine was mimicked by the histamine H1-receptor agonist 2-thiazolylethylamine and was reduced or blocked by the H1-receptor antagonist promethazine, but was not blocked or reduced in the presence of the <protein> histamine H2-receptor </protein> antagonist, <chemical> cimetidine </chemical>.",
    "original_text": "The enhancement of the depolarizing afterpotential by histamine was mimicked by the histamine H1-receptor agonist 2-thiazolylethylamine and was reduced or blocked by the H1-receptor antagonist promethazine, but was not blocked or reduced in the presence of the  histamine H2-receptor  antagonist,  cimetidine .",
    "entity1": "histamine H2-receptor",
    "entity2": "cimetidine"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Kainate-evoked currents showed partial desensitization that was reduced on incubation with concanavalin A (conA) but not cyclothiazide and were attenuated by the non-<protein> N-methyl-D-aspartate (NMDA) receptor </protein> antagonist <chemical> CNQX </chemical> (6-cyano-7-nitro-quinoxalinedione).",
    "original_text": "Kainate-evoked currents showed partial desensitization that was reduced on incubation with concanavalin A (conA) but not cyclothiazide and were attenuated by the non- N-methyl-D-aspartate (NMDA) receptor  antagonist  CNQX  (6-cyano-7-nitro-quinoxalinedione).",
    "entity1": "N-methyl-D-aspartate (NMDA) receptor",
    "entity2": "CNQX"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Kainate-evoked currents showed partial desensitization that was reduced on incubation with concanavalin A (conA) but not cyclothiazide and were attenuated by the non-<protein> N-methyl-D-aspartate (NMDA) receptor </protein> antagonist CNQX (<chemical> 6-cyano-7-nitro-quinoxalinedione </chemical>).",
    "original_text": "Kainate-evoked currents showed partial desensitization that was reduced on incubation with concanavalin A (conA) but not cyclothiazide and were attenuated by the non- N-methyl-D-aspartate (NMDA) receptor  antagonist CNQX ( 6-cyano-7-nitro-quinoxalinedione ).",
    "entity1": "N-methyl-D-aspartate (NMDA) receptor",
    "entity2": "6-cyano-7-nitro-quinoxalinedione"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "<protein> Tamsulosin </protein>, the first prostate-selective <chemical> alpha 1A-adrenoceptor </chemical> antagonist.",
    "original_text": " Tamsulosin , the first prostate-selective  alpha 1A-adrenoceptor  antagonist.",
    "entity1": "Tamsulosin",
    "entity2": "alpha 1A-adrenoceptor"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "In conclusion, our data suggest that chronic <protein> cocaine </protein> use is associated with modestly reduced levels of striatal DA and the <chemical> DA transporter </chemical> in some subjects and that these changes might contribute to the neurological and psychiatric effects of the drug.",
    "original_text": "In conclusion, our data suggest that chronic  cocaine  use is associated with modestly reduced levels of striatal DA and the  DA transporter  in some subjects and that these changes might contribute to the neurological and psychiatric effects of the drug.",
    "entity1": "cocaine",
    "entity2": "DA transporter"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "<protein> GYKI 52466 </protein> decreased the peak amplitude of hippocampal area CA1 <chemical> AMPA receptor </chemical>-mediated excitatory postsynaptic currents (e.p.s.cs) (IC50 10.8 +/- 0.8 microM) with no apparent effect on response kinetics.",
    "original_text": " GYKI 52466  decreased the peak amplitude of hippocampal area CA1  AMPA receptor -mediated excitatory postsynaptic currents (e.p.s.cs) (IC50 10.8 +/- 0.8 microM) with no apparent effect on response kinetics.",
    "entity1": "GYKI 52466",
    "entity2": "AMPA receptor"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "<protein> Cyclothiazide </protein> prolonged the decay time constant of <chemical> AMPA receptor </chemical>-mediated e.p.s.cs (EC50 35.7 +/- 6.5 microM) with less pronounced effects in slowing e.p.s.c. onset kinetics and increasing e.p.s.c. amplitude.",
    "original_text": " Cyclothiazide  prolonged the decay time constant of  AMPA receptor -mediated e.p.s.cs (EC50 35.7 +/- 6.5 microM) with less pronounced effects in slowing e.p.s.c. onset kinetics and increasing e.p.s.c. amplitude.",
    "entity1": "Cyclothiazide",
    "entity2": "AMPA receptor"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "This study was designed to determine the gastroprotective properties of <protein> cinitapride </protein> (CNT), a novel prokinetic benzamide derivative agonist of <chemical> 5-HT4 </chemical> and 5-HT1 receptors and 5-HT2 antagonist, on mucosal injury produced by 50% (v/v) ethanol.",
    "original_text": "This study was designed to determine the gastroprotective properties of  cinitapride  (CNT), a novel prokinetic benzamide derivative agonist of  5-HT4  and 5-HT1 receptors and 5-HT2 antagonist, on mucosal injury produced by 50% (v/v) ethanol.",
    "entity1": "cinitapride",
    "entity2": "5-HT4"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "This study was designed to determine the gastroprotective properties of <protein> cinitapride </protein> (CNT), a novel prokinetic benzamide derivative agonist of 5-HT4 and <chemical> 5-HT1 </chemical> receptors and 5-HT2 antagonist, on mucosal injury produced by 50% (v/v) ethanol.",
    "original_text": "This study was designed to determine the gastroprotective properties of  cinitapride  (CNT), a novel prokinetic benzamide derivative agonist of 5-HT4 and  5-HT1  receptors and 5-HT2 antagonist, on mucosal injury produced by 50% (v/v) ethanol.",
    "entity1": "cinitapride",
    "entity2": "5-HT1"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "This study was designed to determine the gastroprotective properties of cinitapride (CNT), a novel prokinetic <protein> benzamide </protein> derivative agonist of <chemical> 5-HT4 </chemical> and 5-HT1 receptors and 5-HT2 antagonist, on mucosal injury produced by 50% (v/v) ethanol.",
    "original_text": "This study was designed to determine the gastroprotective properties of cinitapride (CNT), a novel prokinetic  benzamide  derivative agonist of  5-HT4  and 5-HT1 receptors and 5-HT2 antagonist, on mucosal injury produced by 50% (v/v) ethanol.",
    "entity1": "benzamide",
    "entity2": "5-HT4"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "This study was designed to determine the gastroprotective properties of cinitapride (CNT), a novel prokinetic <protein> benzamide </protein> derivative agonist of 5-HT4 and <chemical> 5-HT1 </chemical> receptors and 5-HT2 antagonist, on mucosal injury produced by 50% (v/v) ethanol.",
    "original_text": "This study was designed to determine the gastroprotective properties of cinitapride (CNT), a novel prokinetic  benzamide  derivative agonist of 5-HT4 and  5-HT1  receptors and 5-HT2 antagonist, on mucosal injury produced by 50% (v/v) ethanol.",
    "entity1": "benzamide",
    "entity2": "5-HT1"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "This study was designed to determine the gastroprotective properties of cinitapride (<protein> CNT </protein>), a novel prokinetic benzamide derivative agonist of <chemical> 5-HT4 </chemical> and 5-HT1 receptors and 5-HT2 antagonist, on mucosal injury produced by 50% (v/v) ethanol.",
    "original_text": "This study was designed to determine the gastroprotective properties of cinitapride ( CNT ), a novel prokinetic benzamide derivative agonist of  5-HT4  and 5-HT1 receptors and 5-HT2 antagonist, on mucosal injury produced by 50% (v/v) ethanol.",
    "entity1": "CNT",
    "entity2": "5-HT4"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "This study was designed to determine the gastroprotective properties of cinitapride (<protein> CNT </protein>), a novel prokinetic benzamide derivative agonist of 5-HT4 and <chemical> 5-HT1 </chemical> receptors and 5-HT2 antagonist, on mucosal injury produced by 50% (v/v) ethanol.",
    "original_text": "This study was designed to determine the gastroprotective properties of cinitapride ( CNT ), a novel prokinetic benzamide derivative agonist of 5-HT4 and  5-HT1  receptors and 5-HT2 antagonist, on mucosal injury produced by 50% (v/v) ethanol.",
    "entity1": "CNT",
    "entity2": "5-HT1"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "This study was designed to determine the gastroprotective properties of <protein> cinitapride </protein> (CNT), a novel prokinetic benzamide derivative agonist of 5-HT4 and 5-HT1 receptors and <chemical> 5-HT2 </chemical> antagonist, on mucosal injury produced by 50% (v/v) ethanol.",
    "original_text": "This study was designed to determine the gastroprotective properties of  cinitapride  (CNT), a novel prokinetic benzamide derivative agonist of 5-HT4 and 5-HT1 receptors and  5-HT2  antagonist, on mucosal injury produced by 50% (v/v) ethanol.",
    "entity1": "cinitapride",
    "entity2": "5-HT2"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "This study was designed to determine the gastroprotective properties of cinitapride (CNT), a novel prokinetic <protein> benzamide </protein> derivative agonist of 5-HT4 and 5-HT1 receptors and <chemical> 5-HT2 </chemical> antagonist, on mucosal injury produced by 50% (v/v) ethanol.",
    "original_text": "This study was designed to determine the gastroprotective properties of cinitapride (CNT), a novel prokinetic  benzamide  derivative agonist of 5-HT4 and 5-HT1 receptors and  5-HT2  antagonist, on mucosal injury produced by 50% (v/v) ethanol.",
    "entity1": "benzamide",
    "entity2": "5-HT2"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "This study was designed to determine the gastroprotective properties of cinitapride (<protein> CNT </protein>), a novel prokinetic benzamide derivative agonist of 5-HT4 and 5-HT1 receptors and <chemical> 5-HT2 </chemical> antagonist, on mucosal injury produced by 50% (v/v) ethanol.",
    "original_text": "This study was designed to determine the gastroprotective properties of cinitapride ( CNT ), a novel prokinetic benzamide derivative agonist of 5-HT4 and 5-HT1 receptors and  5-HT2  antagonist, on mucosal injury produced by 50% (v/v) ethanol.",
    "entity1": "CNT",
    "entity2": "5-HT2"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "We have identified <protein> adenosine deaminase </protein>, an enzyme involved in <chemical> purine </chemical> metabolism whose deficiency is associated with severe combined immunodeficiency, as a Grb3-3 binding protein that is not able to bind to Grb2.",
    "original_text": "We have identified  adenosine deaminase , an enzyme involved in  purine  metabolism whose deficiency is associated with severe combined immunodeficiency, as a Grb3-3 binding protein that is not able to bind to Grb2.",
    "entity1": "adenosine deaminase",
    "entity2": "purine"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "The hydrolysis of fluorescein <protein> diphosphate </protein> by <chemical> PTP epsilon </chemical> and PTPmeg1 was sensitive to alendronate, with IC50 values of less than 1 microM; PTPsigma, however, under the same conditions, was inhibited by only 50% with 141 microM alendronate.",
    "original_text": "The hydrolysis of fluorescein  diphosphate  by  PTP epsilon  and PTPmeg1 was sensitive to alendronate, with IC50 values of less than 1 microM; PTPsigma, however, under the same conditions, was inhibited by only 50% with 141 microM alendronate.",
    "entity1": "diphosphate",
    "entity2": "PTP epsilon"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "The hydrolysis of fluorescein <protein> diphosphate </protein> by PTP epsilon and <chemical> PTPmeg1 </chemical> was sensitive to alendronate, with IC50 values of less than 1 microM; PTPsigma, however, under the same conditions, was inhibited by only 50% with 141 microM alendronate.",
    "original_text": "The hydrolysis of fluorescein  diphosphate  by PTP epsilon and  PTPmeg1  was sensitive to alendronate, with IC50 values of less than 1 microM; PTPsigma, however, under the same conditions, was inhibited by only 50% with 141 microM alendronate.",
    "entity1": "diphosphate",
    "entity2": "PTPmeg1"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "16,16-dimethyl-PGE2 and two putative <protein> EP1 </protein> antagonists, <chemical> AH6809 </chemical> and SC-19220, did not show any significant binding to this receptor.",
    "original_text": "16,16-dimethyl-PGE2 and two putative  EP1  antagonists,  AH6809  and SC-19220, did not show any significant binding to this receptor.",
    "entity1": "EP1",
    "entity2": "AH6809"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "16,16-dimethyl-PGE2 and two putative <protein> EP1 </protein> antagonists, AH6809 and <chemical> SC-19220 </chemical>, did not show any significant binding to this receptor.",
    "original_text": "16,16-dimethyl-PGE2 and two putative  EP1  antagonists, AH6809 and  SC-19220 , did not show any significant binding to this receptor.",
    "entity1": "EP1",
    "entity2": "SC-19220"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "<protein> M&B-28767 </protein>, a putative <chemical> EP3 </chemical> agonist, and misoprostol, a putative EP2/EP3 agonist, also bound to this receptor with Ki values of 120 nM.",
    "original_text": " M&B-28767 , a putative  EP3  agonist, and misoprostol, a putative EP2/EP3 agonist, also bound to this receptor with Ki values of 120 nM.",
    "entity1": "M&B-28767",
    "entity2": "EP3"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "M&B-28767, a putative EP3 agonist, and <protein> misoprostol </protein>, a putative <chemical> EP2 </chemical>/EP3 agonist, also bound to this receptor with Ki values of 120 nM.",
    "original_text": "M&B-28767, a putative EP3 agonist, and  misoprostol , a putative  EP2 /EP3 agonist, also bound to this receptor with Ki values of 120 nM.",
    "entity1": "misoprostol",
    "entity2": "EP2"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "M&B-28767, a putative EP3 agonist, and <protein> misoprostol </protein>, a putative EP2/<chemical> EP3 </chemical> agonist, also bound to this receptor with Ki values of 120 nM.",
    "original_text": "M&B-28767, a putative EP3 agonist, and  misoprostol , a putative EP2/ EP3  agonist, also bound to this receptor with Ki values of 120 nM.",
    "entity1": "misoprostol",
    "entity2": "EP3"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Intravenous (I.V.) cocaine (0.03-3 mg/kg) produced dose-dependent, rapid, and brief increases in blood pressure (BP) in conscious rats pretreated with the <protein> dopamine receptor </protein> antagonist, <chemical> SCH 23390 </chemical>.",
    "original_text": "Intravenous (I.V.) cocaine (0.03-3 mg/kg) produced dose-dependent, rapid, and brief increases in blood pressure (BP) in conscious rats pretreated with the  dopamine receptor  antagonist,  SCH 23390 .",
    "entity1": "dopamine receptor",
    "entity2": "SCH 23390"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Characterization of binding sites of a new <protein> neurotensin receptor </protein> antagonist, <chemical> [3H]SR 142948A </chemical>, in the rat brain.",
    "original_text": "Characterization of binding sites of a new  neurotensin receptor  antagonist,  [3H]SR 142948A , in the rat brain.",
    "entity1": "neurotensin receptor",
    "entity2": "[3H]SR 142948A"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "The present study describes the characterization of the binding properties and autoradiographic distribution of a new nonpeptide antagonist of <protein> neurotensin receptors </protein>, <chemical> [3H]SR 142948A </chemical> (2-<chemical>5-(2,6-dimethoxyphenyl)-1-(4-(N-(3-dimethylaminopropyl)-N-methyl carbamoyl)-2-isopropylphenyl)-1H-pyrazole-3-carbonyl]-amino]-ad amantane-2-carboxylic acid, hydrochloride), in the rat brain.",
    "original_text": "The present study describes the characterization of the binding properties and autoradiographic distribution of a new nonpeptide antagonist of  neurotensin receptors ,  [3H]SR 142948A  (2-5-(2,6-dimethoxyphenyl)-1-(4-(N-(3-dimethylaminopropyl)-N-methyl carbamoyl)-2-isopropylphenyl)-1H-pyrazole-3-carbonyl]-amino]-ad amantane-2-carboxylic acid, hydrochloride), in the rat brain.",
    "entity1": "neurotensin receptors",
    "entity2": "[3H]SR 142948A"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "The present study describes the characterization of the binding properties and autoradiographic distribution of a new nonpeptide antagonist of <protein> neurotensin receptors </protein>, [3H]SR 142948A (<chemical> 2-<chemical>5-(2,6-dimethoxyphenyl)-1-(4-(N-(3-dimethylaminopropyl)-N-methyl carbamoyl)-2-isopropylphenyl)-1H-pyrazole-3-carbonyl]-amino]-ad amantane-2-carboxylic acid, hydrochloride </chemical>), in the rat brain.",
    "original_text": "The present study describes the characterization of the binding properties and autoradiographic distribution of a new nonpeptide antagonist of  neurotensin receptors , [3H]SR 142948A ( 2-5-(2,6-dimethoxyphenyl)-1-(4-(N-(3-dimethylaminopropyl)-N-methyl carbamoyl)-2-isopropylphenyl)-1H-pyrazole-3-carbonyl]-amino]-ad amantane-2-carboxylic acid, hydrochloride ), in the rat brain.",
    "entity1": "neurotensin receptors",
    "entity2": "2-[[5-(2,6-dimethoxyphenyl)-1-(4-(N-(3-dimethylaminopropyl)-N-methyl carbamoyl)-2-isopropylphenyl)-1H-pyrazole-3-carbonyl]-amino]-ad amantane-2-carboxylic acid, hydrochloride"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Saturation and competition studies in the presence or absence of the <protein> histamine H1 receptor </protein> antagonist, <chemical> levocabastine </chemical>, revealed that [3H]SR 142948A bound with similar affinities to both the levocabastine-insensitive neurotensin NT1 receptors (20% of the total binding population) and the recently cloned levocabastine-sensitive neurotensin NT2 receptors (80% of the receptors) (Kd = 6.8 and 4.8 nM, respectively).",
    "original_text": "Saturation and competition studies in the presence or absence of the  histamine H1 receptor  antagonist,  levocabastine , revealed that [3H]SR 142948A bound with similar affinities to both the levocabastine-insensitive neurotensin NT1 receptors (20% of the total binding population) and the recently cloned levocabastine-sensitive neurotensin NT2 receptors (80% of the receptors) (Kd = 6.8 and 4.8 nM, respectively).",
    "entity1": "histamine H1 receptor",
    "entity2": "levocabastine"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "In conclusion, these findings indicate that <protein> [3H]SR 142948A </protein> is a new potent antagonist radioligand which recognizes with high affinity both <chemical> neurotensin NT1 </chemical> and NT2 receptors and represents thus an excellent tool to study neurotensin receptors in the rat brain.",
    "original_text": "In conclusion, these findings indicate that  [3H]SR 142948A  is a new potent antagonist radioligand which recognizes with high affinity both  neurotensin NT1  and NT2 receptors and represents thus an excellent tool to study neurotensin receptors in the rat brain.",
    "entity1": "[3H]SR 142948A",
    "entity2": "neurotensin NT1"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "In conclusion, these findings indicate that <protein> [3H]SR 142948A </protein> is a new potent antagonist radioligand which recognizes with high affinity both neurotensin NT1 and <chemical> NT2 receptors </chemical> and represents thus an excellent tool to study neurotensin receptors in the rat brain.",
    "original_text": "In conclusion, these findings indicate that  [3H]SR 142948A  is a new potent antagonist radioligand which recognizes with high affinity both neurotensin NT1 and  NT2 receptors  and represents thus an excellent tool to study neurotensin receptors in the rat brain.",
    "entity1": "[3H]SR 142948A",
    "entity2": "NT2 receptors"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "Increased <protein> Cat3 </protein>-mediated cationic <chemical> amino acid </chemical> transport functionally compensates in Cat1 knockout cell lines.",
    "original_text": "Increased  Cat3 -mediated cationic  amino acid  transport functionally compensates in Cat1 knockout cell lines.",
    "entity1": "Cat3",
    "entity2": "amino acid"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "The majority of <protein> L-Arg </protein> transport is mediated by <chemical> System y+ </chemical>, although several other carriers have been kinetically defined.",
    "original_text": "The majority of  L-Arg  transport is mediated by  System y+ , although several other carriers have been kinetically defined.",
    "entity1": "L-Arg",
    "entity2": "System y+"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "<protein> System y+ </protein> cationic <chemical> amino acid </chemical> transport is mediated by proteins encoded by a family of genes, Cat1, Cat2, and Cat3.",
    "original_text": " System y+  cationic  amino acid  transport is mediated by proteins encoded by a family of genes, Cat1, Cat2, and Cat3.",
    "entity1": "System y+",
    "entity2": "amino acid"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "System y+ cationic <protein> amino acid </protein> transport is mediated by proteins encoded by a family of genes, <chemical> Cat1 </chemical>, Cat2, and Cat3.",
    "original_text": "System y+ cationic  amino acid  transport is mediated by proteins encoded by a family of genes,  Cat1 , Cat2, and Cat3.",
    "entity1": "amino acid",
    "entity2": "Cat1"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "System y+ cationic <protein> amino acid </protein> transport is mediated by proteins encoded by a family of genes, Cat1, <chemical> Cat2 </chemical>, and Cat3.",
    "original_text": "System y+ cationic  amino acid  transport is mediated by proteins encoded by a family of genes, Cat1,  Cat2 , and Cat3.",
    "entity1": "amino acid",
    "entity2": "Cat2"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "System y+ cationic <protein> amino acid </protein> transport is mediated by proteins encoded by a family of genes, Cat1, Cat2, and <chemical> Cat3 </chemical>.",
    "original_text": "System y+ cationic  amino acid  transport is mediated by proteins encoded by a family of genes, Cat1, Cat2, and  Cat3 .",
    "entity1": "amino acid",
    "entity2": "Cat3"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "However, the apparent affinity for <protein> lysine </protein> transport was 2.4 times lower in Cat1(-/-) cells when compared with wild type cells, a property characteristic of <chemical> Cat3 </chemical>-mediated transport.",
    "original_text": "However, the apparent affinity for  lysine  transport was 2.4 times lower in Cat1(-/-) cells when compared with wild type cells, a property characteristic of  Cat3 -mediated transport.",
    "entity1": "lysine",
    "entity2": "Cat3"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "These results suggest that <protein> Cat3 </protein> compensates for the loss of functional Cat1 in cells derived from Cat1 knockout mice and mediates the majority of high affinity <chemical> arginine </chemical> transport.",
    "original_text": "These results suggest that  Cat3  compensates for the loss of functional Cat1 in cells derived from Cat1 knockout mice and mediates the majority of high affinity  arginine  transport.",
    "entity1": "Cat3",
    "entity2": "arginine"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "Effect of <protein> lintitript </protein>, a new <chemical> CCK-A receptor </chemical> antagonist, on gastric emptying of a solid-liquid meal in humans.",
    "original_text": "Effect of  lintitript , a new  CCK-A receptor  antagonist, on gastric emptying of a solid-liquid meal in humans.",
    "entity1": "lintitript",
    "entity2": "CCK-A receptor"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "We studied the role of endogenous CCK in the emptying of a solid/liquid meal administering the new, highly specific and potent <protein> CCK-A receptor </protein> antagonist <chemical> lintitript </chemical>.",
    "original_text": "We studied the role of endogenous CCK in the emptying of a solid/liquid meal administering the new, highly specific and potent  CCK-A receptor  antagonist  lintitript .",
    "entity1": "CCK-A receptor",
    "entity2": "lintitript"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "The study demonstrates for the first time the marked gastrokinetic properties of the new <protein> CCK-A receptor </protein> antagonist <chemical> lintitript </chemical> in humans.",
    "original_text": "The study demonstrates for the first time the marked gastrokinetic properties of the new  CCK-A receptor  antagonist  lintitript  in humans.",
    "entity1": "CCK-A receptor",
    "entity2": "lintitript"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "Concanavalin A (Con A)-induced IFN-gamma, GM-CSF, and IL-3 mRNAs are dose-dependently inhibited by the nonselective <protein> betaAR </protein> agonist <chemical> isoproterenol </chemical> and by the selective beta2AR agonist fenoterol.",
    "original_text": "Concanavalin A (Con A)-induced IFN-gamma, GM-CSF, and IL-3 mRNAs are dose-dependently inhibited by the nonselective  betaAR  agonist  isoproterenol  and by the selective beta2AR agonist fenoterol.",
    "entity1": "betaAR",
    "entity2": "isoproterenol"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "Concanavalin A (Con A)-induced IFN-gamma, GM-CSF, and IL-3 mRNAs are dose-dependently inhibited by the nonselective betaAR agonist isoproterenol and by the selective <protein> beta2AR </protein> agonist <chemical> fenoterol </chemical>.",
    "original_text": "Concanavalin A (Con A)-induced IFN-gamma, GM-CSF, and IL-3 mRNAs are dose-dependently inhibited by the nonselective betaAR agonist isoproterenol and by the selective  beta2AR  agonist  fenoterol .",
    "entity1": "beta2AR",
    "entity2": "fenoterol"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "The observed inhibition on IFN-gamma, GM-CSF, and IL-3 mRNA was blocked by the selective <protein> beta2AR </protein> antagonist <chemical> ICI 118,551 </chemical> (10(-6) M) and by timolol (10(-6) M), a nonselective antagonist.",
    "original_text": "The observed inhibition on IFN-gamma, GM-CSF, and IL-3 mRNA was blocked by the selective  beta2AR  antagonist  ICI 118,551  (10(-6) M) and by timolol (10(-6) M), a nonselective antagonist.",
    "entity1": "beta2AR",
    "entity2": "ICI 118,551"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "The observed inhibition on IFN-gamma, GM-CSF, and IL-3 mRNA was blocked by the selective <protein> beta2AR </protein> antagonist ICI 118,551 (10(-6) M) and by <chemical> timolol </chemical> (10(-6) M), a nonselective antagonist.",
    "original_text": "The observed inhibition on IFN-gamma, GM-CSF, and IL-3 mRNA was blocked by the selective  beta2AR  antagonist ICI 118,551 (10(-6) M) and by  timolol  (10(-6) M), a nonselective antagonist.",
    "entity1": "beta2AR",
    "entity2": "timolol"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "The selective <protein> beta1AR </protein> antagonist <chemical> atenolol </chemical> (0.3 x 10(-6) M) did not have any effect.",
    "original_text": "The selective  beta1AR  antagonist  atenolol  (0.3 x 10(-6) M) did not have any effect.",
    "entity1": "beta1AR",
    "entity2": "atenolol"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "Although beta3AR mRNA was detectable in Con A-activated T lymphocytes, we could not demonstrate a functional activity in the regulation of cytokine expression: the <protein> beta3AR </protein> agonist <chemical> BRL 37344 </chemical> had no effect on the accumulation of the studied cytokine mRNAs, and did not significantly affect cellular cAMP levels.",
    "original_text": "Although beta3AR mRNA was detectable in Con A-activated T lymphocytes, we could not demonstrate a functional activity in the regulation of cytokine expression: the  beta3AR  agonist  BRL 37344  had no effect on the accumulation of the studied cytokine mRNAs, and did not significantly affect cellular cAMP levels.",
    "entity1": "beta3AR",
    "entity2": "BRL 37344"
  },
  {
    "_id": 3,
    "label": "Agonist",
    "text": "These results indicate that <protein> carbetocin </protein> is a partial agonist/antagonist to the <chemical> oxytocin receptor </chemical> while the two metabolites carbetocin metabolite I and carbetocin metabolite II are pure antagonists.",
    "original_text": "These results indicate that  carbetocin  is a partial agonist/antagonist to the  oxytocin receptor  while the two metabolites carbetocin metabolite I and carbetocin metabolite II are pure antagonists.",
    "entity1": "carbetocin",
    "entity2": "oxytocin receptor"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "These results indicate that <protein> carbetocin </protein> is a partial agonist/antagonist to the <chemical> oxytocin receptor </chemical> while the two metabolites carbetocin metabolite I and carbetocin metabolite II are pure antagonists.",
    "original_text": "These results indicate that  carbetocin  is a partial agonist/antagonist to the  oxytocin receptor  while the two metabolites carbetocin metabolite I and carbetocin metabolite II are pure antagonists.",
    "entity1": "carbetocin",
    "entity2": "oxytocin receptor"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "These results indicate that carbetocin is a partial agonist/antagonist to the <protein> oxytocin receptor </protein> while the two metabolites <chemical> carbetocin </chemical> metabolite I and carbetocin metabolite II are pure antagonists.",
    "original_text": "These results indicate that carbetocin is a partial agonist/antagonist to the  oxytocin receptor  while the two metabolites  carbetocin  metabolite I and carbetocin metabolite II are pure antagonists.",
    "entity1": "oxytocin receptor",
    "entity2": "carbetocin"
  },
  {
    "_id": 4,
    "label": "Antagonist",
    "text": "These results indicate that carbetocin is a partial agonist/antagonist to the <protein> oxytocin receptor </protein> while the two metabolites carbetocin metabolite I and <chemical> carbetocin </chemical> metabolite II are pure antagonists.",
    "original_text": "These results indicate that carbetocin is a partial agonist/antagonist to the  oxytocin receptor  while the two metabolites carbetocin metabolite I and  carbetocin  metabolite II are pure antagonists.",
    "entity1": "oxytocin receptor",
    "entity2": "carbetocin"
  },
  {
    "_id": 2,
    "label": "Downregulator",
    "text": "All GCs including the antagonistic compound <protein> RU486 </protein> efficiently reduced <chemical> NF-kappaB </chemical>-mediated transactivation to comparable extents, suggesting that ligand-induced nuclear localization of the GR is sufficient for transrepression.",
    "original_text": "All GCs including the antagonistic compound  RU486  efficiently reduced  NF-kappaB -mediated transactivation to comparable extents, suggesting that ligand-induced nuclear localization of the GR is sufficient for transrepression.",
    "entity1": "RU486",
    "entity2": "NF-kappaB"
  },
  {
    "_id": 0,
    "label": "Substrate",
    "text": "These results suggest that SUR1 binds 8-azido-ATP strongly at NBF1 and that MgADP, either by direct binding to NBF2 or by hydrolysis of bound <protein> MgATP </protein> at <chemical> NBF2 </chemical>, stabilizes prebound 8-azido-ATP binding at NBF1.",
    "original_text": "These results suggest that SUR1 binds 8-azido-ATP strongly at NBF1 and that MgADP, either by direct binding to NBF2 or by hydrolysis of bound  MgATP  at  NBF2 , stabilizes prebound 8-azido-ATP binding at NBF1.",
    "entity1": "MgATP",
    "entity2": "NBF2"
  }
]